WO2014093694A1 - Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes - Google Patents
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes Download PDFInfo
- Publication number
- WO2014093694A1 WO2014093694A1 PCT/US2013/074790 US2013074790W WO2014093694A1 WO 2014093694 A1 WO2014093694 A1 WO 2014093694A1 US 2013074790 W US2013074790 W US 2013074790W WO 2014093694 A1 WO2014093694 A1 WO 2014093694A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- crispr
- enzyme
- tracr
- composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 102
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 108010008532 Deoxyribonuclease I Proteins 0.000 title claims description 26
- 102000007260 Deoxyribonuclease I Human genes 0.000 title claims description 26
- 241000206602 Eukaryota Species 0.000 title description 3
- 108091033409 CRISPR Proteins 0.000 claims abstract description 265
- 210000004027 cell Anatomy 0.000 claims abstract description 232
- 230000035772 mutation Effects 0.000 claims abstract description 129
- 239000013598 vector Substances 0.000 claims abstract description 121
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 49
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract 12
- 102000004190 Enzymes Human genes 0.000 claims description 125
- 108090000790 Enzymes Proteins 0.000 claims description 125
- 102000040430 polynucleotide Human genes 0.000 claims description 99
- 108091033319 polynucleotide Proteins 0.000 claims description 99
- 239000002157 polynucleotide Substances 0.000 claims description 99
- 230000014509 gene expression Effects 0.000 claims description 93
- 239000002773 nucleotide Substances 0.000 claims description 59
- 230000001105 regulatory effect Effects 0.000 claims description 58
- 125000003729 nucleotide group Chemical group 0.000 claims description 57
- 108091092236 Chimeric RNA Proteins 0.000 claims description 51
- 241000282414 Homo sapiens Species 0.000 claims description 51
- 230000030648 nucleus localization Effects 0.000 claims description 21
- 230000009870 specific binding Effects 0.000 claims description 15
- 230000003197 catalytic effect Effects 0.000 claims description 10
- 238000009825 accumulation Methods 0.000 claims description 9
- 238000009877 rendering Methods 0.000 claims description 5
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 claims 4
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 claims 2
- 241000766026 Coregonus nasus Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 85
- 238000013461 design Methods 0.000 abstract description 20
- 230000009918 complex formation Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 166
- 229940088598 enzyme Drugs 0.000 description 118
- 108020004414 DNA Proteins 0.000 description 110
- 238000003776 cleavage reaction Methods 0.000 description 103
- 230000007017 scission Effects 0.000 description 102
- 230000008685 targeting Effects 0.000 description 82
- 239000013612 plasmid Substances 0.000 description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 75
- 239000000047 product Substances 0.000 description 62
- 108091079001 CRISPR RNA Proteins 0.000 description 60
- 125000006850 spacer group Chemical group 0.000 description 59
- 102000004169 proteins and genes Human genes 0.000 description 58
- -1 mutant forms thereof Proteins 0.000 description 56
- 235000018102 proteins Nutrition 0.000 description 53
- 238000003556 assay Methods 0.000 description 50
- 201000010099 disease Diseases 0.000 description 46
- 150000007523 nucleic acids Chemical class 0.000 description 42
- 238000010362 genome editing Methods 0.000 description 40
- 238000012217 deletion Methods 0.000 description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 37
- 230000037430 deletion Effects 0.000 description 37
- 102000039446 nucleic acids Human genes 0.000 description 36
- 108020004707 nucleic acids Proteins 0.000 description 36
- 230000009466 transformation Effects 0.000 description 35
- 238000005516 engineering process Methods 0.000 description 34
- 238000002744 homologous recombination Methods 0.000 description 33
- 230000006801 homologous recombination Effects 0.000 description 33
- 238000003780 insertion Methods 0.000 description 33
- 230000037431 insertion Effects 0.000 description 32
- 230000001404 mediated effect Effects 0.000 description 32
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 31
- 101710163270 Nuclease Proteins 0.000 description 31
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 29
- 208000035475 disorder Diseases 0.000 description 29
- 241000193996 Streptococcus pyogenes Species 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 28
- 239000013604 expression vector Substances 0.000 description 28
- 108020005004 Guide RNA Proteins 0.000 description 27
- 229930027917 kanamycin Natural products 0.000 description 27
- 229960000318 kanamycin Drugs 0.000 description 27
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 27
- 229930182823 kanamycin A Natural products 0.000 description 27
- 230000006798 recombination Effects 0.000 description 27
- 238000005215 recombination Methods 0.000 description 27
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 26
- 108091034117 Oligonucleotide Proteins 0.000 description 26
- 241000588724 Escherichia coli Species 0.000 description 25
- 230000004060 metabolic process Effects 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 239000000499 gel Substances 0.000 description 23
- 101150087718 srtA gene Proteins 0.000 description 23
- 241000320123 Streptococcus pyogenes M1 GAS Species 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 22
- 230000004048 modification Effects 0.000 description 22
- 238000012986 modification Methods 0.000 description 22
- 241000196324 Embryophyta Species 0.000 description 20
- 210000004940 nucleus Anatomy 0.000 description 20
- 101100478373 Bacillus subtilis (strain 168) srtD gene Proteins 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 19
- 238000011144 upstream manufacturing Methods 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 101150098466 rpsL gene Proteins 0.000 description 18
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 238000001890 transfection Methods 0.000 description 17
- 108020004705 Codon Proteins 0.000 description 16
- 101150087081 bgaA gene Proteins 0.000 description 16
- 229960005091 chloramphenicol Drugs 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 238000013518 transcription Methods 0.000 description 16
- 230000002068 genetic effect Effects 0.000 description 15
- 238000012163 sequencing technique Methods 0.000 description 15
- 229960005322 streptomycin Drugs 0.000 description 15
- 230000035897 transcription Effects 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 15
- 108091093088 Amplicon Proteins 0.000 description 14
- 210000004962 mammalian cell Anatomy 0.000 description 14
- 238000000636 Northern blotting Methods 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 13
- 229960003276 erythromycin Drugs 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 230000005782 double-strand break Effects 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000006780 non-homologous end joining Effects 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 230000011664 signaling Effects 0.000 description 12
- 230000007018 DNA scission Effects 0.000 description 11
- 101000706121 Homo sapiens Parvalbumin alpha Proteins 0.000 description 11
- 241000194020 Streptococcus thermophilus Species 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 102100030856 Myoglobin Human genes 0.000 description 10
- 241001633172 Streptococcus thermophilus LMD-9 Species 0.000 description 10
- 108091027544 Subgenomic mRNA Proteins 0.000 description 10
- 238000000137 annealing Methods 0.000 description 10
- 108010005774 beta-Galactosidase Proteins 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000005457 optimization Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 102100026189 Beta-galactosidase Human genes 0.000 description 9
- 101001033726 Homo sapiens Methyl-CpG-binding protein 2 Proteins 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000003623 enhancer Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000008439 repair process Effects 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 8
- 238000007400 DNA extraction Methods 0.000 description 8
- 101000635854 Homo sapiens Myoglobin Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 7
- 102100030708 GTPase KRas Human genes 0.000 description 7
- 102100023823 Homeobox protein EMX1 Human genes 0.000 description 7
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 description 7
- 101001048956 Homo sapiens Homeobox protein EMX1 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000010222 PCR analysis Methods 0.000 description 7
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 102100026882 Alpha-synuclein Human genes 0.000 description 6
- 241000702421 Dependoparvovirus Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 6
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 6
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 6
- 101000619805 Homo sapiens Peroxiredoxin-5, mitochondrial Proteins 0.000 description 6
- 101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 description 6
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 6
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 6
- 102100033819 Nuclear pore complex protein Nup214 Human genes 0.000 description 6
- 102100022078 Peroxiredoxin-5, mitochondrial Human genes 0.000 description 6
- 102100035832 Phakinin Human genes 0.000 description 6
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 6
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108091028113 Trans-activating crRNA Proteins 0.000 description 6
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000012350 deep sequencing Methods 0.000 description 6
- 108010025678 empty spiracles homeobox proteins Proteins 0.000 description 6
- 238000003205 genotyping method Methods 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 210000001236 prokaryotic cell Anatomy 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 102100030685 Alpha-sarcoglycan Human genes 0.000 description 5
- 102100032187 Androgen receptor Human genes 0.000 description 5
- 102100025399 Breast cancer type 2 susceptibility protein Human genes 0.000 description 5
- 101150069031 CSN2 gene Proteins 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 108700010070 Codon Usage Proteins 0.000 description 5
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 5
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 5
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 5
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 description 5
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 5
- 101000721642 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Proteins 0.000 description 5
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 5
- 101000846198 Homo sapiens Ribitol 5-phosphate transferase FKRP Proteins 0.000 description 5
- 101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 5
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 101100494762 Mus musculus Nedd9 gene Proteins 0.000 description 5
- 101100101250 Mus musculus Th gene Proteins 0.000 description 5
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 5
- 102100025058 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Human genes 0.000 description 5
- 102100026531 Prelamin-A/C Human genes 0.000 description 5
- 102100022036 Presenilin-2 Human genes 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 102100031774 Ribitol 5-phosphate transferase FKRP Human genes 0.000 description 5
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 5
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 5
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 201000008266 amyotrophic lateral sclerosis type 2 Diseases 0.000 description 5
- 101150038500 cas9 gene Proteins 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000012761 co-transfection Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 208000032799 juvenile amyotrophic lateral sclerosis type 2 Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 229960000268 spectinomycin Drugs 0.000 description 5
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- 102100040069 Aldehyde dehydrogenase 1A1 Human genes 0.000 description 4
- 101710150756 Aldehyde dehydrogenase, mitochondrial Proteins 0.000 description 4
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 4
- 102100032197 Alpha-crystallin A chain Human genes 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 102100029470 Apolipoprotein E Human genes 0.000 description 4
- 102100029388 Beta-crystallin B2 Human genes 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- 238000010446 CRISPR interference Methods 0.000 description 4
- 102100027813 Gamma-crystallin C Human genes 0.000 description 4
- 102100027812 Gamma-crystallin D Human genes 0.000 description 4
- 102100021792 Gamma-sarcoglycan Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 101000920937 Homo sapiens Alpha-crystallin A chain Proteins 0.000 description 4
- 101000703500 Homo sapiens Alpha-sarcoglycan Proteins 0.000 description 4
- 101000919250 Homo sapiens Beta-crystallin B2 Proteins 0.000 description 4
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 4
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 4
- 101000859938 Homo sapiens Gamma-crystallin C Proteins 0.000 description 4
- 101000859943 Homo sapiens Gamma-crystallin D Proteins 0.000 description 4
- 101000616435 Homo sapiens Gamma-sarcoglycan Proteins 0.000 description 4
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 4
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 4
- 101000996563 Homo sapiens Nuclear pore complex protein Nup214 Proteins 0.000 description 4
- 101000992283 Homo sapiens Optineurin Proteins 0.000 description 4
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 4
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 4
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 4
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 4
- 101000617546 Homo sapiens Presenilin-2 Proteins 0.000 description 4
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 4
- 101001026854 Homo sapiens Protein kinase C delta type Proteins 0.000 description 4
- 101001026852 Homo sapiens Protein kinase C epsilon type Proteins 0.000 description 4
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 4
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 4
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 description 4
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 4
- 101000708741 Homo sapiens Transcription factor RelB Proteins 0.000 description 4
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 description 4
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 4
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 description 4
- 101150083522 MECP2 gene Proteins 0.000 description 4
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 4
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 102100031822 Optineurin Human genes 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 102100037499 Parkinson disease protein 7 Human genes 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 102100040375 Peripherin-2 Human genes 0.000 description 4
- 102100029139 Peroxiredoxin-1 Human genes 0.000 description 4
- 108090000709 Phakinin Proteins 0.000 description 4
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 4
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 4
- 102100031014 Phosphatidylinositol-binding clathrin assembly protein Human genes 0.000 description 4
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 4
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 description 4
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 4
- 102100037340 Protein kinase C delta type Human genes 0.000 description 4
- 102100037339 Protein kinase C epsilon type Human genes 0.000 description 4
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 4
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 102100022663 Retinal guanylyl cyclase 1 Human genes 0.000 description 4
- 102100020824 Serine-protein kinase ATM Human genes 0.000 description 4
- 241000694196 Streptococcus pneumoniae R6 Species 0.000 description 4
- 102100040296 TATA-box-binding protein Human genes 0.000 description 4
- 102100032727 Transcription factor RelB Human genes 0.000 description 4
- 102100029290 Transthyretin Human genes 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 4
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 4
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008238 biochemical pathway Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 101150055766 cat gene Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 208000016361 genetic disease Diseases 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 3
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 3
- 239000013607 AAV vector Substances 0.000 description 3
- 102100024378 AF4/FMR2 family member 2 Human genes 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 3
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 3
- 102000007370 Ataxin2 Human genes 0.000 description 3
- 108010032951 Ataxin2 Proteins 0.000 description 3
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 3
- 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 3
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 102100032539 Calpain-3 Human genes 0.000 description 3
- 102100026735 Coagulation factor VIII Human genes 0.000 description 3
- 102100040496 Collagen alpha-2(VIII) chain Human genes 0.000 description 3
- 102100029362 Cone-rod homeobox protein Human genes 0.000 description 3
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 3
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 241000252212 Danio rerio Species 0.000 description 3
- 102100021790 Delta-sarcoglycan Human genes 0.000 description 3
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102100032053 Elongation of very long chain fatty acids protein 4 Human genes 0.000 description 3
- 102100027280 Fanconi anemia group A protein Human genes 0.000 description 3
- 102100034553 Fanconi anemia group J protein Human genes 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 3
- 102000003869 Frataxin Human genes 0.000 description 3
- 108090000217 Frataxin Proteins 0.000 description 3
- 102100030526 Gap junction alpha-3 protein Human genes 0.000 description 3
- 102100021223 Glucosidase 2 subunit beta Human genes 0.000 description 3
- 102100030943 Glutathione S-transferase P Human genes 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102100034047 Heat shock factor protein 4 Human genes 0.000 description 3
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 3
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 3
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 3
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 3
- 101000934858 Homo sapiens Breast cancer type 2 susceptibility protein Proteins 0.000 description 3
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 3
- 101000867715 Homo sapiens Calpain-3 Proteins 0.000 description 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
- 101000749886 Homo sapiens Collagen alpha-2(VIII) chain Proteins 0.000 description 3
- 101000919370 Homo sapiens Cone-rod homeobox protein Proteins 0.000 description 3
- 101000616408 Homo sapiens Delta-sarcoglycan Proteins 0.000 description 3
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 3
- 101000921354 Homo sapiens Elongation of very long chain fatty acids protein 4 Proteins 0.000 description 3
- 101000891683 Homo sapiens Fanconi anemia group D2 protein Proteins 0.000 description 3
- 101000848171 Homo sapiens Fanconi anemia group J protein Proteins 0.000 description 3
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 3
- 101001040875 Homo sapiens Glucosidase 2 subunit beta Proteins 0.000 description 3
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 description 3
- 101001016879 Homo sapiens Heat shock factor protein 4 Proteins 0.000 description 3
- 101000677891 Homo sapiens Iron-sulfur clusters transporter ABCB7, mitochondrial Proteins 0.000 description 3
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 3
- 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 description 3
- 101001055092 Homo sapiens Mitogen-activated protein kinase kinase kinase 7 Proteins 0.000 description 3
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 description 3
- 101000979338 Homo sapiens Nuclear factor NF-kappa-B p100 subunit Proteins 0.000 description 3
- 101000610652 Homo sapiens Peripherin-2 Proteins 0.000 description 3
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 3
- 101000720958 Homo sapiens Protein artemis Proteins 0.000 description 3
- 101000971404 Homo sapiens Protein kinase C iota type Proteins 0.000 description 3
- 101000971468 Homo sapiens Protein kinase C zeta type Proteins 0.000 description 3
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 3
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 101000927774 Homo sapiens Rho guanine nucleotide exchange factor 12 Proteins 0.000 description 3
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 3
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 3
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 3
- 101000671676 Homo sapiens U3 small nucleolar RNA-associated protein 4 homolog Proteins 0.000 description 3
- 101000854875 Homo sapiens V-type proton ATPase 116 kDa subunit a 3 Proteins 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102100021504 Iron-sulfur clusters transporter ABCB7, mitochondrial Human genes 0.000 description 3
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 3
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 3
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 description 3
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 3
- 102100022033 Presenilin-1 Human genes 0.000 description 3
- 102100025918 Protein artemis Human genes 0.000 description 3
- 102100021557 Protein kinase C iota type Human genes 0.000 description 3
- 102100021538 Protein kinase C zeta type Human genes 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
- 102100033193 Rho guanine nucleotide exchange factor 12 Human genes 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 102100030547 Serotonin N-acetyltransferase Human genes 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 3
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 3
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 3
- 102100021947 Survival motor neuron protein Human genes 0.000 description 3
- 238000010459 TALEN Methods 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 3
- 102100040072 U3 small nucleolar RNA-associated protein 4 homolog Human genes 0.000 description 3
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 3
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 3
- 102100020738 V-type proton ATPase 116 kDa subunit a 3 Human genes 0.000 description 3
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 3
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 208000021841 acute erythroid leukemia Diseases 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 108010080146 androgen receptors Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000008436 biogenesis Effects 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 101150055601 cops2 gene Proteins 0.000 description 3
- 108010082025 cyan fluorescent protein Proteins 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000013081 phylogenetic analysis Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108020001580 protein domains Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- YAWWQIFONIPBKT-HXUWFJFHSA-N 2-[[(2r)-2-butyl-6,7-dichloro-2-cyclopentyl-1-oxo-3h-inden-5-yl]oxy]acetic acid Chemical compound C1([C@@]2(C(C3=C(Cl)C(Cl)=C(OCC(O)=O)C=C3C2)=O)CCCC)CCCC1 YAWWQIFONIPBKT-HXUWFJFHSA-N 0.000 description 2
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 2
- 102100031020 5-aminolevulinate synthase, erythroid-specific, mitochondrial Human genes 0.000 description 2
- 102100033092 ATP-binding cassette sub-family G member 8 Human genes 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100033816 Aldehyde dehydrogenase, mitochondrial Human genes 0.000 description 2
- 102100025983 Alpha-2C adrenergic receptor Human genes 0.000 description 2
- 102100040743 Alpha-crystallin B chain Human genes 0.000 description 2
- 102100020895 Ammonium transporter Rh type A Human genes 0.000 description 2
- 102100040894 Amylo-alpha-1,6-glucosidase Human genes 0.000 description 2
- 102100036438 Amyloid beta precursor protein binding family B member 2 Human genes 0.000 description 2
- 102100034594 Angiopoietin-1 Human genes 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 2
- 102100021630 B-cell CLL/lymphoma 7 protein family member A Human genes 0.000 description 2
- 108091012583 BCL2 Proteins 0.000 description 2
- 108700020462 BRCA2 Proteins 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 2
- 102100030686 Beta-sarcoglycan Human genes 0.000 description 2
- 102100021257 Beta-secretase 1 Human genes 0.000 description 2
- 101710150192 Beta-secretase 1 Proteins 0.000 description 2
- 102100027058 Bleomycin hydrolase Human genes 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 101150008921 Brca2 gene Proteins 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 2
- 101150052909 CCL2 gene Proteins 0.000 description 2
- 102100031168 CCN family member 2 Human genes 0.000 description 2
- 101150083327 CCR2 gene Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 208000032325 CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome Diseases 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- 102100026548 Caspase-8 Human genes 0.000 description 2
- 102100021633 Cathepsin B Human genes 0.000 description 2
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 2
- 102100032212 Caveolin-3 Human genes 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 208000037141 Congenital muscular dystrophy, Fukuyama type Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 2
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 description 2
- 102100030299 Cysteine-rich hydrophobic domain-containing protein 2 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 101150082208 DIABLO gene Proteins 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 102100020986 DNA-binding protein RFX5 Human genes 0.000 description 2
- 102100038694 DNA-binding protein SMUBP-2 Human genes 0.000 description 2
- 101100274355 Danio rerio chd gene Proteins 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 102100032248 Dysferlin Human genes 0.000 description 2
- 102100034546 E3 ubiquitin-protein ligase FANCL Human genes 0.000 description 2
- 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 description 2
- 101100275895 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) csnB gene Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- 102100031690 Erythroid transcription factor Human genes 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108010033305 Fanconi Anemia Complementation Group G protein Proteins 0.000 description 2
- 102100027285 Fanconi anemia group B protein Human genes 0.000 description 2
- 102100034555 Fanconi anemia group G protein Human genes 0.000 description 2
- 102000007338 Fragile X Mental Retardation Protein Human genes 0.000 description 2
- 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 2
- 102100036336 Fragile X mental retardation syndrome-related protein 2 Human genes 0.000 description 2
- 208000001914 Fragile X syndrome Diseases 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000036357 GUCY2D-related recessive retinopathy Diseases 0.000 description 2
- 102100025283 Gap junction alpha-8 protein Human genes 0.000 description 2
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100036589 Glycine-tRNA ligase Human genes 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 2
- 101710198293 Guanylyl cyclase C Proteins 0.000 description 2
- 102100028685 H(+)/Cl(-) exchange transporter 7 Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 2
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 2
- 102100029235 Histone-lysine N-methyltransferase NSD3 Human genes 0.000 description 2
- 101001000686 Homo sapiens 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 description 2
- 101000890570 Homo sapiens Aldehyde dehydrogenase 1A1 Proteins 0.000 description 2
- 101000720032 Homo sapiens Alpha-2C adrenergic receptor Proteins 0.000 description 2
- 101000891982 Homo sapiens Alpha-crystallin B chain Proteins 0.000 description 2
- 101001075525 Homo sapiens Ammonium transporter Rh type A Proteins 0.000 description 2
- 101000893559 Homo sapiens Amylo-alpha-1,6-glucosidase Proteins 0.000 description 2
- 101000928680 Homo sapiens Amyloid beta precursor protein binding family B member 2 Proteins 0.000 description 2
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 2
- 101000971230 Homo sapiens B-cell CLL/lymphoma 7 protein family member A Proteins 0.000 description 2
- 101000703495 Homo sapiens Beta-sarcoglycan Proteins 0.000 description 2
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 2
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 description 2
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 2
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 2
- 101000869042 Homo sapiens Caveolin-3 Proteins 0.000 description 2
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 2
- 101000945692 Homo sapiens Cyclin-dependent kinase-like 5 Proteins 0.000 description 2
- 101000991100 Homo sapiens Cysteine-rich hydrophobic domain-containing protein 2 Proteins 0.000 description 2
- 101001075432 Homo sapiens DNA-binding protein RFX5 Proteins 0.000 description 2
- 101000665135 Homo sapiens DNA-binding protein SMUBP-2 Proteins 0.000 description 2
- 101001016184 Homo sapiens Dysferlin Proteins 0.000 description 2
- 101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 description 2
- 101000930952 Homo sapiens Fragile X mental retardation syndrome-related protein 2 Proteins 0.000 description 2
- 101000726577 Homo sapiens Gap junction alpha-3 protein Proteins 0.000 description 2
- 101000930910 Homo sapiens Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 2
- 101000766971 Homo sapiens H(+)/Cl(-) exchange transporter 7 Proteins 0.000 description 2
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 2
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 2
- 101000634046 Homo sapiens Histone-lysine N-methyltransferase NSD3 Proteins 0.000 description 2
- 101001043764 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 2
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101000614618 Homo sapiens Junctophilin-3 Proteins 0.000 description 2
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 2
- 101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 description 2
- 101000983747 Homo sapiens MHC class II transactivator Proteins 0.000 description 2
- 101000585663 Homo sapiens Myocilin Proteins 0.000 description 2
- 101001030184 Homo sapiens Myotilin Proteins 0.000 description 2
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 2
- 101000973618 Homo sapiens NF-kappa-B essential modulator Proteins 0.000 description 2
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 2
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 2
- 101001109698 Homo sapiens Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 2
- 101001098523 Homo sapiens PAX-interacting protein 1 Proteins 0.000 description 2
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 2
- 101000755630 Homo sapiens Peripheral-type benzodiazepine receptor-associated protein 1 Proteins 0.000 description 2
- 101000873719 Homo sapiens Phakinin Proteins 0.000 description 2
- 101000583474 Homo sapiens Phosphatidylinositol-binding clathrin assembly protein Proteins 0.000 description 2
- 101000801640 Homo sapiens Phospholipid-transporting ATPase ABCA3 Proteins 0.000 description 2
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
- 101000692464 Homo sapiens Platelet-derived growth factor receptor-like protein Proteins 0.000 description 2
- 101000718497 Homo sapiens Protein AF-10 Proteins 0.000 description 2
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 2
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 2
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 2
- 101000898985 Homo sapiens Seipin Proteins 0.000 description 2
- 101000904787 Homo sapiens Serine/threonine-protein kinase ATR Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 101000652292 Homo sapiens Serotonin N-acetyltransferase Proteins 0.000 description 2
- 101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 description 2
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 2
- 101000891654 Homo sapiens TATA-box-binding protein Proteins 0.000 description 2
- 101000597193 Homo sapiens Telethonin Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 2
- 101000844521 Homo sapiens Transient receptor potential cation channel subfamily M member 5 Proteins 0.000 description 2
- 101000851865 Homo sapiens Tryptophan 5-hydroxylase 2 Proteins 0.000 description 2
- 101000807668 Homo sapiens Uracil-DNA glycosylase Proteins 0.000 description 2
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 2
- 101000775932 Homo sapiens Vesicle-associated membrane protein-associated protein B/C Proteins 0.000 description 2
- 101000854936 Homo sapiens Visual system homeobox 1 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 2
- 102100036721 Insulin receptor Human genes 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 2
- 102100040488 Junctophilin-3 Human genes 0.000 description 2
- 102100034866 Kallikrein-6 Human genes 0.000 description 2
- 208000027747 Kennedy disease Diseases 0.000 description 2
- 208000005870 Lafora disease Diseases 0.000 description 2
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 2
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 2
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 2
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 2
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 102100026371 MHC class II transactivator Human genes 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- 241001599018 Melanogaster Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 102100029839 Myocilin Human genes 0.000 description 2
- 102100038894 Myotilin Human genes 0.000 description 2
- PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 2
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 2
- 102100022219 NF-kappa-B essential modulator Human genes 0.000 description 2
- 102100031893 Nanos homolog 3 Human genes 0.000 description 2
- 101710203761 Neurexin-1 Proteins 0.000 description 2
- 102100021582 Neurexin-1-beta Human genes 0.000 description 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
- 102100022676 Nuclear receptor subfamily 4 group A member 2 Human genes 0.000 description 2
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 102100040444 P2X purinoceptor 1 Human genes 0.000 description 2
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 2
- 102100037141 PAX-interacting protein 1 Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102100037506 Paired box protein Pax-6 Human genes 0.000 description 2
- 102100028467 Perforin-1 Human genes 0.000 description 2
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 2
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 2
- 101710169596 Phosphatidylinositol-binding clathrin assembly protein Proteins 0.000 description 2
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 description 2
- 102100033623 Phospholipid-transporting ATPase ABCA3 Human genes 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 102100026554 Platelet-derived growth factor receptor-like protein Human genes 0.000 description 2
- 102100030477 Plectin Human genes 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 102100034180 Protein AATF Human genes 0.000 description 2
- 101710155502 Protein AATF Proteins 0.000 description 2
- 102100026286 Protein AF-10 Human genes 0.000 description 2
- 102100026375 Protein PML Human genes 0.000 description 2
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 2
- 102100038188 RNA binding protein fox-1 homolog 1 Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 102000003661 Ribonuclease III Human genes 0.000 description 2
- 108010057163 Ribonuclease III Proteins 0.000 description 2
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 2
- 108091006299 SLC2A2 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102100021463 Seipin Human genes 0.000 description 2
- 102100023921 Serine/threonine-protein kinase ATR Human genes 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 102100023537 Solute carrier family 2, facilitated glucose transporter member 2 Human genes 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 101000910046 Streptococcus thermophilus (strain ATCC BAA-491 / LMD-9) CRISPR-associated endonuclease Cas9 1 Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102100037346 Substance-P receptor Human genes 0.000 description 2
- 102100021997 Synphilin-1 Human genes 0.000 description 2
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 2
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 2
- 101710145783 TATA-box-binding protein Proteins 0.000 description 2
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 2
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 2
- 102000003609 TRPM5 Human genes 0.000 description 2
- 102100028082 Tapasin Human genes 0.000 description 2
- 102100035155 Telethonin Human genes 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 2
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 102100027059 Translation initiation factor eIF-2B subunit alpha Human genes 0.000 description 2
- 102100036474 Tryptophan 5-hydroxylase 2 Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 2
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 2
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 102100032026 Vesicle-associated membrane protein-associated protein B/C Human genes 0.000 description 2
- 102100020673 Visual system homeobox 1 Human genes 0.000 description 2
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 2
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 2
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 201000004525 Zellweger Syndrome Diseases 0.000 description 2
- 102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 201000009562 autosomal recessive limb-girdle muscular dystrophy type 2C Diseases 0.000 description 2
- 201000009561 autosomal recessive limb-girdle muscular dystrophy type 2D Diseases 0.000 description 2
- 208000033651 b subunit deficiency of factor XIII Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 108020001778 catalytic domains Proteins 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 208000003131 cerebrooculofacioskeletal syndrome 1 Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 208000015756 familial Alzheimer disease Diseases 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 238000012268 genome sequencing Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 208000007345 glycogen storage disease Diseases 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 102000049240 human PVALB Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 230000036438 mutation frequency Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 108091008581 nuclear androgen receptors Proteins 0.000 description 2
- 238000011330 nucleic acid test Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 102000045222 parkin Human genes 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical compound C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 102100028734 1,4-alpha-glucan-branching enzyme Human genes 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- 102100038028 1-phosphatidylinositol 3-phosphate 5-kinase Human genes 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JCJIZBQZPSZIBI-UHFFFAOYSA-N 2-[2,6-di(propan-2-yl)phenyl]benzo[de]isoquinoline-1,3-dione Chemical compound CC(C)C1=CC=CC(C(C)C)=C1N(C1=O)C(=O)C2=C3C1=CC=CC3=CC=C2 JCJIZBQZPSZIBI-UHFFFAOYSA-N 0.000 description 1
- DIDGPCDGNMIUNX-UUOKFMHZSA-N 2-amino-9-[(2r,3r,4s,5r)-5-(dihydroxyphosphinothioyloxymethyl)-3,4-dihydroxyoxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=S)[C@@H](O)[C@H]1O DIDGPCDGNMIUNX-UUOKFMHZSA-N 0.000 description 1
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 101710094518 4-aminobutyrate aminotransferase Proteins 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 101710087140 50S ribosomal protein L22, chloroplastic Proteins 0.000 description 1
- 102100036512 7-dehydrocholesterol reductase Human genes 0.000 description 1
- 101150020052 AADAT gene Proteins 0.000 description 1
- 101150092476 ABCA1 gene Proteins 0.000 description 1
- 108091022885 ADAM Proteins 0.000 description 1
- 102100028446 ADP-ribosylation factor-like protein 11 Human genes 0.000 description 1
- 101710184468 AF4/FMR2 family member 2 Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 1
- 102100036618 ATP-binding cassette sub-family A member 13 Human genes 0.000 description 1
- 102100033618 ATP-binding cassette sub-family A member 2 Human genes 0.000 description 1
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
- 102100032922 ATP-dependent 6-phosphofructokinase, muscle type Human genes 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 101150030271 AXIN1 gene Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000034012 Acid sphingomyelinase deficiency Diseases 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 244000202285 Acrocomia mexicana Species 0.000 description 1
- 235000003625 Acrocomia mexicana Nutrition 0.000 description 1
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 102000008161 Adenosine A3 Receptor Human genes 0.000 description 1
- 108010060261 Adenosine A3 Receptor Proteins 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 102100036006 Adenosine receptor A3 Human genes 0.000 description 1
- 102100020925 Adenosylhomocysteinase Human genes 0.000 description 1
- 102100032157 Adenylate cyclase type 10 Human genes 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 241000567147 Aeropyrum Species 0.000 description 1
- 101150029691 Aff2 gene Proteins 0.000 description 1
- 102100038154 Agouti-signaling protein Human genes 0.000 description 1
- 208000024341 Aicardi syndrome Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 208000036022 Alpers' disease Diseases 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 208000033337 Alpha-sarcoglycan-related limb-girdle muscular dystrophy R3 Diseases 0.000 description 1
- 206010068783 Alstroem syndrome Diseases 0.000 description 1
- 201000005932 Alstrom Syndrome Diseases 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 208000026833 Alzheimer disease 4 Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 208000003808 Amyloid Neuropathies Diseases 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 241000192542 Anabaena Species 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 description 1
- 108050009514 Antigen peptide transporter 1 Proteins 0.000 description 1
- 102100033715 Apolipoprotein A-I Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 241000207208 Aquifex Species 0.000 description 1
- 101100224343 Arabidopsis thaliana DOF2.5 gene Proteins 0.000 description 1
- 101100288434 Arabidopsis thaliana LACS2 gene Proteins 0.000 description 1
- 101100345345 Arabidopsis thaliana MGD1 gene Proteins 0.000 description 1
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 description 1
- 101100352184 Arabidopsis thaliana PIP5K1 gene Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000205046 Archaeoglobus Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 1
- 102100024081 Aryl-hydrocarbon-interacting protein-like 1 Human genes 0.000 description 1
- 108010074515 Arylalkylamine N-Acetyltransferase Proteins 0.000 description 1
- 101000690509 Aspergillus oryzae (strain ATCC 42149 / RIB 40) Alpha-glucosidase Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000007372 Ataxin-1 Human genes 0.000 description 1
- 108010032963 Ataxin-1 Proteins 0.000 description 1
- 102100021321 Ataxin-3 Human genes 0.000 description 1
- 102000007368 Ataxin-7 Human genes 0.000 description 1
- 108010032953 Ataxin-7 Proteins 0.000 description 1
- 102100020741 Atrophin-1 Human genes 0.000 description 1
- 108090000806 Atrophin-1 Proteins 0.000 description 1
- 102100032306 Aurora kinase B Human genes 0.000 description 1
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 description 1
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 description 1
- 208000035665 Autosomal dominant Charcot-Marie-Tooth disease type 2D Diseases 0.000 description 1
- 208000026553 Autosomal dominant optic atrophy, classic form Diseases 0.000 description 1
- 208000036075 Autosomal dominant tubulointerstitial kidney disease Diseases 0.000 description 1
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102100035682 Axin-1 Human genes 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101100434786 Bacillus sp amiE gene Proteins 0.000 description 1
- 101100368725 Bacillus subtilis (strain 168) tagF gene Proteins 0.000 description 1
- 201000005943 Barth syndrome Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 102100022794 Bestrophin-1 Human genes 0.000 description 1
- 102100034732 Beta-1,3-glucuronyltransferase LARGE1 Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 102100029334 Beta-crystallin A3 Human genes 0.000 description 1
- 102100030516 Beta-crystallin B1 Human genes 0.000 description 1
- 102100022549 Beta-hexosaminidase subunit beta Human genes 0.000 description 1
- 108010025544 Bleomycin hydrolase Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 206010048409 Brain malformation Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 208000010482 CADASIL Diseases 0.000 description 1
- 108700013048 CCL2 Proteins 0.000 description 1
- 102100031171 CCN family member 1 Human genes 0.000 description 1
- 101150017501 CCR5 gene Proteins 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101150063022 CHRD gene Proteins 0.000 description 1
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 1
- 108010035947 CPLX inhibitor Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 108091011896 CSF1 Proteins 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101000690445 Caenorhabditis elegans Aryl hydrocarbon receptor nuclear translocator homolog Proteins 0.000 description 1
- 101100017502 Caenorhabditis elegans hlh-3 gene Proteins 0.000 description 1
- 101100539485 Caenorhabditis elegans unc-86 gene Proteins 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100027557 Calcipressin-1 Human genes 0.000 description 1
- 102100033093 Calcium/calmodulin-dependent protein kinase type II subunit alpha Human genes 0.000 description 1
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 101000809436 Candida albicans Sterol O-acyltransferase 2 Proteins 0.000 description 1
- 101001110283 Canis lupus familiaris Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- 102100040999 Catechol O-methyltransferase Human genes 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 1
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 201000008958 Charcot-Marie-Tooth disease type 2D Diseases 0.000 description 1
- 241000191366 Chlorobium Species 0.000 description 1
- 241000088885 Chlorops Species 0.000 description 1
- 102100031065 Choline kinase alpha Human genes 0.000 description 1
- 241000588881 Chromobacterium Species 0.000 description 1
- 208000029448 Chylomicron retention disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100029057 Coagulation factor XIII A chain Human genes 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 101710082261 Competence-stimulating peptide Proteins 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 102100035436 Complement factor D Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 102000020856 Copper Transport Proteins Human genes 0.000 description 1
- 108091004554 Copper Transport Proteins Proteins 0.000 description 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 201000009343 Cornelia de Lange syndrome Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102100026359 Cyclic AMP-responsive element-binding protein 1 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102100039693 D-amino acid oxidase activator Human genes 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 101150046567 DAO gene Proteins 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 1
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 108010063593 DNA modification methylase SssI Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 1
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 1
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 1
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 1
- 101100421140 Danio rerio selenon gene Proteins 0.000 description 1
- 208000003471 De Lange Syndrome Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000605716 Desulfovibrio Species 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 102100023319 Dihydrolipoyl dehydrogenase, mitochondrial Human genes 0.000 description 1
- 102100022317 Dihydropteridine reductase Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100022825 Disintegrin and metalloproteinase domain-containing protein 22 Human genes 0.000 description 1
- 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010045061 Dysbindin Proteins 0.000 description 1
- 102000005611 Dysbindin Human genes 0.000 description 1
- 102100031918 E3 ubiquitin-protein ligase NEDD4 Human genes 0.000 description 1
- 101001003194 Eleusine coracana Alpha-amylase/trypsin inhibitor Proteins 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 101710100588 Erythroid transcription factor Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101100326871 Escherichia coli (strain K12) ygbF gene Proteins 0.000 description 1
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 108010082945 Eukaryotic Initiation Factor-2B Proteins 0.000 description 1
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 101150107205 FCGR2 gene Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 101150061264 FXR1 gene Proteins 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 201000007176 Factor XII Deficiency Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 description 1
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 description 1
- 108010027673 Fanconi Anemia Complementation Group C protein Proteins 0.000 description 1
- 102000010634 Fanconi Anemia Complementation Group E protein Human genes 0.000 description 1
- 108010077898 Fanconi Anemia Complementation Group E protein Proteins 0.000 description 1
- 102000012216 Fanconi Anemia Complementation Group F protein Human genes 0.000 description 1
- 108010022012 Fanconi Anemia Complementation Group F protein Proteins 0.000 description 1
- 108700026162 Fanconi Anemia Complementation Group L protein Proteins 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 102100034552 Fanconi anemia group M protein Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100032596 Fibrocystin Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102100036334 Fragile X mental retardation syndrome-related protein 1 Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000002234 Fryns syndrome Diseases 0.000 description 1
- 201000006813 Fukuyama congenital muscular dystrophy Diseases 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 241000611205 Fusarium oxysporum f. sp. lycopersici Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 102100023686 G protein-coupled receptor kinase 6 Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 101150002414 GLC3 gene Proteins 0.000 description 1
- 102100033452 GMP synthase [glutamine-hydrolyzing] Human genes 0.000 description 1
- 101710071060 GMPS Proteins 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000036893 GUCY2D-related dominant retinopathy Diseases 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 208000017462 Galactosialidosis Diseases 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 208000033136 Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5 Diseases 0.000 description 1
- 102100033713 Gamma-secretase subunit APH-1B Human genes 0.000 description 1
- 102100028260 Gamma-secretase subunit PEN-2 Human genes 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 241001135750 Geobacter Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100024008 Glycerol-3-phosphate acyltransferase 1, mitochondrial Human genes 0.000 description 1
- 102100039264 Glycogen [starch] synthase, liver Human genes 0.000 description 1
- 102100029481 Glycogen phosphorylase, liver form Human genes 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 101150089236 Grk2 gene Proteins 0.000 description 1
- 102100032191 Guanine nucleotide exchange factor VAV3 Human genes 0.000 description 1
- 102100025334 Guanine nucleotide-binding protein G(q) subunit alpha Human genes 0.000 description 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 102000000310 HNH endonucleases Human genes 0.000 description 1
- 108050008753 HNH endonucleases Proteins 0.000 description 1
- 241000204988 Haloferax mediterranei Species 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 241000266949 Hemiarius sona Species 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 102100039894 Hemoglobin subunit delta Human genes 0.000 description 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001058479 Homo sapiens 1,4-alpha-glucan-branching enzyme Proteins 0.000 description 1
- 101001025044 Homo sapiens 1-phosphatidylinositol 3-phosphate 5-kinase Proteins 0.000 description 1
- 101000985215 Homo sapiens 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101001083755 Homo sapiens 5-aminolevulinate synthase, erythroid-specific, mitochondrial Proteins 0.000 description 1
- 101000928720 Homo sapiens 7-dehydrocholesterol reductase Proteins 0.000 description 1
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 1
- 101000769457 Homo sapiens ADP-ribosylation factor-like protein 11 Proteins 0.000 description 1
- 101000833172 Homo sapiens AF4/FMR2 family member 2 Proteins 0.000 description 1
- 101100492429 Homo sapiens ASIP gene Proteins 0.000 description 1
- 101000929660 Homo sapiens ATP-binding cassette sub-family A member 13 Proteins 0.000 description 1
- 101000801645 Homo sapiens ATP-binding cassette sub-family A member 2 Proteins 0.000 description 1
- 101000800430 Homo sapiens ATP-binding cassette sub-family G member 8 Proteins 0.000 description 1
- 101000730838 Homo sapiens ATP-dependent 6-phosphofructokinase, muscle type Proteins 0.000 description 1
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 description 1
- 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 description 1
- 101000783645 Homo sapiens Adenosine receptor A3 Proteins 0.000 description 1
- 101000716952 Homo sapiens Adenosylhomocysteinase Proteins 0.000 description 1
- 101000775498 Homo sapiens Adenylate cyclase type 10 Proteins 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000924727 Homo sapiens Alternative prion protein Proteins 0.000 description 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 1
- 101000652582 Homo sapiens Antigen peptide transporter 2 Proteins 0.000 description 1
- 101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 description 1
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 1
- 101000833576 Homo sapiens Aryl-hydrocarbon-interacting protein-like 1 Proteins 0.000 description 1
- 101000895100 Homo sapiens Ataxin-3 Proteins 0.000 description 1
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 1
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 1
- 101001090662 Homo sapiens Beta-1,3-glucuronyltransferase LARGE1 Proteins 0.000 description 1
- 101000919139 Homo sapiens Beta-crystallin A3 Proteins 0.000 description 1
- 101000919505 Homo sapiens Beta-crystallin B1 Proteins 0.000 description 1
- 101001045433 Homo sapiens Beta-hexosaminidase subunit beta Proteins 0.000 description 1
- 101000984541 Homo sapiens Bleomycin hydrolase Proteins 0.000 description 1
- 101000777599 Homo sapiens C-C chemokine receptor type 2 Proteins 0.000 description 1
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
- 101000944249 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit alpha Proteins 0.000 description 1
- 101000793651 Homo sapiens Calreticulin Proteins 0.000 description 1
- 101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 description 1
- 101000983523 Homo sapiens Caspase-9 Proteins 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 description 1
- 101000777314 Homo sapiens Choline kinase alpha Proteins 0.000 description 1
- 101000918352 Homo sapiens Coagulation factor XIII A chain Proteins 0.000 description 1
- 101000737554 Homo sapiens Complement factor D Proteins 0.000 description 1
- 101000855516 Homo sapiens Cyclic AMP-responsive element-binding protein 1 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 101000915170 Homo sapiens Cytosolic 5'-nucleotidase 3A Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000886242 Homo sapiens D-amino acid oxidase activator Proteins 0.000 description 1
- 101000736065 Homo sapiens DNA replication complex GINS protein PSF2 Proteins 0.000 description 1
- 101000806846 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 description 1
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 description 1
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 1
- 101000902365 Homo sapiens Dihydropteridine reductase Proteins 0.000 description 1
- 101000756722 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 22 Proteins 0.000 description 1
- 101000832769 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 description 1
- 101000927562 Homo sapiens Dopamine beta-hydroxylase Proteins 0.000 description 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 1
- 101000848191 Homo sapiens E3 ubiquitin-protein ligase FANCL Proteins 0.000 description 1
- 101000636713 Homo sapiens E3 ubiquitin-protein ligase NEDD4 Proteins 0.000 description 1
- 101000925493 Homo sapiens Endothelin-1 Proteins 0.000 description 1
- 101000938351 Homo sapiens Ephrin type-A receptor 3 Proteins 0.000 description 1
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101000926508 Homo sapiens Eukaryotic translation initiation factor 2-alpha kinase 3 Proteins 0.000 description 1
- 101100119754 Homo sapiens FANCL gene Proteins 0.000 description 1
- 101100335685 Homo sapiens FXR2 gene Proteins 0.000 description 1
- 101000914673 Homo sapiens Fanconi anemia group A protein Proteins 0.000 description 1
- 101000914680 Homo sapiens Fanconi anemia group C protein Proteins 0.000 description 1
- 101000848187 Homo sapiens Fanconi anemia group M protein Proteins 0.000 description 1
- 101000730595 Homo sapiens Fibrocystin Proteins 0.000 description 1
- 101000930945 Homo sapiens Fragile X mental retardation syndrome-related protein 1 Proteins 0.000 description 1
- 101000829473 Homo sapiens G protein-coupled receptor kinase 6 Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101000733778 Homo sapiens Gamma-secretase subunit APH-1B Proteins 0.000 description 1
- 101000579663 Homo sapiens Gamma-secretase subunit PEN-2 Proteins 0.000 description 1
- 101000858024 Homo sapiens Gap junction alpha-8 protein Proteins 0.000 description 1
- 101000904268 Homo sapiens Glycerol-3-phosphate acyltransferase 1, mitochondrial Proteins 0.000 description 1
- 101001072736 Homo sapiens Glycine-tRNA ligase Proteins 0.000 description 1
- 101001036117 Homo sapiens Glycogen [starch] synthase, liver Proteins 0.000 description 1
- 101000700616 Homo sapiens Glycogen phosphorylase, liver form Proteins 0.000 description 1
- 101000775742 Homo sapiens Guanine nucleotide exchange factor VAV3 Proteins 0.000 description 1
- 101000857888 Homo sapiens Guanine nucleotide-binding protein G(q) subunit alpha Proteins 0.000 description 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 1
- 101000856513 Homo sapiens Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Proteins 0.000 description 1
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 description 1
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 101100086477 Homo sapiens KRAS gene Proteins 0.000 description 1
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 1
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 1
- 101000945492 Homo sapiens Killer cell immunoglobulin-like receptor 3DS1 Proteins 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000615657 Homo sapiens MAM domain-containing glycosylphosphatidylinositol anchor protein 2 Proteins 0.000 description 1
- 101000573901 Homo sapiens Major prion protein Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101001012669 Homo sapiens Melanoma inhibitory activity protein 2 Proteins 0.000 description 1
- 101001057159 Homo sapiens Melanoma-associated antigen C3 Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101001005550 Homo sapiens Mitogen-activated protein kinase kinase kinase 14 Proteins 0.000 description 1
- 101000615261 Homo sapiens Multiple coagulation factor deficiency protein 2 Proteins 0.000 description 1
- 101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 description 1
- 101000958866 Homo sapiens Myogenic factor 6 Proteins 0.000 description 1
- 101001030232 Homo sapiens Myosin-9 Proteins 0.000 description 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 1
- 101000603239 Homo sapiens Neuroligin-1 Proteins 0.000 description 1
- 101000603172 Homo sapiens Neuroligin-3 Proteins 0.000 description 1
- 101000996111 Homo sapiens Neuroligin-4, X-linked Proteins 0.000 description 1
- 101000974009 Homo sapiens Nitric oxide synthase, brain Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101000598160 Homo sapiens Nuclear mitotic apparatus protein 1 Proteins 0.000 description 1
- 101000582254 Homo sapiens Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 1
- 101001131829 Homo sapiens P protein Proteins 0.000 description 1
- 101000614405 Homo sapiens P2X purinoceptor 1 Proteins 0.000 description 1
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 description 1
- 101000601647 Homo sapiens Paired box protein Pax-6 Proteins 0.000 description 1
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 1
- 101000987578 Homo sapiens Peripherin Proteins 0.000 description 1
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 description 1
- 101000595674 Homo sapiens Pituitary homeobox 3 Proteins 0.000 description 1
- 101001126471 Homo sapiens Plectin Proteins 0.000 description 1
- 101001074439 Homo sapiens Polycystin-2 Proteins 0.000 description 1
- 101000836337 Homo sapiens Probable helicase senataxin Proteins 0.000 description 1
- 101001135385 Homo sapiens Prostacyclin synthase Proteins 0.000 description 1
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 1
- 101000892338 Homo sapiens Protein AF1q Proteins 0.000 description 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 1
- 101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 1
- 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 description 1
- 101000863978 Homo sapiens Protein downstream neighbor of Son Proteins 0.000 description 1
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 1
- 101100247605 Homo sapiens RCAN1 gene Proteins 0.000 description 1
- 101000665449 Homo sapiens RNA binding protein fox-1 homolog 1 Proteins 0.000 description 1
- 101001110286 Homo sapiens Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 1
- 101001110313 Homo sapiens Ras-related C3 botulinum toxin substrate 2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001075466 Homo sapiens Regulatory factor X-associated protein Proteins 0.000 description 1
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 1
- 101000742938 Homo sapiens Retinol dehydrogenase 12 Proteins 0.000 description 1
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 description 1
- 101000846336 Homo sapiens Ribitol-5-phosphate transferase FKTN Proteins 0.000 description 1
- 101001051706 Homo sapiens Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 101100257362 Homo sapiens SOX2 gene Proteins 0.000 description 1
- 101000873658 Homo sapiens Secretogranin-3 Proteins 0.000 description 1
- 101000683839 Homo sapiens Selenoprotein N Proteins 0.000 description 1
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 description 1
- 101000987315 Homo sapiens Serine/threonine-protein kinase PAK 3 Proteins 0.000 description 1
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101000783373 Homo sapiens Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform Proteins 0.000 description 1
- 101000783404 Homo sapiens Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform Proteins 0.000 description 1
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000755690 Homo sapiens Single-stranded DNA cytosine deaminase Proteins 0.000 description 1
- 101000631929 Homo sapiens Sodium-dependent serotonin transporter Proteins 0.000 description 1
- 101000881247 Homo sapiens Spectrin beta chain, erythrocytic Proteins 0.000 description 1
- 101000652369 Homo sapiens Spermatogenesis-associated protein 7 Proteins 0.000 description 1
- 101000663635 Homo sapiens Sphingosine kinase 1 Proteins 0.000 description 1
- 101000651197 Homo sapiens Sphingosine kinase 2 Proteins 0.000 description 1
- 101000629597 Homo sapiens Sterol regulatory element-binding protein 1 Proteins 0.000 description 1
- 101000617808 Homo sapiens Synphilin-1 Proteins 0.000 description 1
- 101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 description 1
- 101000625330 Homo sapiens T-cell acute lymphocytic leukemia protein 2 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 1
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 1
- 101000649068 Homo sapiens Tapasin Proteins 0.000 description 1
- 101000658622 Homo sapiens Testis-specific Y-encoded-like protein 2 Proteins 0.000 description 1
- 101000802084 Homo sapiens Thiosulfate sulfurtransferase Proteins 0.000 description 1
- 101000715050 Homo sapiens Thromboxane A2 receptor Proteins 0.000 description 1
- 101000785523 Homo sapiens Tight junction protein ZO-2 Proteins 0.000 description 1
- 101000894871 Homo sapiens Transcription regulator protein BACH1 Proteins 0.000 description 1
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 1
- 101000844518 Homo sapiens Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
- 101001057686 Homo sapiens Translation initiation factor eIF-2B subunit alpha Proteins 0.000 description 1
- 101001057681 Homo sapiens Translation initiation factor eIF-2B subunit beta Proteins 0.000 description 1
- 101000925982 Homo sapiens Translation initiation factor eIF-2B subunit delta Proteins 0.000 description 1
- 101000925985 Homo sapiens Translation initiation factor eIF-2B subunit epsilon Proteins 0.000 description 1
- 101001049688 Homo sapiens Translation initiation factor eIF-2B subunit gamma Proteins 0.000 description 1
- 101000631620 Homo sapiens Translocation protein SEC63 homolog Proteins 0.000 description 1
- 101000892398 Homo sapiens Tryptophan 2,3-dioxygenase Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 101000611185 Homo sapiens Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 1
- 101000807306 Homo sapiens Ubiquitin-like modifier-activating enzyme 1 Proteins 0.000 description 1
- 101000749634 Homo sapiens Uromodulin Proteins 0.000 description 1
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 description 1
- 101001104110 Homo sapiens X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Proteins 0.000 description 1
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 description 1
- 101000964425 Homo sapiens Zinc finger and BTB domain-containing protein 16 Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 102000016252 Huntingtin Human genes 0.000 description 1
- 108050004784 Huntingtin Proteins 0.000 description 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 101150034518 Iapp gene Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 201000004029 Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100025509 Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Human genes 0.000 description 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 description 1
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102100039068 Interleukin-10 Human genes 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000034613 Isolated polycystic liver disease Diseases 0.000 description 1
- 208000021548 Jervell and Lange-Nielsen syndrome Diseases 0.000 description 1
- 201000003992 Jervell-Lange Nielsen Syndrome Diseases 0.000 description 1
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 1
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
- 102100034833 Killer cell immunoglobulin-like receptor 3DS1 Human genes 0.000 description 1
- 102100036600 Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108010064700 L-arabinitol 4-dehydrogenase Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000012383 LAMA2-related muscular dystrophy Diseases 0.000 description 1
- 208000031905 Laminin subunit alpha 2-related muscular dystrophy Diseases 0.000 description 1
- 208000005906 Leber congenital amaurosis 3 Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 102100026038 Lens fiber membrane intrinsic protein Human genes 0.000 description 1
- 101710115990 Lens fiber membrane intrinsic protein Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
- 206010048911 Lissencephaly Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 description 1
- 206010057926 Long QT syndrome congenital Diseases 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 102100021319 MAM domain-containing glycosylphosphatidylinositol anchor protein 2 Human genes 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 208000024889 MECP2 duplication syndrome Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101001129124 Mannheimia haemolytica Outer membrane lipoprotein 1 Proteins 0.000 description 1
- 101150003941 Mapk14 gene Proteins 0.000 description 1
- 208000030162 Maple syrup disease Diseases 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108700020845 Medullary Cystic Kidney Disease 2 Proteins 0.000 description 1
- 102100029778 Melanoma inhibitory activity protein 2 Human genes 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010023338 Member 3 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010090822 Member 8 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 241000204675 Methanopyrus Species 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 241000589345 Methylococcus Species 0.000 description 1
- 206010051403 Mitochondrial DNA deletion Diseases 0.000 description 1
- 208000035155 Mitochondrial DNA-associated Leigh syndrome Diseases 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100025211 Mitogen-activated protein kinase kinase kinase 14 Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 208000033180 Monosomy 22q13.3 Diseases 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 208000008955 Mucolipidoses Diseases 0.000 description 1
- 206010072927 Mucolipidosis type I Diseases 0.000 description 1
- 206010072928 Mucolipidosis type II Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 102100021387 Multiple coagulation factor deficiency protein 2 Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100113998 Mus musculus Cnbd2 gene Proteins 0.000 description 1
- 101100144701 Mus musculus Drosha gene Proteins 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 101000834850 Mus musculus KICSTOR complex protein SZT2 Proteins 0.000 description 1
- 101100127196 Mus musculus Kera gene Proteins 0.000 description 1
- 101100078999 Mus musculus Mx1 gene Proteins 0.000 description 1
- 101100350582 Mus musculus Otx2 gene Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 102100038379 Myogenic factor 6 Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 102100038938 Myosin-9 Human genes 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 241000863420 Myxococcus Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010005529 N-acetylglutaminylglutamine amide Proteins 0.000 description 1
- 101710202061 N-acetyltransferase Proteins 0.000 description 1
- KLQXKYZBJWERSF-YUMQZZPRSA-N N2-Acetyl-L-glutaminyl-L-glutamamide Chemical compound NC(=O)CC[C@H](NC(=O)C)C(=O)N[C@@H](CCC(N)=O)C(N)=O KLQXKYZBJWERSF-YUMQZZPRSA-N 0.000 description 1
- 101150019103 NAT2 gene Proteins 0.000 description 1
- 102100031911 NEDD8 Human genes 0.000 description 1
- 108700004934 NEDD8 Proteins 0.000 description 1
- 101150107958 NEDD8 gene Proteins 0.000 description 1
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102100021867 Natural resistance-associated macrophage protein 2 Human genes 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 102000014413 Neuregulin Human genes 0.000 description 1
- 108050003475 Neuregulin Proteins 0.000 description 1
- 208000007382 Neurofibromatosis-Noonan syndrome Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 102100038992 Neuroligin-1 Human genes 0.000 description 1
- 102100038940 Neuroligin-3 Human genes 0.000 description 1
- 102100034441 Neuroligin-4, X-linked Human genes 0.000 description 1
- 101100058191 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) bcp-1 gene Proteins 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 241000605122 Nitrosomonas Species 0.000 description 1
- 108700002045 Nod2 Signaling Adaptor Proteins 0.000 description 1
- 101150083031 Nod2 gene Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 208000035544 Nonketotic hyperglycinaemia Diseases 0.000 description 1
- 102220559792 Notchless protein homolog 1_L43Q_mutation Human genes 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 102100036961 Nuclear mitotic apparatus protein 1 Human genes 0.000 description 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
- 102000002488 Nucleoplasmin Human genes 0.000 description 1
- 208000035023 Oculocerebrorenal syndrome of Lowe Diseases 0.000 description 1
- 101000761187 Odontomachus monticola U-poneritoxin(01)-Om1a Proteins 0.000 description 1
- 101100236423 Oryza sativa subsp. japonica MADS3 gene Proteins 0.000 description 1
- 101100532088 Oryza sativa subsp. japonica RUB2 gene Proteins 0.000 description 1
- 101100532090 Oryza sativa subsp. japonica RUB3 gene Proteins 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 101710189973 P2X purinoceptor 1 Proteins 0.000 description 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150068407 PRKACB gene Proteins 0.000 description 1
- 101150090652 PRKAR2A gene Proteins 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101000579647 Penaeus vannamei Penaeidin-2a Proteins 0.000 description 1
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 1
- 102100022369 Peripheral-type benzodiazepine receptor-associated protein 1 Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000004316 Perry syndrome Diseases 0.000 description 1
- 201000006880 Phelan-McDermid syndrome Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 108010064209 Phosphoribosylglycinamide formyltransferase Proteins 0.000 description 1
- 241000607568 Photobacterium Species 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 241000204826 Picrophilus Species 0.000 description 1
- 101100352419 Pithecopus hypochondrialis psn1 gene Proteins 0.000 description 1
- 102100036088 Pituitary homeobox 3 Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 108010054050 Plectin Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 102100036142 Polycystin-2 Human genes 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 102100025067 Potassium voltage-gated channel subfamily H member 4 Human genes 0.000 description 1
- 101710163352 Potassium voltage-gated channel subfamily H member 4 Proteins 0.000 description 1
- 101150008375 Pou4f1 gene Proteins 0.000 description 1
- 101150104557 Ppargc1a gene Proteins 0.000 description 1
- 108010036908 Presenilin-2 Proteins 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 101150004005 Prkaca gene Proteins 0.000 description 1
- 102100027178 Probable helicase senataxin Human genes 0.000 description 1
- 208000007932 Progeria Diseases 0.000 description 1
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102100033075 Prostacyclin synthase Human genes 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100040665 Protein AF1q Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 101710110949 Protein S100-A12 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102100027331 Protein crumbs homolog 1 Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 208000033876 Proximal Xq28 duplication syndrome Diseases 0.000 description 1
- 208000033522 Proximal spinal muscular atrophy type 2 Diseases 0.000 description 1
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
- 208000033550 Proximal spinal muscular atrophy type 4 Diseases 0.000 description 1
- 241000567197 Puccinia graminis f. sp. tritici Species 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 101710199540 RNA binding protein fox-1 homolog 1 Proteins 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 102100022129 Ras-related C3 botulinum toxin substrate 2 Human genes 0.000 description 1
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 description 1
- 102100025234 Receptor of activated protein C kinase 1 Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 108010044157 Receptors for Activated C Kinase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100024694 Reelin Human genes 0.000 description 1
- 108700038365 Reelin Proteins 0.000 description 1
- 102100021043 Regulatory factor X-associated protein Human genes 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 1
- 102100038054 Retinol dehydrogenase 12 Human genes 0.000 description 1
- 201000008539 Rhizomelic chondrodysplasia punctata type 1 Diseases 0.000 description 1
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 1
- 201000001718 Roberts syndrome Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 101150019520 SGCA gene Proteins 0.000 description 1
- 108091006618 SLC11A2 Proteins 0.000 description 1
- 102000005029 SLC6A3 Human genes 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 101150063267 STAT5B gene Proteins 0.000 description 1
- 101000825534 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S2 Proteins 0.000 description 1
- 101100170553 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) DLD2 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 101100294206 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fta4 gene Proteins 0.000 description 1
- 101100023124 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mfr2 gene Proteins 0.000 description 1
- 102100030053 Secreted frizzled-related protein 3 Human genes 0.000 description 1
- 102100023781 Selenoprotein N Human genes 0.000 description 1
- 241000252141 Semionotiformes Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 description 1
- 102100027911 Serine/threonine-protein kinase PAK 3 Human genes 0.000 description 1
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 description 1
- 102100036140 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform Human genes 0.000 description 1
- 102100036122 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform Human genes 0.000 description 1
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 description 1
- 102220520989 Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit alpha_K42T_mutation Human genes 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 description 1
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 1
- 101150028423 Slc6a4 gene Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 201000007410 Smith-Lemli-Opitz syndrome Diseases 0.000 description 1
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102100037613 Spectrin beta chain, erythrocytic Human genes 0.000 description 1
- 102100030257 Spermatogenesis-associated protein 7 Human genes 0.000 description 1
- 102100039024 Sphingosine kinase 1 Human genes 0.000 description 1
- 102100027662 Sphingosine kinase 2 Human genes 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000205101 Sulfolobus Species 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 101710140334 Synphilin-1 Proteins 0.000 description 1
- 102100029454 T cell receptor alpha chain MC.7.G5 Human genes 0.000 description 1
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 102100025039 T-cell acute lymphocytic leukemia protein 2 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 1
- 108700012457 TACSTD2 Proteins 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 101150115335 TPH2 gene Proteins 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 102000003627 TRPC1 Human genes 0.000 description 1
- 101150017559 TRPC1 gene Proteins 0.000 description 1
- 102000003621 TRPC5 Human genes 0.000 description 1
- 101150042815 TRPC5 gene Proteins 0.000 description 1
- 102000003623 TRPC6 Human genes 0.000 description 1
- 102000003611 TRPM7 Human genes 0.000 description 1
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 1
- 101150117918 Tacstd2 gene Proteins 0.000 description 1
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 102100034917 Testis-specific Y-encoded-like protein 2 Human genes 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 241000186339 Thermoanaerobacter Species 0.000 description 1
- 241000204667 Thermoplasma Species 0.000 description 1
- 241000204652 Thermotoga Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102100036704 Thromboxane A2 receptor Human genes 0.000 description 1
- 102100026637 Tight junction protein ZO-2 Human genes 0.000 description 1
- 241000283907 Tragelaphus oryx Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 1
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 1
- 102100027065 Translation initiation factor eIF-2B subunit beta Human genes 0.000 description 1
- 102100034266 Translation initiation factor eIF-2B subunit delta Human genes 0.000 description 1
- 102100034267 Translation initiation factor eIF-2B subunit epsilon Human genes 0.000 description 1
- 102100023225 Translation initiation factor eIF-2B subunit gamma Human genes 0.000 description 1
- 102100029006 Translocation protein SEC63 homolog Human genes 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
- 101150044377 UBA1 gene Proteins 0.000 description 1
- 101150035006 UBA3 gene Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100037160 Ubiquitin-like modifier-activating enzyme 1 Human genes 0.000 description 1
- 102100040613 Uromodulin Human genes 0.000 description 1
- 208000014769 Usher Syndromes Diseases 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101710177612 Very low-density lipoprotein receptor Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 101150115477 Vldlr gene Proteins 0.000 description 1
- 101150112441 Vsx1 gene Proteins 0.000 description 1
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 description 1
- 101150010310 WNT-4 gene Proteins 0.000 description 1
- 101150019524 WNT2 gene Proteins 0.000 description 1
- 201000006793 Walker-Warburg syndrome Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 108700020986 Wnt-2 Proteins 0.000 description 1
- 102000052556 Wnt-2 Human genes 0.000 description 1
- 102000052548 Wnt-4 Human genes 0.000 description 1
- 108700020984 Wnt-4 Proteins 0.000 description 1
- 241000605941 Wolinella Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 102100040089 X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Human genes 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 101000678336 Xenopus laevis Actin, alpha skeletal muscle 2 Proteins 0.000 description 1
- 101000678338 Xenopus tropicalis Actin, alpha cardiac muscle 2 Proteins 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 201000006960 adult spinal muscular atrophy Diseases 0.000 description 1
- 208000025531 adult-onset foveomacular vitelliform dystrophy Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000009418 agronomic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 102000009899 alpha Karyopherins Human genes 0.000 description 1
- 108010077099 alpha Karyopherins Proteins 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 201000008333 alpha-mannosidosis Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 101150011965 ami gene Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 101150089041 aph-1 gene Proteins 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000030757 autosomal dominant osteopetrosis Diseases 0.000 description 1
- 208000021033 autosomal dominant polycystic liver disease Diseases 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 201000001038 autosomal recessive chronic granulomatous disease cytochrome b-positive type II Diseases 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 101150117416 cas2 gene Proteins 0.000 description 1
- 201000009847 cataract 14 multiple types Diseases 0.000 description 1
- 201000009853 cataract 16 multiple types Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 108010008846 chordin Proteins 0.000 description 1
- 102000006533 chordin Human genes 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000035110 classic form autosomal dominant optic atrophy Diseases 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000003536 colpocephaly Diseases 0.000 description 1
- 238000002742 combinatorial mutagenesis Methods 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 201000006754 cone-rod dystrophy Diseases 0.000 description 1
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 description 1
- 201000000440 cone-rod dystrophy 6 Diseases 0.000 description 1
- 201000000398 cone-rod dystrophy 9 Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000003046 cornea plana Diseases 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 101150064416 csp1 gene Proteins 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108091000099 cysteine desulfurase Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 1
- 201000007386 factor VII deficiency Diseases 0.000 description 1
- 208000005376 factor X deficiency Diseases 0.000 description 1
- 201000007219 factor XI deficiency Diseases 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 208000002153 familial abdominal 3 aortic aneurysm Diseases 0.000 description 1
- 201000007249 familial juvenile hyperuricemic nephropathy Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 201000008049 fucosidosis Diseases 0.000 description 1
- 101150045500 galK gene Proteins 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 201000011205 glycine encephalopathy Diseases 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 101150055960 hemB gene Proteins 0.000 description 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000057382 human EPHA3 Human genes 0.000 description 1
- 102000047119 human OCA2 Human genes 0.000 description 1
- 102000047444 human SOX2 Human genes 0.000 description 1
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
- 208000018949 hyper-IgM syndrome type 2 Diseases 0.000 description 1
- 208000025762 hyper-IgM syndrome type 4 Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 201000001373 immunodeficiency with hyper-IgM type 2 Diseases 0.000 description 1
- 201000001399 immunodeficiency with hyper-IgM type 4 Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000010194 infantile onset spinocerebellar ataxia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 201000006913 intermediate spinal muscular atrophy Diseases 0.000 description 1
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 1
- 235000000396 iron Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 208000008106 junctional epidermolysis bullosa Diseases 0.000 description 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 208000014817 lissencephaly spectrum disease Diseases 0.000 description 1
- 102000004311 liver X receptors Human genes 0.000 description 1
- 108090000865 liver X receptors Proteins 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000000415 mammalian chromosome Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 208000024393 maple syrup urine disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 101150091534 mauC gene Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 201000011561 mitochondrial DNA depletion syndrome 7 Diseases 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 101150036168 ncstn gene Proteins 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000046701 nicastrin Human genes 0.000 description 1
- 108700022821 nicastrin Proteins 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 108060005597 nucleoplasmin Proteins 0.000 description 1
- 201000006352 oculocerebrorenal syndrome Diseases 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 201000008152 organic acidemia Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 201000001937 osteoporosis-pseudoglioma syndrome Diseases 0.000 description 1
- 101150029755 park gene Proteins 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 208000023269 peroxisome biogenesis disease Diseases 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108010034343 phosphoribosylamine-glycine ligase Proteins 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 238000003976 plant breeding Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 201000001204 progressive myoclonus epilepsy Diseases 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 201000006956 rigid spine muscular dystrophy 1 Diseases 0.000 description 1
- 101150024074 rub1 gene Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000010532 sarcoglycanopathy Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 108090000250 sortase A Proteins 0.000 description 1
- 230000004137 sphingolipid metabolism Effects 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000031906 susceptibility to X-linked 2 autism Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 108010059434 tapasin Proteins 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 101150075675 tatC gene Proteins 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 208000016094 thanatophoric dysplasia type 1 Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- KOECRLKKXSXCPB-UHFFFAOYSA-K triiodobismuthane Chemical compound I[Bi](I)I KOECRLKKXSXCPB-UHFFFAOYSA-K 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OHOTVSOGTVKXEL-UHFFFAOYSA-K trisodium;2-[bis(carboxylatomethyl)amino]propanoate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C(C)N(CC([O-])=O)CC([O-])=O OHOTVSOGTVKXEL-UHFFFAOYSA-K 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 208000032521 type II spinal muscular atrophy Diseases 0.000 description 1
- 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
- 208000005606 type IV spinal muscular atrophy Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 208000030954 urea cycle disease Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Definitions
- the present invention generally relates to systems, methods and compositio s used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that may use vector systems related to Clustered Regularly Interspaced Short Palindromic Repeats (CRJSPR) and components thereof,
- sequence targeting such as genome perturbation or gene-editing
- CRJSPR Clustered Regularly Interspaced Short Palindromic Repeats
- the CRISPR/Cas or the CRISPR-Cas system does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target, in other words the Cas enzyme can be recruited to a specific DNA target using said short RNA molecule.
- Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases.
- the invention provides a vector system comprising one or more vectors.
- the system comprises: (a) a first regulatory element operabl linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme compiexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence; wherein components (a) and (b) are located on the same or different vectors of the system, Irs some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control
- component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell.
- the system comprises the tracr sequence under the control of a third regulatory element, such as a polymerase III promoter.
- the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. Determining optimal alignment is within the purview of one of skill in the art.
- the CRISPR complex comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR complex in a detectable amount in the nucleus of a eukaryotic cell.
- a nuclear localization sequence is not necessary for CRISPR complex activity in eukaryotes, but that including such sequences enhances activity of the system, especially as to targeting nucleic acid .molecules in the nucleus.
- the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is 5. pneumoniae, S, pyogenes, or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homoiog or ortholog. In some embodiments, the CRISPR enzyme is codon- optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity.
- the first regulatory element is a polymerase III promoter.
- the second regulatory element is a polymerase II promoter.
- the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15- 20 nucleotides in length.
- vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partial ly double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g.
- vectors refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques.
- viral vector e.g. retroviruses, replication defective retroviruses, adenoviruses, replication detective adenoviruses, and adeno-associated viruses.
- Viral vectors also include polynucleotides carried by a vims for transfection into a host cell.
- vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors.” Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
- Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means thai the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed.
- operbl linked is intended to mean that the nucleotide sequence of interest is linked to the regulatory elemeiit(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host ceil).
- regulatory element is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poiy-U sequences).
- regulatory- elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990).
- Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host ceil and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulator ⁇ ' sequences).
- a tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal -dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific.
- a vector comprises one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g.
- pol III promoters include, but are not limited to, U6 and HI promoters.
- pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with, the CMV enhancer) [see, e.g., Boshart et al, Cell, 41 :521-530 (1985)], the SV40 promoter, the dihydro folate reductase promoter, the ⁇ -actin promoter, the piiosphoglycerol kinase (PGK) promoter, and the EFla promoter.
- RSV Rous sarcoma virus
- CMV cytomegalovirus
- PGK piiosphoglycerol kinase
- enhancer elements such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Mol. Cell. Biol, Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit ⁇ -globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31 , 1981).
- WPRE WPRE
- CMV enhancers the R-U5' segment in LTR of HTLV-I
- SV40 enhancer SV40 enhancer
- the intron sequence between exons 2 and 3 of rabbit ⁇ -globin Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31 , 1981.
- a vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).
- CRISPR clustered regularly interspersed short palindromic repeats
- Advantageous vectors include lentiviruses and adeno-assoeiated viruses, a d types of such vectors can al so be selected for targeting particul ar types of cells.
- the invention provides a vector comprising a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising one or more nuclear localization sequences.
- said regulatory element drives transcription of the CRISPR enzyme in a eukaryotic cell such that said CRISPR enzyme accumulates in a detectable amount in the nucleus of the eukaryotic cell.
- the regulatory element is a polymerase II promoter.
- the CRISPR enzyme is a type II CRISPR system enzyme.
- the CRISPR enzyme is a Cas9 enzyme.
- the Cas9 enzyme is 5. pneumoniae, S. pyogenes or S.
- thermophilus Cas9 and may include mutated Cas9 derived from these organisms.
- the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell.
- the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence.
- the CRISPR enzyme lacks DNA strand cleavage activity.
- the invention provides a CRISPR enzyme comprising one or more uclear localization sequences of sufficient stre gth to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell.
- the CRISPR enzyme is a type II CRISPR system enzyme.
- the CRISPR enzyme is a Cas9 enzyme.
- the Cas9 enzyme is S. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms.
- the enzyme may be a Cas9 homolog or ortholog.
- the CRISPR e zyme lacks the ability to cleave one or more strands of a target sequence to which it binds.
- the invention provides a eukarvotic host cell comprising (a) a first regulatory element operably linked to a tract mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR comple to a target sequence in a eukar otie cell, wherein the CRISPR complex comprises a CRISPR enzyme compiexed with (1) the guide sequence that is hybridized to the target sequence, a d (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence.
- the host cell comprises components (a) and (b).
- component (a), component (b), or components (a) and (b) are stably integrated into a genome of the host eukaryotie cell.
- component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element.
- component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotie cell.
- the eukaryotie host cell further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence.
- the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence com lementarity along the length of the tracr mate sequence when optimally aligned.
- the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotie ceil.
- the CRISPR enzyme is a type ⁇ CRISPR system enzyme.
- the CRISPR enzyme is a Cas9 enzyme.
- the Cas9 enzyme is 5. pneumoniae, S. pyogenes or S, thermophilus Cas9, and may include mutated Cas9 derived from these organisms.
- the enzyme may be a Cas9 homolog or ortholog.
- the CRISPR enzyme is codon -optimized for expression in a eukarvotic cell.
- the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence.
- the CRISPR enzyme lacks DNA strand cleavage activity.
- the first regulatory element is a polymerase ( If promoter.
- the second regulatory element is a polymerase II promoter.
- the guide seque ce is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15- 20 nucleotides in length.
- the invention provides a non-human eukaryotic organism; preferably a multicellular eukaryotie organism, comprising a eukaryotic host cell according to any of the described embodiments.
- the invention provides a eukaryotic organism; preferably a multicellular eukaryotie organism, comprising a eukaryotic host cell according to any of the described embodiments.
- the organism in some embodiments of these aspects may be an animal; for example a mammal. Also, the organism may be an arthropod such as an insect. The organism also may be a plant. Further, the organism may be a fungus.
- the invention provides a kit comprising one or more of the components described herein.
- the kit comprises a vector system and instructions for using the kit.
- the vector system comprises (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR comple to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR.
- the kit comprises components (a) and (b) located on the same or different vectors of the system.
- component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element.
- component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell.
- the system further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence.
- the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.
- the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell.
- the CRISPR enzyme is a type II CRISPR system enzyme
- the CRISP R enzyme is a Cas9 enzyme.
- the Cas9 enzyme is S. pneumoniae, S. pyogenes or S.
- thermophilus Cas9 and may include mutated Cas9 derived from these organisms.
- the enzyme may be a Cas9 homolog or ortholog.
- the CRISPR enzyme is codo -optimized for expression in a eukaryotic cell.
- the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence.
- the CRISPR enzyme lacks DNA strand cleavage activity.
- the first regulatory element is a polymerase III promoter.
- the second regulatory element is a polymerase II promoter.
- the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length.
- the invention provides a method of modifying a target polynucleotide in a eukaryotic cell.
- the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
- said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence.
- the method further comprises delivering one or more vectors to said eukaryotic cell, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.
- said vectors are delivered to the eukaryotic cell in a subject.
- said modifying takes place in said eukaryotic cell in a cell culture.
- the method further comprises isolating said eukaryotic cell from a subject prior to said modifying.
- the method further comprises returning said eukaryotic cell and/or cells derived therefrom to said subject.
- the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell.
- the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
- the method further comprises delivering one or more vectors to said eukaryotic cel ls, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.
- the invention provides a method of generating a model eukaryotic cell comprising a mutated disease gene
- a disease gene is any gene associated an increase in the risk of having or developing a disease.
- the method comprises (a) introducing one or more vectors into a eukaryotic cell, wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and (b) allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said disease gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, thereby generating a model eukaryotic
- said cleavage results in decreased transcription of a target gene.
- the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide.
- said mutation results in one or more amino acid changes in a protein expression from a gene comprising the target sequence.
- a disease gene is any gene associated an increase in the risk of having or developing a disease.
- the method comprises (a) contacting a test compound wit a model cell of any one of the described embodiments; and (b) detecting a change in a readout that is indicative of a reduction or a augmentation of a ceil signaling event associated with said mutation in said disease gene, thereby developing said biologically active agent that modulates said cell signaling event associated with said disease gene.
- the invention provides a recombinant polynucleotide comprising a guide sequence upstream of a tracr mate sequence, wherein the guide sequence when expressed directs sequence-specific binding of a CRJSPR complex to a corresponding target sequence present in a eukaryotic cell.
- the target sequence is a viral sequence present in a eukaryotic cell.
- the target sequence is a proto-oncogene or an oncogene.
- the invention provides for a method of selecting one or more prokaryotic cell(s) by introducing one or more mutations in a gene in the one or more prokaryotic cel l (s), the method comprising: introducing one or more vectors into the prokaryotic cell (s), wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, a tracr sequence, and a editing template; wherein the editing template comprises the one or more mutations that abolish CRISPR enzyme cleavage; al lowing homologous recombination of the editing template with the target polynucleotide in the cell(s) to be selected; allowing a CRJSPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said gene, wherein the CRJSPR complex comprises the CRJSPR enzyme complexed with (1) the guide sequence that is hybridized
- the CRJSPR enzyme is Cas9.
- the cell to be selected may be a eukaryotic cell. Aspects of the invention allow for selection of specific cells without requiring a selection marker or a two-step process that may include a counter-selection system. [0022] Accordingly, it is an object of the invention not to encompass within the invention any previously known product, process of making the product, or method of using the product- such that Applicants reserve the right and hereby disclose a disclaimer of any previously known product, process, or method.
- the invention does not intend to encompass within the scope of the invention any product, process, or making of the product or method of using the product, which does not meet the written description and enablement requirements of the USPTO (35 U.S.C. ⁇ 1 12, first paragraph) or the EPO (Article 83 of the EPC), such that Applicants reserve the right and hereby disclose a disclaimer of any previously described product, process of making the product, or method of using the product,
- FIG. 1 shows a schematic model of the CRISPR system.
- the Cas9 nuclease from Streptococcus pyogenes (yellow) is targeted to genomic DNA by a synthetic guide RNA (sgRNA) consisting of a 20-nt guide sequence (blue) and a scaffold (red).
- the guide sequence base-pairs with the DNA target (blue), directly upstream of a requisite 5 '-NGG protospacer adjacent motif (PAM; magenta), and Cas9 mediates a double-stranded break (DSB) ⁇ 3 bp upstream of the PAM (red triangle).
- Figure 2A-F shows an exemplary CRISPR system, a possible mechanism of action, an example adaptation for expression in eukaryotie cells, and results of tests assessing nuclear localization and CRISPR activity.
- Figure 3 shows an exemplary expression cassette for expression of CRISPR system elements in eukaryotie cells, predicted structures of example guide sequences, and CRISPR system activity as measured in eukaryotie and prokaryotic cells.
- Figure 4A-0 shows results of an evaluation of SpCas9 specificity for an example target.
- Figure 5A-G show an exemplary vector system and results for its use in directing homologous recombination in eukaryotie ceils.
- Figure 6 provides a table of protospacer sequences and summarizes modification efficiency results for protospacer targets designed based on exemplary S. pyogenes and S. thermophilus CRISPR systems with corresponding PAMs against loci in human and mouse genomes.
- Figure 7A-C shows a comparison of different iracrRNA transcripts for Cas9- mediated gene targeting.
- Figure 8 shows a schematic of a surveyor nuclease assay for detection of double strand break-induced micro-insertions and -deletions.
- Figure 9A-B shows exemplary bicistronic expression vectors for expression of CRISPR system elements in eukaryotie cells.
- Figure 10 shows a bacterial plasmid transformation interference assay, expression cassettes and plasmids used therein, and transformation efficiencies of cells used therein.
- Figure llA-C shows histograms of distances between adjacent S. pyogenes SF370 locus I PAM (NGG) ( Figure 10A) and S. thermophilus LMD9 locus 2 PA..VI (NNAGAAW) ( Figure 10B) in the human genome; and distances for each PAM by chromosome (Chr) ( Figure IOC).
- Figure 12A-C shows an exemplary CRISPR system, an example adaptation for expression in eukaryotie cells, and results of tests assessing CRISPR activity.
- Figure 13A-C shows exemplary manipulations of a CRISPR system for targeting of genomic loci in mammalian cells.
- Figure 14A-B shows the results of a Northern blot analysis of erRNA processing in mammalian cel ls.
- Figure 15 shows an exemplary selection of protospacers in the human PVALB and mouse Th loci.
- Figure J 6 shows example protospacer and corresponding PAM sequence targets of the S. thermophilus CRISPR system in the human EMX1 locus.
- Figure 17 provides a table of sequences for primers and probes used for Surveyor, RFLP, genomic sequencing, and Northern blot assays.
- Figure 18A-C shows exemplary manipulation of a CRISPR system with chimeric RNAs and results of SURVEYOR assays for system activity in eukaryotic cells.
- Figure 19A-B shows a graphical representation of the results of SURVEYOR assays for CRJSPR system activity in eukaryotic cells.
- Figure 20 shows an exemplary visualization of some S. pyogenes Cas9 target sites in the human genome using the i CSC genome browser.
- Figure 21 shows predicted secondary structures for exemplary chimeric RNAs comprising a guide sequence, tracr mate sequence, and tracr sequence.
- Figure 22 shows exemplaiy bicistronic expression vectors for expression of CRISPR system elements in eukaryotic cells.
- FIG. 23 shows that Cas9 nuclease activity against endogenous targets may be exploited for genome editing
- the CRISPR targeting construct directed cleavage of a chromosomal locus and was co -transformed with an editing template that recombined with the target to prevent cleavage.
- Kanamycin- resistant transformants that survived CRISPR attack contained modifications introduced by the editing template, tracr, ir ws-activating CRISPR RNA; aphA-3, kanamycin resistance gene,
- Figure 24 shows analysis of PAM and seed sequences that eliminate Cas9 cleavage, (a) PCR products with randomized PAM sequences or randomized seed sequences were transformed in crR6 cells. These cells expressed Cas9 loaded with a crRNA that targeted a chromosomal region of R6' "" " "J ceils (highlighted in pink) that is absent from the R6 genome. More than 2* 105 chloramphenicoi-resistant transformants, carrying inactive PAM or seed sequences, were combined for amplification and deep sequencing of the target region, (b) Relative proportion of number of reads after transformation of the random PAM constructs in crR6 cells (compared to number of reads in R6 transformants).
- the relative abundance for each 3 -nucleotide PAM sequence is shown. Severely underrepresented sequences (NGG) are shown in red; partially underrepresented one in orange ( NAG) (c) Relative proportion of number of reads after transformation of the random seed sequence constmcts in crR6 ceils (compared to number of reads in R6 transformants). The relative abundance of each nucleotide for each position of the first 20 nucleotides of the protospacer sequence is shown. High abundance indicates lack of cleavage by Cas9, i.e. a CRISPR inactivating mutation. The grey line shows the level of the WT sequence. The dotted line represents the level above which a mutation significantly disrupts cleavage (See section "Analysis of deep sequencing data" in Example 5)
- Figure 25 shows introduction of single and multiple mutations using the CRISPR system in S. pneumoniae, (a) Nucleotide and amino acid sequences of the wild-type and edited (green nucleotides; underlined amino acid residues) bgaA. The protospacer, PAM and restriction sites are shown, (b) Transformation efficiency of ceils transformed with targeting constmcts in the presence of an editing template or control, (c) PCR analysis for 8 transformants of each editing experiment followed by digestion with BtgZI (R ⁇ A) and Tsel (NE ⁇ AA).
- bgaA Deletion of bgaA was revealed as a smaller PCR product, (d) Miller assay to measure the ⁇ -galactosidase activity of WT and edited strains, (e) For a single-step, double deletion the targeting construct contained two spacers (in this case matching srtA and bgaA) and was co-transformed with two different editing templates (f) PCR analysis for 8 transformants to detect deletions in srtA and bgaA loci. 6/8 transformants contained deletions of both genes.
- Figure 26 provides mechanisms underlying editing using the CRISPR system
- a stop codon was introduced in the erythromycin resistance gene ermAM to generate strain JENS 3.
- the wild-type sequence can be restored by targeting the stop codon with the CRISPR: :ermA (stop) construct, and using the ermAM wild-type sequence as an editing template
- (b) Mutant and wild-type ermAM sequences (c) Fraction of erythromicyn-resistant (erm R ) cfu calculated from total or kanamyci -resistant (kan R ) cfu.
- FIG. 27 illustrates ge ome editing with the CRISPR system i E. coli.
- a kanamycin-resistant plasmid carrying the CRISPR array (pCRISPR) targeting the gene to edit may be transformed in the HME63 reeombineering strain containing a chloramphenicol-resistant plasmid harboring cas9 and tracr (pCas9), together with an oligonucleotide specifying the mutation,
- pCas9 chloramphenicol-resistant plasmid harboring cas9 and tracr
- pCas9 chloramphenicol-resistant plasmid harboring cas9 and tracr
- pCas9 chloramphenicol-resistant plasmid harboring cas9 and tracr
- strep R Fraction of streptomicyn-resistant (strep R ) cfu calculated from total or kanamycin- resistant (kan R ) cfu.
- FIG. 28 illustrates the transformation of crR6 genomic DNA leads to editing of the targeted locus
- the IS 1167 element of S. pneumoniae R6 was replaced by the CRISPROl locus of S. pyogenes SF370 to generate crR6 strain.
- This locus encodes for the Cas9 nuclease, a CRISPR array with six spacers, the tracrRNA that is required for crRNA biogenesis and Casl , Cas2 and Csn2, proteins not necessary for targeting.
- Strain crR6M contains a minimal functional CRISPR system without casl, casl and csn2.
- the aphA-3 gene encodes kanamycin resistance.
- Protospacers from the streptococcal bacteriophages ⁇ 8232.5 and ⁇ 370.1 were fused to a chloramphenicol resistance gene (cat) and integrated, in the srtA gene of strain R6 to generate strains R68232.5 and R6370.1.
- Right panel PCR analysis of 8 R6 823 transformants with crR6 genomic DNA. Primers that amplify the srtA locus were used for PCR.
- Figure 30 illustrates CRISPR immunity against random S. pneumoniae targets containing different PAMs.
- FIG 31 provides a general scheme for targeted genome editing.
- crR6M was further engineered to contain tracrRNA, Cas9 and only one repeat of the CRISPR array followed by kanamycin resistance marker (aphA-3), generating strain crR6Rk.
- DNA from this strain is used as a template for PCR with primers designed to introduce a new spacer (green box designated with N).
- the left and right PCRs are assembled using the Gibson method to create the targeting construct.
- Both the targeting and editing constructs are then transformed into strain crR6Rc, which is a strain equivalent to crR6Rk but has the kanamycin resistance marker replaced by a chloramphenicol resistance marker (cat).
- Figure 33 illustrates CRISPR-mediated editing of the ermAM locus using genomic DNA as targeting construct.
- genomic DNA To use genomic DNA as targeting construct it is necessary to avoid CRISPR autoimmunity, and therefore a spacer against a sequence not present in the chromosome must be used (in this case the ermAM erythromycin resistance gene), (a) Nucleotide and amino acid sequences of the wild-type and mutated (red letters) ermAM gene. The protospacer and PAM sequences are shown, (b) A schematic for CRISPR-mediated editing of the ermAM locus using genomic DNA.
- a construct carrying an ermvl -targeting spacer (blue box) is made by PCR and Gibson assembly, and transformed into strain crR6Rc, generating strain JEN37.
- the genomic DNA of JEN37 was then used as a targeting construct, and was co-transformed with the editing template into JEN38, a strain in which the srtA gene was replaced by a wild-type copy of ermAM.
- Kanamycin-resistant transformants contain the edited genotype (JEN43).
- Figure 34 illustrates sequential introduction of mutations by CRISPR-mediated genome editing
- R6 is engineered to generate crR6Rk.
- crR6Rk is co-transformed with a srtA -targeting construct fused to cat for chloramphenicol selection of edited cells, along with an editing construct for a AsrtA in-frame deletion.
- Strain crR6 AsrtA is generated by selection on chlramphenicol.
- the AsrtA strain is co-transformed with a bgaA -targeting construct fused to aphA-3 for kanamycin selection of edited cells, and an editing construct containing a AbgaA in-frame deletion.
- the engineered CRISPR locus can be erased from plasmid carrying a bgaA protospacer (pDB97), and selection on spectinomycin.
- pDB97 bgaA protospacer
- ⁇ -galactosidase activity as measured by Miller assay. In S. pneumoniae, this enzyme is anchored to the cell wall by sortase A.
- Figure 35 illustrates the background mutation frequency of CRISPR in S. pneumoniae,
- the difference in kan R CFU between CRISPR::0 and CRISPR: :erm(stop) indicates that Cas9 cleavage kills non-edited cells. Mutants that escape CRISPR interference in the absence of editing template are observed at a frequency of 3x l0- 3 .
- Figure 36 illustrates that the essential elements of the S. pyogenes CRISPR locus 1 are reconstituted in E. coli using pCas9.
- the plasmid contained tracrRNA, Cas9, as well as a leader sequence driving the crRNA array.
- the pCRISPR plasmids contained the leader and the array only. Spacers may be inserted into the crRNA array between Bsal sites using annealed oligonucleotides. Oligonucleotide design is shown at bottom.
- pCas9 carried chloramphenicol resistance (CmR) and is based on the low-copy pACYC184 plasmid backbone.
- CmR chloramphenicol resistance
- pCRISPR is based on the high-copy number pZE21 plasmid. Two plasmids were required because a pCRISPR plasmid containing a spacer targeting the E. coli chromosome may not be constructed using this organism as a cloning host if Cas9 is also present (it will kill the host).
- FIG 37 illustrates CRISPR-directed editing in E.coli MG1655.
- An oligonucleotide (W542) carrying a point mutation that both confers streptomycin resistance and abolishes CRISPR immunity, together with a plasmid targeting rpsL (pCRISPR: :rpsL) or a control plasmid (pCRISPR::0) were co-transformed into wild-type E.coli strain MG1655 containing pCas9. Transformants were selected on media containing either streptomycin or kanamycin. Dashed line indicates limit of detection of the transformation assay.
- Figure 38 illustrates the background mutation frequency of CRISPR in E. coli ⁇ : ⁇ 63.
- Figure 39A-D shows a circular depiction of the phylo genetic analysis revealing five families of Cas9s, including three groups of large Cas9s (- 1400 amino acids) and two of small Cas9s ( ⁇ 1100 amino acids),
- Figure 40A-F shows the linear depiction of the phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (-1400 amino acids) and two of small Cas9s ( ⁇ 1 100 amino acids).
- Figure 41A-M shows sequences where the mutation points are located within the SpCas9 gene.
- Figure 42 shows a schematic construct in which the transcriptional activation domain (VP64) is fused to Cas9 with two mutations in the catalytic domains (D10 and H840).
- Figure 43A-D shows genome editing via homologous recombination
- (a) Schematic of SpCas9 nickase, with D10A mutation in the RuvC I catalytic domain (b) Schematic representing homologous recombination (HR) at the human EMXl locus using either sense or antisense single stranded oligonucleotides as repair templates.
- Red arrow above indicates sgRNA cleavage site; PCR primers for genotyping (Tables J and ) are indicated as arrows in right panel
- Figure 44A-B shows single vector designs for SpCas9.
- Figure 45 shows quantification of cleavage of NLS-Csnl constructs NLS-Csnl , Csnl, Csnl-NLS, NLS-Csnl-NLS, NLS-Csnl -GFP-NLS and UnTFN.
- Figure 46 shows index frequency of NLS-Cas9, Cas9, Cas9-NLS and NLS-Cas9- NLS.
- Figure 47 shows a gel demonstrating that SpCas9 with nickase mutations (individually) do not induce double strand breaks.
- Figure 48 shows a design of the oligo DNA used as Homologous Recombination (HR) template in this experiment and a comparison of HR efficiency induced by different combinations of Cas9 protein and HR template.
- HR Homologous Recombination
- Figure 49A shows the Conditional Cas9, Rosa.26 targeting vector map.
- Figure 49B shows the Constitutive Cas9, Rosa26 targeting vector map.
- Figure 50A-H show the sequences of each element present in the vector maps of
- Figure 51 shows a schematic of the important elements in the Constitutive and Conditional Cas9 constructs.
- Figure 52 shows the functional validation of the expression of Constitutive and Conditional Cas9 constructs.
- Figure 53 shows the validation of Cas9 nuclease activity by Surveyor.
- Figure 54 shows the quantification of Cas9 nuclease activity.
- Figure 55 shows construct design and homologous recombination (HR) strategy.
- Figure 56 shows the genomic PCR genotyping results for the constitutive (Right) and conditional (Left) constructs at two different gel exposure times (top row for 3 min and bottom row for 1 min).
- Figure 57 shows Cas9 activation in mESCs.
- Figure 58 shows a schematic of the strategy used to mediate gene knockout via NHEJ using a nickase version of Cas9 along with two guide RNAs.
- Figure 59 shows how DNA double-strand break (DSB) repair promotes gene editing.
- NHEJ error-prone non-homologous end joining
- Indel random insertion'tieietion
- a repair template in the form of a plasmid or single-stranded oligodeoxynucleotid.es can be supplied to leverage the homology-directed repair (HDR) pathway, which allows high fidelity and precise editing.
- Figure 60 shows the timeline and overview of experiments. Steps for reagent design, construction, validation, and cell line expansion. Custom sgRNAs (Sight blue bars) for each target, as well as genotyping primers, are designed in siiico via our online design tool (available at the website genome-engineering.org/tools). sgRNA expression vectors are then cloned into a plasmid containing Cas9 (PX330) and verified via DNA sequencing. Completed plasmids (pCRISPRs), and optional repair templates for facilitating homology directed repair, are then transfected into cells and assayed for ability to .mediate targeted cleavage. Finally, transfected cel ls can be clonally expanded to derive isogenic cel l lines with defined mutations.
- Custom sgRNAs Light blue bars
- genotyping primers are designed in siiico via our online design tool (available at the website genome-engineering.org/tools).
- sgRNA expression vectors are then clon
- Figiire 61 shows Target selection a d reagent preparation
- 20-bp targets (highlighted in blue) must be followed by 5 '-NGG, which can occur in either strand on genomic DNA. We recommend using the online tool described in this protocol in aiding target selection (www.genome-mgineering.org tools).
- U6 Fwd U6 reverse primer
- U6 Rev U6 reverse primer
- extended DNA oligo Ultramer oiigos from IDT
- guide sequence (blue N's) in U6 Rev- is the reverse complement of the 5'-NGG flanking target sequence
- the guide oligos (blue N's) contain overhangs for ligation into the pair of Bbsl sites on PS330, with the top and bottom strand orientations matching those of the genomic target (i.e. top oligo is the 20-bp sequence preceding 5 ⁇ NGG in genomic DNA). Digestion of PX33Q with Bbsl allows the replacement of the Type lis restriction sites (blue outline) with direct insertion of annealed oiigos. It is worth noting that an extra G was placed before the first base of the guide sequence. Applicants have found that an extra G in front of the guide sequence does not adversely affect targeting efficiency.
- Figure 62 shows the anticipated results for multiplex NHEJ.
- Cas9-mediated cleavage efficiency (% indel) is calculated based on the fraction of cleaved DNA, as determined by integrated intensity of gel bands,
- Two sgRNAs (orange and blue bars) are designed to target the human GRIN2B and DYRKIA loci. SURVEYOR gel shows modification at both loci in transfecied cells. Colored arrows indicated expected fragment sizes for each locus,
- a pair of sgRNAs (light blue and green bars) are designed to excise an exon (dark blue) in the human EMXl locus.
- Target sequences and PAMs (red) are shown in respective colors, and sites of cleavage indicated by red triangle. Predicted junction is shown below.
- Transfecied cells are clonaily isolated and expanded for genotyping analysis for deletions and inversion events. Of the 105 clones are screened, 51 (49%) and 11 (10%) carrying heterozygous and homozygous deletions, respectively. Approximate deletion sizes are given since junctions may be variable.
- Figure 63A-C shows the application of ssODNs and targeting vector to mediate HR with both wifdtype and nickase mutant of Cas9 in HEK293FT and HUES9 cells with efficiencies ranging from 1.0-27%.
- Figure 64 shows a schematic of a PCR-based method for rapid and efficient CRISPR targeting in mammalian ceils.
- a plasmid containing the human RNA polymerase III promoter U6 is PCR-amplified using a U6-specific forward primer and a reverse primer carrying the reverse complement of part of the U6 promoter, the sgRNA(+85) scaffold with guide sequence, and 7 T nucleotides for transcriptional termination.
- the resulting PCR product is purified and co- delivered with a plasmid carrying Cas9 driven by the CBh promoter.
- Figure 65 shows SURVEYOR Mutation Detection Kit from Transgenomics results for each gRNA and respective controls.
- a positive SURVEY R result is one large band corresponding to the genomic PCR and two smaller bands that are the product of the SURVEYOR nuclease making a double-strand break at the site of a mutation.
- Each gRNA was validated in the mouse cell line, Neuro-N2a, by liposomal transient co-transfection with hSpCas9. 72 hours post-transfection genomic DNA was purified using QuickExtract DNA from Epicentre. PCR was performed to amplify the locus of interest.
- Figure 66 shows Surveyor results for 38 live pups (lanes 1-38) 1 dead pup (lane 39) and 1 wild-type pup for comparison (lane 40). Pups 1-19 were injected with gRNA Chd.8.2 and pups 20-38 were injected with gRNA Chd8.3. Of the 38 live pups, 13 were positive for a mutation. The one dead pup also had a mutation. There was no mutation detected in the wild- type sample. Genomic PCR sequencing was consistent with the SURVEYOR assay findings.
- Figure 67 shows a design of different Cas9 NLS constructs.
- Ail Cas9 were the human-codon-optimized version of the Sp Cas9.
- LS sequences are linked to the cas9 gene at either N-terminus or C-terminus. All Cas9 variants with different NLS designs were cloned into a backbone vector containing so it is driven by EFla promoter. On the same vector there is a chimeric RNA targeting human EMXl locus driven by U6 promoter, together forming a two- component system.
- Figure 69A shows a design of the CRISPR-TF (Transcription Factor) with transcriptional activation activity.
- the chimeric RNA is expressed by U6 promoter, while a human-codon-optimized, double-mutant version of the Cas9 protein (hSpCas9m), operably linked to triple NLS and a VP64 functional domain is expressed by a EF l a promoter.
- the double mutations, DIOA and H840A renders the cas9 protein unable to introduce any cleavage but maintained its capacity to bind to target DNA when guided by the chimeric R NA.
- Figure 69B shows transcriptional activation of the human SOX2 gene with CRISPR- TF system (Chimeric RNA and the Cas9-NLS-VP64 fusion protein).
- 293FT cells were transfected with piasmids bearing two components: (I) U6-driven different chimeric RNAs targeting 20-bp sequences within or around the human SOX2 genomic locus, and (2) EF la- driven hSpCas9m (double mutant)-NLS-VP64 fusion protein. 96 hours post transfection, 293FT cells were harvested and the level of activation is measured by the induction of mRNA expression using a qRT-PCR assay.
- Figure 70 depicts NLS architecture optimization for SpCas9.
- Figure 71 shows a QQ plot for NGGNN sequences.
- Figure 72 shows a histogram of the data density with fitted normal distribution (black line) and ,99 quantile (dotted line).
- FIG. 73A-C shows RNA-guided repression of bgaA expression by dgRNA::cas9**.
- the Cas9 protein binds to the tracrR A, and to the precursor CRISPR RNA which is processed by RNAselll to form the crRNA.
- the crRNA directs binding of Cas9 to the bgaA promoter and represses transcription, b.
- the targets used to direct Cas9** to the bgaA promoter are represented. Putative -35, -10 as well as the bgaA start codon are in bold.
- Betagaiactosidase activity as measure by Miller assay in the absence of targeting and for the four different targets.
- Figure 74A-E shows characterization of Cas9** mediated repression, a.
- the gfpmui2 gene and its promoter, including the -35 and -10 signals are represented together with the position of the different target sites used the study, b.
- Relative fluorescence upon targeting of the coding strand c.
- Relative fluorescence upon targeting of the non-coding strand d.
- polynucleotide refers to a polymeric form of nucleotides of any length, either deoxyribonueleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three dimensional structure, and may perform any function, known or unknown.
- polynucleotides coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, in Irons, messenger RNA (mRNA), transfer RNA, ribosomai RNA, short interfering RNA (siRNA), short-hairpin RNA (shR A), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers,
- a polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs.
- modifications to the nucleotide structure may be imparted before or after assembly of the polymer.
- the sequence of nucleotides may be interrupted by non-nuc!eotide components.
- a polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
- chimeric RNA refers to the polynucleotide sequence comprising the guide sequence, the tracr sequence and the tracr mate sequence.
- guide sequence refers to the about 20bp sequence within the guide RNA that specifies the target site and may be used interchangeably with the terms “guide” or “spacer”.
- tracr mate sequence may also be used interchangeably with the term “direct repeat(s)”.
- wild type is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.
- variable should be taken to mean the exhibition of qualities that have a pattern that deviates from what occurs in nature.
- nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature.
- Complementarity refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick base pairing or other non- traditional types.
- a percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100%) complementary).
- Perfectly complementary means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.
- Substantially complementary refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under strirs gen t condi tio s .
- stringent conditions for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non-target sequences.
- Stringent conditions are generally sequence-dependent, and vary depending on a number of factors. In general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. No -limiting examples of stringent conditions are described in detail in Tijssen (1993), Laboratory Techniques In Biochemistry And Molecular Biology- Hybridization With Nucleic Acid Probes Part I, Second Chapter “Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, N.Y.
- Hybridization refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues.
- the hydrogen bonding may occur by Watson Crick base pairing, Hoogstein binding, or in any other sequence specific manner.
- the complex may comprise two strands forming a duplex structure, three or more strands forming a multi stranded complex, a single self hybridizing strand, or any combination of these.
- a hybridization reaction may constitute a step in a more extensive process, such as the initiation of PGR, or the cleavage of a polynucleotide by an enzyme.
- a sequence capable of hybridizing with a given sequence is referred to as the "compl ement" of the given sequence.
- expression refers to the process by which a polynucleotide is transcribed from a DNA template (such as into and mRN A or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins.
- Transcripts and encoded polypeptides may be collectively referred to as "gene product.” If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic ceil.
- polypeptide refers to polymers of amino acids of any length.
- the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non amino acids.
- the terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.
- amino acid includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or I, optical isomers, and amino acid analogs and peptidomimetics.
- subject preferably a mammal, more preferably a human.
- Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed.
- therapeutic agent refers to a molecule or compound that confers some beneficial effect upon administration to a subject.
- the beneficial effect includes enablement of diagnostic determinations; amelioration of a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder or condition; and generally counteracting a disease, symptom, disorder or pathological condition.
- treatment or “treating,” or “palliating” or “ameliorati g” are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit.
- therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment.
- the compositions may be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet bee manifested .
- the term "effective amount” or “therapeutically effective amount” refers to the amount of an agent that is sufficient to effect beneficial or desired results.
- the therapeutically effective amount may vary depending upon one or more of: the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be detennined by one of ordinary skill in the art.
- the term also applies to a dose that will provide an image for detection by any one of the imaging methods described herein.
- the specific dose may vary depending on one or more of: the particular agent chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to be imaged, and the physical delivery system in which it is carried.
- Vectors can be designed for expression of CRISPR transcripts (e.g. nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells.
- CRISPR transcripts e.g. nucleic acid transcripts, proteins, or enzymes
- CRISPR transcripts can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in GoeddeL GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990).
- the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
- Vectors may be introduced and propagated in a prokaryote.
- a prokaryote is used to amplify copies of a vector to be introduced into a eukaryotic cell or as an intermediate vector in the production of a vector to be introduced into a eukaryotic cell (e.g. amplifying a plasmid as part of a viral vector packaging system).
- a prokaryote is used to amplify copies of a vector and express one or more nucleic acids, such as to provide a source of one or more proteins for delivery to a host cell or host organism.
- Fusion vectors add a number of amino acids to a protein encoded therein, such as to the amino terminus of the recombinant protein.
- Such fusion vectors may serve one or more purposes, such as: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
- a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protem to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protem.
- Such enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
- Example fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988.
- GST glutathione S-transferase
- E. coli expression vectors examples include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET l id (Studier et al, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).
- a vector is a yeast expression vector.
- yeast Saccharomyces cerivisae examples include pYepSeel (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa ( uijan and Hersko vitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al, 1987. Gene 54: 1 13-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif).
- a vector drives protein expression in insect cells using baculovirus expression vectors.
- Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the VL series (Lucklow and Summers, 1989. Virology 170: 31-39).
- a vector is capable of driving expression of one or more sequences in mammalian cells using a mammalian expression vector.
- mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195).
- the expression vector's control functions are typically provided by one or more regulatory elements.
- commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art.
- the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid).
- tissue-specific regulatory elements are known in the art.
- suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1 : 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T ceil receptors (Winoto and Baltimore, 1989. EMBO J.
- promoters are also encompassed, e.g., the murine hox promoters ( essel. and Grass, 1990. Science 249: 374-379) and the a-fetoprotein promoter (Campes and Tiighman, 1989. Genes Dev. 3: 537-546).
- a regulatory element is operably linked to one or more elements of a CRISPR system so as to drive expression of the one or more elements of the CRISPR system
- CRISPRs Clustered Regularly Interspaced Short Palindromic Repeats
- SPIDRs Sacer Interspersed Direct Repeats
- D ' NA loci D ' NA loci that are usually specific to a particular bacterial species.
- the CRISPR locus comprises a distinct class of interspersed short sequence repeats (SSRs) that were recognized in E. coli (Ishino et al., J. Bacterid., 169:5429-5433 [1987]; and Nakata et al, J.
- the CRISPR loci typically differ from other SSRs by the stmcture of the repeats, which have been termed short regularly spaced repeats (SRSRs) (Janssen et al., OM1CS J. Meg. Biol, 6:23-33 [2002]; and Mojica et al, Mol. Microbiol, 36:244-246 [2000]).
- SRSRs short regularly spaced repeats
- the repeats are short elements that occur in clusters thai are regularly spaced by unique intervening sequences with a substantially constant length (Mojica et al., [2000], supra).
- CRISPR loci have been identified in more than 40 prokaryotes (See e.g., Jansen et al., Mol.
- CRISPR system refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated (“Cas”) genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer” in the context of an endogenous CRISPR system), or other sequences and transcripts from a CRISPR locus.
- a tracr trans-activating CRISPR
- tracr-mate sequence encompassing a "direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system
- guide sequence also referred to as a "spacer” in the context of an endogenous CRISPR system
- one or more elements of a CRISPR system is derived from a type I, type II, or type III CRISPR system. In some embodiments, one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system).
- target sequence refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence a d a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex.
- a target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides.
- a target sequence is located in the nucleus or cytoplasm of a ceil.
- the target sequence may be withi an organelle of a eukaryotic cell, for example, mitochondrion or chlorop!ast.
- a sequence or template that may be used for recombination into the targeted locus comprising the target sequences is referred to as an "editing template” or “editing polynucleotide” or “editing sequence”.
- an exogenous template poly ucleotide may be referred to as an editing template.
- the recombination is homologous recombination.
- a CRISPR complex comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins
- formation of a CRISPR complex results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence.
- the tracr sequence which may comprise or consist of all or a portion of a wild- type tracr sequence (e.g.
- a wild -type tracr sequence may also form part of a CRISPR complex, such as by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence that is operabiy linked to the guide sequence.
- the tracr sequence has sufficient complementarity to a tracr mate sequence to hybridize and participate in formation of a CRISPR complex. As with the target sequence, it is believed that complete complementarity is not needed, provided there is sufficient to be functional.
- the tracr sequence has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.
- one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites.
- a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operabiy linked to separate regulatory elements on separate vectors.
- two or more of the elements expressed from the same or different regulatory elements may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector.
- CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5" with respect to ("upstream” of) or 3' with, respect to ("downstream” of) a second element.
- the coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction.
- a single promoter drives expression of a transcript encoding a C ISPR enzyme and one or more of the guide sequence, tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g. each in a different intron, two or more in at least one intron, or all in a single intron).
- the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter.
- a vector comprises one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a "cloning site").
- one or more insertion sites e.g. about or more than about I, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites are located upstream and/or downstream of one or more sequence elements of one or more vectors.
- a vector comprises an insertion site upstream of a tracr mate sequence, and optionally downstream of a regulator ⁇ ' element operably linked to the tracr mate sequence, such that following insertion of a guide sequence into the insertion site and upon expression the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic ceil.
- a vector comprises two or more insertion sites, each insertion site being located between two tracr mate sequences so as to al low insertion of a guide sequence at each site.
- the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or combinations of these.
- a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell.
- a single vector may comprise about or more than about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more guide sequences. In some embodiments, about or more than about .1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more such guide-sequenee-containing vectors may be provided, and optionally delivered to a cell.
- a vector comprises a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, such as a Cas protein.
- Cas proteins include Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), Ca lO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl , Cse2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Cmrl , Cmr3, Cmr4, Cmr5, Cnrr6, Csbl , Csb2, Csb3, Csxl7, CsxM, Csx lO, Cs l6, CsaX, Csx3, Cs l, Csxl5, Csfl , Csf2, Csf
- the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9.
- the CRISPR enzyme is Cas9, and may be Cas9 from S. pyogenes or S. pneumoniae.
- the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence.
- the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence.
- a vector encodes a CRISPR enzyme that is mutated to with respect to a corresponding wifd-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence.
- D10A aspartate -to-a!anine substitution
- pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand).
- Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A.
- a Cas9 nickase may be used in combination with guide sequenc(es), e.g., two guide sequences, which target respectively sense and a tisense strands of the DNA target. This combination allows both strands to be nicked and used to induce NHEJ.
- Applicants have demonstrated (data not shown) the efficacy of two nickase targets (i.e., sgRNAs targeted at the same location but to different strands of DNA) in inducing mutagenic NHEJ.
- a single nickase (Cas9-D10A with a single sgRNA) is unable to induce NBEJ and create indels but Applicants have shown that double nickase (Cas9 ⁇ D10A and two sgRNAs targeted to different strands at the same location) can do so in human embryonic stem cells (hESCs).
- the efficiency is about 50% of nuclease (i.e., regular Cas9 without D10 mutation) in hESCs.
- two or more catalytic domains of Cas9 may be mutated to produce a mutated Cas9 substantial ly lacking all DNA cleavage activity.
- a DI0A mutation is combined with one or more of H840A, N854A, or N863A mutations to produce a Cas9 enzyme substantially lacking all DNA cleavage activity.
- a CRISPR enzyme is considered to substantially lack all DNA cleavage activity when the DNA cleavage activity of the mutated enzyme is less than about 25%, 10%, 5%, 1%, 0.1%, 0.01 %, or lower with respect to its non-mutated form.
- Other mutations may be useful; where the Cas9 or other CRISPR enzyme is from a species other than S. pyogenes, mutations in corresponding amino acids may be made to achieve similar effects.
- an enzyme coding sequence encoding a CRISPR enzyme is codon optimized for expression in particular ceils, such as eukaryotie ceils.
- the eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human primate.
- codon optimization refers to a process of modifying a nucleic acid sequence for enhan ced expression in the host cells of interest by replacing at least one codon (e.g.
- Codon bias differences in codon usage between organisms
- mRNA messenger RNA
- tRNA transfer RNA
- genes can be tailored for optimal gene expression in a given organism based on codon optimization.
- Codon usage tables are readily available, for example, at the "Codon Usage Database", and these tables can be adapted in a number of ways. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nuci. Acids Res, 28:292 (2000), Computer algorithms for codon optimizing a particular sequence for expression in a particular host ceil are also available, such as Gene Forge (Aptagen: Jacobus, PA), are also available.
- one or more codons e.g. 1 , 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons
- one or more codons in a sequence encoding a CRISPR enzyme correspond to the most frequently used codon for a particular amino acid.
- a vector encodes a CR ISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs.
- the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino-termmus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more N LSs at or near the carboxy-terminus, or a combination of these (e.g. one or more NLS at the ammo-terminus and one or more NLS at the carboxy terminus).
- the CRISPR enzyme comprises at most 6 NLSs, In some embodiments, an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus.
- an NLS consists of one or more short sequences of positively charged lysines or arginines exposed on the protein surface, but other types of NLS are known.
- Non- limiting examples of NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV; the NLS from nucleopSasmin (e.g. the nucleoplasm bipartite NLS with the sequence KRPAATKKAGQAKKKK); the c-myc NLS having the amino acid sequence PAA RV LD or RQRR.NELKRSP; the hRNPAl M9 NLS having the sequence NQSSNFGPM GGNFGGRSSGPYGGGGQYFAKPRNQGGY; the sequence R RIZFK KGKDTA:ELRRRRVE 7 S 7 ELRKAKKDEQILKRRNV of the IBB domain from importin-alpha; the sequences VSRKRPRP and PPKKARED of the myoma T protein; the sequence POP KKPL of human p53; the sequence SAIJ KKKKM AP of mouse c- abl IV; the sequences DRLRR
- the one or more NLSs are of sufficient strength to drive accumulation of the CRISPR enzyme in a delectable amount in the nucleus of a eukaryotic cell.
- strength of nuclear localization activity may derive from the number of NLSs in the CRISPR enzyme, the particular NLS(s) used, or a combination of these factors.
- Detection of accumulation in the nucleus may be performed by any suitable technique.
- a detectable marker may be fused to the CRISPR enzyme, such that location within a cell may be visualized, such as in combination with a means for detecting the location of the nucleus (e.g. a stain specific for the nucleus such as DAPI).
- detectable markers include fluorescent proteins (such as Green fluorescent proteins, or GFP; RFP; CFP), and epitope tags (HA tag, flag tag, SNAP lag).
- Cell nuclei may also be isolated from cells, the contents of which may then be analyzed, by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or e zyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of CRISPR complex formation (e.g.
- a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence.
- the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alig ment algorithm is about or more than about. 50%. 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
- Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), ClustalW, Ciustal X, BLAT, Novoalign (NovOC.ra.ft Technologies, ELAND (Illumina, Sa Diego, CA), SOAP (available at. soap.genomics.org.cn), and Maq (available at. maq.sourceforge.net).
- a guide sequence Is about or more tha about 5, 10, I I, 12, 13, 14, 15, 16, 17, 18, 19, 20, 2.1 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, .15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence- specific binding of a CRISPR complex to a target sequence may be assessed by any suitable assay.
- the components of a CRISPR system sufficient to .form a CRISPR complex, including the guide sequence to be tested, may be provided to a host ceil having the corresponding target sequence, such as by transfection with vectors encoding the components of the CR ISPR sequence, followed by an assessment of preferential cleavage within the target, sequence, such as by Surveyor assay as described herein.
- cleavage of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions.
- Other assays are possible, and will occur to those skilled in the art.
- a guide sequence may be selected to target any target sequence.
- the target sequence is a sequence within a genome of a cel l.
- Exemplary target sequences include those that are u ique in the target genome.
- a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMMNNNNNNNNNNNNNNXGG where NNNNNNNNNNXGG (N is A, G, T, or C; and X can be anything) has a single occurrence in the genome.
- a unique target sequence in a genome may include an S.
- a unique target sequence in a genome may include a Cas9 target site of the form MMMMM MMMNNNNNNNNNNXXAGAA W where NNNNN N NNNNNXX AG A A W (N is A, G, T, or C; X can be anything; and W is A or T) has a single occurrence in the genome.
- a unique target sequence in a genome may include an S. thermophilus CRISPRl Cas9 target site of the form M MMMMMMMNNNNNNNNNXXAGAAW where
- NNNNNNNNNNNXXAGAAW N is A, G, T, or C; X can be anything; and W is A or T
- a unique target sequence in a genome may include a Cas9 target site of the form MMMMMM MMNNNNNNNNNNNNNNNNXGGXG where N N N NNNNNNXGGXG (N is A, G, T, or C; a d X can be anything) has a single occurrence in the genome
- a unique target sequence in a genome may include an S.
- N is A, G, T, or C; and can be anything
- M may be A, G, T, or C, and need not be considered in identifying a sequence as unique.
- a guide sequence is selected to reduce the degree of secondary structure within the guide sequence.
- Secondary structure may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another example folding algorithm is the online webserver RNAfokl, developed at Institute for Theoretical Chemistry at the University of Vienna, using the eentroid structure prediction algorithm (see e.g. A.R. Gruber et ., 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62). Further algorithms may be found in U.S. application Serial No. TBA (attorney docket 44790.11.2022; Broad Reference BI-2013/004A); incorporated herein by reference.
- TBA attorney docket 44790.11.2022; Broad Reference
- a tracr mate sequence includes any sequence that has sufficient complementarity with a tracr sequence to promote one or more of: (1) excision of a guide sequence flanked by tracr mate sequences in a cell containing the corresponding tracr sequence; and (2) formation of a CRISPR complex at a target sequence, wherein the CRISPR complex comprises the tracr mate sequence hybridized to the tracr sequence.
- degree of complementarity is with reference to the optimal alignment of the tracr mate sequence and tracr sequence, along the length of the shorter of the two sequences.
- Optimal alignment may be determined by any suitable alignment algorithm, and may further account for secondary structures, such as self-complementarity within either the tracr sequence or tracr mate sequence.
- the degree of complementarity between the tracr sequence and tracr mate sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher.
- Example illustrations of optimal alignment between a tracr sequence and a tracr mate sequence are provided in Figures 12B and I3B.
- the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length.
- the tracr sequence and tracr mate sequence are contained within a single transcript, such that hybridization between the two produces a transcript having a secondary structure, such as a hairpin.
- Preferred loop forming sequences for use in hairpin structures are four nucleotides in length, and most preferably have the sequence GAAA. However, longer or shorter loop sequences may be used, as may alternative sequences.
- the sequences preferably include a nucleotide triplet (for example, AAA), and an additional nucleotide (for example C or G).
- loop forming sequences include CAAA and AAAG.
- the transcript or transcribed polynucleotide sequence has at least two or more hairpins.
- the transcript has two, three, four or five hairpins.
- the transcript has at most five hairpins.
- the single transcript further includes a transcription termination sequence; preferably this is a polyT sequence, for example six T nucleotides. An example illustration of such a hairpin structure is provided in the lower portion of Figure 13B, where the portion of the sequence 5' of the final "N" and upstream of the loop corresponds to the tracr mate sequence, and the portion of the sequence 3' of the loop corresponds to the tracr sequence.
- non- limiti g examples of single polynucleotides comprising a guide sequence, a tracr mate sequence, and a tracr sequence are as follows (listed 5' to 3'), where "N" represents a base of a guide sequence, the first block of lower case letters represent the tracr mate sequence, and the second block of lower case letters represent the tracr sequence, and the final poly-T sequence represents the transcription terminator: (1 ) catgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT; (2) isnsnsnsnsnsnsnsnsnsns ⁇
- sequences (1) to (3) are used in combination with Cas9 from S. thermophilus CRJSPR1.
- sequences (4) to (6) are used in combination with Cas9 from S. pyogenes.
- the tracr sequence is a separate transcript from a transcript comprising the tracr mate sequence (suc as illustrated in the top portion of Figure 13B).
- a recombination template is also provided.
- a recombination template may be a component of another vector as described herein, contained in a separate vector, or provided as a separate polynucleotide.
- a recombination template is designed to serve as a template in homologous recombination, such as within or near a target sequence nicked or cleaved by a CRISPR enzyme as a part of a CRISPR complex.
- a template polynucleotide may be of any suitable length, such as about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length.
- the template polynucleotide is com lementary to a portion of a polynucleotide comprising the target sequence.
- a template polynucleotide might overlap with one or more nucleotides of a target sequences (e.g. about or more than about 1 , 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more nucleotides).
- the nearest nucleotide of the template polynucleotide is within about 1 , 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides from the target sequence.
- the CRISPR enzyme is part of a fusion protein comprising one or more heterologous protein domains (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the CRISPR enzyme).
- a CR ISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains.
- epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
- reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP).
- GST glutathione-S-transferase
- HRP horseradish peroxidase
- CAT chloramphenicol acetyltransferase
- beta-galactosidase beta-galactosidase
- beta-glucuronidase beta-galactosidase
- luciferase green fluorescent protein
- GFP green fluorescent protein
- HcRed HcRed
- DsRed cyan fluorescent protein
- a CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that bind DNA molecules or bind other cellular molecules, mcludmg but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP! 6 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US20110059502, incorporated herein by reference. In some embodiments, a tagged CRJSPR enzyme is used to identify the location of a target sequence.
- MBP maltose binding protein
- DBD Lex A DNA binding domain
- HSV herpes simplex virus
- the invention provides methods comprising delivering one or more polynucleotides, such as or one or more vectors as described herein, one or more transcripts thereof, and/or one or proteins transcribed therefrom, to a host. cell.
- the invention further provides cells produced by such methods, and organisms (such as animals, plants, or fungi) comprising or produced from such cells.
- a CRJSPR. enzyme in combination with (and optionally compiexed with) a guide sequence is delivered to a cell.
- Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian cells or target tissues.
- Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid compiexed with a delivery vehicle, such as a liposome.
- Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
- Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, poiycation or lipid :nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA.
- Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., TransfectamTM and LipofectinTM).
- Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration).
- RNA or DNA viral based systems for the deliveiy of nucleic acids takes advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus.
- Viral vectors can be administered directly to patients (in vivo) or they ca be used to treat cells in vitro, and the modified cells may optionally be administered to patients (ex vivo).
- Conventional viral based systems could include retroviral, lentivirus, adenoviral, adeno-associaied and herpes simplex virus vectors for gene transfer.
- Retroviral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral tilers. Selection of a retroviral gene transfer system would therefore depend on the target tissue. Retroviral vectors are comprised of cis-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cis-acting LT s are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cel l to provide permanent transgene expression.
- Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia vims (GaLV), Simian Immuiio deficiency vims (SIV), human immuno deficiency vims (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731 -2739 (1992); Johann et al, J. Virol. 66: 1635-1640 (1992); Sommnerfelt ei al., Virol 176:58-59 (1990); Wilson et al, J. Virol 63:2374-2378 (1989); Miller et al, J. Virol.
- MiLV murine leukemia virus
- GaLV gibbon ape leukemia vims
- SIV Simian Immuiio deficiency vims
- HV human immuno deficiency vims
- adenoviral based systems may be used.
- Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require ceil division. With such vectors, high titer and levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system.
- Adeno-associated vims may also be used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al,, Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93/24641 ; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94: 1351 (1994), Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No.
- Packaging cells are typically used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and ⁇ 2 cells or PA317 cells, which package retrovirus.
- Viral vectors used in gene therapy are usually generated by producing a cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the polynucleotide ⁇ ) to be expressed. The missing viral functions are typically supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess 1TR sequences from the AAV genome which are required for packaging and integration into the host genome.
- Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences.
- the cell line may also be infected with adenovirus as a helper.
- the helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid.
- the helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV. Additional methods for the delivery of nucleic acids to cells are known to those skilled in the art. See, for example, US200300878 17, incorporated herein by reference.
- a host cell is transiently or non-transiently transfecte with one or more vectors described herein.
- a cell is transfected as it naturally occurs in a subject.
- a cell that Is transfected is taken from a subject.
- the cell is derived from cells taken from a subject, such as a cell line. A wide variety of ceil lines for tissue culture are known in the art.
- cell lines include, but are not limited to, C8161, CCRF-CEM, MOLT, mlMCD-3, NHDF, HeLa-S3, Huhl , Huh4, euh7, HUVEC, HASMC, HERn, HE a, MiaPaCell, Panel, PC-3, TF1, CTLL-2, C1R, Rat6, CV 1, RPTE, A10, T24, J82, A375, ARH-77, Calul, SW480, SW620, S OV3, SK-UT, CaCo2, P388D1, SEM-K2, WEHI-231, HB56, TIB55, Jurkat, J45.Q1 , LRMB, Bcl-1 , BC-3, IC21, DLD2, R.aw264.7, NR , NR -52E, MR.C5, MEF, Hep G2, HeLa B, HeLa T4, COS, COS-1, COS-6, COS-M6A, BS-
- a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences.
- a cel l transiently transfected with the components of a CR iSPR system as described herein is used to establish a new cell line comprising ceils containing the modification but lacking any other exogenous sequence.
- cells transiently or non-transiently transfected with one or more vectors described herein, or cell lines derived from such ceils are used in assessing one or more test compounds.
- one or more vectors described herein are used to produce a non-human transgenic animal or transgenic plant.
- the transgenic animal is a mammal, such as a mouse, rat, or rabbit.
- the organism or subject is a plant.
- the organism or subject or plant is algae. Methods for producing transgenic plants and animals are known in the art, and generally begin with a method of cell transfeeiion, such as described herein.
- the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell.
- the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
- the invention provides a method of modifying expression of a polynucleotide in a eukaryotic ceil.
- the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
- the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell, which may be in vivo, ex vivo or in vitro.
- the method comprises sampling a cell or population of cells from a human or non- human animal or plant (including micro-algae), and modifying the cell or cells. C alluring may occur at any stage ex vivo. The cell or cells may even be re-introduced into the non-human animal or plant (including micro-algae).
- pathogens are often host-specific.
- Fusarium oxysporum f. sp. lycopersici causes tomato wilt but attacks only tomato
- Plants have existing and induced defenses to resist most pathogens. Mutations and recombination events across plant generations lead to genetic variability that gives rise to susceptibility, especially as pathogens reproduce with more frequency than plants.
- there can be non-host resistance e.g., the host and pathogen are incompatible.
- Horizontal Resistance e.g., partial resistance against all races of a pathogen, typically controlled by many genes
- Vertical Resistance e.g., complete resistance to some races of a pathogen but not to other races, typically controlled by a few genes.
- Plant and pathogens evolve together, and the genetic changes in one balance changes in other. Accordingly, using Natural Variability, breeders combine most useful genes for Yield, Quality, Uniformity, Hardiness, Resistance.
- the sources of resistance genes include native or foreign Varieties, Heirloom Varieties, Wild Plant Relatives, and Induced Mutations, e.g., treating plant material with mutagenic agents.
- plant breeders are provided with a new tool to induce mutations. Accordingly, one skilled in the art can analyze the genome of sources of resistance genes, and in Varieties having desired characteristics or traits employ the present invention to induce the rise of resistance genes, with more precision than previous mutagenic agents and hence accelerate and improve plant breeding programs.
- the invention provides kits containing any one or more of the elements disclosed in the above methods and compositions, in some embodiments, the kit comprises a vector system and instructions for using the kit.
- the vector system comprises (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting a guide sequence upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme eompiexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence.
- Elements may be provide individual ly or in combinations, and may be provided in any suitable container, such as
- a kit comprises one or more reagents for use in a process utilizing one or more of the elements described herein.
- Reagents may be provided in any suitable container.
- a kit may provide one or more reaction or storage buffers.
- Reagents may be provided in a form that is usable in a particular assay, or in a form that requires addition of one or more other components before use (e.g. in concentrate or lyopiiiiized form).
- a buffer can be any buffer, including but not limited to a sodium carbonate buffer, a sodium bicarbonate buffer, a borate buffer, a Tris buffer, a MOPS buffer, a HEPES buffer, and combinations thereof.
- the buffer is alkaline.
- the buffer has a pH from about 7 to about 10.
- the kit comprises one or more oligonucleotides corresponding to a guide sequence for insertion into a vector so as to operably link the guide sequence and a regulatory element, in some embodiments, the kit comprises a homologous recombination template polynucleotide.
- the invention provides methods for using one or more elements of a CRISPR system.
- the CRISPR complex of the invention provides an effective means for modifying a target polynucleotide.
- the CRISPR complex of the invention has a wide variety of utility including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types.
- modifying e.g., deleting, inserting, translocating, inactivating, activating
- the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, and prognosis.
- An exemplary CRISPR complex comprises a CRISPR enzyme eompiexed with a guide sequence hybridized to a target sequence within the target polynucleotide.
- the guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.
- the target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell.
- the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic cell.
- the target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulator ⁇ ' polynucleotide or a junk DNA).
- a gene product e.g., a protein
- a non-coding sequence e.g., a regulator ⁇ ' polynucleotide or a junk DNA.
- PAM protospacer adjacent motif
- PAMs are typically 2-5 base pair sequences adjacent the protospacer (thai is, the target sequence) Examples of PAM sequences are given in the examples section below, and the skilled person will be able to identify further PAM sequences for use with a given CRISPR enzyme.
- the target polynucleotide of a CRISPR complex may include a number of disease- associated genes and polynucleotides as well as signaling biochemical pathway-associated genes and polynucleotides as listed in US provisional patent applications 61 /736,527 and 61/748,427 having Broad reference BI-2011/008/WSGR Docket No. 44063-701.1 Gland BI- 201 1/008/WSGR Docket No. 44063-701 .102 respectively, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on December 12, 2012 and January 2, 2013, respectively, the contents of all of which are herein incorporated by reference in their entirety.
- target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide.
- target polynucleotides include a disease associated gene or polynucleotide.
- a "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cel ls of a non disease control.
- a disease-associated gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease.
- the transcribed or translated products may be known or unknown, and may be at a normal or abnormal level.
- Parkinson's Disease x-Synuelcin DJ-1; 1.RR 2: Parkin; PINK!
- Hernophagocytic lynrphohistiocyiosis disorders PRF1, HPLH2,
- BCL7A BCL7
- Leukemia TALI, and oncology TCL5, SCL, TAL2, FLT3, NBS i, NBS, ZNFN1A1, IKi, LYFi, diseases and disorders HGXD4, HQX4B, BCR, CML, PHL, ALL, ARNT, KRAS2, RASK2,
- GMPS GMPS, AF10, ARHGEF12, LARG, KIAA0382, CALM, CLTH, CEBPA, CEBP, CHIC2, BTL, FLT3, KIT, PBT, 1 PP.
- STATS B AF10, CALM, CLTH, ARLIL ARLTS1, P2RX7, P2X7, BCR, CML, PHL, ALL, GRAF, NF1, VRNF, WSS, NFNS, PTPN11, PTP2C, SHP2, NSi, BCL2, CCNDi, PR A 1)1.
- BCLi TCRA, GATAl, GFL ERYF1, NFE1, ABLl, NQOl, DIA4, NMOR1, NUP214, D9S46E, CAN, CAIN).
- SCIDs Severe combined Immunodeficiencies (SCIDs)(JA 3, JA L, DCLRE1C, ARTEMIS, SCIDA, RAG I, RAG2, ADA, PTPRC, CD45, LCA, IL7R, CD3D, T3D, IL2RG, SCIDX I, SCIDX, IMD4).
- CF MR.P7
- Glycogen storage diseases SLC2A2, GLUT2, G6PC, G6PT, G6PTL GAA, LAMP2, LAMPB, AGL, GDE, GBE1, GYS2, PYGL, PFKM
- Hepatic adenoma 142330 (TCFl, HNF1 A, MODY3), Hepatic failure, early onset, and neurologic disorder (SCODL SCOl), Hepatic lipase deficiency (LIPC), Hepatoblastoma, cancer and carcinomas
- CNNBl PDGFRL, PDGRL, PRLTS, AX I I , AXIN, CTNNB1, TP53, P53, LFS1, IGF2R, MPRI, MET, CASP8, MCH5
- Medullary cystic kidney disease UMOD, HNFJ, FJHN, MC D2, ADMCKD2
- Phenylketonuria PAH, PKU1, QDPR, DI I
- Muscular / Skeletal Becker muscular dystrophy (DMD, BMD, MYF6), Duchenne Muscular dseases and disorders Dystrophy (DM D, BMD); Eniery-Dreifuss muscular dystrophy (LMNA, LMN1, EMD2, FPU).
- EMD2, FPLD, CMD1A Facioscapulohumeral muscular dystrophy (FSHMD 1 A, FS HD 1 A); Muscular dystrophy (FKRP, MDC 1 C,
- LGMD2I L.AMA.2, LAMM, LARGE, KIAA0609, MDC ID, FCMD, TTID, MYOT, CAPN3, CANP3, DYSF, LGMD2B, SGCG, LGMD2C, DMDA1, SCG3, SGCA, ADL, DAG2, LGMD2D, DMDA2, SGCB, LGMD2E, SGCD, SGD, LGMD2F, CMD1L, TCAP, LGMD.2G, CMD1N, TRIM32, HT2A, LGMD2H, FKRP, MDC1C. LGMD2I, TTN.
- Neurological and ALS SOD1, ALS2, STEX, FUS, TARDBP, VEGF (VEGF-a, VEGF-b, neuronal, diseases and VEGF-c); Alzheimer disease iAPP, AAA, CVAP, AD.1, APOE, AD2, disorders PSEN2, AD4, STM2, APBB2, FE65L1, NOS3, PLAU, URK, ACE,
- DCPl ACEL MPO, PACIP1, PAXIP1L, PTIP, A2M, BLMH, BMH, PSEN1, AD3); Autism (Mecp2, B.ZRAP1, MDGA2, SemaSA, Neurexin 1, GLOl, MECP2, RTT, PPMX, MRX16, MRX79, NLGN3, NLGN4, IAA1260, AUTSX2); Fragile X Syndrome (FMR2, FXR1, FXR2, mGLURS); Huntington's disease and disease like disorders (HD, IT15, PRNP, PR1P, J PI 13.
- Autism Mecp2, B.ZRAP1, MDGA2, SemaSA, Neurexin 1, GLOl, MECP2, RTT, PPMX, MRX16, MRX79, NLGN3, NLGN4, IAA1260, AUTSX2
- Fragile X Syndrome FMR2, FXR1, FXR2, mGLURS
- Parkinson disease (NR4A2, NUR 1, NOT, TINUR, SNCAIP, TBP, SCA17, SNCA, NACP, PARK I, PARK4, DJ1, PARK7, LRRK2, PARKS, ⁇ 1, PARK6, UCHL1, PARKS, SNCA, N ACP, PARK1, PARK4, PRKN, P.ARK2, PDJ, DBH, NDUFV.2); Rett, syndrome (MECP.2, RTT, PPMX, MRX16, MRX79, CDKL5, STK9, MECP2, RTT, PPMX, MRX16, MRX79, x-Synuclein, DJ-1); Schizophrenia (Neuregulinl (Nrgl), Erb4 (receptor for Neuregulin), Complexinl (Cplxl), Tphl Tiyptophan hydroxylase, Tph2, Tryptophan hydroxylase 2, Neurexin 1,
- VLDLR VLDLR
- Occular diseases and Age-related macular degeneration Abcr, Ccl2, Cc2, cp (ceruloplasmin), disorders Ti.mp3, cathepsinD, Vidir, Ccr2); Cataract. (CR.YAA, CRYA1, CRYBB2,
- IGF-1 Signaling IGF1; PRKCZ; ELK1; MAPKl; PTPN11; NEDD4; AKT2;
- PIK3CA PRKCI; PTK2; FOS; PIK3CB; PIK3C3; MAPK8;
- IGF1R insulin receptor
- IRS1 MAPK3
- IGFBP7 IGFBP7
- KRAS PIK3C2A
- PDPK1 MAP2K1; IGFBP2; SI N; JUN; CYR61; AKT3;
- NRF2 ⁇ mediated PRKCE EP300; SOD2; PRKCZ; MAPKl; SQSTMl;
- PRKDl PRKDl
- MAPK3 KRAS
- PRKCD PRKCD
- GSTP1 PRK9: FTL
- IGFIR insulin receptor RI
- IL6R RELA
- TLR4 PDGFRB
- TNF RELB
- IL8 IL8
- PDGFRA NFKBI
- TGFBR1 TGFBR1
- SMAD4 VEGFA
- BAX BAX
- NRJP1 KRAS
- PPARG RELA
- STATS A TRAF2;
- PPARGC1A PDGFRB
- TNF PDGFRB
- INSR RAF1
- IKBKG IKBKG
- MAP2K1 MAP2K1; NFKBI; JUN; IL1R1; HSP90AA1
- PRKD1 MAPK3; MAPK10; KRAS; MAPKl 3; PRKCD;
- MAPK9 PIK3C2A
- BTK PIK3C2A
- MAPK14 TNF; RATI; FYN;
- MAP2K2 MAP2K2; AKT1; PIK3R1; PDPK1; MAP2K1; AKT3;
- PIK3C3 MAPK3; KRAS; RELA; SRC; PIK3C2A; RAF1;
- PDPK1 PDPK1; STAT3; MAP2KI; NFKBI; BRAF; ATF4; AKT3;
- Inositol Phosphate PRKCE Inositol Phosphate PRKCE; IRAKI; PRKAA2; EIF2AK2; PTEN; GRK6;
- MAP2K1 MAP2K1; PAK3; ATM; TTK; CSNK1A1; BRAF; SGK
- Glutathione Metabolism 11)1 12 GSTP1; ANPEP; ! l i l
- Methionine Metabolism DNMT1 ; DNMT3B; AHCY; DNMT3A
- Trpal Pome; Cgrp; Crf; Pka; Era; Nr2b; TRPM5; Prkaca;
- Prkacb Prkarl a
- Prkar2a Prkacb
- Wnt2b Wnt3a; Wnt4; WntSa; Wnt6; Wnt7b; Wnt8b;
- Dkk-1 Frizzled related proteins; Otx-2; Gbx2; FGF-8;
- Embodiments of the invention also relate to methods and compositions related to knocking out genes, amplifying genes and repairmg particular mutations associated with DNA repeat instability and neurological disorders (Robert D, Wells, Tetsuo Ashizawa, Genetic Instabilities and Neurological Diseases, Second Edition, Academic Press, Oct 13, 201 1 - Medical). Specific aspects of tandem repeat sequences have been found to be responsible for more than twenty human diseases (New insights into repeal instability: role of RNA 3 ⁇ 4 DNA hybrids. Mclvor EI, Polak U, Napierala M. RNA Biol. 2010 Sep-Oct;7(5):551-8). The CRISPR- Cas system may be harnessed to correct these defects of genomic instability.
- a further aspect of the invention relates to utilizing the CRISPR-Cas system for correcting defects in the EMP2A and EMP2B genes that have been identified to be associated with Lafora disease.
- Lafora disease is an autosomal recessive condition which is characterized by progressive myoclonus epilepsy which may start as epileptic seizures in adolescence, A few cases of the disease may be caused by mutations in genes yet to be identified. The disease causes seizures, muscle spasms, difficulty walking, dementia, and eventually death. There is currently no therapy that has proven effective against disease progression.
- the CRISPR-Cas system may be used to correct ocular defects that arise from several genetic mutations further described in Genetic Diseases of the Eye, Second Edition, edited by Elias I. Traboulsi, Oxford University Press, 2012.
- the genetic brain diseases may include but are not limited to Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Aicardi Syndrome, Alpers' Disease, Alzheimer's Disease, Barth Syndrome, Batten Disease, CADASIL, Cerebellar Degeneration, Fabry's Disease, Gerstmann-Straussier-Scheinker Disease, Huntington's Disease and other Triplet Repeat Disorders, Leigh's Disease, Lesch-Nyhan Syndrome, Menkes Disease, Mitochondrial Myopathies and NINDS Colpocephaly. These diseases are further described on the website of the National Institutes of Health under the subsection Genetic Brain Disorders.
- the condition may be neoplasia.
- the genes to be targeted are any of those listed in Table A (in this case PTEN and so forth).
- the condition may be Age-related Macular Degeneration,
- the condition may be a Schizophrenic Disorder.
- the condition may be a Trinucleotide Repeat Disorder.
- the condition may be Fragile X Syndrome.
- the condition may be a Secretase Related Disorder.
- the condition may be a Prion - related disorder.
- the condition may be ALS.
- the condition may be a drug addiction. In some embodiments, the condition may be Autism. In some embodiments, the condition may be Alzheimer's Disease. In some embodiments, the condition may be inflammation. In some embodiments, the condition may be Parkinson 's Disease.
- proteins associated with Parkinson 's disease include but are not limited to a-synuclein, DJ ⁇ 1 , LRRK2, ⁇ 1 , Parkin, UCHL1 , Synphilin-1 , and XL RR i .
- Examples of addiction-related proteins may include ABAT for example.
- inflammation-related proteins may include the monocyte ehemoattraetant protein- 1 (MCP1 ) encoded by the Ccr2 gene, the C-C chemokine receptor type 5
- CCR5 encoded by the Ccr5 gene
- FCGR2b also termed CD32
- FCERl g Fc epsi lon Ri g
- cardiovascular diseases associated proteins may include IL1B (mterieiikm 1 , beta), XDH (xanthine dehydrogenase), TPS 3 (tumor protein p53 ), PTGIS (prostaglandin 12 (prostacyclin) synthase), MB (myoglobin), TLA (interieukm 4), ANGPT1 (angiopoietin 1), ABCG8 (ATP-binding cassette, sub-family G (WHITE), member 8), or CTS (cathepsin K), for example.
- Examples of Alzheimer's disease associated proteins may include the very low density lipoprotein receptor protein (VLDLR) encoded by the VLDLR gene, the ubiquitin-like modifier activating enzyme I (UBA1) encoded by the UBA1 gene, or the NEDD8 ⁇ activating enzyme El catalytic subunit protein (UBE1 C) encoded by the UBA3 gene, for example.
- VLDLR very low density lipoprotein receptor protein
- UBA1 ubiquitin-like modifier activating enzyme I
- UBE1 C El catalytic subunit protein
- proteins associated Autism Spectrum Disorder may include the benzodiazepine receptor (peripheral) associated protein 1 (BZRA P1 ) encoded by the BZRAP1 gene, the AF4/FMR2 family member 2 protein (AFF2) encoded by the AFF2 gene (also termed MFR2), the fragile X mental retardation autosomal homolog 1 protein (FXR 1 ) encoded by the FXR1 gene, or the fragile X mental retardation autosomal homolog 2 protein (FXR2) encoded by the FXR2 gene, for example.
- BZRA P1 benzodiazepine receptor (peripheral) associated protein 1
- AFF2 AF4/FMR2 family member 2 protein
- FXR 1 fragile X mental retardation autosomal homolog 1 protein
- FXR2 fragile X mental retardation autosomal homolog 2 protein
- proteins associated Macular Degeneration may include the ATP-binding cassette, sub-family A (ABCl) member 4 protein (ABCA4) encoded by the ABCR gene, the apolipoprotein E protein (APOE) encoded by the APOE gene, or the chemokine (C-C motif) Ligand 2 protein (CCL2) encoded by the CCL2 gene, for example.
- ABCl sub-family A
- APOE apolipoprotein E protein
- CCL2 chemokine Ligand 2 protein
- proteins associated Schizophrenia may include NRG l , ErbB4, CPLX! , TPHl , TPH2, NRXNl , GS 3A, BDNF, DISC I , GSK3B, and combinations thereof.
- proteins involved in tumor suppression may include ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homoiog 2), ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homoiog 3), ERBB4 (v-erb-b2 erythroblastic leukemia viral oncogene homoiog 4), Notch 1, Notch2, Notch 3, or Notch 4, for example.
- ATM ataxia telangiectasia mutated
- ATR ataxia telangiectasia and Rad3 related
- EGFR epidermatitise
- ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homoiog 2
- ERBB3 v-erb-b2 ery
- proteins associated with a secretase disorder may include PSENEN (presenilis enhancer 2 homoiog (C. elegans)), CTSB (cathepsin B), PSEN1 (preseniSin 1 ), APP (amyloid beta (A4) precursor protein), APH1B (anterior pharynx defective 1 homoiog B (C, elegans)), PSEN2 (presenilin 2 (Alzheimer disease 4)), or BACE1 (beta-site APP-cleaving enzyme 1), for example.
- proteins associated with Amyotrophic Lateral Sclerosis may include SODl (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascuiar endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.
- proteins associated with prion diseases may include SODl (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA. (vascular endothelial growth factor A), VAGFB (vascuiar endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.
- proteins related to neurodegenerative conditions in prion disorders may include A2M (Alpha-2-Macroglobulin), AATF (Apoptosis antagonizing transcription factor), ACPP (Acid phosphatase prostate), ACTA2 (Actin alpha 2 smooth muscle aorta), ADAM22 (ADAM metailopeptidase domain), ADORA3 (Adenosine A3 receptor), or ADRAID (Alpha- ID adrenergic receptor for Alpha- I D adrenoreceptor), for example.
- A2M Alpha-2-Macroglobulin
- AATF Apoptosis antagonizing transcription factor
- ACPP Acid phosphatase prostate
- ACTA2 Actin alpha 2 smooth muscle aorta
- ADAM22 ADAM metailopeptidase domain
- ADORA3 Addenosine A3 receptor
- ADRAID Alpha- ID adrenergic receptor for Alpha- I D adrenoreceptor
- proteins associated with Immunodeficiency may include A2M [aipha-2- macroglobulinj; AANAT [arylalkylamine N-acetyltransferase] ; ABCA1 [ATP -binding cassette, sub-family A (ABC1), member 1]; ABCA2 [ATP-binding cassette, sub-family A (ABO), member 2]; or ABCA3 [ATP-binding cassette, sub-family A (ABC1), member 3]; for example.
- A2M aipha-2- macroglobulinj
- AANAT arylalkylamine N-acetyltransferase
- ABCA1 ATP -binding cassette, sub-family A (ABC1), member 1]
- ABCA2 ATP-binding cassette, sub-family A (ABO), member 2]
- ABCA3 [ATP-binding cassette, sub-family A (ABC1), member 3] for example.
- proteins associated with Trinucleotide Repeat Disorders include AR (androgen receptor), FMR1 (fragile X mental retardation 1), HTT (huntingtm), or DMPK (dystrophia myotonic a-protem kinase), FXN (frataxin), ATXN2 (ataxin 2), for example.
- proteins associated with Neurotransmission Disorders include SST (somatostatin), NOSI (nitric oxide synthase 1 (neuronal)), ADRA2A (adrenergic, a!pha-2A-, receptor), ADRA2C (adrenergic, alpha-2C-, receptor), TACR1 (tachykinin receptor 1), or HTR2c (5-hydroxytryptamme (serotonin) receptor 2C), for example.
- neurodevelopmental-associated sequences include A2BP1 [ataxin 2- binding protein 1 ], AADAT [ammoadipate aminotransferase] , AANAT [arylalkyiamine N- acetyltransferase], ABAT [4-aminobutyrate aminotransferase], ABCA 1 [ATP-binding cassette, sub-family A (ABO), member 1], or ABCA13 [ATP-binding cassette, sub-family A (ABO), member 13], for example.
- A2BP1 ataxin 2- binding protein 1
- AADAT ammoadipate aminotransferase
- AANAT arylalkyiamine N- acetyltransferase
- ABAT 4-aminobutyrate aminotransferase
- ABCA 1 ATP-binding cassette, sub-family A (ABO), member 1
- ABCA13 ATP-binding cassette, sub-family A (ABO), member 13
- FIG. 1 Aieardi-Goutieres Syndrome; Alexander Disease; Allan-Herndon-Dudiey Syndrome; POLG-Related Disorders; Alpha-Mannosidosis (Type II and III); Alstrom Syndrome; Angelman; Syndrome; Ataxia-Telangiectasia; Neuronal Ceroid-Lipofuscinoses; Beta- r rhalassemia; Bilateral Optic Atrophy and (Infantile) Optic Atrophy Type 1; Retinoblastoma (bilateral); Canavan Disease; Cerebrooculofacioskeletal Syndrome 1 [COFS1]; Cerebrotcndinous Xanthomatosis; Cornelia de Lange Syndrome; MAPT-Reiated Disorders; Genetic Prion Diseases; Dravet Syndrome; Early-Onset Familial Alzheimer Disease; Friedreich Ataxia [FRDA]; Fryns Syndrome; Fucosidosis; Fukuyama Congenital Muscular Dyst
- the present system can be used to target any polynucleotide sequence of interest.
- Some examples of conditions or diseases that might be usefully treated using the present system are included in the Tables above and examples of genes currently associated with those conditions are also provided there. However, the genes exemplified are not exhaustive.
- Example I CRISP R Complex Activity in the Nucleus of a Eukaryotic Cell
- An example type II CRISPR system is the type II CRISPR locus from Streptococcus pyogenes SF370, which contains a cluster of four genes Cas9, Casl, Cas2, and Csnl, as well as two non-coding RNA elements, tracrRNA and a characteristic array of repetitive sequences (direct repeats) interspaced by short stretches of non-repetitive sequences (spacers, about 30bp each).
- DSB targeted DNA double-strand break
- Figure 2A First, two non-coding RNAs, the pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus.
- tracrRNA hybridizes to the direct repeats of pre- crRNA, which is then processed into mature crRNAs containing individual spacer sequences.
- the mature crRNA:tracrRNA complex directs Cas9 to the DNA target consisting of the protospacer and the corresponding PAM via heterodupiex formation between the spacer region of the crRNA and the protospacer DNA.
- Cas9 mediates cleavage of target DNA upstream of PAM to create a DSB within the protospacer ( Figure 2A).
- This example describes an example process for adapting this RNA-programmable nuclease system to direct CRISPR complex activity in the nuclei of eukaryotic cel ls.
- HEK cell line HEK 293FT Human embryonic kidney (HEK) cell line HEK 293FT (Life Technologies) was maintained in Duibeeeo's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), 2 m VI GlutaMAX ( Life Technologies), lOOU/mL penicillin, and 100p.g/mL streptomycin at 37°C with 5% C0 2 incubation.
- DMEM Duibeeeo's modified Eagle's Medium
- HyClone fetal bovine serum
- 2 m VI GlutaMAX Life Technologies
- streptomycin 100p.g/mL streptomycin at 37°C with 5% C0 2 incubation.
- N2A cell line ATCC was maintained with DMEM supplemented with 5% fetal bovine semm (HyClone), 2mM GlutaMAX (Life Technologies), lOOU/mL penicillin, and l OQ g/mL streptomycin at 37°C with 5% CO;.
- HEK 293 FT or N2A cells were seeded into 24-wel! plates (Corning) one day prior to transfection at a density of 200,000 ceils per well. Cells were transfected using Lipofectamine
- HEK 293FT or N2A cells were transfected with plasmid DNA as described above.
- the cells were incubated at 37°C for 72 hours before genomic DNA extraction.
- the genomic region surrounding a CRISPR target site for each gene was PGR amplified, and products were purified using QiaQuick Spin Column (Qiagen) following manufacturer's protocol.
- a total of 00ng of the purified PGR products were mixed with 2 ⁇ 1 10 Taq polymerase PGR buffer (Enzymaties) and ultrapure water to a final volume of 20 ⁇ 1, and subjected to a re-annealing process to enable heterodupiex formation: 95°C for lOmin, 95°C to 85°C ramping at - 2°C/s, 85°C to 25°C at - 0.25°C/s, and 25°C hold for 1 minute.
- HE 293FT and N2A cells were transfected with plasmid DNA, and incubated at 37°C for 72 hours before genomic DNA extraction as described above.
- the target genomic region was PGR amplified using primers outside the homology arms of the homologous recombination (HR) template.
- PGR products were separated on a 1% agarose gel and extracted with MinElute GelExtraetion Kit (Qiagen). Purified products were digested with Hmdlll (Fermentas) and analyzed on a 6% Novex TBE poly-acrylamide gel (Life Technologies).
- RNA secondary structure prediction was performed using the online webserver RNAfold developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g. A.R. Gruber et at, 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62).
- Elements of the S. pyogenes CRISPR locus 1 sufficient for CRISPR activity were reconstituted in E. coli using pCRISPR plasmid (schematically illustrated in Figure 10A), pCRISPR contained tracrRNA, SpCas9, and a leader sequence driving the crRNA array.
- Spacers also referred to as "guide sequences” were inserted into the crRNA array between Bsal sites using annealed oligonucleotides, as illustrated.
- Challenge plasmids used in the interference assay were constructed by inserting the protospacer (also referred to as a "target sequence") sequence along with an adjacent CRISPR motif sequence (PAM) into pUC19 (see Figure 10B).
- FIG. 10D illustrates competence of each pCRISPR- carrying E. cofi strain used in assays illustrated in Figure 4C.
- FJEK 293FT cells were maintained and transfected as stated above. Cells were harvested by trypsinization followed by washing in phosphate buffered saline (PBS). Total cell RNA was extracted with TRI reagent (Sigma) following manufacturer's protocol. Extracted total RNA was quantified using Naonodrop (Thermo Scientific) and normalized to same concentration.
- RNAs were mixed with equal volumes of 2X loading buffer (Ambion), heated to 95°C for 5 min, chilled on ice for 1 min, and then loaded onto 8% denaturing polyacrylamide gels (SequaGel, National Diagnostics) after pre-running the gel for at least 30 minutes. The samples were electrophoresed for 1.5 hours at 40W limit. Afterwards, the RNA was transferred to Hybond N+ membrane (GE Healthcare) at 300 mA in a semi-dry transfer apparatus (Bio-rad) at room temperature for 1 .5 hours. The RNA was crosslinked to the membrane using autocrossiink button on Stratagene UV Crosslinker the Stratalinker (Stratagene).
- the membrane was pre-hyhridized in ULTRAhyb-Oligo Hybridization Buffer (Ambion) for 30 min with rotation at 42°C, and probes were then added and hybridized overnight. Probes were ordered from IDT and labeled with [gamma- "" ?] ATP s erk in Elmer) with T4 polynucleotide kinase (New England Biolabs). The membrane was washed once with pre-warmed (42°C) 2xSSC, 0.5% SDS for 1 min followed by two 30 minute washes at 42°C. The membrane was exposed to a phosphor screen for one hour or overnight at room temperature and then scanned with a phosphorimager (Typhoon).
- CRISPR locus elements including tracrRNA, Cas9, and leader were PGR amplified from Streptococcus pyogenes SF370 genomic DNA with flanking homology arms for Gibson. Assembly. Two Bsal type IIS sites were introduced in between two direct repeats to facilitate easy insertion of spacers ( Figure 9). PGR products were cloned into EcoRV-digested pACYC184 downstream of the tet promoter using Gibson Assembly Master Mix (NEB). Other endogenous CRISPR system elements were omitted, with the exception of the last 50bp of Csn2.
- Oligos Integrated DNA Technology encoding spacers with complimentary overhangs were cloned into the i&al-digested vector pDCOOO (NEB) and then ligated with T7 ligase (Enzymatics) to generate pCRISPR plasmids.
- Challenge pfasmids containing spacers with PAM sequences also referred to herein as "CRISPR motif sequences" were created by ligating hybridized oligos carrying compatible overhangs (Integrated DNA Technology) into BanMl- digested pUC19. Cloning for all constructs was performed in E. coli strai JM109 f'Zymo Research).
- pCRJSPR-carrying cells were made competent using the Z-Competent E. coli Transformation Kit and Buffer Set (Zymo Research, T3001 ) according to manufacturer's instructions. In the transformation assay, 50uL aliquots of competent cells carrying pCRISPR were thawed on ice and tra sformed with lug of spacer plasmid or pUC19 on ice for 30 minutes, followed by 45 second heat shock at 42°C and 2 minutes on ice.
- a version of SpCas9 with an NLS attached to both N- and C-termini (2xNLS-SpCas9) was also generated. Constructs containing NLS-fused SpCas9 and SpRNase III were transfected into 293FT human embryonic kidney (HEK) cells, and the relative positioning of the NLS to SpCas9 and SpRNase III was found to affect their nuclear localization efficiency. Whereas the C -terminal NLS was sufficient to target SpRNase II I to the nucleus, attachment of a single copy of these particular NLS's to either the N- or C -terminus of SpCas9 was unable to achieve adequate nuclear localization in this system. In this example, the C-terminal.
- NLS was that of nucleoplasmin (KRPAAT KAGQAKKKK), and the C-terminal NLS was that of the SV40 large T-antigen (P KKRKV).
- P KKRKV SV40 large T-antigen
- the tracrRNA from the CRISPR locus of S. pyogenes SF370 has two transcriptional start sites, giving rise to two transcripts of 89 ⁇ nucleotid.es (nt) and 171nt that are subsequently processed into identical 75nt mature tracrR As.
- the shorter 89nt tracrRNA was selected for expression in mammalian cells (expressio constructs illustrated in Figure 7 A, with functionality as determined by results of the Surveyor assay shown in Figure 7B). Transcription start, sites are marked as +1, and transcription terminator and the sequence probed by northern blot are also indicated. Expression of processed tracrRNA was also confirmed by Northern blot.
- Figure 7C shows results of a Northern blot analysis of total RNA extracted from 293FT cells transfected with U6 expression constructs carrying long or short tracrRNA, as well as SpCas9 and DR- EMX1(1)-DR.
- Left and right panels are from 293FT cells transfected without or with SpRNase III, respectively.
- U6 indicate loading control blotted with a probe targeting human U6 snRNA.
- Transfection of the short tracrRNA expression construct led to abundant levels of the processed form of tracrRNA ( ⁇ 75bp). Very low amounts of long tracrRNA are detected on the Northern blot.
- RNA polymerase Ill-based U6 promoter was selected to drive the expression of tracrRNA ( Figure 2C).
- a U6 promoter-based construct was developed to express a pre-crRNA array consisting of a single spacer flanked by two direct repeats (DRs, also encompassed by the term "tracr-mate sequences"; Figure 2C).
- the initial spacer was designed to target a 33-base-pair (bp) target site (30-bp proto spacer plus a 3 -bp CRISPR motif (PAM) sequence satisfying the NGG recognition motif of Cas9) in the human EMXl locus ( Figure 2C), a key gene in the development of the cerebral cortex.
- bp 33-base-pair
- PAM 3 -bp CRISPR motif
- HEK 293FT cells were transfected with combinations of CRISPR components. Since DSBs in mammalian nuclei are partially repaired by the non-homologous end joining (NHEJ) pathway, which leads to the formation of indels, the Surveyor assay was used to detect potential cleavage activity at the target.
- NHEJ non-homologous end joining pathway
- Figure 14 provides an additional Northern blot analysis of crRNA processing in mammalian ceils.
- Figure 14A illustrates a schematic showing the expression vector for a single spacer flanked by two direct repeats (DR-EMXl(i)-DR). The 30bp spacer targeting the human EMX1 locus protospacer 1 (see Figure 6) and the direct repeat sequences are shown in the sequence beneath Figure 14 A. The line indicates the region whose reverse-complement sequence was used to generate Northern blot probes for EMX1(1) crRNA detection.
- Figure 14B shows a Northern blot analysis of total RNA extracted from 293 FT cells transtected with U6 expression constructs carrying DR-EMX 1(1 )-DR.
- DR-EMX1 (1 )-DR was processed into mature crR ' NAs only in the presence of SpCas9 and short tracrRNA and was not dependent on the presence of SpRNase III.
- the mature crRNA detected from traiisfected 293FT total RNA is ⁇ 33bp and is shorter than the 39-42bp mature crRNA from S, pyogenes.
- Figure 2 illustrates the bacterial CRISPR system described in this example.
- Figure 2 A illustrates a schematic showing the CRISPR locus 1 from Streptococcus pyogenes SF370 and a proposed mechanism of CRISPR -mediated DNA cleavage by this system.
- Mature crRNA processed from the direct repeat-spacer array directs Cas9 to genomic targets consisting of complimentary protospacers and a protospacer-adjacent motif (PAM).
- PAM protospacer-adjacent motif
- Cas9 mediates a double-strand break in the target DNA.
- Figure 2B illustrates engineering of S.
- FIG. 2C illustrates mammalian expression of SpCas9 and SpRNase 111 driven by the constitutive EFla promoter and tracrRNA and pre-crRNA array (DR-Spacer-DR) driven by the RNA Pol3 promoter U6 to promote precise transcription initiation and termination.
- DR-Spacer-DR pre-crRNA array
- FIG. 2D illustrates surveyor nuclease assay for SpCas9-mediated minor insertions and deletions.
- SpCas9 was expressed with and without SpRNase III, tracrRNA, and a pre-crRNA array carrying the EMX1- target spacer.
- Figure 2E illustrates a schematic representation of base pairing between target locus and EMXl -targeting crRNA, as well as an example chromatogram showing a micro deletion adjacent to the SpCas9 cleavage site.
- Figure 2F illustrates mutated alleles identified from sequencing analysis of 43 clonal amplicons showing a " variety of micro insertions and deletions. Dashes indicate deleted bases, and non-aligned or mismatched bases indicate insertions or mutations. Scale bar ::: lOjim.
- a chimeric crRNA-tracrRNA hybrid desig was adapted, where a mature crRNA (comprising a guide sequence) is fused to a partial tracrRNA via a stem-loop to mimic the natural crRNA:tracrRNA duplex (Figure 3A).
- a bicistronic expression vector was created to drive co- expression of a chimeric RNA and SpCas9 in transfected ceils ( Figures 3 A and 8).
- Figure 9 provides schematic illustrations of bicistronic expression vectors for pre- crRNA array ( Figure 9 A) or chimeric crRNA (represented by the short line downstream of the guide sequence insertion site and upstream of the EF l a promoter in Figure 9B) with hSpCas9, showing locationo of various elements and the point of guide sequence insertion.
- the expanded sequence around the location of the guide sequence insertion site in Figure 9B also shows a partial DR sequence (GTTTAGAGCTA) and a partial tracrRNA sequence (TAGCAAGTTAAAATAAGGCTAGTCCGTTTTT).
- Guide sequences can be inserted between Bbsl sites using annealed oligonucleotides. Sequence design for the oligonucleotides are shown below the schematic illustrations in Figure 9, with appropriate ligation adapters indicated.
- WPRE represents the Woodchuck hepatitis virus post-transcription al regulatory element. The efficiency of chimeric RNA-mediated cleavage was tested by targeting the same EMXl locus described above. Using both Surveyor assay and Sanger sequencing of amplicons, Applicants confirmed that the chimeric RNA design facilitates cleavage of human EMXl locus with approximately a 4.7% modification rate (Figure 4).
- Protospacers on the sense and anti-sense strands are indicated above and below the DNA sequences, respectively.
- a modification rate of 6.3% and 0.75% was achieved for the human P VALB and mouse Th loci respectively, demonstrating the broad applicabi lity of the CRISPR system in modifying different loci across multiple organisms ( Figures 3B and 6). While cleavage was only detected with one out of three spacers for each locus using the chimeric constructs, all target sequences were cleaved with efficiency of indel production reaching 27%> when using the co-expressed pre-crRNA arrangement (Figure 6).
- Figure 13 provides a further illustration that SpCas9 can be reprogrammed to target multiple genomic loci in mammalian cells.
- Figure 13A provides a schematic of the human EMXl Socus showing the location of five protospacers, indicated by the underlined sequences.
- Figure 13B provides a schematic of the pre-crRNA/trcrRNA complex showing hybridization between the direct repeat region of the pre-crRNA and tracrRNA (top), and a schematic of a chimeric RNA design comprising a 20bp guide sequence, and tracr mate and tracr sequences consisting of partial direct repeat and tracrRNA sequences hybridized in a hairpin structure (bottom).
- Figure 3 illustrates example expression vectors.
- Figure 3 A provides a schematic of a bi-cistronic vector for driving the expression of a synthetic crRNA-tracrRNA chimera (chimeric RNA) as well as SpCas9.
- the chimeric guide RNA contains a 20-bp guide sequence corresponding to the protospacer in the genomic target site.
- the folding algorithm produced an output with each base colored according to its probability of assuming the predicted secondary structure, as indicated by a rainbow scale that is reproduced in Figure 3B in gray scale.
- FIG 44 Further vector designs for SpCas9 are shown in Figure 44, which illustrates single expression vectors incorporating a U6 promoter linked to an insertion site for a guide oligo, and a Cbh promoter linked to SpCas9 coding sequence.
- the vector shown in Figure 44b includes a tracrRNA coding sequence linked to an HI promoter.
- Figure 4A illustrates results of a Surveyor nuclease assay comparing the cleavage efficiency of Cas9 when paired with different mutant chimeric RNAs, Single-base mismatch up to 12-bp 5' of the PAM substantially abrogated genomic cleavage by SpCas9, whereas spacers with mutations at farther upstream positions retained activity against the original protospacer target ( Figure 4B).
- SpCas9 has single-base specificity within the last 12-bp of the spacer. Furthermore, CRISPR is able to mediate genomic cleavage as efficiently as a pair of TALE nucleases (TALEN) targeting the same EMXl protospacer.
- RNA to program sequence-specific DNA cleavage defines a new class of genome engineering tools for a variety of research and industrial applications.
- CRISPR system can be further improved to increase the efficiency and versatility
- Optimal Cas9 activity may depend on the availability of free Mg " at levels higher than that present in the mammalian nucleus (see e.g. Jinek et al, 2012, Science, 337:816), and the preference for an NGG motif immediately downstream of the protospacer restricts the ability to target on average every 12-bp in the human genome ( Figure 1 1 , evaluating both plus and minus strands of human chromosomal sequences).
- FIG. 12 illustrates adaptation of the Type II CRISPR system from CRISPR 1 of Streptococcus thennophilus LMD-9 for heterologous expression in mammalian cells to achieve CRISPR-mediated genome editing.
- Figure 12A provides a Schematic il lustration of CRISPR 1 from S. thennophilus LMD-9.
- Figure 12B illustrates the design of an expression system for the S. thermophilus CRISPR system. Human eodon-optimized hSiCas is expressed using a constitutive EFla promoter.
- tracrRNA and crRNA are expressed using the U6 promoter to promote precise transcription initiation. Sequences from the mature crRNA and tracrRNA are illustrated. A single base indicated by the lower case "a" in the crRNA sequence is used to remove the polyU sequence, which serves as a RNA polIII transcriptional terminator.
- Figure 12C provides a schematic showing guide sequences targeting the human EMX1 locus as well as their predicted secondary structures. The modification efficiency at each target site is indicated below the RNA secondary structures. The algorithm generating the structures colors each base according to its probability of assuming the predicted secondary structure, which is indicated by a rainbow scale reproduced in Figure 12C in gray scale.
- Figure 12D shows the results of hStCas9-mediated cleavage in the target locus using the Surveyor assay.
- RNA guide spacers 1 and 2 induced 14% and 6.4%, respectively.
- Statistical analysis of cleavage activity across biological replica at these two protospacer sites is also provided in Figure 6.
- Figure 16 provides a schematic of additional protospacer and corresponding PAM sequence targets of the S. thermophilus CRISPR system in the human EMX! locus. Two protospacer sequences are highlighted and their corresponding PAM sequences satisfying NNAGAAW motif are indicated by underlining 3' with respect to the corresponding highlighted sequence. Both protospacers target the anti-sense strand.
- Example 3 Sample target sequence selection algorithm.
- a software program is designed to identify candidate CRISPR target sequences on both strands of an input DNA sequence based on desired guide sequence length and a CRISPR motif sequence (PAM) for a specified CRISPR enzyme.
- PAM CRISPR motif sequence
- target sites for Cas9 from S. pyogenes, with PAM sequences NGG may be identified by searching for 5'-N x -NGG-3' both on the input sequence and on the reverse-complement of the input.
- target sites for Cas9 of S. thermophilus CRISPR 1, with PAM sequence NNAGAAW may be identified by searching for 5 '-N x -N AGAAW-3 ' both on the input sequence and on the reverse-complement of the input.
- target sites for Cas9 of S. thermophihis CRISPR3, with PAM sequence NGGNG may be identified by searching for 5'-N x - GGNG-3' both on the input sequence and on the reverse-complement of the input.
- the value "x" in N x . may be fixed by the program or specified by the user, such as 20.
- the program filters out sequences based on the number of times they appear in the relevant reference genome.
- the filtering step may be based on the seed sequence.
- results are filtered based on the number of occurrences of the seed:PA sequence in the relevant genome. The user may be allowed to choose the length of the seed sequence.
- the user may also be allowed to specify the number of occurrences of the seed:PAM sequence in a genome for purposes of passing the filter.
- the default is to screen for unique sequences. Filtration level is altered by changing both the length of the seed sequence and the number of occurrences of the sequence in the genome.
- the program may in addition or alternatively provide the sequence of a guide sequence complementary to the reported target sequence(s) by providing the reverse complement of the identified target sequence(s).
- chimeric RNAs comprising a guide sequence, a tracr mate sequence, and a tracr sequence in a single transcript
- Figure 18a illustrates a schematic of a bicistronic expression vector for chimeric RNA.
- Cas9 is driven by the CBh promoter and the chimeric RNA is driven by a U6 promoter.
- the chimeric guide RNA consists of a 20bp guide sequence (Ns) joined to the tracr sequence (running from the first "U" of the lower strand to the end of the transcript), which is truncated at various positions as indicated.
- Protospacer IDs and their corresponding genomic target, protospacer sequence, PAM sequence, and strand location are provided in Table D. Guide sequences were designed to be com lementary to the entire protospacer sequence in the case of separate transcripts in the hybrid system, or only to the underlined portion in the case of chimeric RNAs.
- HEK cell line 293FT Human embryonic kidney (HEK) cell line 293FT (Life Technologies) was maintained in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), 2mM GlutaMAX (Life Technologies), 1 00! m i . penicillin, and IQQjig/mL streptomycin at 37°C with 5% C0 2 incubation. 293FT cells were seeded onto 24-well plates (Coming) 24 hours prior to transfection at a density of 150,000 ceils per well. Cells were transfected using Lipofectamine 2000 (Life Technologies) following the manufacturer's recommended protocol. For each well of a 24- well plate, a total of 500ng plasmid was used.
- SURV EY OR assay for genome modification [00229] 293 FT cells were transfected with plasmid DNA as described above. Cells were incubated at 37°C for 72 hours post-transfection prior to genomic DNA extraction. Genomic DNA was extracted using the QuickExtract DNA Extraction Solution (Epicentre) following the manufacturer's protocol. Briefly, pelleted cells were resuspended in QuickExtract solution and incubated at 65°C for 15 minutes and 98°C for 10 minutes. The genomic region flanking the CRISPR target site for each gene was PGR amplified (primers listed in Table E), and products were purified using QiaQuick Spin Column (Qiagen) following the manufacturer ' s protocol.
- 400ng total of the purified PCR products were mixed with 2 ⁇ 1 10X Taq DNA Polymerase PGR buffer (Enzymatics) and ultrapure water to a final volume of 20 ⁇ 1, and subjected to a re- annealing process to enable heteroduplex formation: 95°C for lOmin, 95°C to 85°C ramping at - 2°C/s, 85°C to 25°C at - 0.25°C/s, and 25°C hold for 1 minute.
- products were treated with SURVEYOR nuclease and SURVEYOR enhancer S (Transgcnomies) following the manufacturer's recommended protocol, and analyzed on 4-20% Novex TBE poly-acrylamide gels (Life Technologies). Gels were stained with SYBR Gold DNA stain (Life Technologies) for 30 minutes and imaged with a Gel Doc gel imaging system (Bio-rad). Quantification was based on relative band intensities.
- each SpCas9 target site was operationally defined as a 20bp sequence followed by an NGG protospacer adjacent motif (PAM) sequence, and we identified all sequences satisfying this 5'-N2o-NGG-3' definition on all chromosomes.
- PAM NGG protospacer adjacent motif
- a 'seed' sequence which can be, for example, approximately 1 1 -12bp sequence 5' from the PAM sequence
- 5 '-NNNNNNN N -NGG-3 ' sequences were selected to be unique in the relevant genome. All genomic sequences were downloaded from the UCSC Genome Browser (Human genome hgl9, Mouse genome mm9, Rat genome rn5, Zebrafish genome danRer?, D. melanogaster genome dm4 and C. elegans genome cel O). The full search results are available to browse using UCSC Genome Browser information. An example vi sualization of some target si tes in the human genome is provided in Figure 21.
- Chimeric RNAs containing longer fragments of wild-type tracrRN A (chiRNA(+67) and chiRNA(+85)) mediated DNA cleavage at all three EMX1 target sites, with chiRNA(+85) in particular demonstrating significantly higher levels of DNA cleavage than the corresponding crRNA/tracrRNA hybrids that expressed guide and tracr sequences in separate transcripts ( Figures 18b and 19a).
- Two sites in the PVALB locus that yielded no detectable cleavage using the hybrid system (guide sequence and tracr sequence expressed as separate transcripts) were also targeted using chiRNAs.
- chiRNA(+67) and chiRNA(+85) were able to mediate significant cleavage at the two PVALB protospacers ( Figures 1 8c and 19b).
- chimeric RNA may be loaded onto Cas9 more efficiently than its native hybrid counterpart.
- all predicted unique target sites for the S. pyogenes Cas9 were computationally identified in the human, mouse, rat, zebra fish, C. elegans, and D. melanogaster genomes.
- Chimeric RNAs can be designed for Cas9 enzymes from other microbes to expand the target space of CR ISPR RNA -programmable nucleases.
- Figure 22 illustrates an exemplary bicistro ic expression vector for expression of chimeric RNA including up to the +85 nucleotide of wild-type tracr RNA sequence, and SpCas9 with nuclear localization sequences.
- SpCas9 is expressed from a CBh promoter and terminated with the bGH po yA signal (bGH pA).
- the expanded sequence illustrated immediately below the schematic corresponds to the region surrounding the guide sequence insertion site, and includes, from 5' to 3', 3 '-portion of the U6 promoter (first shaded region), Bbsl cleavage sites (arrows), partial direct repeat (tracr mate sequence GTTTTAGAGCTA, underlined), loop sequence GAAA, and +85 tracr sequence (underlined sequence following loop sequence).
- An exemplary guide sequence insert is illustrated below the guide sequence insertion site, with nucleotides of the guide sequence for a selected target represented by an "N".
- NLS-SpCas9-EGFP NLS-SpCas9-EGFP
- GMRKPAFLSGEQKKATvT LLFKTTSIRKV KQLKEDYFKK]ECFDSVEISGVEDRFNASL
- GIRD QSG ILDFL SDGFANRNFMQLJHDDSL FKEDIQKAQ ⁇ SGQGDSLHEH:IANLA
- GEGRPYEGTQTAKLKYT GGPLPFAWDILSPQFMYGS AYVKHPADIPDYL LSFPEGF
- NLS-SpCas9ii-NLS (the D10A nickase mutation is lowercase):
- N guide sequence; first underline :::: tracr mate sequence; second underline ::: tracr sequence; bold ::::: terminator)
- Example chimeric RNA for S. thermophilus LMD-9 CRISPRl Cas9 (with PA M of
- N guide sequence; first underline :::: tracr mate sequence; second underline ::: tracr sequence; bold :::: terminator)
- Example chimeric RNA for S. thennophilus LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)
- N guide sequence
- Example chimeric RNA for S. thermophilus LMD-9 CRISPR1 Cas9 (with PAM of
- Example chimeric RNA for S. thermophilus LMD-9 CRISP 3 Cas9 (with PAM of NGGNG)
- Example 5 RNA-guided editing of bacterial genomes using CRISPR-Cas systems
- Applicants used the CRIS PR-associated endonuclease Cas9 to introduce precise mutations in the genomes of Streptococcus pneumoniae and Escherichia coli.
- the approach relied on Cas9-directed cleavage at the targeted site to kill unmutated cells and circumvented the need for selectable markers or counter-selection systems.
- Cas9 specificity was reprogrammed by changing the sequence of short CRISPR RNA (crRNA) to make si gle- and muiti-iiucieotide changes carried on editing templates. Simultaneous use of two erRNAs enabled multiplex mutagenesis. In S.
- mutagenesis in eukaryotes is achieved by the use of sequence-specific nucleases that promote homologous recombination of a template DNA containing the mutation of interest.
- Zinc finger nucleases ZFNs
- transcription activator-like effector nucleases TALE s
- mutagenesis methods either introduce a selection marker in the edited locus or require a two-step process that includes a counter- selection system.
- phage recombination proteins have been used for recombineering, a tech ique that promotes homologuous recombination of linear DNA or oligonucleotides.
- recombineering efficiency can be relatively low (0.1 -10% for point mutations down to 10 "5 -10 "6 for larger modifications), in many cases requiring the screening of a large number of colonies. Therefore new technologies that are affordable, easy to use and efficient are still in need for the genetic engineering of both eukaryottc and prokaryotic organisms.
- CRISPR loci are composed of a series of repeats separated by 'spacer' sequences that match the genomes of bacteriophages and other mobile genetic elements.
- the repeat-spacer array is transcribed as a long precursor and processed within repeat sequences to generate small crRNA that specify the target sequences (also known as protospacers) cleaved by CRISPR systems.
- Cas9 is a dsDNA endonuclease that uses a crRNA guide to specify the site of cleavage. Loading of the crRNA guide onto Cas9 occurs during the processing of the crRNA precursor and requires a small R A amisense to the precursor, the tracrRNA, and RNAse III. In contrast to genome editing with ZFNs or TALENs, changing Cas9 target specificity does not require protein engineering but only the design of the short crRNA guide.
- Applicants recently showed in S. pneumoniae that the introduction of a CRISPR system targeting a chromosomal locus leads to the killing of the transformed cells. It was observed that occasional survivors contained mutations in the target region, suggesting that Cas9 dsDNA endonuclease activity against endogenous targets could be used for genome editing. Applicants showed that marker-less mutations can be introduced through the transformation of a template DNA fragment that will recombine in the genome and eliminate Cas9 target recognition. Directing the specificity of Cas9 with several different crR As allows for the introduction of multiple mutations at the same time. Applicants also characterized in detail the sequence requirements for Cas9 targeting and show that the approach can be combined with recombmeering for genome editing in E. coli.
- RESULTS Genome editing by Cas9 cleavage of a chromosomal target
- S. pneumoniae strain crR6 contains a Cas9-based CRISPR system that cleaves a target sequence present in the bacteriophage ⁇ 8232.5. This target was integrated into the srtA chromosomal locus of a second strain R6 b2j2' ⁇ An altered target sequence containing a mutation in the PAM region was integrated into the srtA locus of a third strain R6 3 /0J , rendering this strain 'immune' to CR1SPR cleavage ( Figure 28a).
- Another way to disrupt Cas9 ⁇ mediated cleavage is to introduce mutations in the protospacer region of the editing template. It is known that point mutations within the 'seed sequence' (the 8 to 10 protospacer nucleotides immediately adjacent to the PAM) can abolish cleavage by CRISPR nucleases. However, the exact length of this region is not known, and it is unclear whether mutations to any nucleotide in the seed can disrupt Cas9 target recognition. Applicants followed the same deep sequencing approach described above to randomize the entire protospacer sequence involved in base pair contacts with the crRNA and to determine all sequences that disrupt targeting.
- Cas9-mediated editing can also be used to generate multiple mutations for the study of biological pathways. Applicants decided to illustrate this for the sortase-dependent pathway that anchors surface proteins to the envelope of Gram-positive bacteria. Applicants introduced a .sona.se deletion by co-transformation of a chloramphenicol-resistant targeting construct and a AsrtA editing template ( Figure 33a,b), followed by a AbgaA deletion using a kanamycin-resistant targeting construct that replaced the previous one. In S, pneumoniae, ⁇ -galactosidase is covalentiy linked to the cell wall by sortase.
- deletion of srtA results in the release of the surface protein into the supernatant, whereas the double deletion has no detectable ⁇ - galactosidase activity ( Figure 34c).
- Such a sequential selection can be iterated as many times as required to generate multiple mutations.
- Spectinomycin-resistant transformants that retain the plasmid eliminated the CRISPR sequences ( Figure 34a,d).
- Mechanism and efficiency of editing To understand the mechanisms underlying genome editing with Cas9, Applicants designed an experiment in which the editing efficiency was measured independently of Cas9 cleavage. Applicants integrated the ermAM erythromycin resistance gene in the srtA locus, and introduced a premature stop codon using Cas9-mediated editing ( Figure 33). The resulting strain (JEN53) contains an ermAM(stop) allele and is sensitive to erythromycin. This strain may be used to assess the efficiency at which the ermAM gene is repaired by measuring the fraction of cells that restore antibiotic resistance with or without the use of Cas9 cleavage.
- JENS 3 was transformed with an editing template that restores the wild- type allele, together with either a kanamycin-resistant CRISPR construct targeting the ermAM(stop) allele (CRISPR: : ermAM (stop)) or a control construct without a spacer (CRISPR: :0) ( Figure 26a,b).
- CRISPR: : ermAM (stop) CRISPR: : ermAM (stop)
- CRISPR: :0 spacer
- Transformation of the CRISPR: : ermAM (stop) construct followed by kanamycin selection resulted in an increase of the fraction of erythromycin-resistant, edited cells to 99 % ( Figure 26c).
- Figure 26c To determine if this increase is caused by the killing of non-edited cells, Applicants compared the kanamycin- resistant colony forming units (cfu) obtained after co-transformation of JEN53 cells with the CRISPR: :ermAM(stop) or CRISPR: :0 constructs.
- This background frequency may be calculated as the ratio of CRISPR: :ermAM(stop)/CRISPR : :0 cfu, 2.6* 10 "3 (7.J xl0V2.7xl0 4 ) in this experiment, meaning that if the recombination frequency of the editing template is less than this value, CRISPR selection may not efficiently recover the desired mutants above the background.
- Applicants sought to introduce an A to C transversion in the rpsL gene that confers streptomycin resistance.
- the pCas9 plasmid was first introduced into E.
- CRISPR-Cas systems may be used for targeted genome editing in bacteria by the co-introduction of a targeting construct that ki lled wild-type cells and an editing template that both eliminated CRISPR cleavage and introduced the desired mutations.
- Different types of mutations insertions, deletions or sear-less single-nucleoiide substitutions
- Multiple mutations may be introduced at the same time.
- the specificity and versatility of editing using the CRISPR system relied on several unique properties of the Cas9 endonuclease: (i) its target specificity may be programmed with a small RNA, without the need for enzyme engineering, (ii) target specificity was very high, determined by a 20 bp RNA-DNA interaction with low probability of no -target recognition, (iii) almost any sequence may be targeted, the only requirement being the presence of an adjacent NGG sequence, (iv) almost any mutation in the NGG sequence, as well as mutations in the seed sequence of the protospacer, eliminates targeting.
- S. pneumoniae strain R6 was provided by Dr. Alexander Tomasz. Strain crR6 was generated in a previous study. Liquid cultures of S. pneumoniae were grown in THYE medium (30g/l Todd-Hewitt agar, 5 g/1 yeast extract). Cells were plated on tryptic soy agar (TSA) supplemented with 5 % defibrinated sheep blood. When appropriate, antibiotics were added as followings: kanamycin (400 ug/ml), chloramphenicol (5 erythromycin (1 ⁇ g/m ⁇ ) streptomycin (100 .g/ml) or spectinomycin (100 uu rn! ). Measurements of ⁇ -galactosidase activity were made using the Miller assay as previously described.
- E, coli strai s MG1655 and HME63 (derived from MG1655, A(argF-lac) U169 ⁇ cI857 Acro-bioA galK tyr 145 UAG mutS ⁇ >amp) (31) were provided by Jeff Roberts and Donald Court, respectively. Liquid cultures of E. coli were grown in LB medium (Difco). When appropriate, antibiotics were added as followings: chloramphenicol (25 ⁇ -g/ml), kanamycin (25 ⁇ / ⁇ ) and streptomycin (50 ⁇ ' ⁇ ).
- Competent cells were prepared as described previously (23). For all genome editing transformations, cells were gently thawed on ice and resuspended in 10 volumes of M2 medium supplemented with 100 ng/ml of competence- stimulating peptide CSP1(40), and followed by addition of editing constmcts (editing constructs were added to cells at a final concentration between 0.7 ng/ ⁇ to 2.5 p,g/ul). Cells were incubated 20 min at 37 °C before the addition of 2 ⁇ of targeting constmcts and then incubated 40 min at 37 °C. Serial dilutions of cells were plated on the appropriate medium to determine the colony forming units (efu) count.
- E coli Lambda-red reeonifoiiieering.
- Strain HME63 was used for ail recombineermg experiments. Recombineering cells were prepared and handled according to a previously published protocol (6). Briefly, a 2 ml overnight culture (LB medium) inoculated from a single colony obtained from a plate was grown at 30 °C. The overnight culture was diluted 100-fold and grown at 30 °C with shaking (200rpm) until the ODeoo is from 0.4-0.5 (approximately 3 hrs). For Lambda-red induction, the culture was transferred to a 42 °C water bath to shake at 200rpm for 15 min.
- the culture was swirled in an ice- water slurry and chilled on ice for 5-10 min. Ceils were then washed and aliquoted according to the protocol.
- 50 ⁇ ! of cells were mixed with ImM of salt-free oligos (IDT) or 100-150 ng of piasmid DNA (prepared by QIAprep Spin Miniprep Kit, Qiagen).
- Cel ls were electroporated using 1mm Gene Module cuvette (Bio-rad) at 1.8kV and were immediately resuspended in 1 ml of room temperature LB medium. Cells were recovered at 30 °C for 1-2 hrs before being plated on LB agar with appropriate antibiotic resistance and incubated at 32 °C overnight.
- S. pneumoniae genomic DNA was extracted using the Wizard Genomic DNA Purification Kit, following instructions provided by the manufacturer (Promega).
- S. pneumoniae genomic DNA was extracted using the Wizard Genomic DNA Purification Kit, following instructions provided by the manufacturer (Promega).
- genotyping purposes 700ul of overnight S. pneumoniae cultures were pelleted, resuspended in 60ul of lysozyme solution (2mg/ml) and incubated 30min at 37°C.
- the genomic DNA was extracted using QIAprep Spin Miniprep Kit (Qiagen).
- the resulting PGR product was transformed into competent S, pneumoniae crR6 cells and chloramphenicol -resistant transformants were selected.
- S. pneumoniae crR6M S. pneumoniae crR6 genomic DNA was amplified by PGR using primers L409/L488 and L448/L481, respectively.
- Each PGR product was gel -purified and they were fused by SOEing PGR with primers L409/L481 .
- the resulting PGR product was transformed into competent S. pneumoniae LAM226 cells and kanamycm-resistant transformants were selected,
- S. pneumoniae crR6M genomic DNA was amplified by PGR using primers L430/W286, and S. pneumoniae LA 226 genomic DNA was amplified by PGR using primers W288/L481.
- Each PGR product was gel-purified and they were fused by SOEing PGR. with primers L43Q/L481.
- the resulting PGR product was transformed into competent S. pneumoniae crR6M cells and chloramphenicol-resistant transformants were selected.
- S. pneumoniae crR6M genomic DNA was amplified by PGR using primers L430/W286 and W287/L481, respectively.
- Each PGR product was gel-purified and they were fused by SOEing PGR with primers L430/L481.
- the resulting PGR product was transformed into competent S. pneumoniae crR6Re ceils and kanamyein- resistant transformants were selected.
- S. pneumoniae crR6Rk genomic DNA was amplified by PGR using primers L430/W356 and W357/L481 , respectively. Each PGR product was gel-purified and they were fused by SOEing PGR with primers L430/L481. The resulting PGR. product was transformed into competent S. pneumoniae crR6Rc cells and kanamyc in-resistant transformants were selected.
- JEN38 R6 genomic DNA was amplified using primers L422/L461 and L459/L426, respectively.
- the ermAM gene (specifying erythromycin resistance) was amplified from plasmid pFW 15 43 using primers L457/L458.
- Each PGR product was gel-purified and ail three were fused by SOEing PGR with primers L422/L426, The resulting PGR. product was transformed into competent S. pneumoniae crR6Rc cells and erythromycin-resistant transformants were selected.
- S. pneumoniae JEN 53 was generated in two steps. First JE 43 was constructed as illustrated in Figure 33. JEN53 was generated by transforming genomic DNA of JEN25 into competent JEN43 cells and selecting on both chloramphenicol and erythromycin.
- S, pneumoniae crR.6Rk genomic DNA was amplified by PGR using primers W256/W365 and W366/L403, respectively.
- PGR product was purified and ligated by Gibson assembly.
- the assembly product was transformed into competent S. pneumoniae crR6Rc cells and kanamycin-resistant transformants were selected.
- pDB97 was constructed through phosphorylation and annealing of oligonucleotides B296/B297, followed by ligation in pLZ12spec digested by EcoRI/BamHI. Applicants fully sequenced pLZ12spec and deposited its sequence in genebank (accession: C1 12384).
- pDB98 was obtained after cloning the CRJSPR leader sequence was cloned together with a repeat-spacer-repeat unit into pLZ12spec. This was achieved through amplification of crR6Rc DNA with primers B298/B320 and B299/B321 , followed by SOEing PGR of both products and cloning in pLZ12spec with restriction sites BamHI/EcoRI. In this way the spacer sequence in pDB98 was engineered to contain two Bsal restriction sites in opposite directions that allow for the scar-less cloning of new spacers.
- pDB99 to pDBlQS were constructed by annealing of oligonucleotides B300/B301 (pDB99), B302/B303 (pDBlOO), B304/B305 (pDB lOl), B306/B307 (pDB102), B308/B309 (pDB103), B310/B311 (pDB104), B312/B313 (pDB105), B314/B315 (pDB106), B315/B317 (pDB107), B318/B319 (pDB108), followed by ligation in pDB98 cut by Bsal.
- the pCas9 plasmid was constructed as follow.
- Essential CRISPR elements were amplified from Streptococcos pyogenes SF370 genomic DNA with flanking homology arms for Gibson Assembly.
- the tracrRNA and Cas9 were amplified with oiigos HC008 and HC010.
- the leader and CRISPR sequences were amplified HCOl 1/HC014 and HC015/HC009, so that two Bsal type IIS sites were introduced in between two direct repeats to facilitate easy insertion of spacers.
- pCRISPR was constructed by subcloning the pCas9 CRISPR array in pZE21-MCSl through amplification with oiigos B298+B299 and restriction with EcoRI and BamHI.
- the rpsL targeting spacer was cloned by annealing of oiigos B352+B353 and cloning in the Bsal cut pCRISPR giving pCRISPR::rpsL.
- Gesieratiosi of targetlsig and editing constructs were made by Gibson assembly of Left PCRs and Right PCRs (Table G).
- Editing constructs were made by SOEing PGR fusing PGR products A (PGR A), PGR products B (PGR B) and PGR products C (PGR C) when applicable (Table G).
- the CRISPR::0 and CRISP R: :ermAM(stop) targeting constructs were generated by PGR amplification of JEN62 and crR6 genomic DNA respectively, with oiigos L409 and L481.
- Samples for the randomized targets were prepared using the following primers: B280-B290/L426 to randomize bases I -10 of the target and B269-B278/L426 to randomize bases 10-20, Primers L422/B268 and L422/B279 were used to amplify the cat gene and srtA upstream region to be assembled with the first and last 10 PGR products respectively.
- the assembled constructs were pooled together and 30 ng was transformed in R6 and crR6. After transformation, cells were plated on chloramphenicol selection. For each sample more than 2x 10" cells were pooled together in I ml of THYE and genomic DNA was extracted with the Promega Wizard kit.
- Primers B250/B251 were used to amplify the target region.
- PGR products were tagged and run on one Illumina MiSeq paired-end lane using 300 cycles.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CR ISPR/Cas system.
Description
CRISPR-CA ITIONS FOR
RE LAI' ED APPLICATIONS AND INCORPORATION BY REFERENCE
[0001 ] This application claims priority to US provisional patent applications 61/736,527, 61/748,427, 61/791,409 and 61/835,931 all entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on December 12, 2012, January 2, 2013, March 15, 2013 and June 17, 2013, respectively. This application also claims priority to US provisional patent application 63/802,174 entitled ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, filed on March 15, 2013.
[0002] Reference is made to US provisional patent applications 61/758,468; 61/769,046; 61/802,174; 61/806,375; 61/814,263; 61/819,803 and 61/828,130, each entitled ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, filed on January 30, 2013; February 25, 2013; March 15, 2013; March 28, 2033; April 20, 2013; May 6, 2013 and May 28, 2013 respectively. Reference is also made to US provisional patent applications 61/835,936, 61/836,127, 61/836,101, 61/836,080 and 61/835,973 each filed June 17, 2033. Reference is also made to US provisional patent application 61/842,322 and US patent application 14/054,414, each having Broad reference BI -201 1 /008 A, entitled CRISPR-CAS SYSTEMS AND METHODS FOR ALTERING EXPRESSION OF GENE PRODUCTS filed on July 2, 2013 and October 15, 2013 respectively.
[0003] The foregoing applications, and all documents cited therein or during their prosecution ("appln cited documents") and all documents cited or referenced in the appin cited documents, and all documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individual ly indicated to be incorporated by reference.
FIELD OF THE INVENTION
[0004] The present invention generally relates to systems, methods and compositio s used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that may use vector systems related to Clustered Regularly Interspaced Short Palindromic Repeats (CRJSPR) and components thereof,
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0005] This invention was made with government support under the NIH Pioneer Award DP 1MH 100706, awarded by the National Institutes of Health. The government has certain rights in the in ention.
BACKGROUND OF T! IF IN VENTION
[0006] Recent advances in genome sequencing techniques and analysis methods have significantly accelerated the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnological, and medical applications. Although genome-editing techniques such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for producing targeted genome perturbations, there remains a need for new genome engineering technologies that are affordable, easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome.
SUMMARY OF THE INVENTION
[0007] There exists a pressing eed for alternative and robust systems and techniques for sequence targeting with a wide array of applications. This invention addresses this need and provides related advantages. The CRISPR/Cas or the CRISPR-Cas system (both terms are used interchangeably throughout this application) does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target, in other words the Cas enzyme can be recruited to a specific DNA target using said short RNA molecule. Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may
significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. To utilize the CRISPR-Cas system effectively for genome editing without deleterious effects, it is critical to un derstan d aspects of engineering and optimization of these genome engineering tools, which are aspects of the claimed in vention.
[0008] In one aspect, the invention provides a vector system comprising one or more vectors. In some embodiments, the system comprises: (a) a first regulatory element operabl linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme compiexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence; wherein components (a) and (b) are located on the same or different vectors of the system, Irs some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system comprises the tracr sequence under the control of a third regulatory element, such as a polymerase III promoter. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. Determining optimal alignment is within the purview of one of skill in the art. For example, there are publically and commercially available alignment algorithms and programs such as, but not limited to, ClustalW, Smith- Waterman in matlab. Bowtie, Geneious, Biopython and SeqMan. In some embodiments, the CRISPR complex comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR complex in a detectable amount in the nucleus of a eukaryotic cell. Without wishing to be bound by theory, it is believed that a nuclear localization sequence is not necessary for CRISPR complex activity in
eukaryotes, but that including such sequences enhances activity of the system, especially as to targeting nucleic acid .molecules in the nucleus. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is 5. pneumoniae, S, pyogenes, or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homoiog or ortholog. In some embodiments, the CRISPR enzyme is codon- optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15- 20 nucleotides in length. In general, and throughout this specification, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partial ly double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein vira!iy-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, replication defective retroviruses, adenoviruses, replication detective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a vims for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors." Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
[0009] Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means thai the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operabl linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory elemeiit(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host ceil).
[0010] The term "regulatory element" is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poiy-U sequences). Such regulatory- elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host ceil and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulator}' sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal -dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector comprises one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g. 1, 2, 3, 4, 5, or more pol J promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and HI promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with, the CMV enhancer) [see, e.g., Boshart et al, Cell, 41 :521-530 (1985)], the SV40 promoter, the dihydro folate reductase promoter, the β-actin promoter, the piiosphoglycerol kinase (PGK) promoter, and the EFla promoter. Also encompassed by the term "regulatory element" are enhancer elements, such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Mol. Cell. Biol, Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and
the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31 , 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).
[0011] Advantageous vectors include lentiviruses and adeno-assoeiated viruses, a d types of such vectors can al so be selected for targeting particul ar types of cells.
[0012] In one aspect, the invention provides a vector comprising a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising one or more nuclear localization sequences. In some embodiments, said regulatory element drives transcription of the CRISPR enzyme in a eukaryotic cell such that said CRISPR enzyme accumulates in a detectable amount in the nucleus of the eukaryotic cell. In some embodiments, the regulatory element is a polymerase II promoter. I some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is 5. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity.
[0013] in one aspect, the invention provides a CRISPR enzyme comprising one or more uclear localization sequences of sufficient stre gth to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR e zyme lacks the ability to cleave one or more strands of a target sequence to which it binds.
[0014] In one aspect, the invention provides a eukarvotic host cell comprising (a) a first regulatory element operably linked to a tract mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR comple to a target sequence in a eukar otie cell, wherein the CRISPR complex comprises a CRISPR enzyme compiexed with (1) the guide sequence that is hybridized to the target sequence, a d (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. In some embodiments, the host cell comprises components (a) and (b). In some embodiments, component (a), component (b), or components (a) and (b) are stably integrated into a genome of the host eukaryotie cell. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotie cell. In some embodiments, the eukaryotie host cell further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence com lementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotie ceil. In some embodiments, the CRISPR enzyme is a type Π CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. I some embodiments, the Cas9 enzyme is 5. pneumoniae, S. pyogenes or S, thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon -optimized for expression in a eukarvotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase ( If promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide seque ce is at
least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15- 20 nucleotides in length. In an aspect, the invention provides a non-human eukaryotic organism; preferably a multicellular eukaryotie organism, comprising a eukaryotic host cell according to any of the described embodiments. In other aspects, the invention provides a eukaryotic organism; preferably a multicellular eukaryotie organism, comprising a eukaryotic host cell according to any of the described embodiments. The organism in some embodiments of these aspects may be an animal; for example a mammal. Also, the organism may be an arthropod such as an insect. The organism also may be a plant. Further, the organism may be a fungus.
[0015] In one aspect, the invention provides a kit comprising one or more of the components described herein. In some embodiments, the kit comprises a vector system and instructions for using the kit. In some embodiments, the vector system comprises (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR comple to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR. enzyme comprising a nuclear localization sequence. In some embodiments, the kit comprises components (a) and (b) located on the same or different vectors of the system. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence. In some ernbodirnenis, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type
II CRISPR system enzyme, in some embodiments, the CRISP R enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codo -optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length.
[0016] In one aspect, the invention provides a method of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cell, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence. In some embodiments, said vectors are delivered to the eukaryotic cell in a subject. In some embodiments, said modifying takes place in said eukaryotic cell in a cell culture. In some embodiments, the method further comprises isolating said eukaryotic cell from a subject prior to
said modifying. In some embodiments, the method further comprises returning said eukaryotic cell and/or cells derived therefrom to said subject.
[0017] In one aspect, the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cel ls, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.
[0018] In one aspect, the invention provides a method of generating a model eukaryotic cell comprising a mutated disease gene, In some embodiments, a disease gene is any gene associated an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) introducing one or more vectors into a eukaryotic cell, wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and (b) allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said disease gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, thereby generating a model eukaryotic cell comprising a mutated disease gene, in some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expression from a gene comprising the target sequence.
[0019] In one aspect, the invention provides a method for developing a biologically active agent that modulates a cell signaling event associated with a disease gene. In some embodiments, a disease gene is any gene associated an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) contacting a test compound wit a model cell of any one of the described embodiments; and (b) detecting a change in a readout that is indicative of a reduction or a augmentation of a ceil signaling event associated with said mutation in said disease gene, thereby developing said biologically active agent that modulates said cell signaling event associated with said disease gene.
[0020} In one aspect, the invention provides a recombinant polynucleotide comprising a guide sequence upstream of a tracr mate sequence, wherein the guide sequence when expressed directs sequence-specific binding of a CRJSPR complex to a corresponding target sequence present in a eukaryotic cell. In some embodiments, the target sequence is a viral sequence present in a eukaryotic cell. In some embodiments, the target sequence is a proto-oncogene or an oncogene.
[0021] In one aspect the invention provides for a method of selecting one or more prokaryotic cell(s) by introducing one or more mutations in a gene in the one or more prokaryotic cel l (s), the method comprising: introducing one or more vectors into the prokaryotic cell (s), wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, a tracr sequence, and a editing template; wherein the editing template comprises the one or more mutations that abolish CRISPR enzyme cleavage; al lowing homologous recombination of the editing template with the target polynucleotide in the cell(s) to be selected; allowing a CRJSPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said gene, wherein the CRJSPR complex comprises the CRJSPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target poiynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein binding of the CRISPR complex to the target polynucleotide induces cell death, thereby allowing one or more prokaryotic cell(s) in which one or more mutations have been introduced to be selected. In a preferred embodiment, the CRJSPR enzyme is Cas9. In another aspect of the invention the cell to be selected may be a eukaryotic cell. Aspects of the invention allow for selection of specific cells without requiring a selection marker or a two-step process that may include a counter-selection system.
[0022] Accordingly, it is an object of the invention not to encompass within the invention any previously known product, process of making the product, or method of using the product- such that Applicants reserve the right and hereby disclose a disclaimer of any previously known product, process, or method. It is further noted that the invention does not intend to encompass within the scope of the invention any product, process, or making of the product or method of using the product, which does not meet the written description and enablement requirements of the USPTO (35 U.S.C. § 1 12, first paragraph) or the EPO (Article 83 of the EPC), such that Applicants reserve the right and hereby disclose a disclaimer of any previously described product, process of making the product, or method of using the product,
[0023] It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as "comprises", "comprised", "comprising" and the like ca have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of and "consists essentially of have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention. These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0025] Figure 1 shows a schematic model of the CRISPR system. The Cas9 nuclease from Streptococcus pyogenes (yellow) is targeted to genomic DNA by a synthetic guide RNA (sgRNA) consisting of a 20-nt guide sequence (blue) and a scaffold (red). The guide sequence base-pairs with the DNA target (blue), directly upstream of a requisite 5 '-NGG protospacer adjacent motif (PAM; magenta), and Cas9 mediates a double-stranded break (DSB) ~3 bp upstream of the PAM (red triangle).
[0026] Figure 2A-F shows an exemplary CRISPR system, a possible mechanism of action, an example adaptation for expression in eukaryotie cells, and results of tests assessing nuclear localization and CRISPR activity.
[0027] Figure 3 shows an exemplary expression cassette for expression of CRISPR system elements in eukaryotie cells, predicted structures of example guide sequences, and CRISPR system activity as measured in eukaryotie and prokaryotic cells.
[0028] Figure 4A-0 shows results of an evaluation of SpCas9 specificity for an example target.
[0029] Figure 5A-G show an exemplary vector system and results for its use in directing homologous recombination in eukaryotie ceils.
[0030] Figure 6 provides a table of protospacer sequences and summarizes modification efficiency results for protospacer targets designed based on exemplary S. pyogenes and S. thermophilus CRISPR systems with corresponding PAMs against loci in human and mouse genomes. Cells were transfected with Cas9 and either pre-erRNA/tracrRjN A or chimeric RNA, and analyzed 72 hours after transfection. Percent indeis are calculated based on Surveyor assay- results from indicated cell lines (N:=3 for all protospacer targets, errors are S.E.M., N.D. indicates not detectable using the Surveyor assay, and N.T. indicates not tested in this study).
[0031] Figure 7A-C shows a comparison of different iracrRNA transcripts for Cas9- mediated gene targeting.
[0032] Figure 8 shows a schematic of a surveyor nuclease assay for detection of double strand break-induced micro-insertions and -deletions.
[0033] Figure 9A-B shows exemplary bicistronic expression vectors for expression of CRISPR system elements in eukaryotie cells.
[0034] Figure 10 shows a bacterial plasmid transformation interference assay, expression cassettes and plasmids used therein, and transformation efficiencies of cells used therein.
[0035] Figure llA-C shows histograms of distances between adjacent S. pyogenes SF370 locus I PAM (NGG) (Figure 10A) and S. thermophilus LMD9 locus 2 PA..VI (NNAGAAW) (Figure 10B) in the human genome; and distances for each PAM by chromosome (Chr) (Figure IOC).
[0036] Figure 12A-C shows an exemplary CRISPR system, an example adaptation for expression in eukaryotie cells, and results of tests assessing CRISPR activity.
[0037] Figure 13A-C shows exemplary manipulations of a CRISPR system for targeting of genomic loci in mammalian cells.
[0038] Figure 14A-B shows the results of a Northern blot analysis of erRNA processing in mammalian cel ls.
[0039] Figure 15 shows an exemplary selection of protospacers in the human PVALB and mouse Th loci.
[0040] Figure J 6 shows example protospacer and corresponding PAM sequence targets of the S. thermophilus CRISPR system in the human EMX1 locus.
[0041 ] Figure 17 provides a table of sequences for primers and probes used for Surveyor, RFLP, genomic sequencing, and Northern blot assays.
[0042] Figure 18A-C shows exemplary manipulation of a CRISPR system with chimeric RNAs and results of SURVEYOR assays for system activity in eukaryotic cells.
[0043] Figure 19A-B shows a graphical representation of the results of SURVEYOR assays for CRJSPR system activity in eukaryotic cells.
[0044] Figure 20 shows an exemplary visualization of some S. pyogenes Cas9 target sites in the human genome using the i CSC genome browser.
[ 0045] Figure 21 shows predicted secondary structures for exemplary chimeric RNAs comprising a guide sequence, tracr mate sequence, and tracr sequence.
[0046] Figure 22 shows exemplaiy bicistronic expression vectors for expression of CRISPR system elements in eukaryotic cells.
[0047] Figure 23 shows that Cas9 nuclease activity against endogenous targets may be exploited for genome editing, (a) Concept of genome editing using the CRISPR system. The CRISPR targeting construct directed cleavage of a chromosomal locus and was co -transformed with an editing template that recombined with the target to prevent cleavage. Kanamycin- resistant transformants that survived CRISPR attack contained modifications introduced by the editing template, tracr, ir ws-activating CRISPR RNA; aphA-3, kanamycin resistance gene, (b) Transformation of crR6M DNA in j 8"2'5 cells with no editing template, the R6 wild-type srtA or the R6370.1 editing templates. Recombination of either R6 srtA or R6"' ) 1 prevented cleavage by Cas9. Transformation efficiency was calculated as colony forming units (cfu) per μg of crR6 DNA; the mean values with standard deviations from at least three independent experiments are shown. PCR analysis was performed on 8 clones in each transformation. "Un."
indicates the unedited srtA locus of strain Κβ^'^; "Ed." shows the editing template. R68 3?"5 and R6J "J 1 targets are distinguished by restriction with Eael.
[0048] Figure 24 shows analysis of PAM and seed sequences that eliminate Cas9 cleavage, (a) PCR products with randomized PAM sequences or randomized seed sequences were transformed in crR6 cells. These cells expressed Cas9 loaded with a crRNA that targeted a chromosomal region of R6'""""J ceils (highlighted in pink) that is absent from the R6 genome. More than 2* 105 chloramphenicoi-resistant transformants, carrying inactive PAM or seed sequences, were combined for amplification and deep sequencing of the target region, (b) Relative proportion of number of reads after transformation of the random PAM constructs in crR6 cells (compared to number of reads in R6 transformants). The relative abundance for each 3 -nucleotide PAM sequence is shown. Severely underrepresented sequences (NGG) are shown in red; partially underrepresented one in orange ( NAG) (c) Relative proportion of number of reads after transformation of the random seed sequence constmcts in crR6 ceils (compared to number of reads in R6 transformants). The relative abundance of each nucleotide for each position of the first 20 nucleotides of the protospacer sequence is shown. High abundance indicates lack of cleavage by Cas9, i.e. a CRISPR inactivating mutation. The grey line shows the level of the WT sequence. The dotted line represents the level above which a mutation significantly disrupts cleavage (See section "Analysis of deep sequencing data" in Example 5)
[0049] Figure 25 shows introduction of single and multiple mutations using the CRISPR system in S. pneumoniae, (a) Nucleotide and amino acid sequences of the wild-type and edited (green nucleotides; underlined amino acid residues) bgaA. The protospacer, PAM and restriction sites are shown, (b) Transformation efficiency of ceils transformed with targeting constmcts in the presence of an editing template or control, (c) PCR analysis for 8 transformants of each editing experiment followed by digestion with BtgZI (R→A) and Tsel (NE→AA). Deletion of bgaA was revealed as a smaller PCR product, (d) Miller assay to measure the β-galactosidase activity of WT and edited strains, (e) For a single-step, double deletion the targeting construct contained two spacers (in this case matching srtA and bgaA) and was co-transformed with two different editing templates (f) PCR analysis for 8 transformants to detect deletions in srtA and bgaA loci. 6/8 transformants contained deletions of both genes.
[00S0] Figure 26 provides mechanisms underlying editing using the CRISPR system, (a) A stop codon was introduced in the erythromycin resistance gene ermAM to generate strain JENS 3.
The wild-type sequence can be restored by targeting the stop codon with the CRISPR: :ermA (stop) construct, and using the ermAM wild-type sequence as an editing template, (b) Mutant and wild-type ermAM sequences, (c) Fraction of erythromicyn-resistant (ermR) cfu calculated from total or kanamyci -resistant (kanR) cfu. (d) Fraction of total cel ls that acquire both the CRISPR construct and the editing template. Co-transformation of the CRISPR targeti g construct produced more transformants (t-test, p=0.011). In all cases the values show the meani-s.d. for three independent experiments.
[0051] Figure 27 illustrates ge ome editing with the CRISPR system i E. coli. (a) A kanamycin-resistant plasmid carrying the CRISPR array (pCRISPR) targeting the gene to edit may be transformed in the HME63 reeombineering strain containing a chloramphenicol-resistant plasmid harboring cas9 and tracr (pCas9), together with an oligonucleotide specifying the mutation, (b) A K42T mutation conferring streptomycin resistance was introduced in the rpsL gene (c) Fraction of streptomicyn-resistant (strepR) cfu calculated from total or kanamycin- resistant (kanR) cfu. (d) Fraction of total cells that acquire both the pCRISPR plasmid and the editing oligonucleotide. Co-transformation of the pCRISPR targeting plasmid produced more transformants (t-test, p=0.004). In al l cases the values showed the meani-s.d. for three independent experiments.
[0052] Figure 28 illustrates the transformation of crR6 genomic DNA leads to editing of the targeted locus (a) The IS 1167 element of S. pneumoniae R6 was replaced by the CRISPROl locus of S. pyogenes SF370 to generate crR6 strain. This locus encodes for the Cas9 nuclease, a CRISPR array with six spacers, the tracrRNA that is required for crRNA biogenesis and Casl , Cas2 and Csn2, proteins not necessary for targeting. Strain crR6M contains a minimal functional CRISPR system without casl, casl and csn2. The aphA-3 gene encodes kanamycin resistance. Protospacers from the streptococcal bacteriophages φ8232.5 and φ370.1 were fused to a chloramphenicol resistance gene (cat) and integrated, in the srtA gene of strain R6 to generate strains R68232.5 and R6370.1. (b) Left panel: Transfomiation of crR6 and crR6M genomic DNA in R6C and R As a control of cell competence a streptomycin resistant gene was also transformed. Right panel: PCR analysis of 8 R6823 transformants with crR6 genomic DNA. Primers that amplify the srtA locus were used for PCR. 7/8 genotyped colonies replaced the R68232.5 srtA locus by the WT locus from the crR6 genomic DNA.
study. In all cases the wild-type and mutant protospacer and PAM sequences (or their reverse complement) are indicated. When relevant, the amino acid sequence encoded by the protospacer is provided. For each editing experiment, all strains for which PCR and restriction analysis corroborated the introduction of the desired modification were sequenced. A representative chromatogram is shown, (a) Chromatogram for the introduction of a PAM mutation into the R68232 5 target (Figure 23d). (b) Chromatograms for the introduction of the R>A and NE>AA mutations into β-galactosidase (bgaA) (Figure 25c). (c) Chromatogram for the introduction of a 6664 bp deletion within bgaA ORF (Figures 25c and 25f). The dotted line indicates the limits of the deletion, (d) Chromatogram for the introduction of a 729 bp deletion within srtA ORF (Figure 25f). The dotted line indicates the limits of the deletion, (e) Chromatograms for the generation of a premature stop codon within ermAM (Figure 33). (f) rpsL editing in E. coli (Figure 27).
[0054] Figure 30 illustrates CRISPR immunity against random S. pneumoniae targets containing different PAMs. (a) Position of the 10 random targets on the S. pneumoniae R6 genome. The chosen targets have different PAMs and are on both strands, (b) Spacers corresponding to the targets were cloned in a minimal CRISPR array on plasmid pLZ12 and transformed into strain crR6Rc, which supplies the processing and targeting machinery in trans, (c) Transformation efficiency of the different plasmids in strain R6 and crR6Rc. No colonies were recovered for the transformation of pDB99-108 (T1-T10) in crR6Rc. The dashed line represents limit of detection of the assay.
[0055] Figure 31 provides a general scheme for targeted genome editing. To facilitate targeted genome editing, crR6M was further engineered to contain tracrRNA, Cas9 and only one repeat of the CRISPR array followed by kanamycin resistance marker (aphA-3), generating strain crR6Rk. DNA from this strain is used as a template for PCR with primers designed to introduce a new spacer (green box designated with N). The left and right PCRs are assembled using the Gibson method to create the targeting construct. Both the targeting and editing constructs are then transformed into strain crR6Rc, which is a strain equivalent to crR6Rk but has the kanamycin resistance marker replaced by a chloramphenicol resistance marker (cat). About 90 % of the kanamycin-resistant transformants contain the desired mutation.
are considered to be valid PAMs. Data is shown for the S. pneumoniae R6 genome as well as for a random sequence of the same length and with the same GC-content (39.7 %). The dotted line represents the average distance (12) between PAMs in the R6 genome.
[0057] Figure 33 illustrates CRISPR-mediated editing of the ermAM locus using genomic DNA as targeting construct. To use genomic DNA as targeting construct it is necessary to avoid CRISPR autoimmunity, and therefore a spacer against a sequence not present in the chromosome must be used (in this case the ermAM erythromycin resistance gene), (a) Nucleotide and amino acid sequences of the wild-type and mutated (red letters) ermAM gene. The protospacer and PAM sequences are shown, (b) A schematic for CRISPR-mediated editing of the ermAM locus using genomic DNA. A construct carrying an ermvl -targeting spacer (blue box) is made by PCR and Gibson assembly, and transformed into strain crR6Rc, generating strain JEN37. The genomic DNA of JEN37 was then used as a targeting construct, and was co-transformed with the editing template into JEN38, a strain in which the srtA gene was replaced by a wild-type copy of ermAM. Kanamycin-resistant transformants contain the edited genotype (JEN43). (c) Number of kanamycin-resistant cells obtained after co-transformation of targeting and editing or control templates. In the presence of the control template 5.4* 10 cfu ml were obtained, and 4.3x 10 cfu ml when the editing template was used. This difference indicates an editing efficiency of about 99 % [(4.3 l05-5.4x l03)/4.3x l05]. (d) To check for the presence of edited cells seven kanamycin-resistant clones and JEN38 were streaked on agar plates with (erm+) or without (erm-) erythromycin. Only the positive control displayed resistance to erythromycin. The ermAM mut genotype of one of these transformants was also verified by DNA sequencing (Figure 29e).
[0058] Figure 34 illustrates sequential introduction of mutations by CRISPR-mediated genome editing, (a) A schematic for sequential introduction of mutations by CRISPR-mediated genome editing. First, R6 is engineered to generate crR6Rk. crR6Rk is co-transformed with a srtA -targeting construct fused to cat for chloramphenicol selection of edited cells, along with an editing construct for a AsrtA in-frame deletion. Strain crR6 AsrtA is generated by selection on chlramphenicol. Subsequently, the AsrtA strain is co-transformed with a bgaA -targeting construct fused to aphA-3 for kanamycin selection of edited cells, and an editing construct containing a AbgaA in-frame deletion. Finally, the engineered CRISPR locus can be erased from
plasmid carrying a bgaA protospacer (pDB97), and selection on spectinomycin. (b) PCR analysis for 8 chloramphenicol (Cam)-resistant transformants to detect the deletion in the srtA locus, (c) β-galactosidase activity as measured by Miller assay. In S. pneumoniae, this enzyme is anchored to the cell wall by sortase A. Deletion of the srtA gene results in the release of β-galactosidase into the supernatant. AbgaA mutants show no activity, (d) PCR analysis for 8 spectinomycin (Spec)-resistant transformants to detect the replacement of the CRISPR locus by wild-type IS 1167.
[0059] Figure 35 illustrates the background mutation frequency of CRISPR in S. pneumoniae, (a) Transformation of the CRISPR: :0 or CRISPR: :erm(stop) targeting constructs in JEN53, with or without the ermAM editing template. The difference in kanR CFU between CRISPR::0 and CRISPR: :erm(stop) indicates that Cas9 cleavage kills non-edited cells. Mutants that escape CRISPR interference in the absence of editing template are observed at a frequency of 3x l0-3. (b) PCR analysis of the CRISPR locus of escapers shows that 7/8 have a spacer deletion, (c) Escaper #2 carries a point mutation in cas9.
[0060] Figure 36 illustrates that the essential elements of the S. pyogenes CRISPR locus 1 are reconstituted in E. coli using pCas9. The plasmid contained tracrRNA, Cas9, as well as a leader sequence driving the crRNA array. The pCRISPR plasmids contained the leader and the array only. Spacers may be inserted into the crRNA array between Bsal sites using annealed oligonucleotides. Oligonucleotide design is shown at bottom. pCas9 carried chloramphenicol resistance (CmR) and is based on the low-copy pACYC184 plasmid backbone. pCRISPR is based on the high-copy number pZE21 plasmid. Two plasmids were required because a pCRISPR plasmid containing a spacer targeting the E. coli chromosome may not be constructed using this organism as a cloning host if Cas9 is also present (it will kill the host).
[0061] Figure 37 illustrates CRISPR-directed editing in E.coli MG1655. An oligonucleotide (W542) carrying a point mutation that both confers streptomycin resistance and abolishes CRISPR immunity, together with a plasmid targeting rpsL (pCRISPR: :rpsL) or a control plasmid (pCRISPR::0) were co-transformed into wild-type E.coli strain MG1655 containing pCas9. Transformants were selected on media containing either streptomycin or kanamycin. Dashed line indicates limit of detection of the transformation assay.
[0062] Figure 38 illustrates the background mutation frequency of CRISPR in E. coli ί:ΪΜΕ63. (a) Transformation of the pCRISPR::0 or pCRISPR::rpsL plasmids into HME63 competent cells. Mutants that escape CRISPR interference were observed at a frequency of 2. 10 \ (b) Anrplification of the CRISPR array of escapers showed that 8/8 have deleted the spacer.
[0063] Figure 39A-D shows a circular depiction of the phylo genetic analysis revealing five families of Cas9s, including three groups of large Cas9s (- 1400 amino acids) and two of small Cas9s (~1100 amino acids),
[0064] Figure 40A-F shows the linear depiction of the phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (-1400 amino acids) and two of small Cas9s (~1 100 amino acids).
10065] Figure 41A-M shows sequences where the mutation points are located within the SpCas9 gene.
[0066] Figure 42 shows a schematic construct in which the transcriptional activation domain (VP64) is fused to Cas9 with two mutations in the catalytic domains (D10 and H840).
[0067] Figure 43A-D shows genome editing via homologous recombination, (a) Schematic of SpCas9 nickase, with D10A mutation in the RuvC I catalytic domain, (b) Schematic representing homologous recombination (HR) at the human EMXl locus using either sense or antisense single stranded oligonucleotides as repair templates. Red arrow above indicates sgRNA cleavage site; PCR primers for genotyping (Tables J and ) are indicated as arrows in right panel, (c) Sequence of region modified by HR. d, SURVEYOR assay for wildtype (wt) and nickase (D10A) SpCas9-mediated indels at the EMXl target 1 locus in =3), Arrows indicate positions of expected fragment sizes.
[0068] Figure 44A-B shows single vector designs for SpCas9.
[0069] Figure 45 shows quantification of cleavage of NLS-Csnl constructs NLS-Csnl , Csnl, Csnl-NLS, NLS-Csnl-NLS, NLS-Csnl -GFP-NLS and UnTFN.
[0070] Figure 46 shows index frequency of NLS-Cas9, Cas9, Cas9-NLS and NLS-Cas9- NLS.
[0071] Figure 47 shows a gel demonstrating that SpCas9 with nickase mutations (individually) do not induce double strand breaks.
[0072] Figure 48 shows a design of the oligo DNA used as Homologous Recombination (HR) template in this experiment and a comparison of HR efficiency induced by different combinations of Cas9 protein and HR template.
[0073] Figure 49A shows the Conditional Cas9, Rosa.26 targeting vector map.
[0074] Figure 49B shows the Constitutive Cas9, Rosa26 targeting vector map.
[0075] Figure 50A-H show the sequences of each element present in the vector maps of
Figures 49A-B.
[0076] Figure 51 shows a schematic of the important elements in the Constitutive and Conditional Cas9 constructs.
[0077] Figure 52 shows the functional validation of the expression of Constitutive and Conditional Cas9 constructs.
[0078] Figure 53 shows the validation of Cas9 nuclease activity by Surveyor.
[0079] Figure 54 shows the quantification of Cas9 nuclease activity.
[0080] Figure 55 shows construct design and homologous recombination (HR) strategy.
[0081] Figure 56 shows the genomic PCR genotyping results for the constitutive (Right) and conditional (Left) constructs at two different gel exposure times (top row for 3 min and bottom row for 1 min).
[0082] Figure 57 shows Cas9 activation in mESCs.
[0083] Figure 58 shows a schematic of the strategy used to mediate gene knockout via NHEJ using a nickase version of Cas9 along with two guide RNAs.
[0084] Figure 59 shows how DNA double-strand break (DSB) repair promotes gene editing. In the error-prone non-homologous end joining (NHEJ) pathway, the ends of a DSB are processed by endogenous DN A repair machineries and rejoined together, which can result in random insertion'tieietion (indel) mutations at the site of junction. Indel mutations occurring within the coding region of a gene can result in frame-shift and a premature stop codon, leading to gene knockout. Alternatively, a repair template in the form of a plasmid or single-stranded oligodeoxynucleotid.es (ssODN) can be supplied to leverage the homology-directed repair (HDR) pathway, which allows high fidelity and precise editing.
[0085] Figure 60 shows the timeline and overview of experiments. Steps for reagent design, construction, validation, and cell line expansion. Custom sgRNAs (Sight blue bars) for each target, as well as genotyping primers, are designed in siiico via our online design tool (available
at the website genome-engineering.org/tools). sgRNA expression vectors are then cloned into a plasmid containing Cas9 (PX330) and verified via DNA sequencing. Completed plasmids (pCRISPRs), and optional repair templates for facilitating homology directed repair, are then transfected into cells and assayed for ability to .mediate targeted cleavage. Finally, transfected cel ls can be clonally expanded to derive isogenic cel l lines with defined mutations.
[0086] Figiire 61 shows Target selection a d reagent preparation, (a) For S. pyogenes Cas9, 20-bp targets (highlighted in blue) must be followed by 5 '-NGG, which can occur in either strand on genomic DNA. We recommend using the online tool described in this protocol in aiding target selection (www.genome-mgineering.org tools). (b) Schematic for co-transfection of Cas9 expression plasmid (PX 165) and PCR-amplified U6-driven sgRNA expression cassette. Using a U6 promoter-containing PCR template and a fixed forward primer (U6 Fwd), sgRNA - encoding DNA can appended onto the U6 reverse primer (U6 Rev) and synthesized as an extended DNA oligo (Ultramer oiigos from IDT). Note the guide sequence (blue N's) in U6 Rev- is the reverse complement of the 5'-NGG flanking target sequence, (c) Schematic for scarless cloning of the guide sequence oiigos into a plasmid containing Cas9 and sgRNA scaffold (PX330). The guide oligos (blue N's) contain overhangs for ligation into the pair of Bbsl sites on PS330, with the top and bottom strand orientations matching those of the genomic target (i.e. top oligo is the 20-bp sequence preceding 5 ~NGG in genomic DNA). Digestion of PX33Q with Bbsl allows the replacement of the Type lis restriction sites (blue outline) with direct insertion of annealed oiigos. It is worth noting that an extra G was placed before the first base of the guide sequence. Applicants have found that an extra G in front of the guide sequence does not adversely affect targeting efficiency. In cases when the 20-nt guide sequence of choice does not begin with guanine, the extra guanine will ensure the sgRNA is efficient])? transcribed by the U6 promoter, which prefers a guanine in the first base of the transcript.
[0087] Figure 62 shows the anticipated results for multiplex NHEJ. (a) Schematic of the SURVEYOR assay used to determine inde percentage. First, genomic DNA from the heterogeneous population of Cas9-targeted cells is amplified by PCR.. Amplicons are then reannealed slowly to generate heteroduplexes. The reannealed hcteroduplexes are cleaved by SURVEYOR nuclease, whereas homoduplexes are left intact. Cas9-mediated cleavage efficiency (% indel) is calculated based on the fraction of cleaved DNA, as determined by integrated intensity of gel bands, (b) Two sgRNAs (orange and blue bars) are designed to target the human
GRIN2B and DYRKIA loci. SURVEYOR gel shows modification at both loci in transfecied cells. Colored arrows indicated expected fragment sizes for each locus, (c) A pair of sgRNAs (light blue and green bars) are designed to excise an exon (dark blue) in the human EMXl locus. Target sequences and PAMs (red) are shown in respective colors, and sites of cleavage indicated by red triangle. Predicted junction is shown below. Individual clones isolated from cell populations transfecied with sgRNA 3, 4, or both are assayed by PCR (OUT Fwd, OUT Rev), reflecting a deletion of ~270-bp. Representative clones with no modification (12/23), mono- allelic (10/23), and bi-allelic (1/23) modifications are shown. IN Fwd and ΓΝ Rev primers are used to screen for inversion events (Fig. 6d). (d) Quantification of clonal lines with EMXl exon deletions. Two pairs of sgRNAs (3.1, 3.2 left-flanking sgRNAs; 4.1, 4.2, right flanking sgRNAs) are used to mediate deletions of variable sizes around one EMXl exon. Transfecied cells are clonaily isolated and expanded for genotyping analysis for deletions and inversion events. Of the 105 clones are screened, 51 (49%) and 11 (10%) carrying heterozygous and homozygous deletions, respectively. Approximate deletion sizes are given since junctions may be variable.
[0088] Figure 63A-C shows the application of ssODNs and targeting vector to mediate HR with both wifdtype and nickase mutant of Cas9 in HEK293FT and HUES9 cells with efficiencies ranging from 1.0-27%.
[0089] Figure 64 shows a schematic of a PCR-based method for rapid and efficient CRISPR targeting in mammalian ceils. A plasmid containing the human RNA polymerase III promoter U6 is PCR-amplified using a U6-specific forward primer and a reverse primer carrying the reverse complement of part of the U6 promoter, the sgRNA(+85) scaffold with guide sequence, and 7 T nucleotides for transcriptional termination. The resulting PCR product is purified and co- delivered with a plasmid carrying Cas9 driven by the CBh promoter.
[0090] Figure 65 shows SURVEYOR Mutation Detection Kit from Transgenomics results for each gRNA and respective controls. A positive SURVEY R result is one large band corresponding to the genomic PCR and two smaller bands that are the product of the SURVEYOR nuclease making a double-strand break at the site of a mutation. Each gRNA was validated in the mouse cell line, Neuro-N2a, by liposomal transient co-transfection with hSpCas9. 72 hours post-transfection genomic DNA was purified using QuickExtract DNA from Epicentre. PCR was performed to amplify the locus of interest.
[0091] Figure 66 shows Surveyor results for 38 live pups (lanes 1-38) 1 dead pup (lane 39) and 1 wild-type pup for comparison (lane 40). Pups 1-19 were injected with gRNA Chd.8.2 and pups 20-38 were injected with gRNA Chd8.3. Of the 38 live pups, 13 were positive for a mutation. The one dead pup also had a mutation. There was no mutation detected in the wild- type sample. Genomic PCR sequencing was consistent with the SURVEYOR assay findings.
[0092] Figure 67 shows a design of different Cas9 NLS constructs. Ail Cas9 were the human-codon-optimized version of the Sp Cas9. LS sequences are linked to the cas9 gene at either N-terminus or C-terminus. All Cas9 variants with different NLS designs were cloned into a backbone vector containing so it is driven by EFla promoter. On the same vector there is a chimeric RNA targeting human EMXl locus driven by U6 promoter, together forming a two- component system.
[0093] Figure 68 shows the efficiency of genomic cleavage induced by Cas9 variants bearing different NLS designs. The percentage indicate the portion of human EMXl genomic DNA that were cleaved by each construct. Ail experiments are from 3 biological replicates, n = 3, error indicates S.E.M,
[0094] Figure 69A shows a design of the CRISPR-TF (Transcription Factor) with transcriptional activation activity. The chimeric RNA is expressed by U6 promoter, while a human-codon-optimized, double-mutant version of the Cas9 protein (hSpCas9m), operably linked to triple NLS and a VP64 functional domain is expressed by a EF l a promoter. The double mutations, DIOA and H840A, renders the cas9 protein unable to introduce any cleavage but maintained its capacity to bind to target DNA when guided by the chimeric R NA.
[0095] Figure 69B shows transcriptional activation of the human SOX2 gene with CRISPR- TF system (Chimeric RNA and the Cas9-NLS-VP64 fusion protein). 293FT cells were transfected with piasmids bearing two components: (I) U6-driven different chimeric RNAs targeting 20-bp sequences within or around the human SOX2 genomic locus, and (2) EF la- driven hSpCas9m (double mutant)-NLS-VP64 fusion protein. 96 hours post transfection, 293FT cells were harvested and the level of activation is measured by the induction of mRNA expression using a qRT-PCR assay. All expression levels are normalized against the control group (grey bar), which represents results from cells transfected with the CRISPR-TF backbone plasmid without chimeric RNA. The qRT-PCR probes used for detecting the SOX2 mRNA is
Taqman Human Gene Expression Assay (Life Technologies). All experiments represents data from 3 biological replicates, n::::3, error bars show s.e.m.
[0096] Figure 70 depicts NLS architecture optimization for SpCas9.
[0097] Figure 71 shows a QQ plot for NGGNN sequences.
[CI098] Figure 72 shows a histogram of the data density with fitted normal distribution (black line) and ,99 quantile (dotted line).
[0099] Figure 73A-C shows RNA-guided repression of bgaA expression by dgRNA::cas9**. a. The Cas9 protein binds to the tracrR A, and to the precursor CRISPR RNA which is processed by RNAselll to form the crRNA. The crRNA directs binding of Cas9 to the bgaA promoter and represses transcription, b. The targets used to direct Cas9** to the bgaA promoter are represented. Putative -35, -10 as well as the bgaA start codon are in bold. c. Betagaiactosidase activity as measure by Miller assay in the absence of targeting and for the four different targets.
[00100] Figure 74A-E shows characterization of Cas9** mediated repression, a. The gfpmui2 gene and its promoter, including the -35 and -10 signals are represented together with the position of the different target sites used the study, b. Relative fluorescence upon targeting of the coding strand, c. Relative fluorescence upon targeting of the non-coding strand, d. Northern blot with probes B477 and B478 on RNA extracted from T5, T10, B10 or a control strain without a target, e. Effect of an increased number of mutations in the 5' end of the crRNA of Bl, T5 and B10.
[00101] The figures herein are for illustrative purposes only and are not necessarily drawn to scale,
DETAILED DESCRIPTION OF THE INVENTION
[00102] The terms "polynucleotide", "nucleotide", "nucleotide sequence", "nucleic acid" and "Oligonucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonueleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, in Irons, messenger RNA (mRNA), transfer RNA, ribosomai RNA, short interfering RNA (siRNA), short-hairpin RNA (shR A), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides,
branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers, A polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nuc!eotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
[00103] In aspects of the invention the terms "chimeric RNA", "chimeric guide RNA", "guide RNA", "single guide RNA" and "synthetic guide RNA" are used interchangeably and refer to the polynucleotide sequence comprising the guide sequence, the tracr sequence and the tracr mate sequence. The term "guide sequence" refers to the about 20bp sequence within the guide RNA that specifies the target site and may be used interchangeably with the terms "guide" or "spacer". The term "tracr mate sequence" may also be used interchangeably with the term "direct repeat(s)".
[00104] As used herein the term "wild type" is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.
[00105] As used herein the term "variant" should be taken to mean the exhibition of qualities that have a pattern that deviates from what occurs in nature.
[00106] The terms "non-naturally occurring" or "engineered" are used interchangeably and indicate the involvement of the hand of man. The terms, when referring to nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature.
[00107] "Complementarity" refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick base pairing or other non- traditional types. A percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100%) complementary). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a
second nucleic acid sequence. "Substantially complementary" as used herein refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under strirs gen t condi tio s .
[00108] As used herein, "stringent conditions" for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non-target sequences. Stringent conditions are generally sequence-dependent, and vary depending on a number of factors. In general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. No -limiting examples of stringent conditions are described in detail in Tijssen (1993), Laboratory Techniques In Biochemistry And Molecular Biology- Hybridization With Nucleic Acid Probes Part I, Second Chapter "Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, N.Y.
[00109] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson Crick base pairing, Hoogstein binding, or in any other sequence specific manner. The complex may comprise two strands forming a duplex structure, three or more strands forming a multi stranded complex, a single self hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of PGR, or the cleavage of a polynucleotide by an enzyme. A sequence capable of hybridizing with a given sequence is referred to as the "compl ement" of the given sequence.
[00110] As used herein, "expression" refers to the process by which a polynucleotide is transcribed from a DNA template (such as into and mRN A or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as "gene product." If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic ceil.
[00111] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may
comprise modified amino acids, and it may be interrupted by non amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. As used herein the term "amino acid" includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or I, optical isomers, and amino acid analogs and peptidomimetics.
[00112 J The terms "subject," "individual," and "patient" are used interchangeably herein to refer to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed.
[00113] The terms "therapeutic agent", "therapeutic capable agent" or "treatment agent" are used interchangeably and refer to a molecule or compound that confers some beneficial effect upon administration to a subject. The beneficial effect includes enablement of diagnostic determinations; amelioration of a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder or condition; and generally counteracting a disease, symptom, disorder or pathological condition.
[00114] As used herein, "treatment" or "treating," or "palliating" or "ameliorati g" are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment. For prophylactic benefit, the compositions may be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet bee manifested .
[00115] The term "effective amount" or "therapeutically effective amount" refers to the amount of an agent that is sufficient to effect beneficial or desired results. The therapeutically effective amount may vary depending upon one or more of: the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be detennined by one of ordinary skill in the art. The term also applies to a dose that will provide an image for detection by any one of the
imaging methods described herein. The specific dose may vary depending on one or more of: the particular agent chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to be imaged, and the physical delivery system in which it is carried.
[00116] The practice of the present invention employs, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cel l biology, genomics and recombinant D A, which are within the skill of the art. See Sambrook, Fritsch and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, et al. eds., (1987)); the series METHODS IN EN ZYM OLOGY (Academic Press, Inc.): PGR 2: A PRACTICAL APPROACH (M.J. MacPherson, B.D. Flames and G.R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE. (R.I. Fresliney, ed. (1987)).
[00117] Several aspects of the invention relate to vector systems comprising one or more vectors, or vectors as such. Vectors can be designed for expression of CRISPR transcripts (e.g. nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells. For example, CRISPR transcripts can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in GoeddeL GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
[00118] Vectors may be introduced and propagated in a prokaryote. In some embodiments, a prokaryote is used to amplify copies of a vector to be introduced into a eukaryotic cell or as an intermediate vector in the production of a vector to be introduced into a eukaryotic cell (e.g. amplifying a plasmid as part of a viral vector packaging system). In some embodiments, a prokaryote is used to amplify copies of a vector and express one or more nucleic acids, such as to provide a source of one or more proteins for delivery to a host cell or host organism. Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, such as to the
amino terminus of the recombinant protein. Such fusion vectors may serve one or more purposes, such as: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protem to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protem. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Example fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31 -40), pMAL (New England Biolabs, Beverly, Mass.) and pRJT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
[001191 Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET l id (Studier et al, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).
[00120] In some embodiments, a vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerivisae include pYepSeel (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa ( uijan and Hersko vitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al, 1987. Gene 54: 1 13-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif).
[00121] In some embodiments, a vector drives protein expression in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the VL series (Lucklow and Summers, 1989. Virology 170: 31-39).
[00122] In some embodiments, a vector is capable of driving expression of one or more sequences in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are typically provided by one or more regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art. For other suitable expression systems for both
prokaryotic and eukaryotie cells see, e.g., Chapters 16 and 17 of Sambrook, ct al., MOLECULAR. CLONING: A LABORATORY MANUAL. 2nd ed,, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
[00123] In some embodiments, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue- specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1 : 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T ceil receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Baneiji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741 -748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al, 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally- regulated promoters are also encompassed, e.g., the murine hox promoters ( essel. and Grass, 1990. Science 249: 374-379) and the a-fetoprotein promoter (Campes and Tiighman, 1989. Genes Dev. 3: 537-546).
[00124] In some embodiments, a regulatory element is operably linked to one or more elements of a CRISPR system so as to drive expression of the one or more elements of the CRISPR system, i general, CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats), also known as SPIDRs (SPacer Interspersed Direct Repeats), constitute a family of D'NA loci that are usually specific to a particular bacterial species. The CRISPR locus comprises a distinct class of interspersed short sequence repeats (SSRs) that were recognized in E. coli (Ishino et al., J. Bacterid., 169:5429-5433 [1987]; and Nakata et al, J. Bacterid., 171 :3553- 3556 [ 1989]), and associated genes. Similar interspersed SSRs have been identified in Haloferax mediterranei, Streptococcus pyogenes, Anabaena, and Mycobacterium tuberculosis (See, Groenen et al., Mol. Microbiol, 10: 1057- 1065 [1993]; Hoe et al., Emerg. Infect. Dis., 5:254-263 [1999]; Masepohl et al, Biochim. Biophys. Acta 1307:26-30 [1996]; and Mojica et al, Mol. Microbiol., 17:85-93 [1995]). The CRISPR loci typically differ from other SSRs by the stmcture of the repeats, which have been termed short regularly spaced repeats (SRSRs) (Janssen et al.,
OM1CS J. Meg. Biol, 6:23-33 [2002]; and Mojica et al, Mol. Microbiol, 36:244-246 [2000]). In general, the repeats are short elements that occur in clusters thai are regularly spaced by unique intervening sequences with a substantially constant length (Mojica et al., [2000], supra). Although the repeat sequences are highly conserved between strains, the number of interspersed repeats and the sequences of the spacer regions typically differ from strain to strain (van Embden et al., J. Bacterid., 182:2393-2401 [2000]). CRISPR loci have been identified in more than 40 prokaryotes (See e.g., Jansen et al., Mol. Microbiol., 43: 1565-1575 [2002]; and Mojica et al., [2005]) including, but not limited to Aeropyrum, Pyrobac lum, Sulfolobus, Archaeoglobus, Halocarcula, M ethanobacterium, M ethanococcus, M ethanosarcina, Methanopyrus, Pyrococcus, Picrophilus, Thermoplasma, Corynebacterium, Mycobacterium, Streptomyces, Aquifex, Porphyromonas, Chlorobium, Thermus, Bacillus, Listeria, Staphylococcus, Clostridium, Thermoanaerobacter, Mycoplasma, Fusobacterium, Azarcus, Chromobacterium, Neisseria, Nitrosomonas, Desulfovibrio, Geobacter, Myxococcus, Campylobacter, Wolinella, Acinetobacter, Erwinia, Escherichia, Legionella, Methylococcus, Pasteurella, Photobacterium, Salmonella, Xanthomonas, Yersinia, Treponema, and Thermotoga.
[00125] In general, "CRISPR system" refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), or other sequences and transcripts from a CRISPR locus. In some embodiments, one or more elements of a CRISPR system, is derived from a type I, type II, or type III CRISPR system. In some embodiments, one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system). In the context of formation of a CRISPR complex, "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence a d a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient
complementarity to cause hybridization and promote formation of a CRISPR complex. A target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides. In some embodiments, a target sequence is located in the nucleus or cytoplasm of a ceil. In some embodiments, the target sequence may be withi an organelle of a eukaryotic cell, for example, mitochondrion or chlorop!ast. A sequence or template that may be used for recombination into the targeted locus comprising the target sequences is referred to as an "editing template" or "editing polynucleotide" or "editing sequence". In aspects of the invention, an exogenous template poly ucleotide may be referred to as an editing template. In an aspect of the invention the recombination is homologous recombination.
[00126] Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. Without wishing to be bound by theory, the tracr sequence, which may comprise or consist of all or a portion of a wild- type tracr sequence (e.g. about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of a wild -type tracr sequence), may also form part of a CRISPR complex, such as by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence that is operabiy linked to the guide sequence. In some embodiments, the tracr sequence has sufficient complementarity to a tracr mate sequence to hybridize and participate in formation of a CRISPR complex. As with the target sequence, it is believed that complete complementarity is not needed, provided there is sufficient to be functional. In some embodiments, the tracr sequence has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites. For example, a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operabiy linked to separate regulatory elements on separate vectors. Alternatively, two or more of the elements expressed from the same or different regulatory elements, may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. CRISPR system elements that are combined
in a single vector may be arranged in any suitable orientation, such as one element located 5" with respect to ("upstream" of) or 3' with, respect to ("downstream" of) a second element. The coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction. In some embodiments, a single promoter drives expression of a transcript encoding a C ISPR enzyme and one or more of the guide sequence, tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g. each in a different intron, two or more in at least one intron, or all in a single intron). In some embodiments, the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter.
[00.1.27] In some embodiments, a vector comprises one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a "cloning site"). In some embodiments, one or more insertion sites (e.g. about or more than about I, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites) are located upstream and/or downstream of one or more sequence elements of one or more vectors. In some embodiments, a vector comprises an insertion site upstream of a tracr mate sequence, and optionally downstream of a regulator}' element operably linked to the tracr mate sequence, such that following insertion of a guide sequence into the insertion site and upon expression the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic ceil. In some embodiments, a vector comprises two or more insertion sites, each insertion site being located between two tracr mate sequences so as to al low insertion of a guide sequence at each site. In such an arrangement, the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or combinations of these. When multiple different guide sequences are used, a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell. For example, a single vector may comprise about or more than about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more guide sequences. In some embodiments, about or more than about .1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more such guide-sequenee-containing vectors may be provided, and optionally delivered to a cell.
[00128] In some embodiments, a vector comprises a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, such as a Cas protein. Non-limiting examples of Cas proteins include Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9
(also known as Csnl and Csxl2), Ca lO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl , Cse2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5,
Cmrl , Cmr3, Cmr4, Cmr5, Cnrr6, Csbl , Csb2, Csb3, Csxl7, CsxM, Csx lO, Cs l6, CsaX, Csx3, Cs l, Csxl5, Csfl , Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof. These enzymes are known; for example, the amino acid sequence of S. pyogenes Cas9 protein may be found in the SwissProt database under accession number Q99ZW2, In some embodiments, the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9. In some embodiments the CRISPR enzyme is Cas9, and may be Cas9 from S. pyogenes or S. pneumoniae. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. In some embodiments, a vector encodes a CRISPR enzyme that is mutated to with respect to a corresponding wifd-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. For example, an aspartate -to-a!anine substitution (D10A) in the RuvC I catalytic domain of Cas9 from 5. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A. In some embodiments, a Cas9 nickase may be used in combination with guide sequenc(es), e.g., two guide sequences, which target respectively sense and a tisense strands of the DNA target. This combination allows both strands to be nicked and used to induce NHEJ. Applicants have demonstrated (data not shown) the efficacy of two nickase targets (i.e., sgRNAs targeted at the same location but to different strands of DNA) in inducing mutagenic NHEJ. A single nickase (Cas9-D10A with a single sgRNA) is unable to induce NBEJ and create indels but Applicants have shown that double nickase (Cas9~D10A and two sgRNAs targeted to different strands at the same location) can do so in human embryonic stem cells (hESCs). The efficiency is about 50% of nuclease (i.e., regular Cas9 without D10 mutation) in hESCs.
[00129] As a further example, two or more catalytic domains of Cas9 (RuvC I, RuvC II, and RuvC I II) may be mutated to produce a mutated Cas9 substantial ly lacking all DNA cleavage activity. In some embodiments, a DI0A mutation is combined with one or more of H840A,
N854A, or N863A mutations to produce a Cas9 enzyme substantially lacking all DNA cleavage activity. In some embodiments, a CRISPR enzyme is considered to substantially lack all DNA cleavage activity when the DNA cleavage activity of the mutated enzyme is less than about 25%, 10%, 5%, 1%, 0.1%, 0.01 %, or lower with respect to its non-mutated form. Other mutations may be useful; where the Cas9 or other CRISPR enzyme is from a species other than S. pyogenes, mutations in corresponding amino acids may be made to achieve similar effects.
[00130] In some embodiments, an enzyme coding sequence encoding a CRISPR enzyme is codon optimized for expression in particular ceils, such as eukaryotie ceils. The eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human primate. In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhan ced expression in the host cells of interest by replacing at least one codon (e.g. about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRN As in a ceil is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the "Codon Usage Database", and these tables can be adapted in a number of ways. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nuci. Acids Res, 28:292 (2000), Computer algorithms for codon optimizing a particular sequence for expression in a particular host ceil are also available, such as Gene Forge (Aptagen: Jacobus, PA), are also available. In some embodiments, one or more codons (e.g. 1 , 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in a sequence encoding a CRISPR enzyme correspond to the most frequently used codon for a particular amino acid.
[00131] In some embodiments, a vector encodes a CR ISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, or more NLSs. In some embodiments, the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino-termmus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more N LSs at or near the carboxy-terminus, or a combination of these (e.g. one or more NLS at the ammo-terminus and one or more NLS at the carboxy terminus). When more than one NLS is present, each may be selected independently of the others, such that a single NLS may be present in more than one copy and/or in combination with one or more other NLSs present in one or more copies. In a preferred embodiment of the invention, the CRISPR enzyme comprises at most 6 NLSs, In some embodiments, an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus. Typically, an NLS consists of one or more short sequences of positively charged lysines or arginines exposed on the protein surface, but other types of NLS are known. Non- limiting examples of NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV; the NLS from nucleopSasmin (e.g. the nucleoplasm bipartite NLS with the sequence KRPAATKKAGQAKKKK); the c-myc NLS having the amino acid sequence PAA RV LD or RQRR.NELKRSP; the hRNPAl M9 NLS having the sequence NQSSNFGPM GGNFGGRSSGPYGGGGQYFAKPRNQGGY; the sequence R RIZFK KGKDTA:ELRRRRVE 7S 7ELRKAKKDEQILKRRNV of the IBB domain from importin-alpha; the sequences VSRKRPRP and PPKKARED of the myoma T protein; the sequence POP KKPL of human p53; the sequence SAIJ KKKKM AP of mouse c- abl IV; the sequences DRLRR and PKQKKRK of the influenza vims NS1 ; the sequence RKLKKKIKKL of the Hepatitis virus delta antigen; the sequence REKKKFLKRR of the mouse Mx1 protein; the sequence KR GDEVDGVDEVAKKKSKK of the human poly(ADP-ribose) polymerase; and the sequence RKCLQAGMNLEARKTKK of the steroid hormone receptors (human) glucocorticoid.
0Θ 2] In general, the one or more NLSs are of sufficient strength to drive accumulation of the CRISPR enzyme in a delectable amount in the nucleus of a eukaryotic cell. In general, strength of nuclear localization activity may derive from the number of NLSs in the CRISPR enzyme, the particular NLS(s) used, or a combination of these factors. Detection of accumulation in the nucleus may be performed by any suitable technique. For example, a detectable marker may be fused to the CRISPR enzyme, such that location within a cell may be
visualized, such as in combination with a means for detecting the location of the nucleus (e.g. a stain specific for the nucleus such as DAPI). Examples of detectable markers include fluorescent proteins (such as Green fluorescent proteins, or GFP; RFP; CFP), and epitope tags (HA tag, flag tag, SNAP lag). Cell nuclei .may also be isolated from cells, the contents of which may then be analyzed, by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or e zyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of CRISPR complex formation (e.g. assay for DNA cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or CRISPR enzyme activity), as compared to a control no exposed to the CRISPR enzyme or complex, or exposed to a CRISPR enzyme lacking the one or more NLSs.
[00133] In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alig ment algorithm, is about or more than about. 50%. 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more. Optimal alignment, may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), ClustalW, Ciustal X, BLAT, Novoalign (NovOC.ra.ft Technologies, ELAND (Illumina, Sa Diego, CA), SOAP (available at. soap.genomics.org.cn), and Maq (available at. maq.sourceforge.net). In some embodiments, a guide sequence Is about or more tha about 5, 10, I I, 12, 13, 14, 15, 16, 17, 18, 19, 20, 2.1 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, .15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence- specific binding of a CRISPR complex to a target sequence may be assessed by any suitable assay. For example, the components of a CRISPR system sufficient to .form a CRISPR complex, including the guide sequence to be tested, may be provided to a host ceil having the corresponding target sequence, such as by transfection with vectors encoding the components of the CR ISPR sequence, followed by an assessment of preferential cleavage within the target, sequence, such as by Surveyor assay as described herein. Similarly, cleavage of a target
polynucleotide sequence may be evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions. Other assays are possible, and will occur to those skilled in the art.
[00134] A guide sequence may be selected to target any target sequence. In some embodiments, the target sequence is a sequence within a genome of a cel l. Exemplary target sequences include those that are u ique in the target genome. For example, for the S. pyogenes Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMMNNNNNNNNNNNNXGG where NNNNNNNNNNNNXGG (N is A, G, T, or C; and X can be anything) has a single occurrence in the genome. A unique target sequence in a genome may include an S. pyogenes Cas9 target site of the form MMMMMMMMMNNN NNN N XGG where NNNNNNNNNNNXGG (N is A, G, T, or C; and X can be anything) has a single occurrence in the genome. For the S. thermophilics CRISPRl Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMM MMMNNNNNNNNNNNNXXAGAA W where NNNNN N NNNNNXX AG A A W (N is A, G, T, or C; X can be anything; and W is A or T) has a single occurrence in the genome. A unique target sequence in a genome may include an S. thermophilus CRISPRl Cas9 target site of the form M MMMMMMMNNNNNNNNNNNXXAGAAW where
NNNNNNNNNNNXXAGAAW (N is A, G, T, or C; X can be anything; and W is A or T) has a single occurrence in the genome. For the S. pyogenes Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMM MMNNNNNNNNNNNNXGGXG where N N N NNNNNNXGGXG (N is A, G, T, or C; a d X can be anything) has a single occurrence in the genome, A unique target sequence in a genome may include an S. pyogenes Cas9 target site of the form MMMMMMMMMNNNNNNNNNNNXGGXG where NNNNNNNNNNNXGGXG (N is A, G, T, or C; and can be anything) has a single occurrence in the genome. In each of these sequences "M" may be A, G, T, or C, and need not be considered in identifying a sequence as unique.
[00135] In some embodiments, a guide sequence is selected to reduce the degree of secondary structure within the guide sequence. Secondary structure may be determined by any suitable
polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another example folding algorithm is the online webserver RNAfokl, developed at Institute for Theoretical Chemistry at the University of Vienna, using the eentroid structure prediction algorithm (see e.g. A.R. Gruber et ., 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62). Further algorithms may be found in U.S. application Serial No. TBA (attorney docket 44790.11.2022; Broad Reference BI-2013/004A); incorporated herein by reference.
[00136] In general, a tracr mate sequence includes any sequence that has sufficient complementarity with a tracr sequence to promote one or more of: (1) excision of a guide sequence flanked by tracr mate sequences in a cell containing the corresponding tracr sequence; and (2) formation of a CRISPR complex at a target sequence, wherein the CRISPR complex comprises the tracr mate sequence hybridized to the tracr sequence. In general, degree of complementarity is with reference to the optimal alignment of the tracr mate sequence and tracr sequence, along the length of the shorter of the two sequences. Optimal alignment may be determined by any suitable alignment algorithm, and may further account for secondary structures, such as self-complementarity within either the tracr sequence or tracr mate sequence. In some embodiments, the degree of complementarity between the tracr sequence and tracr mate sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher. Example illustrations of optimal alignment between a tracr sequence and a tracr mate sequence are provided in Figures 12B and I3B. In some embodiments, the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length. In some embodiments, the tracr sequence and tracr mate sequence are contained within a single transcript, such that hybridization between the two produces a transcript having a secondary structure, such as a hairpin. Preferred loop forming sequences for use in hairpin structures are four nucleotides in length, and most preferably have the sequence GAAA. However, longer or shorter loop sequences may be used, as may alternative sequences. The sequences preferably include a nucleotide triplet (for example, AAA), and an additional nucleotide (for example C or G). Examples of loop forming sequences include CAAA and AAAG. In an embodiment of the invention, the transcript or transcribed polynucleotide sequence
has at least two or more hairpins. In preferred embodiments, the transcript has two, three, four or five hairpins. In a further embodiment of the invention, the transcript has at most five hairpins. In some embodiments, the single transcript further includes a transcription termination sequence; preferably this is a polyT sequence, for example six T nucleotides. An example illustration of such a hairpin structure is provided in the lower portion of Figure 13B, where the portion of the sequence 5' of the final "N" and upstream of the loop corresponds to the tracr mate sequence, and the portion of the sequence 3' of the loop corresponds to the tracr sequence. Further non- limiti g examples of single polynucleotides comprising a guide sequence, a tracr mate sequence, and a tracr sequence are as follows (listed 5' to 3'), where "N" represents a base of a guide sequence, the first block of lower case letters represent the tracr mate sequence, and the second block of lower case letters represent the tracr sequence, and the final poly-T sequence represents the transcription terminator: (1 ) catgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT; (2) isnsnsnsnsnsnsnsns ^
acaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT; (3)
N N N N N N NNNNNNNNgtttttgtactctcaGAA^'Vtgcagaagctacaaagataaggcttcatgccgaaatca acaccctgtcattttatggcagggtgtTTTTTT; (4) NNNNNNNNNNNNNNNNNNNNgttttagagctaGAAAtagcaagttaaaataaggetagtcegttatcaacttgaaaa agtggcaccgagtcggtgcTTTTTT; (5)
NNNNNNNNNNN NgttttagagctaGAAAl'AGcaagttaaaataaggctagtccgttatcaacttgaa aaa gtgTTTTTTT; and (6)
N NNNNgttttagagctagAAATAGcaagttaaaataaggctagtccgttatcaTTTTT TTT. In some embodiments, sequences (1) to (3) are used in combination with Cas9 from S. thermophilus CRJSPR1. In some embodiments, sequences (4) to (6) are used in combination with Cas9 from S. pyogenes. In some embodiments, the tracr sequence is a separate transcript from a transcript comprising the tracr mate sequence (suc as illustrated in the top portion of Figure 13B).
[00137] In some embodiments, a recombination template is also provided. A recombination template may be a component of another vector as described herein, contained in a separate vector, or provided as a separate polynucleotide. In some embodiments, a recombination
template is designed to serve as a template in homologous recombination, such as within or near a target sequence nicked or cleaved by a CRISPR enzyme as a part of a CRISPR complex. A template polynucleotide may be of any suitable length, such as about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length. In some embodiments, the template polynucleotide is com lementary to a portion of a polynucleotide comprising the target sequence. When optimally aligned, a template polynucleotide might overlap with one or more nucleotides of a target sequences (e.g. about or more than about 1 , 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more nucleotides). In some embodiments, when a template sequence and a polynucleotide comprising a target sequence are optimally aligned, the nearest nucleotide of the template polynucleotide is within about 1 , 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides from the target sequence.
[0Θ 8] In some embodiments, the CRISPR enzyme is part of a fusion protein comprising one or more heterologous protein domains (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the CRISPR enzyme). A CR ISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains. Examples of protein domains that may be fused to a CRISPR enzyme include, without limitation, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methyiase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP). A CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that bind DNA molecules or bind other cellular molecules, mcludmg but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP! 6 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in
US20110059502, incorporated herein by reference. In some embodiments, a tagged CRJSPR enzyme is used to identify the location of a target sequence.
[00139] In some aspects, the invention provides methods comprising delivering one or more polynucleotides, such as or one or more vectors as described herein, one or more transcripts thereof, and/or one or proteins transcribed therefrom, to a host. cell. In some aspects, the invention further provides cells produced by such methods, and organisms (such as animals, plants, or fungi) comprising or produced from such cells. In some embodiments, a CRJSPR. enzyme in combination with (and optionally compiexed with) a guide sequence is delivered to a cell. Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of a CRJSPR system to cells in culture, or in a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid compiexed with a delivery vehicle, such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see Anderson, Science 256:808-813 ( 1992); Nabef & Feigner, TIBTECH 1 1 :21.1- 217 (1993); Mitani & Caskey, TIBTECH 1 1 : 162-166 ( 1993); Dillon, TIBTECH 11 :167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10): 1149-1154 (1988); Vigne, Restorative Neurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51(l):31 -44 (1995); Haddada et. a!., in Current Topics in Microbiology and Immunology, Doerfler and J3ohm (eds) (1995); and Yu et al., Gene Therapy 1 : 13-26 ( .1994).
[00140] Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, poiycation or lipid :nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration).
[00141 J The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, Science
270:404-410 ( 1995); Blaese et al., Cancer Gene Ther. 2:291-297 ( 1995); Behr et al, Bioconjugate Chem. 5:382-389 (1994); Remy et al, Bioconjugate Chem, 5:647-654 (1994); Gao et al, Gene Therapy 2:710-722 (1995); Ahmad et al, Cancer Res. 52:4817-4820 (1992); U.S. Pat. Nos, 4,186,183, 4,217,344, 4,235,871 , 4,261 ,975, 4,485,054, 4,501 ,728, 4,774,085, 4,837,028, and 4,946,787).
[00142] The use of RNA or DNA viral based systems for the deliveiy of nucleic acids takes advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be administered directly to patients (in vivo) or they ca be used to treat cells in vitro, and the modified cells may optionally be administered to patients (ex vivo). Conventional viral based systems could include retroviral, lentivirus, adenoviral, adeno-associaied and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeiio-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in ma )? different cell types and target tissues.
[00143 J The tropism of a retrovirus can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lentiviral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral tilers. Selection of a retroviral gene transfer system would therefore depend on the target tissue. Retroviral vectors are comprised of cis-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cis-acting LT s are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cel l to provide permanent transgene expression. Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia vims (GaLV), Simian Immuiio deficiency vims (SIV), human immuno deficiency vims (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731 -2739 (1992); Johann et al, J. Virol. 66: 1635-1640 (1992); Sommnerfelt ei al., Virol 176:58-59 (1990); Wilson et al, J. Virol 63:2374-2378 (1989); Miller et al, J. Virol. 65:2220-2224 (1991); PCT/US94/05700).In applications where transient expression is preferred, adenoviral based systems may be used. Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require ceil division. With such vectors, high titer and levels of expression have been obtained. This
vector can be produced in large quantities in a relatively simple system. Adeno-associated vims ("AAV") vectors may also be used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al,, Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93/24641 ; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94: 1351 (1994), Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251 -3260 (1985); Tratschin, et al, Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81 :6466- 6470 (1984); and Samulski et al, J. Virol. 63:03822-3828 (1989).
[00144] Packaging cells are typically used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and ψ2 cells or PA317 cells, which package retrovirus. Viral vectors used in gene therapy are usually generated by producing a cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the polynucleotide^) to be expressed. The missing viral functions are typically supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess 1TR sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. The cell line may also be infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV. Additional methods for the delivery of nucleic acids to cells are known to those skilled in the art. See, for example, US200300878 17, incorporated herein by reference.
[00145] In some embodiments, a host cell is transiently or non-transiently transfecte with one or more vectors described herein. In some embodiments, a cell is transfected as it naturally occurs in a subject. In some embodiments, a cell that Is transfected is taken from a subject. In some embodiments, the cell is derived from cells taken from a subject, such as a cell line. A wide variety of ceil lines for tissue culture are known in the art. Examples of cell lines include,
but are not limited to, C8161, CCRF-CEM, MOLT, mlMCD-3, NHDF, HeLa-S3, Huhl , Huh4, euh7, HUVEC, HASMC, HERn, HE a, MiaPaCell, Panel, PC-3, TF1, CTLL-2, C1R, Rat6, CV 1, RPTE, A10, T24, J82, A375, ARH-77, Calul, SW480, SW620, S OV3, SK-UT, CaCo2, P388D1, SEM-K2, WEHI-231, HB56, TIB55, Jurkat, J45.Q1 , LRMB, Bcl-1 , BC-3, IC21, DLD2, R.aw264.7, NR , NR -52E, MR.C5, MEF, Hep G2, HeLa B, HeLa T4, COS, COS-1, COS-6, COS-M6A, BS-C-1 monkey kidney epithelial, BALB/ 3T3 mouse embryo fibroblast, 3T3 Swiss, 3T3-L1, 132-d5 human fetal fibroblasts; 10.1 mouse fibroblasts, 293-T, 3T3, 721, 9L, A2780, A2780ADR, A2780cis, A172, A20, A253, A431, A-549, ALC, B16, B35, BCP-1 cells, BEAS- 2B, bEnd.3, BHK-21 , BR 293, BxPC3, C3H-10T1/2, C6/36, ( 'a 1-27. CHO, CHO-7, CHO-IR, CHO-K1, CHO-K2, CHO-T, CHO Dhfr -/-, COR-L23, COR-L23/CPR, COR-L23/5010, COR- L23/R23, COS-7, COV-434, CML Tl , CMT, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6/AR1 , EMT6/AR10.0, FM3, HI 299, H69, HB54, HB55, HCA2, HE -293, HeLa, Hepalclc7, HL-60, HMEC, HT-29, Jurkat, JY cells, 562 cells, u812, CL22, G1, KYOl, L Cap, Ma-Mel 1-48, MC-38, MCF-7, MCF-IOA, MDA-MB-231, MDA-MB-468, MDA-MB- 435, MDCK IL MDCK II, MOR/0.2R, MONO-MAC 6, MTD-IA, MyEnd, NCI-H69/CPR, 'NCI-H69/L 10, NCI-H69/LX20, NCI-H69/LX4, NIH-3T3, NALM-1 , NW-145, OPCN / OPCT cell lines, Peer, PNT-1A / PNT 2, RenCa, RIN-5F, RMA/RMAS, Saos-2 cells, Sf-9, SkBr3, T2, T-47D, T84, THP1 cell line, U373, U87, U937, VCaP, Vero cells, WM39, WT-49, X63, YAC-1, YAR, and transgenic varieties thereof. Cell lines are available from a variety of sources known to those with skill in the art (see, e.g., the American Type Culture Collection (ATCC) (Manassus, Va.j). Irs some embodiments, a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences. In some embodiments, a cel l transiently transfected with the components of a CR iSPR system as described herein (such as by transient transfection of one or more vectors, or transfection with RNA), and modified through the activity of a CR1SPR complex, is used to establish a new cell line comprising ceils containing the modification but lacking any other exogenous sequence. In some embodiments, cells transiently or non-transiently transfected with one or more vectors described herein, or cell lines derived from such ceils are used in assessing one or more test compounds.
|00146| In some embodiments, one or more vectors described herein are used to produce a non-human transgenic animal or transgenic plant. In some embodiments, the transgenic animal
is a mammal, such as a mouse, rat, or rabbit. In certain embodiments, the organism or subject is a plant. In certain embodiments, the organism or subject or plant is algae. Methods for producing transgenic plants and animals are known in the art, and generally begin with a method of cell transfeeiion, such as described herein.
[00147] In one aspect, the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
[0Θ148] In one aspect, the invention provides a method of modifying expression of a polynucleotide in a eukaryotic ceil. In some embodiments, the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
[00149] With recent advances in crop genomics, the ability to use CRISPR-Cas systems to perform efficient and cost effective gene editing and manipulation will allow the rapid selection and comparison of single and multiplexed genetic manipulations to transform such genomes for improved production and enhanced traits. In this regard reference is made to US patents and publications: US Patent No. 6,603,061 - Agrobacterium- Mediated Plant Transformation Method; US Patent No. 7,868,149 - Plant Genome Sequences and Uses Thereof and US 2009/0100536 - Transgenic Plants with Enhanced Agronomic Traits, all the contents and disclosure of each of which are herein incorporated by reference in their entirety. In the practice of the invention, the contents and disclosure of Morrell et al "Crop genomicstadvances and applications" Nat Rev Genet. 201 1 Dec 29;13(2):85-96 are also herein incorporated by reference in their entirety. In an advantageous embodiment of the invention, the CRISPR/Cas9 system is used to engineer microalgae (Example 15). Accordingly, reference herein to animal cells may also apply, mutatis mutandis, to plant cells unless otherwise apparent.
[00150] In one aspect, the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell, which may be in vivo, ex vivo or in vitro. In some embodiments, the method comprises sampling a cell or population of cells from a human or non- human animal or plant (including micro-algae), and modifying the cell or cells. C alluring may occur at any stage ex vivo. The cell or cells may even be re-introduced into the non-human animal or plant (including micro-algae).
[00151] In plants, pathogens are often host-specific. For example, Fusarium oxysporum f. sp. lycopersici causes tomato wilt but attacks only tomato, and F. oxysporum f. dianthii Puccinia graminis f. sp. tritici attacks only wheat. Plants have existing and induced defenses to resist most pathogens. Mutations and recombination events across plant generations lead to genetic variability that gives rise to susceptibility, especially as pathogens reproduce with more frequency than plants. In plants there can be non-host resistance, e.g., the host and pathogen are incompatible. There can also be Horizontal Resistance, e.g., partial resistance against all races of a pathogen, typically controlled by many genes and Vertical Resistance, e.g., complete resistance to some races of a pathogen but not to other races, typically controlled by a few genes. In a Gene-for-Gene level, plants and pathogens evolve together, and the genetic changes in one balance changes in other. Accordingly, using Natural Variability, breeders combine most useful genes for Yield, Quality, Uniformity, Hardiness, Resistance. The sources of resistance genes include native or foreign Varieties, Heirloom Varieties, Wild Plant Relatives, and Induced Mutations, e.g., treating plant material with mutagenic agents. Using the present invention, plant breeders are provided with a new tool to induce mutations. Accordingly, one skilled in the art can analyze the genome of sources of resistance genes, and in Varieties having desired characteristics or traits employ the present invention to induce the rise of resistance genes, with more precision than previous mutagenic agents and hence accelerate and improve plant breeding programs.
[ 00152] In one aspect, the invention provides kits containing any one or more of the elements disclosed in the above methods and compositions, in some embodiments, the kit comprises a vector system and instructions for using the kit. In some embodiments, the vector system comprises (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting a guide sequence upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a
target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme eompiexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. Elements may be provide individual ly or in combinations, and may be provided in any suitable container, such as a vial, a bottle, or a tube. In some embodiments, the kit includes instructions in one or more languages, for example in more than one language.
[00153] In some embodiments, a kit comprises one or more reagents for use in a process utilizing one or more of the elements described herein. Reagents may be provided in any suitable container. For example, a kit may provide one or more reaction or storage buffers. Reagents may be provided in a form that is usable in a particular assay, or in a form that requires addition of one or more other components before use (e.g. in concentrate or lyopiiiiized form). A buffer can be any buffer, including but not limited to a sodium carbonate buffer, a sodium bicarbonate buffer, a borate buffer, a Tris buffer, a MOPS buffer, a HEPES buffer, and combinations thereof. In some embodiments, the buffer is alkaline. In some embodiments, the buffer has a pH from about 7 to about 10. In some embodiments, the kit comprises one or more oligonucleotides corresponding to a guide sequence for insertion into a vector so as to operably link the guide sequence and a regulatory element, in some embodiments, the kit comprises a homologous recombination template polynucleotide.
[00154] In one aspect, the invention provides methods for using one or more elements of a CRISPR system. The CRISPR complex of the invention provides an effective means for modifying a target polynucleotide. The CRISPR complex of the invention has a wide variety of utility including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types. As such the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, and prognosis. An exemplary CRISPR complex comprises a CRISPR enzyme eompiexed with a guide sequence hybridized to a target sequence within the target polynucleotide. The guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.
[00155] The target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell. For example, the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic cell. The target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulator}' polynucleotide or a junk DNA). Without wishing to be bound by theory, it is believed that the target sequence should be associated with a PAM (protospacer adjacent motif); that is, a short sequence recognized by the CR ISPR complex. The precise sequence and length requirements for the PAM differ depending on the CRISPR enzyme used, but PAMs are typically 2-5 base pair sequences adjacent the protospacer (thai is, the target sequence) Examples of PAM sequences are given in the examples section below, and the skilled person will be able to identify further PAM sequences for use with a given CRISPR enzyme.
0Θ156] The target polynucleotide of a CRISPR complex may include a number of disease- associated genes and polynucleotides as well as signaling biochemical pathway-associated genes and polynucleotides as listed in US provisional patent applications 61 /736,527 and 61/748,427 having Broad reference BI-2011/008/WSGR Docket No. 44063-701.1 Gland BI- 201 1/008/WSGR Docket No. 44063-701 .102 respectively, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on December 12, 2012 and January 2, 2013, respectively, the contents of all of which are herein incorporated by reference in their entirety.
[00157] Examples of target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide. Examples of target polynucleotides include a disease associated gene or polynucleotide. A "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cel ls of a non disease control. It may be a gene that becomes expressed at an abnormally high level; it may be a gene that becomes expressed at an abnormally low level, where the altered expression correlates with the occurrence and/or progression of the disease. A disease-associated gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease. The transcribed or translated products may be known or unknown, and may be at a normal or abnormal level.
[00158] Examples of disease-associated genes and polynucleotides are available from McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), available on the World Wide Web.
[00159] Examples of disease-associated genes and polynucleotides are listed in Tables A and B. Disease specific information is available from McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), available on the World Wide Web. Examples of signaling biochemical pathway-associated genes and polynucleotides are listed in Table C.
[00160] Mutations in these genes and pathways can result in production of improper proteins or proteins in improper amounts which affect function. Further examples of genes, diseases and proteins are hereby incorporated by reference from US Provisional applications 61/736,52.7 filed on December 12, 2012 and 61/748,427 filed January 2, 2013. Such genes, proteins and pathways may be the target polynucleotide of a CRISPR complex.
Table A
Parkinson's Disease x-Synuelcin: DJ-1; 1.RR 2: Parkin; PINK!
Blood and Anemia (CDA 1 , CDA1, RPSI9, DBA, P LR, PKl, NT5C3, UMPHL coagulation diseases PSN1, RHAG, RH50A, NRAMP2, SPTB, ALAS2, ANH1, ASB, and disorders ABCB7, ABC7, ASAT); Bare lymphocyte syndrome (TAPBP, TPSN.
TAP2, ABCB3, PSF2, RING 11, MHC2TA, C2TA, RFX5, RFXAP, RFX5), Bleeding disorders (TBXA2R, P2RX1, P2X1); Factor H and factor H-iike 1 (HF1, CFH, HUS); Factor V and factor VIII (MCFD2); Factor VII deficiency (F7); Factor X deficiency (F10); Factor XI deficiency (Fll); Factor XII deficiency (F12, HAF); Factor ΧΪΙΙΑ deficiency (F13AL F13A); Factor XIIIB deficiency (F13B); Fanconi anemia (FANCA, FACA, FAl, FA, FAA, FAAP95, FAAP90, FLJ34064, FA CB, FANCC, FACC, BRCA2, FANCD1, FA CD2, FANCD, FACD, FAD, FANCE, FACE, FANCF, XRCC9, FANCG, BRIP1, BACH1, FANCJ, PHF9, FANCL, FANCM, IAA1596);
Hernophagocytic lynrphohistiocyiosis disorders (PRF1, HPLH2,
UNCI 3D, MUNCI3~4, HPLH3, HLH3, FHL3); Hemophilia A (F8, F8C, HEMA); Hemophilia B ( 1 '9. HEMB), Hemorrhagic disorders (PI, ATT, F5); Leukocyde deficiencies and disorders (ITGB2, CD 18, LCAMB, LAD, EIF2B1, EIF2BA, EIF2B2, EIF2B3, EIF2B5, LV WM, CACH, CLE, EIF2B4); Sickle cell anemia (HBB); Thalassemia (HBA2, HBB,
HBD, LCRB, HBA1).
Cell dysregulation B-cell non-Hodgkin lymphoma (BCL7A, BCL7); Leukemia (TALI, and oncology TCL5, SCL, TAL2, FLT3, NBS i, NBS, ZNFN1A1, IKi, LYFi, diseases and disorders HGXD4, HQX4B, BCR, CML, PHL, ALL, ARNT, KRAS2, RASK2,
GMPS, AF10, ARHGEF12, LARG, KIAA0382, CALM, CLTH, CEBPA, CEBP, CHIC2, BTL, FLT3, KIT, PBT, 1 PP. NPMi, NUP214, D9S46E, CAN, CAIN, RUNX1, CBFA2, AMI i. WHSC1L1, NSD3, FLT3, AF1Q, NPMI, NUMA1, ZNF145, PLZF, PML, MYL. STATS B, AF10, CALM, CLTH, ARLIL ARLTS1, P2RX7, P2X7, BCR, CML, PHL, ALL, GRAF, NF1, VRNF, WSS, NFNS, PTPN11, PTP2C, SHP2, NSi, BCL2, CCNDi, PR A 1)1. BCLi, TCRA, GATAl, GFL ERYF1, NFE1, ABLl, NQOl, DIA4, NMOR1, NUP214, D9S46E, CAN, CAIN).
I flammation and AIDS (KIR3DL1, NKAT3. NKB1, AMBIL KIR3DS1, IFNG, CXCL12, immune related SDF1); Autoimmune lymphoproliferative syndrome (TNFRSF6, APT1, diseases and disorders FAS, CD95, ALPS 1 A); Combined immunodeficiency, (IL2RG,
SCIDX1, SCIDX, IMD4); HiV-i (CCL5, SCYA5, DI7S136E, TCP228), HIV susceptibility or infection (ILK), CSIF, CMKBR2, CCR2,
CMKBR5, CCCKR5 (CCR.5)); Immunodeficiencies (CD3E, CD3G, A CDA, AID, HIGM2, TNFRSF5, CD40, IJNG, DGU, HIGM4, TNFSF5. CD40LG. HIGML IGM, FOXP3.1PEX, AIID, XPID. PIDX, TNFRSF14B, TACI); Inflammation (LL-IG, IL-1 (IL-la, IL-lb), IL-13, f I - 17 (ll.-i ?a (CTLA8), IL-17b, IL-17c, Il.-I7d. IL-17f), H-23, Cx3crl, ptpn22, TNFa, NOD2/CARD15 for IBD, IL-6, IL-12 (IL-12a, II,-12b), CTLA4, Cx3cll); Severe combined Immunodeficiencies (SCIDs)(JA 3, JA L, DCLRE1C, ARTEMIS, SCIDA, RAG I, RAG2, ADA, PTPRC, CD45, LCA, IL7R, CD3D, T3D, IL2RG, SCIDX I, SCIDX, IMD4).
Metabolic, liver, Amyloid neuropathy (TTR, PALB); Amyloidosis (APOA1, APP, AAA, kidney and protein CVAP, ADl, GSN, FGA, LYZ, TTR, PALB); Cirrhosis (KRT18, KRT8, diseases and disorders CIRH1A, NAIC, TEX292, KJAA1988); Cystic fibrosis (CFTR, ABCC7,
CF, MR.P7); Glycogen storage diseases (SLC2A2, GLUT2, G6PC, G6PT, G6PTL GAA, LAMP2, LAMPB, AGL, GDE, GBE1, GYS2, PYGL, PFKM); Hepatic adenoma, 142330 (TCFl, HNF1 A, MODY3), Hepatic failure, early onset, and neurologic disorder (SCODL SCOl), Hepatic lipase deficiency (LIPC), Hepatoblastoma, cancer and carcinomas (CTNNBl, PDGFRL, PDGRL, PRLTS, AX I I , AXIN, CTNNB1, TP53, P53, LFS1, IGF2R, MPRI, MET, CASP8, MCH5; Medullary cystic kidney disease (UMOD, HNFJ, FJHN, MC D2, ADMCKD2); Phenylketonuria (PAH, PKU1, QDPR, DI IPR, PTS); Polycystic kidney and hepatic disease (FCYT, PKHDl, ARPKD, PKDl, P oi. PKD4, PKDTS, PRKCSH, G19P1, PCLD, SEC63).
Muscular / Skeletal Becker muscular dystrophy (DMD, BMD, MYF6), Duchenne Muscular dseases and disorders Dystrophy (DM D, BMD); Eniery-Dreifuss muscular dystrophy (LMNA,
LMN1, EMD2, FPU). CMD.1 A, !!GPS. LGMD1B, LMNA, LMNl,
EMD2, FPLD, CMD1A); Facioscapulohumeral muscular dystrophy (FSHMD 1 A, FS HD 1 A); Muscular dystrophy (FKRP, MDC 1 C,
LGMD2I, L.AMA.2, LAMM, LARGE, KIAA0609, MDC ID, FCMD, TTID, MYOT, CAPN3, CANP3, DYSF, LGMD2B, SGCG, LGMD2C, DMDA1, SCG3, SGCA, ADL, DAG2, LGMD2D, DMDA2, SGCB, LGMD2E, SGCD, SGD, LGMD2F, CMD1L, TCAP, LGMD.2G, CMD1N, TRIM32, HT2A, LGMD2H, FKRP, MDC1C. LGMD2I, TTN. CMD.1G, TMD, LGMD2.I, PO T1 , CAV3, LGMD1C, SEPN.1, SEEN, RSMD1, PLEC1, PLTN, EBSl); Osteopetrosis (LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, CLCN7, CLC7, OPTA.2, OSTMl, GL, TCIRG1, TIRC7, OC116, OPTBl); Muscular atrophy (VAPB, VA.PC, ALS8, SMN1. SMAL SMA2, SMA3, SMA4, BSCL2, SPG17, GARS, SMADI, CMT2D, HEXB, IGHMBP2, SMUBP2, CATF.1, SMARDl).
Neurological and ALS (SOD1, ALS2, STEX, FUS, TARDBP, VEGF (VEGF-a, VEGF-b, neuronal, diseases and VEGF-c); Alzheimer disease iAPP, AAA, CVAP, AD.1, APOE, AD2, disorders PSEN2, AD4, STM2, APBB2, FE65L1, NOS3, PLAU, URK, ACE,
DCPl , ACEL MPO, PACIP1, PAXIP1L, PTIP, A2M, BLMH, BMH, PSEN1, AD3); Autism (Mecp2, B.ZRAP1, MDGA2, SemaSA, Neurexin 1, GLOl, MECP2, RTT, PPMX, MRX16, MRX79, NLGN3, NLGN4, IAA1260, AUTSX2); Fragile X Syndrome (FMR2, FXR1, FXR2, mGLURS); Huntington's disease and disease like disorders (HD, IT15, PRNP, PR1P, J PI 13. JP3, HDL2, TBP, SCA17); Parkinson disease (NR4A2, NUR 1, NOT, TINUR, SNCAIP, TBP, SCA17, SNCA, NACP, PARK I, PARK4, DJ1, PARK7, LRRK2, PARKS, ΡΓΝΚ1, PARK6, UCHL1, PARKS, SNCA, N ACP, PARK1, PARK4, PRKN, P.ARK2, PDJ, DBH, NDUFV.2); Rett, syndrome (MECP.2, RTT, PPMX, MRX16, MRX79, CDKL5, STK9, MECP2, RTT, PPMX, MRX16, MRX79, x-Synuclein, DJ-1); Schizophrenia (Neuregulinl (Nrgl), Erb4 (receptor for Neuregulin), Complexinl (Cplxl), Tphl Tiyptophan hydroxylase, Tph2, Tryptophan hydroxylase 2, Neurexin 1, GSK3, GSK3a", GSK3b, 5-HTT (Slc6a4)," COMT, DRD (Drdla), SLC6A3, DAOA, DTNBP1, Dao (Daol)); Secretase Related Disorders (APH-1 (alpha and beta), Presenilin (Psenl), nicastrin, (Ncstn), PEN-2, Nosl, Parpl, Natl, Nat2); Trinucleotide Repeat Disorders (HTT (Huntington's Dx), SBMA/SMAX1/AR (Kennedy's Dx), FXN/X25 (Friedrich's Ataxia), ATX3 (Machado- Joseph's Dx), ATXN1 and ATXN2
(spinocerebellar ataxias), DMPK (myotonic dystrophy), Atrophin-1 and Atnl (DRPLADx), CBP (Creb-BP - global instability), VLDLR
(Alzheimer's), Atxn7, AtxrslO).
Occular diseases and Age-related macular degeneration (Abcr, Ccl2, Cc2, cp (ceruloplasmin), disorders Ti.mp3, cathepsinD, Vidir, Ccr2); Cataract. (CR.YAA, CRYA1, CRYBB2,
CRYB2, PITX3, BFSP2, CP49, CP47, CRYAA, CRYA1, PAX6, AN2, MGDA, CRYBA.1, CRYB1, CRYGC, CRYG3, (XL. L1M2, MP19,
CRYGD, CRYG4, BFSP2, CP49, CP47, HSF4, CTM, FISF4, CTM,
MIP, AQPO, CRYAB, CRYA2, CTPP2, CRYBB1, CRYGD, CRYG4, CRYBB2, CRYB2, CRYGC, CRYG3, CCL, CRYAA, CRYAl , GJA8, CX50, CAEl, GJA3, CX46, CZP3, CAE3, CCMl, CAM, KRLTi); Corneal clouding and dystrophy (APGA1, TGFBI, CSD2, CDGGl, CSD, BIGH3, CDG2, TACSTD2, TROP2, 1S1 , VSX!. RINX, PPCD, PPD, KTCN, CQL8A2, FECD, PPCD2, PIP5K3, CFD); Cornea plana congenital (KERA, CNA2); Glaucoma (MYOC, TIGR, GLCIA, JO AG, GPOA, OPTN, GLC1E, FIP2, FIYPL, NRP, CYPIBI, GLC3 A, OPA1, NTG, NPG, CYPIBI, GLC3A); Leber congenital amaurosis iCRBi, RP12, CRX, CORD2, CRD, RPGRIPl, LCA6, CORD9, RPE65, RP20, AIPLi, LCA4, GUCY2D, GUC2D, LCAi, CORD6, RDH12, LCA3); Macular dystrophy (ELOVL4, ADMD, STGD2, STGD3, RDS, RP7, PRPH2, PRPH, AV I). AOFMD, VMD2).
TRAF2; TLR4; TNF; INSR; 1 B KG; RELB; MAP3K7; IL8;
CHUK; NR1H2; TJP2; NFKB1; ESR1; SREBF1; FGFR.4;
JUN; ILIRI; PRKCA; IL6
IGF-1 Signaling IGF1; PRKCZ; ELK1; MAPKl; PTPN11; NEDD4; AKT2;
PIK3CA; PRKCI; PTK2; FOS; PIK3CB; PIK3C3; MAPK8;
IGF1R; IRS1; MAPK3; IGFBP7; KRAS; PIK3C2A;
YWHAZ; PXV. RAF1; CASP9; MAP2 2; AKT1; PJK3R1;
PDPK1; MAP2K1; IGFBP2; SI N; JUN; CYR61; AKT3;
FOXOl; SRF; CTGF; RPS6KB1
NRF2~mediated PRKCE; EP300; SOD2; PRKCZ; MAPKl; SQSTMl;
Oxidative
Stress Response NQOl; PIK3CA; PRKCI; FOS; PIK3CB; PIK3C3; MAPK8;
PRKDl; MAPK3; KRAS; PRKCD; GSTP1; MAPK9: FTL;
NFE2L2; PIK3C2A; MAPKl 4; RAF1; MAP3K7; CREBBP;
MAP2K2; AK.T1; PIK3R1 ; MAP2K1; PPIB; JUN; KEAP1;
GSK3B; ATF4; PRKCA; EIF2AK3; !!SPvOAAi
Hepatic Fibrosis/ epatic EDN1; IGF l ; KDR; FLTl; SMAD2; FGFR1; MET; PGF;
Stellate Cell Activation SMAD3; EGFR; FAS; CSF1; NFKB2; BCL2; MYH9;
IGFIR; IL6R; RELA; TLR4; PDGFRB; TNF; RELB; IL8;
PDGFRA; NFKBI; TGFBR1; SMAD4; VEGFA; BAX;
ILIRI; CCL2; HGF; MMPl; STAT1; IL6; CTGF; MMP9
PPAR Signaling EP300; IN : TRAF6; PPARA; RXRA; MAPKl; 1KB KB;
NCOR2; FOS; NFKB2; MAP3K14; STAT5B; MAPK3;
NRJP1; KRAS; PPARG; RELA; STATS A; TRAF2;
PPARGC1A; PDGFRB; TNF; INSR; RAF1; IKBKG;
RELB; MAP3K7; CREBBP; MAP2K2; CeiJK; PDGFRA;
MAP2K1; NFKBI; JUN; IL1R1; HSP90AA1
Fc Epsilon RI Signaling PRKCE; RAC 1 ; PRKCZ; LYN; MAPKl ; RAC2; PTPN11 ;
AKT2; PIK3CA; SYK; PRKCI; PIK3CB; PIK3C3; MAPK8;
PRKD1; MAPK3; MAPK10; KRAS; MAPKl 3; PRKCD;
MAPK9; PIK3C2A; BTK; MAPK14; TNF; RATI; FYN;
MAP2K2; AKT1; PIK3R1; PDPK1; MAP2K1; AKT3;
VAV3; PRKCA
G-Protein Coupled PRKCE; RAP! A; RGSI6; MAPKl; GNAS; AKT2; 1KBKB;
Receptor Signaling P1K3CA; CREB1; GNAQ; NFKB2; CAMK2A; P1K3CB;
PIK3C3; MAPK3; KRAS; RELA; SRC; PIK3C2A; RAF1;
IKBKG; RELB; FYN; MAP2K2; AKT1; PJK3R1; CHUK;
PDPK1; STAT3; MAP2KI; NFKBI; BRAF; ATF4; AKT3;
PRKCA
Inositol Phosphate PRKCE; IRAKI; PRKAA2; EIF2AK2; PTEN; GRK6;
Metabolism MAP l; PLKl; AKT2; PIK3CA; CDK8; PIK3CB; PIK3C3;
MAPK8; MAPK3; PRKCD; PRKAAl ; MAPK9; CDK2;
PIM1; PIK3C2A; DYRK!A; MAP2K2; PIP5K1 A; PIK3R1;
MAP2K1; PAK3; ATM; TTK; CSNK1A1; BRAF; SGK
Signaling
Regulation PRKDC; ATM; SFN; CDKN2A
Signaling
Coagulation System BDKRBl ; F2 ; SERPINE1 ; F3
Dopamine Receptor PPP2R1A; PPP2CA; PP 1CC; PPP2R5C
Signaling
Glutathione Metabolism 11)1 12: GSTP1; ANPEP; ! l i l
Glyeerolipid Metabolism ALDH1A 1; GPAM; SPHK l ; SPH 2
Liiioleic Acid PRDX6; GR ; YWHAZ; CYPIBI
Metabolism
Methionine Metabolism DNMT1 ; DNMT3B; AHCY; DNMT3A
Pyruvate Metabolism GLOl ; ALDH IA I ; PKM2; LDHA
Argiiiine and Proline ALDH1A1; NOS3; NOS2A
Metabolism
Eicosanoid Signali g PRDX6; GRN; YWHAZ
Fructose and Mannose HK2; GCK; UK I
Metabolism
Galactose Metabolism HK2; GCK; HK1
Sti!bene, Coumarirse and PRDX6; PRDX1 ; TYR
Lignin Biosynthesis
Antigen Presentation CALR; B2M
Pathway
Biosy thesis of Steroids NQ01; DHCR7
Butanoate Metabolism ALDHIAI; NLGN1
Citrate Cvcle 11» 12; IDHl
Fatty Acid Metabolism ALDHIAI ; CYPIBI
Glyeerophospholipid PRDX6; CHKA
Metabolism
Histidirse Metabolism PRMT5; ALDHI AI
Inositol Metabolism EROIL; APEX1
Metabolism of GSTP1; CY IBI
Xenobiotics
by Cytochrome p450
Methane Metabolism PRDX6; PRDX1
Phenylalanine PRDX6; PRDX1
Metabolism
Propanoate Metabolism ALDHI AI; LDHA
Selenoamino Acid PRMT5; A1:-ICY
Metabolism
Sphingolipid Metabolism SPHKl ; SPHK2
Aminophosplionate PRMT5
Metabolism
Androgen and Estrogen PRMT5
Metabolism
Ascorbate and Aldarate ALDHIAI
Metabolism
Bile Acid Biosynthesis ALDHIAI
Cysteine Metabolism LDHA
Fatty Acid Biosynthesis FASN
Glutamate Receptor GNB2L1
Signaling
NRF2 -mediated PRDX1
Oxidative
Stress Response
Pentose Phosphate GPI
Pathway
Pentose and Glucuronate UCHL1
Iiiterconversions
Retinol Metabolism ALDH1A1
Riboflavin Metabolism TYR
Tyrosine etabolism PRMT5, TYR
Ubiquinone Biosynthesis PRMT5
Valine, Leucine and ALDH1 A 1
Isoleucine Degradation
Glycine, Serine and CH A
Threonine Metabolism
Lysine Degradation ALDH1 A 1
Pain/Taste TRPM5; TRPA1
Pain TRPM7; TRPC5; TRPC6; TRPC1 ; ( m l : cnr2; Grk2;
Trpal ; Pome; Cgrp; Crf; Pka; Era; Nr2b; TRPM5; Prkaca;
Prkacb; Prkarl a; Prkar2a
Mitochondrial Function AIF; CytC; SMAC (Diablo); Aifm-1 ; Aifm-2
Developmental BMP-4; Chordin (Chrd); Noggin (Nog); WNT (Wnt2;
Neurology
Wnt2b; Wnt3a; Wnt4; WntSa; Wnt6; Wnt7b; Wnt8b;
Wnt9a; Wnt9b; Wntl Oa; Wntl Ob; Wn l6); beta-catenin;
Dkk-1 ; Frizzled related proteins; Otx-2; Gbx2; FGF-8;
Reelin; Dab! ; unc-86 (Pou4fl or Brn3a); Numb; Rein
[00161] Embodiments of the invention also relate to methods and compositions related to knocking out genes, amplifying genes and repairmg particular mutations associated with DNA repeat instability and neurological disorders (Robert D, Wells, Tetsuo Ashizawa, Genetic Instabilities and Neurological Diseases, Second Edition, Academic Press, Oct 13, 201 1 - Medical). Specific aspects of tandem repeat sequences have been found to be responsible for more than twenty human diseases (New insights into repeal instability: role of RNA¾DNA hybrids. Mclvor EI, Polak U, Napierala M. RNA Biol. 2010 Sep-Oct;7(5):551-8). The CRISPR- Cas system may be harnessed to correct these defects of genomic instability.
[00162] A further aspect of the invention relates to utilizing the CRISPR-Cas system for correcting defects in the EMP2A and EMP2B genes that have been identified to be associated
with Lafora disease. Lafora disease is an autosomal recessive condition which is characterized by progressive myoclonus epilepsy which may start as epileptic seizures in adolescence, A few cases of the disease may be caused by mutations in genes yet to be identified. The disease causes seizures, muscle spasms, difficulty walking, dementia, and eventually death. There is currently no therapy that has proven effective against disease progression. Other genetic abnormalities associated with epilepsy may also be targeted by the CRISPR-Cas system and the underlying genetics is further described in Genetics of Epilepsy and Genetic Epilepsies, edited by Giuliano Avanzini, Jeffrey L. Noebels, Mariani Foundation Paediatric Neurology:20; 2009),
[00163] In yet another aspect of the invention, the CRISPR-Cas system .may be used to correct ocular defects that arise from several genetic mutations further described in Genetic Diseases of the Eye, Second Edition, edited by Elias I. Traboulsi, Oxford University Press, 2012.
[00164] Several further aspects of the invention relate to correcting defects associated with a wide range of genetic diseases which are further described on the website of the National Institutes of Elealth under the topic subsection Genetic Disorders (website at health.nih.gov/topic/GeneticDisorders). The genetic brain diseases may include but are not limited to Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Aicardi Syndrome, Alpers' Disease, Alzheimer's Disease, Barth Syndrome, Batten Disease, CADASIL, Cerebellar Degeneration, Fabry's Disease, Gerstmann-Straussier-Scheinker Disease, Huntington's Disease and other Triplet Repeat Disorders, Leigh's Disease, Lesch-Nyhan Syndrome, Menkes Disease, Mitochondrial Myopathies and NINDS Colpocephaly. These diseases are further described on the website of the National Institutes of Health under the subsection Genetic Brain Disorders.
[00165] In some embodiments, the condition may be neoplasia. In some embodiments, where the condition is neoplasia, the genes to be targeted are any of those listed in Table A (in this case PTEN and so forth). In some embodiments, the condition may be Age-related Macular Degeneration, In some embodiments, the condition may be a Schizophrenic Disorder. In some embodiments, the condition may be a Trinucleotide Repeat Disorder. In some embodiments, the condition may be Fragile X Syndrome. In some embodiments, the condition may be a Secretase Related Disorder. In some embodiments, the condition may be a Prion - related disorder. In some embodiments, the condition may be ALS. In some embodiments, the condition may be a drug addiction. In some embodiments, the condition may be Autism. In some embodiments, the
condition may be Alzheimer's Disease. In some embodiments, the condition may be inflammation. In some embodiments, the condition may be Parkinson 's Disease.
[00166] Examples of proteins associated with Parkinson 's disease include but are not limited to a-synuclein, DJ~1 , LRRK2, ΡΓΝ 1 , Parkin, UCHL1 , Synphilin-1 , and XL RR i .
[00167] Examples of addiction-related proteins may include ABAT for example.
[00168] Examples of inflammation-related proteins may include the monocyte ehemoattraetant protein- 1 (MCP1 ) encoded by the Ccr2 gene, the C-C chemokine receptor type 5
(CCR5) encoded by the Ccr5 gene, the IgG receptor IIB (FCGR2b, also termed CD32) encoded by the Fcgr2b gene, or the Fc epsi lon Ri g (FCERl g) protein encoded by the Fcerl g gene, for example.
[00169] Examples of cardiovascular diseases associated proteins may include IL1B (mterieiikm 1 , beta), XDH (xanthine dehydrogenase), TPS 3 (tumor protein p53 ), PTGIS (prostaglandin 12 (prostacyclin) synthase), MB (myoglobin), TLA (interieukm 4), ANGPT1 (angiopoietin 1), ABCG8 (ATP-binding cassette, sub-family G (WHITE), member 8), or CTS (cathepsin K), for example.
[00170] Examples of Alzheimer's disease associated proteins may include the very low density lipoprotein receptor protein (VLDLR) encoded by the VLDLR gene, the ubiquitin-like modifier activating enzyme I (UBA1) encoded by the UBA1 gene, or the NEDD8~activating enzyme El catalytic subunit protein (UBE1 C) encoded by the UBA3 gene, for example.
[00171] Examples of proteins associated Autism Spectrum Disorder may include the benzodiazepine receptor (peripheral) associated protein 1 (BZRA P1 ) encoded by the BZRAP1 gene, the AF4/FMR2 family member 2 protein (AFF2) encoded by the AFF2 gene (also termed MFR2), the fragile X mental retardation autosomal homolog 1 protein (FXR 1 ) encoded by the FXR1 gene, or the fragile X mental retardation autosomal homolog 2 protein (FXR2) encoded by the FXR2 gene, for example.
0Θ172] Examples of proteins associated Macular Degeneration may include the ATP-binding cassette, sub-family A (ABCl) member 4 protein (ABCA4) encoded by the ABCR gene, the apolipoprotein E protein (APOE) encoded by the APOE gene, or the chemokine (C-C motif) Ligand 2 protein (CCL2) encoded by the CCL2 gene, for example.
[00173] Examples of proteins associated Schizophrenia may include NRG l , ErbB4, CPLX! , TPHl , TPH2, NRXNl , GS 3A, BDNF, DISC I , GSK3B, and combinations thereof.
[00174] Examples of proteins involved in tumor suppression may include ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homoiog 2), ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homoiog 3), ERBB4 (v-erb-b2 erythroblastic leukemia viral oncogene homoiog 4), Notch 1, Notch2, Notch 3, or Notch 4, for example.
[00175] Examples of proteins associated with a secretase disorder may include PSENEN (presenilis enhancer 2 homoiog (C. elegans)), CTSB (cathepsin B), PSEN1 (preseniSin 1 ), APP (amyloid beta (A4) precursor protein), APH1B (anterior pharynx defective 1 homoiog B (C, elegans)), PSEN2 (presenilin 2 (Alzheimer disease 4)), or BACE1 (beta-site APP-cleaving enzyme 1), for example.
[00176] Examples of proteins associated with Amyotrophic Lateral Sclerosis may include SODl (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascuiar endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.
[00177] Examples of proteins associated with prion diseases may include SODl (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA. (vascular endothelial growth factor A), VAGFB (vascuiar endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.
[ 00178] Examples of proteins related to neurodegenerative conditions in prion disorders may include A2M (Alpha-2-Macroglobulin), AATF (Apoptosis antagonizing transcription factor), ACPP (Acid phosphatase prostate), ACTA2 (Actin alpha 2 smooth muscle aorta), ADAM22 (ADAM metailopeptidase domain), ADORA3 (Adenosine A3 receptor), or ADRAID (Alpha- ID adrenergic receptor for Alpha- I D adrenoreceptor), for example.
[00179] Examples of proteins associated with Immunodeficiency may include A2M [aipha-2- macroglobulinj; AANAT [arylalkylamine N-acetyltransferase] ; ABCA1 [ATP -binding cassette, sub-family A (ABC1), member 1]; ABCA2 [ATP-binding cassette, sub-family A (ABO), member 2]; or ABCA3 [ATP-binding cassette, sub-family A (ABC1), member 3]; for example.
[00180] Examples of proteins associated with Trinucleotide Repeat Disorders include AR (androgen receptor), FMR1 (fragile X mental retardation 1), HTT (huntingtm), or DMPK (dystrophia myotonic a-protem kinase), FXN (frataxin), ATXN2 (ataxin 2), for example.
[00181 ] Examples of proteins associated with Neurotransmission Disorders include SST (somatostatin), NOSI (nitric oxide synthase 1 (neuronal)), ADRA2A (adrenergic, a!pha-2A-, receptor), ADRA2C (adrenergic, alpha-2C-, receptor), TACR1 (tachykinin receptor 1), or HTR2c (5-hydroxytryptamme (serotonin) receptor 2C), for example.
[00182] Examples of neurodevelopmental-associated sequences include A2BP1 [ataxin 2- binding protein 1 ], AADAT [ammoadipate aminotransferase] , AANAT [arylalkyiamine N- acetyltransferase], ABAT [4-aminobutyrate aminotransferase], ABCA 1 [ATP-binding cassette, sub-family A (ABO), member 1], or ABCA13 [ATP-binding cassette, sub-family A (ABO), member 13], for example.
[00183] Further examples of preferred conditions treatable with the present system include may be selected from: Aieardi-Goutieres Syndrome; Alexander Disease; Allan-Herndon-Dudiey Syndrome; POLG-Related Disorders; Alpha-Mannosidosis (Type II and III); Alstrom Syndrome; Angelman; Syndrome; Ataxia-Telangiectasia; Neuronal Ceroid-Lipofuscinoses; Beta- rrhalassemia; Bilateral Optic Atrophy and (Infantile) Optic Atrophy Type 1; Retinoblastoma (bilateral); Canavan Disease; Cerebrooculofacioskeletal Syndrome 1 [COFS1]; Cerebrotcndinous Xanthomatosis; Cornelia de Lange Syndrome; MAPT-Reiated Disorders; Genetic Prion Diseases; Dravet Syndrome; Early-Onset Familial Alzheimer Disease; Friedreich Ataxia [FRDA]; Fryns Syndrome; Fucosidosis; Fukuyama Congenital Muscular Dystrophy; Galactosialidosis; Gaucher Disease; Organic Acidemias; Hemophagocytic Lymphohistiocytosis; Hutehin son-Gilford Progeria Syndrome; Mucolipidosis II; Infantile Free Sialic Acid Storage Disease; PLA2G6- Associated Neurodegeiieration; Jervell and Lange-Nielsen Syndrome; Junctional Epidermolysis Bullosa; Huntington Disease; Kxabbe Disease (Infantile); Mitochondrial DNA-Associated Leigh Syndrome and NARP; Lesch-Nyhan Syndrome; LIS1- Associated Lissencephaly; Lowe Syndrome; Maple Syrup Urine Disease; MECP2 Duplication Syndrome; ATP7A-Related Copper Transport Disorders; LAMA2-Related Muscular Dystrophy; Arylsulfatase A Deficiency; Mucopolysaccharidosis Types I, II or III; Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum; Neurodegeneration with Brain Iron Accumulation Disorders; Acid Sphingomyelinase Deficiency; Niemann-Pick Disease Type C; Glycine
Encephalopathy; ARX-Related Disorders; Urea Cycle Disorders; COL 1 Al /2-Related Osteogenesis Imperfecta; Mitochondrial DNA Deletion Syndromes; PLP1 -Related Disorders; Perry Syndrome; Phelan-McDermid Syndrome; Glycogen Storage Disease Type 11 (Pompe Disease) (Infantile); MAPT-Related Disorders; MECP2 -Related Disorders; Rhizomelic Chondrodysplasia Punctata Type 1 ; Roberts Syndrome; Sandhoff Disease; Sehindler Disease - Type 1; Adenosine Deaminase Deficiency; Smith-Lemli-Opitz Syndrome; Spinal Muscular Atrophy; Infantile-Onset Spinocerebellar Ataxia; Hexosaminidase A Deficiency; Thanatophoric Dysplasia Type 1; Collagen Type VI-Related Disorders; Usher Syndrome Type I; Congenital Muscular Dystrophy; Wolf-Birsehhora Syndrome; Lysosomal Acid Lipase Deficiency; and Xeroderma Pigmentosum.
[00184] As wil l be apparent, it is envisaged that the present system can be used to target any polynucleotide sequence of interest. Some examples of conditions or diseases that might be usefully treated using the present system are included in the Tables above and examples of genes currently associated with those conditions are also provided there. However, the genes exemplified are not exhaustive.
EXAMPLES
[00185] The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplar}', and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.
Example I: CRISP R Complex Activity in the Nucleus of a Eukaryotic Cell
[00186] An example type II CRISPR system is the type II CRISPR locus from Streptococcus pyogenes SF370, which contains a cluster of four genes Cas9, Casl, Cas2, and Csnl, as well as two non-coding RNA elements, tracrRNA and a characteristic array of repetitive sequences (direct repeats) interspaced by short stretches of non-repetitive sequences (spacers, about 30bp each). n this system, targeted DNA double-strand break (DSB) is generated in four sequential steps (Figure 2A). First, two non-coding RNAs, the pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus. Second, tracrRNA hybridizes to the direct repeats of pre-
crRNA, which is then processed into mature crRNAs containing individual spacer sequences. Third, the mature crRNA:tracrRNA complex directs Cas9 to the DNA target consisting of the protospacer and the corresponding PAM via heterodupiex formation between the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates cleavage of target DNA upstream of PAM to create a DSB within the protospacer (Figure 2A). This example describes an example process for adapting this RNA-programmable nuclease system to direct CRISPR complex activity in the nuclei of eukaryotic cel ls.
[00187] Cell culture and transfection
[00188] Human embryonic kidney (HEK) cell line HEK 293FT (Life Technologies) was maintained in Duibeeeo's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), 2 m VI GlutaMAX ( Life Technologies), lOOU/mL penicillin, and 100p.g/mL streptomycin at 37°C with 5% C02 incubation. Mouse neuro2A (N2A) cell line (ATCC) was maintained with DMEM supplemented with 5% fetal bovine semm (HyClone), 2mM GlutaMAX (Life Technologies), lOOU/mL penicillin, and l OQ g/mL streptomycin at 37°C with 5% CO;.
[00189] HEK 293 FT or N2A cells were seeded into 24-wel! plates (Corning) one day prior to transfection at a density of 200,000 ceils per well. Cells were transfected using Lipofectamine
2000 (Life Technologies) following the manufacturer's recommended protocol. For each well of a 24-weil plate a total of 800ng of plasmids were used.
[00190] Surveyor assay and sequencing analysis for genome modification
[00191] HEK 293FT or N2A cells were transfected with plasmid DNA as described above.
After transfection, the cells were incubated at 37°C for 72 hours before genomic DNA extraction.
Genomic DNA was extracted using the QuickExtract DNA extraction kit (Epicentre) following the manufacturer's protocol. Briefly, cells were resuspended in QuickExtract solution and incubated at 65°C for 15 minutes and 98°C for 10 minutes. Extracted genomic DNA. was immediately processed or stored at -20°C.
[00192] The genomic region surrounding a CRISPR target site for each gene was PGR amplified, and products were purified using QiaQuick Spin Column (Qiagen) following manufacturer's protocol. A total of 00ng of the purified PGR products were mixed with 2μ1 10 Taq polymerase PGR buffer (Enzymaties) and ultrapure water to a final volume of 20μ1, and subjected to a re-annealing process to enable heterodupiex formation: 95°C for lOmin, 95°C
to 85°C ramping at - 2°C/s, 85°C to 25°C at - 0.25°C/s, and 25°C hold for 1 minute. After re- annealing, products were treated with Surveyor nuclease and Surveyor enhancer S (Transgenomics) following the manufacturer's recommended protocol, and analyzed on 4-20% Novex TBE poly-acrylamide gels (Life Technologies). Gels were stained with SYBR Gold DNA stain (Life Technologies) for 30 minutes and imaged with a Gel Doc gel imaging system (Bio-rad). Quantification was based on relative band intensities, as a measure of the fraction of cleaved DNA. Figure 8 provides a schematic il lustration of this Surveyor assay.
[00193] Restriction fragment length polymorphism assay for detection of homologous recombination
[00194] HE 293FT and N2A cells were transfected with plasmid DNA, and incubated at 37°C for 72 hours before genomic DNA extraction as described above. The target genomic region was PGR amplified using primers outside the homology arms of the homologous recombination (HR) template. PGR products were separated on a 1% agarose gel and extracted with MinElute GelExtraetion Kit (Qiagen). Purified products were digested with Hmdlll (Fermentas) and analyzed on a 6% Novex TBE poly-acrylamide gel (Life Technologies).
[00195] RN A secondary structure prediction and analysis
[00196] RNA secondary structure prediction was performed using the online webserver RNAfold developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g. A.R. Gruber et at, 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62).
[00197] Bacterial plasmid transformation interference assay
[00198] Elements of the S. pyogenes CRISPR locus 1 sufficient for CRISPR activity were reconstituted in E. coli using pCRISPR plasmid (schematically illustrated in Figure 10A), pCRISPR contained tracrRNA, SpCas9, and a leader sequence driving the crRNA array. Spacers (also referred to as "guide sequences") were inserted into the crRNA array between Bsal sites using annealed oligonucleotides, as illustrated. Challenge plasmids used in the interference assay were constructed by inserting the protospacer (also referred to as a "target sequence") sequence along with an adjacent CRISPR motif sequence (PAM) into pUC19 (see Figure 10B). The challenge plasmid contained ampicillin resistance. Figure IOC provides a schematic representation of the interference assay. Chemical ly competent E. coli strains already carrying pCRISPR and the appropriate spacer were transformed with the challenge plasmid containing the
corresponding protospacer-PAM sequence. pUC19 was used to assess the transformation efficiency of each pCRIS PR-carrying competent strain. CRISPR activity resulted in cleavage of the pPSP piasmid carrying the protospacer, precluding ampicillin resistance otherwise conferred by pUC19 lacking the protospacer. Figure 10D illustrates competence of each pCRISPR- carrying E. cofi strain used in assays illustrated in Figure 4C.
[00199] RNA purification
[00200] FJEK 293FT cells were maintained and transfected as stated above. Cells were harvested by trypsinization followed by washing in phosphate buffered saline (PBS). Total cell RNA was extracted with TRI reagent (Sigma) following manufacturer's protocol. Extracted total RNA was quantified using Naonodrop (Thermo Scientific) and normalized to same concentration.
[00201] Northern blot analysis ofcrRNA and tracrKNA expression in mammalian cells
[00202] RNAs were mixed with equal volumes of 2X loading buffer (Ambion), heated to 95°C for 5 min, chilled on ice for 1 min, and then loaded onto 8% denaturing polyacrylamide gels (SequaGel, National Diagnostics) after pre-running the gel for at least 30 minutes. The samples were electrophoresed for 1.5 hours at 40W limit. Afterwards, the RNA was transferred to Hybond N+ membrane (GE Healthcare) at 300 mA in a semi-dry transfer apparatus (Bio-rad) at room temperature for 1 .5 hours. The RNA was crosslinked to the membrane using autocrossiink button on Stratagene UV Crosslinker the Stratalinker (Stratagene). The membrane was pre-hyhridized in ULTRAhyb-Oligo Hybridization Buffer (Ambion) for 30 min with rotation at 42°C, and probes were then added and hybridized overnight. Probes were ordered from IDT and labeled with [gamma-""?] ATP s erk in Elmer) with T4 polynucleotide kinase (New England Biolabs). The membrane was washed once with pre-warmed (42°C) 2xSSC, 0.5% SDS for 1 min followed by two 30 minute washes at 42°C. The membrane was exposed to a phosphor screen for one hour or overnight at room temperature and then scanned with a phosphorimager (Typhoon).
[0Θ203] Bacterial CRISPR system construction and evaluation
[00204] CRISPR locus elements, including tracrRNA, Cas9, and leader were PGR amplified from Streptococcus pyogenes SF370 genomic DNA with flanking homology arms for Gibson. Assembly. Two Bsal type IIS sites were introduced in between two direct repeats to facilitate easy insertion of spacers (Figure 9). PGR products were cloned into EcoRV-digested
pACYC184 downstream of the tet promoter using Gibson Assembly Master Mix (NEB). Other endogenous CRISPR system elements were omitted, with the exception of the last 50bp of Csn2. Oligos (Integrated DNA Technology) encoding spacers with complimentary overhangs were cloned into the i&al-digested vector pDCOOO (NEB) and then ligated with T7 ligase (Enzymatics) to generate pCRISPR plasmids. Challenge pfasmids containing spacers with PAM sequences (also referred to herein as "CRISPR motif sequences") were created by ligating hybridized oligos carrying compatible overhangs (Integrated DNA Technology) into BanMl- digested pUC19. Cloning for all constructs was performed in E. coli strai JM109 f'Zymo Research).
[00205] pCRJSPR-carrying cells were made competent using the Z-Competent E. coli Transformation Kit and Buffer Set (Zymo Research, T3001 ) according to manufacturer's instructions. In the transformation assay, 50uL aliquots of competent cells carrying pCRISPR were thawed on ice and tra sformed with lug of spacer plasmid or pUC19 on ice for 30 minutes, followed by 45 second heat shock at 42°C and 2 minutes on ice. Subsequently, 250ul SOC (Invitrogen) was added followed by shaking incubation at 37°C for Ihr, and 100 uL of the post- SOC outgrowth was plated onto double selection plates (12.5 ug/ml chloramphenicol, 100 ug/ml ampicillin). To obtain cfu/ng of DNA, total colony numbers were multiplied by 3.
[00206] To improve expression of CRISPR components in mammalian cells, two genes from the SF370 locus 1 of Streptococcus pyogenes (S. pyogenes) were codon-optimized, Cas9 (SpCas9) and RNase III (SpRNase III). To facilitate nuclear localization, a nuclear localization signal (NLS) was included at the amino (N)- or carboxyl (C)-termini of both SpCas9 and SpRNase III (Figure 2B). To facilitate visualization of protein expression, a fluorescent protein marker was also included at the N- or C-termini of both proteins (Figure 2B). A version of SpCas9 with an NLS attached to both N- and C-termini (2xNLS-SpCas9) was also generated. Constructs containing NLS-fused SpCas9 and SpRNase III were transfected into 293FT human embryonic kidney (HEK) cells, and the relative positioning of the NLS to SpCas9 and SpRNase III was found to affect their nuclear localization efficiency. Whereas the C -terminal NLS was sufficient to target SpRNase II I to the nucleus, attachment of a single copy of these particular NLS's to either the N- or C -terminus of SpCas9 was unable to achieve adequate nuclear localization in this system. In this example, the C-terminal. NLS was that of nucleoplasmin (KRPAAT KAGQAKKKK), and the C-terminal NLS was that of the SV40 large T-antigen
(P KKRKV). Of the versions of SpCas9 tested, only 2xNLS-SpCas9 exhibited nuclear localization (Figure 2B).
[002071 The tracrRNA from the CRISPR locus of S. pyogenes SF370 has two transcriptional start sites, giving rise to two transcripts of 89~nucleotid.es (nt) and 171nt that are subsequently processed into identical 75nt mature tracrR As. The shorter 89nt tracrRNA was selected for expression in mammalian cells (expressio constructs illustrated in Figure 7 A, with functionality as determined by results of the Surveyor assay shown in Figure 7B). Transcription start, sites are marked as +1, and transcription terminator and the sequence probed by northern blot are also indicated. Expression of processed tracrRNA was also confirmed by Northern blot. Figure 7C shows results of a Northern blot analysis of total RNA extracted from 293FT cells transfected with U6 expression constructs carrying long or short tracrRNA, as well as SpCas9 and DR- EMX1(1)-DR. Left and right panels are from 293FT cells transfected without or with SpRNase III, respectively. U6 indicate loading control blotted with a probe targeting human U6 snRNA. Transfection of the short tracrRNA expression construct led to abundant levels of the processed form of tracrRNA (~75bp). Very low amounts of long tracrRNA are detected on the Northern blot.
[00208] To promote precise transcriptional initiation, the RNA polymerase Ill-based U6 promoter was selected to drive the expression of tracrRNA (Figure 2C). Similarly, a U6 promoter-based construct was developed to express a pre-crRNA array consisting of a single spacer flanked by two direct repeats (DRs, also encompassed by the term "tracr-mate sequences"; Figure 2C). The initial spacer was designed to target a 33-base-pair (bp) target site (30-bp proto spacer plus a 3 -bp CRISPR motif (PAM) sequence satisfying the NGG recognition motif of Cas9) in the human EMXl locus (Figure 2C), a key gene in the development of the cerebral cortex.
[00209] To test whether heterologous expression of the CRISPR system (SpCas9, SpRNase III, tracrRNA, and pre-crRNA) in mammalian cells can achieve targeted cleavage of mammalian chromosomes, HEK 293FT cells were transfected with combinations of CRISPR components. Since DSBs in mammalian nuclei are partially repaired by the non-homologous end joining (NHEJ) pathway, which leads to the formation of indels, the Surveyor assay was used to detect potential cleavage activity at the target. EMXl locus (Figure 8) (see e.g. Guschin et al., 2010, Methods Moi Biol 649: 2.47). Co -transfection of ail four CRISPR components was able to
induce up to 5.0% cleavage in the protospacer (see Figure 2D). Co-transfection of all CRJSPR components minus SpRNase I I I also induced up to 4.7% indel in the protospacer, suggesting that there may he endogenous mammalian RNases that are capable of assisting with crRNA maturation, suc as for example the related Dicer and Drosha enzymes. Removing any of the remaining three components abolished the genome cleavage activity of the CRISPR system (Figure 2D). Sanger sequencing of amplicons containing the target locus verified the cleavage activity: in 43 sequenced clones, 5 mutated alleles (1 1 .6%) were found. Similar experiments using a variety of guide sequences produced indel percentages as high as 29% (see Figures 4-7, 12, and 13). These results define a three-component system for efficient CRISP R-mediaied genome modification in mammalian cells. To optimize the cleavage efficiency, Applicants also tested whether different isoforms of tracrRNA affected the cleavage efficiency and found that, in this example system, only the short (89-bp) transcript form was able to mediate cleavage of the human EMX1 genomic locus (Figure 7B).
[002 J O] Figure 14 provides an additional Northern blot analysis of crRNA processing in mammalian ceils. Figure 14A illustrates a schematic showing the expression vector for a single spacer flanked by two direct repeats (DR-EMXl(i)-DR). The 30bp spacer targeting the human EMX1 locus protospacer 1 (see Figure 6) and the direct repeat sequences are shown in the sequence beneath Figure 14 A. The line indicates the region whose reverse-complement sequence was used to generate Northern blot probes for EMX1(1) crRNA detection. Figure 14B shows a Northern blot analysis of total RNA extracted from 293 FT cells transtected with U6 expression constructs carrying DR-EMX 1(1 )-DR. Left and right panels are from 293 FT cells transtected without or with SpRNase III respectively. DR-EMX1 (1 )-DR was processed into mature crR'NAs only in the presence of SpCas9 and short tracrRNA and was not dependent on the presence of SpRNase III. The mature crRNA detected from traiisfected 293FT total RNA is ~33bp and is shorter than the 39-42bp mature crRNA from S, pyogenes. These results demonstrate that a CRISPR system can be transplanted into eukaryotic cells and reprogrammed to facilitate cleavage of endogenous mammalian target polynucleotides.
[00211] Figure 2 illustrates the bacterial CRISPR system described in this example. Figure 2 A illustrates a schematic showing the CRISPR locus 1 from Streptococcus pyogenes SF370 and a proposed mechanism of CRISPR -mediated DNA cleavage by this system. Mature crRNA processed from the direct repeat-spacer array directs Cas9 to genomic targets consisting of
complimentary protospacers and a protospacer-adjacent motif (PAM). Upon target-spacer base pairing, Cas9 mediates a double-strand break in the target DNA. Figure 2B illustrates engineering of S. pyogenes Cas9 (SpCas9) and RNase III (SpRNase III) with nuclear localization signals (NLSs) to enable import into the mammalian nucleus. Figure 2C illustrates mammalian expression of SpCas9 and SpRNase 111 driven by the constitutive EFla promoter and tracrRNA and pre-crRNA array (DR-Spacer-DR) driven by the RNA Pol3 promoter U6 to promote precise transcription initiation and termination. A protospacer from the human EMXl locus with a satisfactory PAM sequence is used as the spacer in the pre-crRNA array. Figure 2D illustrates surveyor nuclease assay for SpCas9-mediated minor insertions and deletions. SpCas9 was expressed with and without SpRNase III, tracrRNA, and a pre-crRNA array carrying the EMX1- target spacer. Figure 2E illustrates a schematic representation of base pairing between target locus and EMXl -targeting crRNA, as well as an example chromatogram showing a micro deletion adjacent to the SpCas9 cleavage site. Figure 2F illustrates mutated alleles identified from sequencing analysis of 43 clonal amplicons showing a "variety of micro insertions and deletions. Dashes indicate deleted bases, and non-aligned or mismatched bases indicate insertions or mutations. Scale bar ::: lOjim.
0Θ212] To further simplify the three-component system, a chimeric crRNA-tracrRNA hybrid desig was adapted, where a mature crRNA (comprising a guide sequence) is fused to a partial tracrRNA via a stem-loop to mimic the natural crRNA:tracrRNA duplex (Figure 3A). To increase co-delivery efficiency, a bicistronic expression vector was created to drive co- expression of a chimeric RNA and SpCas9 in transfected ceils (Figures 3 A and 8). In parallel, the bicistronic vectors were used to express a pre-crRNA (DR-guide sequence-DR) with SpCas9, to induce processing into crRNA with a separately expressed tracrRNA (compare Figure 13B top and bottom). Figure 9 provides schematic illustrations of bicistronic expression vectors for pre- crRNA array (Figure 9 A) or chimeric crRNA (represented by the short line downstream of the guide sequence insertion site and upstream of the EF l a promoter in Figure 9B) with hSpCas9, showing locatio of various elements and the point of guide sequence insertion. The expanded sequence around the location of the guide sequence insertion site in Figure 9B also shows a partial DR sequence (GTTTAGAGCTA) and a partial tracrRNA sequence (TAGCAAGTTAAAATAAGGCTAGTCCGTTTTT). Guide sequences can be inserted between Bbsl sites using annealed oligonucleotides. Sequence design for the oligonucleotides are shown
below the schematic illustrations in Figure 9, with appropriate ligation adapters indicated. WPRE represents the Woodchuck hepatitis virus post-transcription al regulatory element. The efficiency of chimeric RNA-mediated cleavage was tested by targeting the same EMXl locus described above. Using both Surveyor assay and Sanger sequencing of amplicons, Applicants confirmed that the chimeric RNA design facilitates cleavage of human EMXl locus with approximately a 4.7% modification rate (Figure 4).
[00213] Genera!izability of C ISPR -mediated cleavage in eukaryotic ceils was tested by targeting additional genomic loci in both human and mouse ceils by designing chimeric RNA targeting multiple sites in the human EMXl and PVALB, as well as the .mouse Th loci. Figure 15 illustrates the selection of some additional targeted protospacers in human PVALB (Figure 15 A) and mouse Th (Figure 15B) loci. Schematics of the gene loci and the location of three protospacers within the last exon of each are provided. The underlined sequences include 30bp of protospacer sequence and 3bp at the 3' end corresponding to the PAM sequences. Protospacers on the sense and anti-sense strands are indicated above and below the DNA sequences, respectively. A modification rate of 6.3% and 0.75% was achieved for the human P VALB and mouse Th loci respectively, demonstrating the broad applicabi lity of the CRISPR system in modifying different loci across multiple organisms (Figures 3B and 6). While cleavage was only detected with one out of three spacers for each locus using the chimeric constructs, all target sequences were cleaved with efficiency of indel production reaching 27%> when using the co-expressed pre-crRNA arrangement (Figure 6).
[00214] Figure 13 provides a further illustration that SpCas9 can be reprogrammed to target multiple genomic loci in mammalian cells. Figure 13A provides a schematic of the human EMXl Socus showing the location of five protospacers, indicated by the underlined sequences. Figure 13B provides a schematic of the pre-crRNA/trcrRNA complex showing hybridization between the direct repeat region of the pre-crRNA and tracrRNA (top), and a schematic of a chimeric RNA design comprising a 20bp guide sequence, and tracr mate and tracr sequences consisting of partial direct repeat and tracrRNA sequences hybridized in a hairpin structure (bottom). Results of a Surveyor assay comparing the efficacy of Cas9-mediated cleavage at five protospacers in the human EMXl locus is illustrated in Figure 13C. Each protospacer is targeted using either processed pre-crR A/tracrRNA complex (crRNA) or chimeric RNA (chiRNA).
[00215] Since the secondary stmcture of RNA can be crucial for intermolecuiar interactions, a structure prediction algorithm based on minimum free energy and Boltzmann-weighted structure ensemble was used to compare the putative secondary structure of all guide sequences used in our genome targeting experiment (Figure 3B) (see e.g. Gruber et al, 2008, Nucleic Acids Research, 36: W70). Analysis revealed that in most cases, the effective guide sequences in the chimeric crRNA context were substantially free of secondary structure motifs, whereas the ineffective guide sequences were more likely to form internal secondary structures that could prevent base pairing with the target protospacer DNA. It is thus possible that variability in the spacer secondary structure might impact the efficiency of CRISPR-mediated interference when using a chimeric crRNA.
[00216] Figure 3 illustrates example expression vectors. Figure 3 A provides a schematic of a bi-cistronic vector for driving the expression of a synthetic crRNA-tracrRNA chimera (chimeric RNA) as well as SpCas9. The chimeric guide RNA contains a 20-bp guide sequence corresponding to the protospacer in the genomic target site. Figure 3B provides a schematic showing guide sequences targeting the human EMXI, PVALB, and mouse Th loci, as well as their predicted secondary structures. The modification efficiency at each target site is indicated below the RNA secondary structure drawing (EMXI, n = 216 amplicon sequencing reads; PVALB, n 224 reads; Th, n— 265 reads). The folding algorithm produced an output with each base colored according to its probability of assuming the predicted secondary structure, as indicated by a rainbow scale that is reproduced in Figure 3B in gray scale. Further vector designs for SpCas9 are shown in Figure 44, which illustrates single expression vectors incorporating a U6 promoter linked to an insertion site for a guide oligo, and a Cbh promoter linked to SpCas9 coding sequence. The vector shown in Figure 44b includes a tracrRNA coding sequence linked to an HI promoter.
[00217] To test whether spacers containing secondary structures are able to function in prokaryotic cells where CRISPRs naturally operate, transformation interference of protospacer- bearing plasmids were tested in an E, coli strain heterologously expressing the S. pyogenes SF370 CR1SPR locus 1 (Figure 10). The CRiSPR locus was cloned into a low-copy E. coli expression vector and the crRNA array was replaced with a single spacer flanked by a pair of DRs (pCRlSPR). E. coli strains harboring different pCRlSPR plasmids were transformed with challenge plasmids containing the corresponding protospacer and PAM sequences (Figure IOC).
In the bacterial assay, all spacers facilitated efficient CRISPR interference (Figure 4C). These results suggest that there may be additional factors affecting the efficiency of CRISPR activity in mammalian cells.
[00218] To investigate the specificity of CRISPR-mediated cleavage, the effect of single- nucleotide mutations in the guide sequence on protospacer cleavage in the mammalian genome was a alyzed using a series of EMXl -targeting chimeric crRNAs with single point mutations (Figure 4A). Figure 4B illustrates results of a Surveyor nuclease assay comparing the cleavage efficiency of Cas9 when paired with different mutant chimeric RNAs, Single-base mismatch up to 12-bp 5' of the PAM substantially abrogated genomic cleavage by SpCas9, whereas spacers with mutations at farther upstream positions retained activity against the original protospacer target (Figure 4B). In addition to the PAM, SpCas9 has single-base specificity within the last 12-bp of the spacer. Furthermore, CRISPR is able to mediate genomic cleavage as efficiently as a pair of TALE nucleases (TALEN) targeting the same EMXl protospacer. Figure 4C provides a schematic showing the design of TALENs targeting EMXL and Figure 4D shows a Surveyor gel comparing the efficiency of TALEN and Cas9 (n=3).
[00219] Having established a set of components for achieving CRISPR-mediated gene editing in mammalian cells through the error-prone N EJ mechanism, the ability of CRISPR to stimulate homologous recombination (HR), a high fidelity gene repair pathway for making precise edits in the genome, was tested. The wild type SpCas9 is able to mediate site-specific DSBs, which can be repaired through both NHEJ and HR. In addition, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of SpCas9 was engineered to convert the nuclease into a nickase (SpCas9n; illustrated in Figure 5 A) (see e.g. Sapranauskas et al, 2011, Nucleic Acids Research, 39: 9275; Gasiunas et al, 2012, Proc. Natl. Acad. Sci. USA, 109:E2579), such that nicked genomic DNA undergoes the high-fidelity homo logy-directed repair (HDR). Surveyor assay confirmed that SpCas9n does not generate indels at the EMXl protospacer target. As illustrated in Figure 5B, co-expression of EMXl -targeting chimeric crRNA with SpCas9 produced indels in the target site, whereas co-expression with SpCas9n did not (n=3). Moreover, sequencing of 327 amplicons did not detect any indels induced by SpCas9n. The same locus was selected to test CRISPR-mediated HR by co-transfecting HE 293FT cells with the chimeric RNA targeting EMXl, hSpCas9 or hSpCas9n, as well as a HR template to introduce a pair of restriction sites (Hindlll and NheT) near the protospacer. Figure
5C provides a schematic illustration of the HR strategy, with relative locations of recombination points and primer annealing sequences (arrows). SpCas9 and SpCas9n indeed catalyzed integration of the HR template into the EMXl locus. PCR amplification of the target region followed by restriction digest with HwdlH revealed cleavage products corresponding to expected fragment sizes (arrows in restriction fragment length polymorphism gel analysis shown in Figure 5D). with SpCas9 and SpCas9n mediating similar levels of HR efficiencies. Applicants further verified HR using Sanger sequencing of genomic amplicons (Figure 5E). These results demonstrate the utility of CRISPR for facilitating targeted gene insertion in the mammalian genome. Given the 14-bp (12-bp from the spacer and 2 -bp from the PA ) target specificity of the wild type SpCas9, the availability of a nickase can significantly reduce the likelihood of off- target modifications, since single strand breaks are not substrates for the error-prone NHEJ pathway.
[00220] Expression constructs mimicking the natural architecture of CRISPR loci with arrayed spacers (Figure 2A) were constructed to test the possibility of multiplexed sequence targeting. Using a single CRISPR array encoding a pair of EMXl- and J¾Z2?-targeting spacers, efficient cleavage at both loci was detected (Figure 4F, showing both a schematic design, of the crRNA array and a Surveyor blot showing efficient mediation of cleavage). Targeted deletion of larger genomic regions through concurrent DSBs using spacers against two targets within EMXl spaced by 119bp was also tested, and a 1 .6% deletion efficacy (3 out of 182 amplicons; Figure 4G) was detected. This demonstrates that the CRISPR system can mediate multiplexed editing within a single genome.
Example 2: CRISPR system modifications and alternatives
[00221] The ability to use RNA to program sequence-specific DNA cleavage defines a new class of genome engineering tools for a variety of research and industrial applications. Several aspects of the CRISPR system can be further improved to increase the efficiency and versatility
•J _|_ of CRISPR. targeting. Optimal Cas9 activity may depend on the availability of free Mg" at levels higher than that present in the mammalian nucleus (see e.g. Jinek et al, 2012, Science, 337:816), and the preference for an NGG motif immediately downstream of the protospacer restricts the ability to target on average every 12-bp in the human genome (Figure 1 1 , evaluating both plus and minus strands of human chromosomal sequences). Some of these constraints can be overcome by exploring the diversity of CRISPR loci across the microbial metagenome (see
e.g. Makarova et al, 2011, Nat Rev Microbiol, 9:467). Other CRISPR loci may be transplanted into the mammalian cellular milieu by a process similar to that described in Example 1. For example, Figure 12 illustrates adaptation of the Type II CRISPR system from CRISPR 1 of Streptococcus thennophilus LMD-9 for heterologous expression in mammalian cells to achieve CRISPR-mediated genome editing. Figure 12A provides a Schematic il lustration of CRISPR 1 from S. thennophilus LMD-9. Figure 12B illustrates the design of an expression system for the S. thermophilus CRISPR system. Human eodon-optimized hSiCas is expressed using a constitutive EFla promoter. Mature versions of tracrRNA and crRNA are expressed using the U6 promoter to promote precise transcription initiation. Sequences from the mature crRNA and tracrRNA are illustrated. A single base indicated by the lower case "a" in the crRNA sequence is used to remove the polyU sequence, which serves as a RNA polIII transcriptional terminator. Figure 12C provides a schematic showing guide sequences targeting the human EMX1 locus as well as their predicted secondary structures. The modification efficiency at each target site is indicated below the RNA secondary structures. The algorithm generating the structures colors each base according to its probability of assuming the predicted secondary structure, which is indicated by a rainbow scale reproduced in Figure 12C in gray scale. Figure 12D shows the results of hStCas9-mediated cleavage in the target locus using the Surveyor assay. RNA guide spacers 1 and 2 induced 14% and 6.4%, respectively. Statistical analysis of cleavage activity across biological replica at these two protospacer sites is also provided in Figure 6. Figure 16 provides a schematic of additional protospacer and corresponding PAM sequence targets of the S. thermophilus CRISPR system in the human EMX! locus. Two protospacer sequences are highlighted and their corresponding PAM sequences satisfying NNAGAAW motif are indicated by underlining 3' with respect to the corresponding highlighted sequence. Both protospacers target the anti-sense strand.
Example 3: Sample target sequence selection algorithm.
[00222] A software program is designed to identify candidate CRISPR target sequences on both strands of an input DNA sequence based on desired guide sequence length and a CRISPR motif sequence (PAM) for a specified CRISPR enzyme. For example, target sites for Cas9 from S. pyogenes, with PAM sequences NGG, may be identified by searching for 5'-Nx-NGG-3' both on the input sequence and on the reverse-complement of the input. Likewise, target sites for Cas9 of S. thermophilus CRISPR 1, with PAM sequence NNAGAAW, may be identified by
searching for 5 '-Nx-N AGAAW-3 ' both on the input sequence and on the reverse-complement of the input. Likewise, target sites for Cas9 of S. thermophihis CRISPR3, with PAM sequence NGGNG, may be identified by searching for 5'-Nx- GGNG-3' both on the input sequence and on the reverse-complement of the input. The value "x" in Nx .may be fixed by the program or specified by the user, such as 20.
[00223] Since multiple occurrences in the genome of the DNA target site may lead to nonspecific genome editing, after identifying all potential sites, the program filters out sequences based on the number of times they appear in the relevant reference genome. For those CRISPR enzymes for which sequence specificity is determined by a 'seed' sequence, such as the l i~12bp 5 ' from the PAM sequence, including the PAM sequence itself, the filtering step may be based on the seed sequence. Thus, to avoid editing at additional genomic loci, results are filtered based on the number of occurrences of the seed:PA sequence in the relevant genome. The user may be allowed to choose the length of the seed sequence. The user may also be allowed to specify the number of occurrences of the seed:PAM sequence in a genome for purposes of passing the filter. The default is to screen for unique sequences. Filtration level is altered by changing both the length of the seed sequence and the number of occurrences of the sequence in the genome. The program may in addition or alternatively provide the sequence of a guide sequence complementary to the reported target sequence(s) by providing the reverse complement of the identified target sequence(s).
[00224] Further details of methods and algorithms to optimize sequence selection can be found in U.S. application Serial No. 61/836,080 (attorney docket 44790.1 1.2022); incorporated herein by reference.
Example 4: Evaluation of multiple chimeric crRNA-tracrRNA hybrids
[00225] This example describes results obtained for chimeric RNAs (chiRNAs; comprising a guide sequence, a tracr mate sequence, and a tracr sequence in a single transcript) having tracr sequences that incorporate different lengths of wild-type tracrRNA. sequence. Figure 18a illustrates a schematic of a bicistronic expression vector for chimeric RNA. and Cas9. Cas9 is driven by the CBh promoter and the chimeric RNA is driven by a U6 promoter. The chimeric guide RNA consists of a 20bp guide sequence (Ns) joined to the tracr sequence (running from the first "U" of the lower strand to the end of the transcript), which is truncated at various positions as indicated. The guide and tracr sequences are separated by the tracr-mate sequence
GUUUUAGAGCUA followed by the loop sequence GAAA. Results of SU RVEYOR assays for Cas9-mediated indels at the human EMX1 and PVALB loci are illustrated in Figure 1 8b and 1 8c, respectively. Arrows indicate the expected SURVEYOR fragments. ChiRNAs are indicated by their "+n" designation, and crRNA refers to a hybrid NA where guide and tracr sequences are expressed as separate transcripts. Quantification of these results, performed in triplicate, are illustrated by histogram in Figures 19a and 19b, corresponding to Figures 18b and 18c, respectively ("N.D." indicates no indels detected). Protospacer IDs and their corresponding genomic target, protospacer sequence, PAM sequence, and strand location are provided in Table D. Guide sequences were designed to be com lementary to the entire protospacer sequence in the case of separate transcripts in the hybrid system, or only to the underlined portion in the case of chimeric RNAs.
[00226] Cell culture and transfection
[00227] Human embryonic kidney (HEK) cell line 293FT (Life Technologies) was maintained in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), 2mM GlutaMAX (Life Technologies), 1 00! m i . penicillin, and IQQjig/mL streptomycin at 37°C with 5% C02 incubation. 293FT cells were seeded onto 24-well plates (Coming) 24 hours prior to transfection at a density of 150,000 ceils per well. Cells were transfected using Lipofectamine 2000 (Life Technologies) following the manufacturer's recommended protocol. For each well of a 24- well plate, a total of 500ng plasmid was used. 100228] SURV EY OR assay for genome modification
[00229] 293 FT cells were transfected with plasmid DNA as described above. Cells were incubated at 37°C for 72 hours post-transfection prior to genomic DNA extraction. Genomic DNA was extracted using the QuickExtract DNA Extraction Solution (Epicentre) following the manufacturer's protocol. Briefly, pelleted cells were resuspended in QuickExtract solution and incubated at 65°C for 15 minutes and 98°C for 10 minutes. The genomic region flanking the CRISPR target site for each gene was PGR amplified (primers listed in Table E), and products were purified using QiaQuick Spin Column (Qiagen) following the manufacturer's protocol. 400ng total of the purified PCR products were mixed with 2μ1 10X Taq DNA Polymerase PGR buffer (Enzymatics) and ultrapure water to a final volume of 20μ1, and subjected to a re- annealing process to enable heteroduplex formation: 95°C for lOmin, 95°C to 85°C ramping at - 2°C/s, 85°C to 25°C at - 0.25°C/s, and 25°C hold for 1 minute. After re-annealing, products were treated with SURVEYOR nuclease and SURVEYOR enhancer S (Transgcnomies) following the manufacturer's recommended protocol, and analyzed on 4-20% Novex TBE poly-acrylamide gels (Life Technologies). Gels were stained with SYBR Gold DNA stain (Life Technologies) for 30 minutes and imaged with a Gel Doc gel imaging system (Bio-rad). Quantification was based on relative band intensities.
Table E:
[00230] Com utational identification of unique CRISPR target sites
[00231] To identify unique target sites for the S. pyogenes SF370 Cas9 (SpCas9) enzyme in the human, mouse, rat, zebrafish, fruit fly, and C. elegans genome, we developed a software package to scan both strands of a DNA sequence and identify all possible SpCas9 target sites. For this example, each SpCas9 target site was operationally defined as a 20bp sequence followed by an NGG protospacer adjacent motif (PAM) sequence, and we identified all sequences satisfying this 5'-N2o-NGG-3' definition on all chromosomes. To prevent non-specific genome editing, after identifying all potential sites, all target sites were filtered based on the number of times they appear in the relevant reference genome. To take advantage of sequence specificity of
Cas9 activity conferred by a 'seed' sequence, which can be, for example, approximately 1 1 -12bp sequence 5' from the PAM sequence, 5 '-NNNNNNN N -NGG-3 ' sequences were selected to be unique in the relevant genome. All genomic sequences were downloaded from the UCSC Genome Browser (Human genome hgl9, Mouse genome mm9, Rat genome rn5, Zebrafish genome danRer?, D. melanogaster genome dm4 and C. elegans genome cel O). The full search results are available to browse using UCSC Genome Browser information. An example vi sualization of some target si tes in the human genome is provided in Figure 21.
[00232] Initially, three sites within the EMX1 locus in human HEK 293FT cells were targeted. Genome modification efficiency of each cm'RNA was assessed using the SURVEYOR nuclease assay, which detects mutations resulting from DNA double-strand breaks (DSBs) and their subsequent repair by the non-homologous end joining (NHEJ) DNA damage repair pathway. Constructs designated chiRNA(+n) indicate that up to the +n nucleotide of wild-type tracrRNA is included in the chimeric RNA construct, with values of 48, 54, 67, and 85 used for n. Chimeric RNAs containing longer fragments of wild-type tracrRN A (chiRNA(+67) and chiRNA(+85)) mediated DNA cleavage at all three EMX1 target sites, with chiRNA(+85) in particular demonstrating significantly higher levels of DNA cleavage than the corresponding crRNA/tracrRNA hybrids that expressed guide and tracr sequences in separate transcripts (Figures 18b and 19a). Two sites in the PVALB locus that yielded no detectable cleavage using the hybrid system (guide sequence and tracr sequence expressed as separate transcripts) were also targeted using chiRNAs. chiRNA(+67) and chiRNA(+85) were able to mediate significant cleavage at the two PVALB protospacers (Figures 1 8c and 19b).
[00233] For all five targets in the EMX1 and PVALB loci, a consistent increase in genome modification efficiency with increasing tracr sequence length was observed. Without wishing to be bound by any theory, the secondary structure formed by the 3' end of the tracrRNA may play a role in enhancing the rate of CR1SPR complex formation. An illustration of predicted secondary structures for each of the chimeric RNAs used in this example is provided in Figure 21. The secondary structure was predicted using RNAfold (https://ma.tbi.univie.ac.at/cgi- bin/RNAfold.cgi) using minimum free energy and partition function algorithm. Pseudocolor for each based (reproduced in grayscale) indicates the probability of pairing. Because chiRNAs with longer tracr sequences were able to cleave targets that were not cleaved by native CRISPR crRNA''tracrRNA hybrids, it is possible that chimeric RNA may be loaded onto Cas9 more
efficiently than its native hybrid counterpart. To facilitate the application of Cas9 for site- specific genome editing in eukaryotic cells and organisms, all predicted unique target sites for the S. pyogenes Cas9 were computationally identified in the human, mouse, rat, zebra fish, C. elegans, and D. melanogaster genomes. Chimeric RNAs can be designed for Cas9 enzymes from other microbes to expand the target space of CR ISPR RNA -programmable nucleases.
[00234] Figure 22 illustrates an exemplary bicistro ic expression vector for expression of chimeric RNA including up to the +85 nucleotide of wild-type tracr RNA sequence, and SpCas9 with nuclear localization sequences. SpCas9 is expressed from a CBh promoter and terminated with the bGH po yA signal (bGH pA). The expanded sequence illustrated immediately below the schematic corresponds to the region surrounding the guide sequence insertion site, and includes, from 5' to 3', 3 '-portion of the U6 promoter (first shaded region), Bbsl cleavage sites (arrows), partial direct repeat (tracr mate sequence GTTTTAGAGCTA, underlined), loop sequence GAAA, and +85 tracr sequence (underlined sequence following loop sequence). An exemplary guide sequence insert is illustrated below the guide sequence insertion site, with nucleotides of the guide sequence for a selected target represented by an "N".
|00235| Sequences described in the above examples are as follows (polynucleotide sequences are 5' to 3'):
[00236] U6~short tracrRNA (Streptococcus pyogenes SF370):
[00237] GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCT
GTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAA
TACX iXjACXTI GAAAGTAATAATTTCn'TGGGTAGTTTGC^AGTTTTAAAATTATGTTTT
AAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT
ATATCTTGTGGAAAGGACGAAACACCGGAACCATTCAAAACAGCATAGCAAGTTA
AAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTT
TTT (bold = tracrRNA sequence; underline = terminator sequence)
[0Θ238] U6-long tracrRNA (Streptococcus pyogenes SF370):
[00239] GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCT GTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAA TACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTT
ATATCTTGTGGAAAGGACGAAACACCGGTAGTATTAAGTATTGTTTTATGGCTGATA
AATTTCTTTGAATTTCTCCTTGATTATTTGTTATAAAAGTTATAAAATAATCTTGTTG
GAACCATTCAAAACAGCATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGA
AAAAGTGGCACCGAGTCGGTGCTT TTTT
[00240] U6-DR-BbsI backbone-DR {Streptococcus pyogenes SF370):
[00241] ΟΑΟί: ϊ(: Ί Ί 1 : ; :ΑΊ :ίΑΤΊ ΤΊΧΑΊ Ί Ί :κΑΊ Ί,Α(θΑΊ εΑΑΟΟ€Ί^
GTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAA
TACGTGACXri GAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTT
AAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT
ATATCTTGTGGAAAGGACGAAACACCGGGTTTTAGAGCTATGCTGTTTTGAATGGTC
CCAAAACGGGTCTTCGAGAAGACGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAA
AC
[0Θ242] U6-cliimeric RNA-BbsI backbone (Streptococcus pyogenes SF370)
[00243] GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCT
GTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAA.
TACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTT
ΑΛΑΛΊ GGACX7Yr<VVrA/rG( T
ATATCTTGTGGAAAGGACGAAACACCGGGTCTTCGAGAAGACCTGTTTTAGAGCTA
GAAATAGCAAGTTAAAATAAGGCTAGTCCG
[00244] NLS-SpCas9-EGFP:
[00245] MD Y DHDGD YKDH DID YK.DD DD KM AP K KRKVGIHG VP A ADKK.YS iGLDI
GTNSVGWAVITDEYKVPSKKFKVLGNTDR SIK NLIGALLFDSGETAEATRL RTARR
RYTRR RICYLQEIFSNEMAKVDDSFFHRLEESFLVTEDKKHERHPIFGNIVDEVAYHE
KYPTIYHLR LVDSTDKADLRLIYLALAHMIKFRGHFUEGDLNPD'NSDVDKLFIQLVQ
TYNQLFEENPLNASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFG LIALSLGLTPN
F SNFDLAEDA LQLSKDTYDDDLDNLLAQ1GDQYADLFLAA. NLSDAILLSDILR.VNT
ElTKAPLSASMIi RYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKj GYAGYIDGGASQ
EEFY FI PILEKMDGTEELLVKL REDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY
PFLKDNREKIEOLTFRiPYYVGPLARGNSRFAWMTiKSEETITPWNFEEVVD GASAQS
FIERMTNFDKNLPNE VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKLAIV
DLLFKTNRKVTV QL EDYFKKJECFDSVEISGVEDRFNASLGTYHDLL IIKDKDFLDN
EENEDILEDR'XTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLIN
GIRD QSG: ILDFL SDGFANRNFMQLJHDDSL FKEDIQKAQ\^SGQGDSLHEH:IANLA
GSPAIKKGILQTVKA7VDELVKYMGRH PENIVIEMARENQTTQ GQKNSRERM RIEEG
I ELGSQIL E PVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVD IVPQSF
LKDDSIDNKYL RSDK RGKSDNVPSEEVV M NYWRQLLNAKIJTQRK.FDNLTKAE
RGGLSELD AGFI RQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVS
DFRKDFQFYKVREINNYHHAHDAYLNA A7GTALJKXYPKLESEFVYGDY VYDVRKLVLI
AKSEQEIGKJ^TAKYFFYSNIMNFFKTEITI^NGEIRKRPLIETNGETGEIVWDKGRDFATV
RKAXSMPQ IV XTEVQTGGFSKE.SILPKRNSDKLIARKXDWDPK YGGFDSPTVAYS
VLVVAKYEKGKSKKL SVKELLGiTiMERSSFE NPIDFLEAKGYKEV KDLlIKLP YS
LFELENGRKRMLASAGELQKGNELALPS YVNFLYLASHYEKL GSPEDNEQ QLFVE
QFiKFr^LDElIEQISEFS RVlLADANLDKVLSAYNKHRD PiREQAENiifiLFTLTNLGAP
AAF YFDTTIDR RYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDAAAVSKGEELFTG
VVPILVELDGD GHKFSVSGEGEGDATYGKLTLKFICTTGKLP\7PWPTL\7TTLTYGVQ
CFSRYPDHMKQHDFF SAMPEGYVQERTIFFKDDGNYKTRAEV FEGDTLVNRIEL GI
DFKSDGNILGHKXEYNYNSHNVYIMADKQKNGIKA'NFKIRFiNIEDGSVQLADHYQQNT
PIGDGPVLLPDNHYLSTQSALS DPNE RDHMVLLEFVTAAGITLGMDELY
i 002461 SpCas9-EGFP-NLS :
[00247] MDKKYS1GLDIGTNSVGWAVITDEYKWSKKFKVLGNTDRHSIKK LIGALLF DSGETAEATRLKRTARRRYTRRK RICYLQElFSNEMAKVDDSFFHRLEESFLVEEDiCK HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEG DLNPDNSDVD LFIQLVQTYNQLFEENPnSfASGVDAKAILSARLS SRRLENLIAQLPGE
KKNGLFGNLIALSLGLTP FKS FDLAEDAKLQLSKDTYDDDLD LLAQIGDQYADLFL
AA NLSDAlI.LSDlLRV TEITKAPLSASMl RYDEHHQDi rLLKALVRQQLPEKYKEIFF
DQSKNGYAGYIDGGASQEEFYKFIKPILEK¾'1DGTEELLVKLNREDLLRKQRTFDNGSIPH
QIHLGELEiAILRRQEDFYPFLIO^NREKJEKILTFRIPYYVGPLARGNSRFAWMTRKSEETI
TPWNFEEVVD GASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVY ELT V YVTE
GMRKPAFLSGEQKKATvT)LLFKTTSIRKV KQLKEDYFKK]ECFDSVEISGVEDRFNASL
GTYHDLLKIJKDKDFLD EENEDILEDIYLTLTLFEDREIVIIEERL TYABLFDDKVM QL
KRRRYTGWGRLSRK1..INGIRD QSG TILDFL SDGFANRNFMQLIHDDSLTFKEDIQKA
QVSGQGDSiJrlEHJANLAGSPAiKKGJLQTV YVDELV VMGRBKPE iVIE ARE QTT
Q GQK SRERMKRIEEGIKELGSQILKEHPVENTQLQ EKLYLYYLQNGRDMYVDQEL
DIN LSDYDVDHIVPQSFL DDS1DNKVLTRSD RG SDNVPSEEVVKKMKNYWRQL I XA lj1'OHKF[) i;! AFRi!G[Af:[J) AG!:! RQF VF ! ROrr )[VAQ!lj)SkV!X ! KY!)|; D lIREVKVITLKSKLVSDFR DFQFYKVREINNYHFLAHDAYLNAVVGTALiKKYPKL
ESEFVYGDY VYDVRKMIAKSEQEIG ATAKYFFYSNIMNFF TEITLANGEIRKRPLIET
NGETGEIVWDKGRDFATVRKVLSMPQVNIV KTEVQTGGFSKESILPKRNSDKLIARKK
DWDPK YGGFDSPTVAYSVLVVAK G SKKL S\7KELLGITIMERSSFEKNPIDFLE
AKGYKEVK DLII LP YS LFELENGRKRM LAS AGELQKGNEL ALPS Y VNF LYLAS Y
EKL GSPEDNEQKQLFVEQBKBYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI
REQAENIiBLFTLTNLGAPAAF YFDTTIDRKRYTSTKEVLDATLIFiQSrTGLYETRJDLSQ
LGGDAAAVSKGEELFTGWPILVELDGDVNGH FSVSGEGEGDATYGKLTLKFICTTG
LPVPWPTLVTTLTYGVQCFSRYPDBMKQBDFFKSAMPEGYVQERTIFF DDGNY TRA
EV FEGDTLVNRIELKGIDFKEDGNJLGB LEYNYNSHNVYIMADKQKNG1 V F IRH
NIEDGSVQLADHYQQNTPIGDGP 7LLPDNHYLSTQSALSKDPNEKRDHMVLLEF 7TAAG
ITLGMDELY KRPAAT AGQAK K
[00248] NLS-SpCas9-EGFP-NLS :
[002491 DY DBDGDYKDFIDIDY DDDDKMAPK KRKVGIFIGVPAADK YSIGLDI
GTNSVGWAVITDEYKVPSK F VLGNTDRBSIKKNLIGALLFDSGETAEATRLKJITARR
RYTRR NRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKBERHPIFGNIVDEVAYHE YPTFYHLRKKLVDSTD ADLRLRYLALAHMI F'RGBFLIEGDLNPD'NSDVD LFIQLVQ
TYNQLFEENPINASGVDA. AJLSARLSK.SRRLENLIAQLPGE KNGLFGNLIALSLGLTPN
FKSNFDI^EDAKLQLSKZ)TYDDDLDNLI^Q]GDQYADLFI^A NLSDAILLSD[LRVNT
EITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE YKEIFFDQSKNGYAGYIDGGASQ
EEFYKFIKPILE MDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY
PFLKDNREKIEKILTFRIPYY 7GPLARGNSRFAWMTR SEETITPTOFEEVVDKGASAQS
FIERMTT^FDKNLPNEKVLPKFISI YEYFTVYNEI V YVTEGMRKPAFLSGEQ ALV
DLLIT TNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDN
EENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLIN
GIRD QSG: ILDFL SDGFANRNFMQLJHDDSL FKEDIQKAQ\^SGQGDSLHEH:IANLA
GSPAIKKGILQTV V^DELV VMGRHKPE IVIEMARENQTTQ GQKNSRERMKRIEEG
I ELGSQILKEBPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDBIVPQSF
L DDSIDN VLTRSDKNRGKSDNVPSEEVVKK¾'1KNYWRQLLNA LITQRKFDNLTKAE
RGGLSELD AGFIKIlQLVETRQiTKHYAQILDSRMNT YDENDKLIREVKVITL S LVS
DFR DFQFY Y^REiNNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKYYDVR MI
A SEQEJGKATA YFFYS iMNFF TEITLA GEIR RPLlETNGETGEIVWD GRDFATV
R VLSMPQVNIVKKTEVQTGGFSKESILP RNSDKLIAR K.DWDPK. YGGFDSPTV YS
VLVVAKVE GK-SKXL SVKELLGrriMERSSFEKNPIDFLEAKGY EVKKDLII LPKYS
LFELENGR R_MLASAGELQKGNELALPS YVNFLYLASHYEKL GSPEDNEQ QLFVE
QH HYLDEIIEQISEFSKRVILADANLD VLSAYN HRDKPIREQAENIIHLFTLTNLGAP
AAF YFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDAAAVS GEELFTG
VVPiLVEL GDVNGfi FSVSGEGEGDATYG LTLKFiCTTGKLPVPWPTLVTTLTYGVQ
CFSRWDHMKQHDFF SAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIEL GI
DFKEDGNlLGfi LEYNYNSFINVYIMADKQKNGl VNF IRFINIEDGSVQLADFiYQQNT
PlGDGPVLLPDNHYLSTQSALSiGDPNEiOUDHMVLLEFVTAAGITLGlsmELYiGaiPAATK
KAGQAKKKK
[00250] NLS-SpCas9-NLS :
[00251] MDYKDHDGDYKDHDroYKDDDDKMAPKKKRKVGfflGWAADKKYSIGLDI
GTNSVGWAVITDEYKVPSKKFKVLGNTDR SIK NLIGALLFDSGETAEATRL RTARR RYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDK HERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADLRLIYLAIAH^
TYNQLFEENPRNASGVDAKALLSARLSKSRRLENLIAQLPGEKKNGLFGNLL\LSLGLTPN FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQ
EITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQS NGYAGYIDGGASQ
EEFYKFIKPILEKA'IDGTEELLV LNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY
PFL DNREKIE JLTFRIPYYVGPLARGNSRFAWMTR SEETITPWNFEEVVD GASAQS
FIERMTNFDK LPNEKVLPKHSLLYEYFTV ¾TELT V YVTEGMRKPAFLSGEQKiLAlV
!)IJj;K1'NR V ^' QF ΐ )ΥΓ ΚΠ (Ί F)SVH[S( V! )R!; ASIXnY'!! lJ !!K!) !)!;F I)\
EENEDlLEDIYLTLTLFEDREMIEERL TYAHLFDD VM QLKI]ilYTGWGRLSRKLIN
GIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLA
GSPAJ KGiLQTVKVVDELVKVMGRHKPE iVIEMAJENQTTQKGQKNSRERMKRIEEG
IKELGSQILKE.HPVENTQLQNEKLYLYYLQNGRDMYVDQELDF RLSDYDVDHIVPQSF
LKDDSIDN VLTRSDKNRGKSDNVPSEEVVKKMKNYWR.QLLNA LITQRKFDNLTKAE
RGGLSELDKAGFIKRQLVETRQITKIiV'AQILDSRMNT YDENDKI-IREVKVITL SKLV'S
DFRKDFQFYKVREIN TVHHAHDAYLNAVVGTALIK YPKLESEFVYGDYKVYDVRKIVII
AKSEQEIGKATA YFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATV'
RKVLSMPQWIVKKTEVQTGGFS ESILPKRNSDKLIARK DWDPK YGGFDSPTVAYS
VLVVAKYEKGKSKKL SVKELLGiTiMERSSFE NPIDFLEAKGYKEV KDLilKLP YS
LFELENGR RMLASAGELQ GNELALPSKYVNFLYLASHYE LKGSPEDNEQ .QLFVE
QHKHYLDEIIEQISEFS R\7ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAP
AAFKYFDTTIDR RYTST EVLDATLIHQSITGLYETRIDLSQLGGD RPAAT XAGQA
KK
[00252] NLS-mCherry-SpRNase3 :
[00253] MFLFLSLTSFLSSSRTLVSKGEEDNMAHKEFMRFKVHMEGSVNGHEFEIEGE
GEGRPYEGTQTAKLKYT GGPLPFAWDILSPQFMYGS AYVKHPADIPDYL LSFPEGF
KWERVM FEDGGVVTVTQDSSLQDGEFJY VKLRGTNFPSDGPVMQK TMGWEASSE
RA1YPEDGAL GEIKQRLKL DGGHYDAEVKTTYK,\KKP\7QLPGAYNWIKLDITSHNE
DYTIVEQYERAEGRHSTGGMDELYKGS QLEELLSTSFDIQFNDLTLLETAFT TSYANE
HRLLNVSHNERLEFLGDAVLQLIISEYLFAKYPKKTEGDMSKLRSMIVREE.SLAGFSRFC
SFDAYIKLGKGEEKSGGRRRDTILGDLFEAFLGALLLDKGIDAVRRFL QVMIPQVEKG
NFERVKDYKTCLQEFLQTKGDVAIDYQVISEKGPAHAKQFEVSIWNGAVLS GLGKSK
KLAEQDAAKNALAQLSEV
[00254] SpRNase3-mCherry-NLS :
[00255] MKQLEELLSTSFDIQFNDLTLLETAFTHTSYANEHRLLNVSHNERLEFLGDAV LQLIISEYLFAKYP KTEGDMS LRSMIVREESLAGFSRFCSFDAYIKLGKGEE SGGRR
RDTILGDLFEAFLGALLLDKGIDAVRRFLKQVMIPQVE GNFERVKDY TCLQEFLQTK
GDVAIDYQVISE GPAHA QFEVSIWNGAVLSKGLGKSKKLAEQDAA NALAQLSEV
GSVSKGEEDNMAIIKEFMRFKVHA1EGSWGHEFEIEGEGEGRPYEGTQTAKL VT GGP
LPFAWDlLSPQF YGSKAYVKIiPADIPDYLKISFPEGFKWERVMNFEDGGVVTV QDS
SLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEI QRLiiLKD
GGIWDAEVKTTY A KPVQLPGAY VNI LDITSHNEDYTIVEQYERAEGRHSTGGMD
ELYK 1RPAAT KAGQAKKKK
[00256] NLS-SpCas9ii-NLS (the D10A nickase mutation is lowercase):
[002571 DY DHDGDYKDHDIDY DDDDKMAPK KRKVGIHGVPAADK YSiGLai
GTNSVGWA\7ITDEY 7PSKKFKVLGNTDRHSIK NLIGALLFDSGETAEATRLKRTARR
RYTRRK RJCYLQEIFSNEMAKVDDSFFHRLEESFLVEED XHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADLRLIYI^AHMIKFRGHFLIEGDL PDNSDVDKLFIQLVQ
TYNQLFEENPINASGVDAKAILSARLS SRRLENLIAQLPGE KNGLFGNLIALSLGLTPN
FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK LSDAILLSDILRVNT
EIT APLSASMI RYDEFIHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQ
EEFYKFIKPILEKMDGTEELLVKL REDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY
PFL DNREKIE n ll¾lPYYVGPLARG SRFAWMTR SEE r]TPW FE:EVVDKGASAQS
FIERA1TNFDKNLPNE VLPKHSLLYEYFTV ¾TELTKVKY 7TEGMRKPAFLSGEQKKAIV
DLLFKTNRKVTVKQLKEDYF KIECFDSVEISGVEDRFNASLGTYHDLLKIIKD DFLDN
EENEDILEDIVLTLTLFEDREMffiERLKTYAHLFDD VMKQLKRRRYTGWGRLSRKLIN
GiRDKQSGKTlLDFLKSDGFA R TMQLIHDDSLTFKEDIQKAQVSGQGDSLilEHiANLA
GSPAIK GlLQTV VVDELV VMGiH J'E iVIEMARENQTTQ GQKNSRERM lIllEEG
I EEGSQILKEHPVENTQLQNEKLYLYYLQNGRDAIYVDQELDINRLSDYDVDHIVPQSF
L DDSIDNKVLTRSDK^iRG SDNVPSEEVV KMKNYWRQLLNA LITQRiFDNLT AE
RGGLSELD AGFIKRQLVE RQITKH\7AQILDSRAINTKYDENDKLIREV VITLKSKLA7S
DFRKDFQFYK.VREINNYHHAHDAYLNAVVGTALI KYP LESEFVYGDYKVYDVRKMI
AKSEQElGiATAKYFFYSNIMNFF TEITLANGEIRKRPLlETNGETGEIVWDKGRDFATV
R VLSMPQV IVK TEVQTGGFS ESIL-P RNSDKLIARKKDWDP KYGGFDSPTVAYS
VLWAKVE GKSKKLKSVKELLGITIMERSSFEKNProFLEAKGYKEVKKDLII LP YS
LFELENGRKRMLASAGELQ GNELALPS YVNFLYLASfiYEKLKGSPEDNEQ QLFVE
QHKHYLDE] 1EQISEFS RVJ LADA LDKVLSAYNKFiRD PlREQAE lIFILFTLTNLGAP
AAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDKRPAATKKAGQAK
K K
[00258] hEMXl-HR Template-Hindn-Nhel:
[00259] GAATGCTGCCCTCAGACCCGCTTCCTCCCTGTCCTTGTCTGTCCAAGGAGA ATGAGGTCTCACTGGTGGATTTCGGACTACCCTGAGGAGCTGGCACCTGAGGGACA AGGCCCCCCACCTGCCCAGCTCCAGCCTCTGATGAGGGGTGGGAGAGAGCTACATG AGGTTGCTAAGAAAGCCTCCCCTGAAGGAGACCACACAGTGTGTGAGGTTGGAGTC
TCTAGCAGCGGGTTCTGTGCCCCCAGGGATAGTCTGGCTGTCCAGGCACTGCTCTTG ΑΊΑ'ΓΛΛΛί Λ(Χ Λ( 'Ί (X'l'AC) 1 'ΓΛΊ (ίΛΑΛ('( Λ'Γ(}ί ( ('ΛΊΊ ("1 (i( C''f'C Ύ< 'TGTATGGAA AAGAGCATGGGGCTGGCCCGTGGGGTGGTGTCCACTTTAGGCCCTGTGGGAGATCA
TGGGAACCCACGCAGTGGGTCATAGGCTCTCTCATTTACTACTCACATCCACTCTGT GAAGAAGCGATTATGATCTCTCCTCTAGAAACTCGTAGAGTCCCATGTCTGCCGGCT
TCCAGAGCCTGCACTCCTCCACCTTGGCTTGGCTTTGCTGGGGCTAGAGGAGCTAGG
ATGCACAGCAGCTCTGTGACCCTTTGTTTGAGAGGAACAGGAAAACCACCCTTCTCT
nXX XXVVCTGTGTC ίΊΧ Ί'Ί'( ( Ί'(!('('ί Ί'ί;('('ΛΊ'( ('('(']'!'('] (}Ί'ί·ΛΛ'Γ(!'ΓΊ'Λ(ίΛ('( ( ΛΊ
GGGAGCAGCTGGTCAGAGGGGACCCCGGCCTGGGGCCCCTAACCCTATGTAGCCTC
Λ( ) ] (' ] '!'( ΧΧ'ΛΊΧ 'Λί ;G( Ί ( Ί'( Λ(ί( '!'( AGC X'TG AGTGTIX ·Λ( ;G( ί C '( 'Λ( ΠΧΧ ·( ΊΧΧ Ί ( Τ
GGGGGCCTCCTGAGTTTCTCATCTGTGCCCCTCCCTCCCTGGCCCAGGTGAAGGTGT
GGTTCCAGAACCGGAGGACAAAGTACAAACGGCAGAAGCTGGAGGAGGAAGGGCC
TGAGTCCGAGCAGAAGAAGAAGGGCTCCCATCACATCAACCGGTGGCGCATTGCCA
CGAAGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACaagcttgctagcGGTGG
GCAACCACAAACCCACGAGGGCAGAGTGCTGCTTGCTGCTGGCCAGGCCCCTGCGT
GGGCCCAAGCTGGACTCTGGCCACTCCCTGGCCAGGCTTTGGGGAGGCCTGGAGTC
GCTGGCTGAGGCCTGGGACCACTTGGCCTTCTCCTCGGAGAGCCTGCCTGCCTGGGC
( ί( XsC '( '( s( '( '( X ·( X 'AC C XX A.GC " f'C '( X'AGi Ί'ί ·( " f'C " f'C '( ΧΠί Γ( " f'C X 'ΛΛΊΧ " Γ( '( "Π " Γ I ϊ
TT TGATGCATTTCTGT TTAATTTATTTTCCAGGCACCACTGTAGTTTAGTGATCCCC
AGTGTCCCCCTTCCCTATGGGAATAATAAAAGTCTCTCTCTTAATGACACGGGCATC
CAGCTCCAGCCCCAGAGCCTGGGGTGGTAGATTCCGGCTCTGAGGGCCAGTGGGGG
CTGGTAGAGCAAACGCGTTCAGGGCCTGGGAGCCTGGGGTGGGGTACTGGTGGAGG
GGGTC AA TAATTrAr! AAaCXTaCT^
CAGCTCCACAGCAGGAGAAACAGGCTAGACATAGGGAAGGGCCATCCTGTATCTTG
Λ(ί( XsAGG AC 'Λί XX C X'AC Π { "ΠΊΧΎΎΛΑί XJFATT A AC Π ( XX JAA.TC 'Λί XX C '( 'AC s
GTAGTTCAATGGGAGAGGGAGAGTGCTTCCCTCTGCCTAGAGACTCTGGTGGCTTCT
CCAGTTGAGGAGAAACCAGAGGAAAGGGGAGGATTGGGGTCTGGGGGAGGGAACA
CCATTCACAAAGGCTGACGGTTCCAGTCCGAAGTCGTGGGCCCACCAGGATGCTCA
CCTGTCCTTGGAGAACCGCTGGGCAGGTTGAGACTGCAGAGACAGGGCTTAAGGCT
GAGCCTGCAACCAGTCCCCAGTGACTCAGGGCCTCCTCAGCCCAAGAAAGAGCAAC
GTGCCAGGGCCCGCTGAGCTCTTGTGTTCACCTG
[00261] V! RPAA AGQA S !A GlJ)i(i]GSVG\OU^ V Xn;flf! XSR!F!}A A(^i:\NlAR! rNRQGR ! AKRK !IRR\1U NRIJ:hf:SG[J ! ΙΊ' Ι ΙΝΙ ΡΥΟΙ.Κλ' ί!!.
TDELSNEELFIALK MVKHRGISYLDDASDDGNSSVGDYAQIVKENS QLET TPGQIQL
ERYQTYGQLRGDFTVEKDGKK RLINVFPTSAYRSEALRJLQTQQEFNPQITDEFINRYL
EILTG R YYHGPGNEK.SRTDYGRYRTSGETLD JFGI UG CTFYPDEFRAAKASYTAQ
EF LLNDLNNLTVPTETKELSKT.QKNQIINY\7KNEILAMGPAKLF YIAKLLSCD\7ADIK
GYRIDKSGI AEIHTFEAYR MKTLETLDIEQMDRETLDKLAYVLTLNTEREGIQEALEHE
FADGSFSQ QVDEL 7QFRK,ANSSIFG GWHNFSVKLMMELIPELYETSEEQMTILTRLG
KQK TSSSN TKYIDEKIJ.TEE]YNPVVA.KSVRQA:I IVNAAIKRY:RGDFDNLVIEMARE N
EDDEKKAIQKIQKAN-ODEKDAAMLKAA ^
GERCI^TGKTISIHDLINNSNQFEVDHILPLSLTFDDSLANKVLVYATANQEKGQRTPYQ ALDSMDDAWSFRELKAFVRES TLSNKKKEYLLTEEDISKFDVRKKFIERNLVDTRYAS
RV\XNALQEHFRAHK1DTK\7S\7VRGQFTSQLRRHWGIEKTRDTYHHHAVDALIIAASSQ
LNLWKKQ NTLVSYSEDQLLDIETGELISDDEY ESVF APYQHFVDTL S EFEDSILF
SYQVDSKF R ISDATIYATRQAK 7GKDKADETYVLGK1KDIYTQDGYDAFMK1YKKD
KSKFLMYRHDPQTFE VIEPILENYPN QINEKGKEVPCNPFLKYKEEHGYIRKYSKKGN
GPEIKSLKYYDSKLGNHIDITPKDSNN VVLQSVSPWRADVYFNKTTG YEILGL YAD
LQFE GTGTY ISQEKYNDIK. KEGVDSDSEFKFTLY NDLLLV DTET EQQLFRFLSR
TMP Q BYVELKI^D Q FEGGEALIKVLG VANSGQC KGLG SNiSIYKVRTDVLG
NQHIIK EGDKPKLDFKRPAATKKAGQAKKKK
[00262] U6-St_tracrRNA(7-97):
[002631 GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCT GTTAGAGAGATAATTGGAATTAATTTGACTGTA^
TACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTT
AAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT
ATATCTTGTGGAAAGGACGAAACACCGTTACTTAAATCTTGCAGAAGCTACAAAGA
TAAGGCTTCATGCCGAAATCAACACCCTGTCATTTTATGGCAGGGTGTTTTCGTTATT
TAA
[00264] U6-DR-spacer-DR (S. pyogenes SF370)
[00265] gagggcctatttcccaigattccttcatatttgcaiatacgatacaaggctgtiagagagataattggaattaatttgactgtaaa cacaaagatattagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgt^
ttaccgtaacttgaaagtatttcgatitctiggctttatatatctigtggaaaggacgaaacaccgggitttagagctatgctgttttgaatggiccc cNNNNNNNNNNNN^
TTTTTT (lowercase underline = direct repeat; N = guide sequence; bold = terminator)
[00266] Chimeric RNA containing +48 tracr RNA (S, pyogenes SF370)
[00267] gagggcetatttcccatgattccttcatatttgcatatacgatacaaggctgitagagagataattggaattaatttgactgtaaa cacaaagatattagtacaaaataegtgacgtagaaagt^
ttaccgtaacttgaaagtatttcgaittettggctttataiatettgtggaaaggacgaaacaccN NNNNNN N gttttagagctagaaatagcaagttaaaataaggctagtccgTTTTTTT (N = guide sequence; first underline = tracr mate sequence; second underline = tracr sequence; bold = terminator)
[00268] Chimeric RNA containing +54 tracr RNA (S. pyogenes SF370)
[00269] gagggcciatticccatgattccttcataittgcatatacgatacaaggctgttagag
cacaaagatattagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgc ttaccgtaacttgaaagtatttcgarrtcttggcttt^^
NNgttttagagctagaaatagcaagttaaaataaggctagtccgttatcaTTTTTTTT (N = guide sequence; first underline = tracr mate sequence; second underline = tracr sequence; bold = terminator)
|00270| Chimeric UNA containing +67 tracr RNA (S. pyogenes SF370)
[00271 ] gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaa cacaaagataitagtacaaaatacgtgacgtagaaagtaataatitctigggiagtltgcagttttaaa
ttaccgtaacttgaaagtatttcgatttcttggctttatatatcttgtggaaaggacgaaacaccNNNNNNNNNNNNNNNNNN Ngt ttagagc ^ (N = guide sequence; first underline :::: tracr mate sequence; second underline ::: tracr sequence; bold :::: terminator)
[00272] Chimeric RNA containing +85 tracr RNA (S. pyogenes SF370)
[00273] gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaa cacaaagatattagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagrtttaaaa
ttaccgtaacttgaaagtatttcgatttcttggctttatatatcttgtggaaaggacgaaacaccNNiNN;NN;NN;NN;NN;NNNNNN Ngttttagagcta^
(N = guide sequence; first underline = tracr mate sequence; second underline = tracr sequence; bold = terminator)
! 00274 ! CBh-NLS-SpCas9-NLS
[00275] CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACC CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTT TCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATC AAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG
C '( "FGC ·( 'ΛΤΤΛΊΧ sCX X AGTAC 'ΛΊ'ί · Α( X ΊΎΑΊ XsG AC ΊΊΊ X X TAC1 TGi ·( 'AC Π'ΛΓΛΎί Ί'Α
CGTATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTC
χ ATCTCXX χ CXXXTCX C χ AC C χχχ^
TGCAGCGATGGGGGCGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGG
GGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCG
GCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAA
AAGCGAAGCGCGCGGCGGGCGGGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCC
GCTCCGCCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCAC
AGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCTGAGCAAGAGG
ΊΑΛ(;θ(ΠΊΊΑΛ(;θ(;ΛΊΧ;αΊΊΟ(ΠΊΧΧΠΧ;( ΠΑΊΊΑΛΊΧΠΊΊΑΛΊΊΛ( (Ί ίΛίίί'Λί
CTGCCTGAAATCACTTTTTTTCAGGTTGGaccggtgccaccATGGACTATAAGGACCACGA
CGGAGACTAC ^
CAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTA
CAGC XCi^
AGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGC
ATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCGAGGC
( Λ(Χ XiGClXiAAGAGAACX ( X A(iAA(iAA(iA Ί Λ( Λ( X AGACXiGAAC-AACXX iA'SX
TGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTC
C 'A( AGACTGC s AAGAG!C X TTC X TC sG'IX ;G A AC ; AC sG AT A AG A AC iCAC 'GAGi X ;GC A( X X
CATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCT
ACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATC
TATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGAC
CTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTA
CAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCA
TCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTG
(XX ϊ(ί( '(.ΪΑ(.ΪΑ AC i AACiA ΑΊ'( ;G( X TC ;TTC G( ·( ΆΑ(ΧΊ G ATTGC XX TC s AC s( Ί X ;G( ·( T
GACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAGCTGA
GCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAG TACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGAC ATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAA GAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGC
Λ(ί('Ί Ϊ('{ Ί'(·Λ{;ΛΛ(}'ΓΛ('ΛΛΛ{;Λ{;Λ'Π F'f'C ΊΊΧ GAC( AGA X A G AACG Xl AC XXX GGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCAT
('( I ;G Α ΑΛ AC ; ΑΤ( ;G Α( ΧΚ X'AC '( XiAGC s AACTGC TC X ;TGA AC X'TGA AC 'Λ( ·Λ( ·Λ( ;G AC ' CTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCT GGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGG ACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGC CCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAA CCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGC TTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCC
C 'ΛΛ(.Ϊ{ A.CAC )( { IX K' GTAC '(.ΪΛ(.ΪΊ'Λ( "ΠΧ A( C X sTGTATA AC C ΪΑΧ ϊ( T( ·Λ( X A AAGTC s A AATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAA
( { Α Γ(Χ |{;αΛ(ΧΊ Ο(ΊΧΠΊΧ \Λ(}Λ(ΧΑΛ( { ( iAAA(n ;A{ CX7r(iAA( AG( Ί(;Λ AAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTG GAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAG GACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCT GACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATG
( ( ( A( (Ί ΠΊΧ (iΛCX}A(AAACΠ :;AΊ iΛ (ΊC { :Ί }ΛA{ : i( :;AGAΊA(^A( ^ S(iG(iG( AGGCfGAGC (X GAAGCiGA AA( ( iCA ( (iGCiACAACiC AGK ( (iC AA GAC'AATC ΧΊΧΧ-ΛΊ l lXXl GAACnXXXiAC XiGCX l C X : A ( ΛGΛ Λ(ΊΊX VΓ(X { :Ί^ G ·I X^A(X X} (Ά( (KiA( (ΊΊΊ AAAGAGGAC ATrCAGAAAG( ( ( AGGTGTC CG GCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATT AAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGG CCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCC AGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAA AGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGA AC XJAGAAC K' GTAC X'TGTAC "f'AC IX X'AC ΪΛ ATGC ;GC X XsC iATATGTAC 'G'i GC ;AC '( 'AC ) GAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAG
TTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACC
GGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTA
CTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGA
CCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAG
GGA iAACAC 'SAACn-AC GA( GAGAATGA( AAGrTGAT(X'GG( AGTGAAAGTGA Λ(ΧΧΊ (ί (;'Γ(ΧΆΑ(ί('ΊΧ)(ίΊΧ;'Γ(ΧΧί ΊΊ'Ί XX iAAGCiA'jT j (X AGTI FTAC AAAGTC- CGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGG AACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACT ACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAA GGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGAT TACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAA CCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTG AG AIXK X AAGTGAAj7\T( iTGAAAAAGA(X IAGG1X
CAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGG
AC ΊΧ ϊ(ί( SAC XX'T G AC sTAC C sGC X ϊ(ί( "f'TC G AC 'AC ;(XX A( X X ΠΧ ·( ΧΊΆΊΊ CTGTC j( '
TGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGA
GCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACT
TTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCT
AAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGG
(Χ·ΑΑ(ΊΧ AGAACiGCiA CX AAC 1(X: ΊΧ Χ ΊΧ C\\AAl AlXnX}AACll(XlX
ACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAA
C Ά( ;('TG"i TG'i G ΪΛ C AGC ACAA ;C 'AC TA(X"i GC iAC 'G AG ATC ΆΊ ( ; AC K'AC s TC AG
CGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGC
CTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACC
TGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCA
TCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCAC
CAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGA
CTTTCTTTTTCTTAGCTTGACCAGCTTTCTTAGTAGCAGCAGGACGCTTTAA (underline LS-hSpCas9-NLS)
[00276] Example chimeric RNA for S. thermophilus LMD-9 CRISPRl Cas9 (with PAM of NNAGAAW)
i 00277! N N N N NNNNNNNNNNNNgtttttgtacictcaa atttaGAAAtaaatcttgcagaagctacaa agataagacttcatgccgaaatc^c (N ::: guide sequence; first underline :::: tracr mate sequence; second underline ::: tracr sequence; bold ::: terminator)
[00278j Example chimeric RNA for S. thermophilus LMD-9 CRISPRl Cas9 (with PAM of NNAGAAW)
[00279! ]\ Ν ΝΠΝΤ ΝΝΝ^
tgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT (N guide sequence; first underline
= tracr mate sequence; second underline = tracr sequence; bold = terminator)
[00280] Example chimeric RNA for S. thermophilus LMD-9 CRISPRl Cas9 (with PA M of
NNAGAAW)
[00281] Ν Ν Ν ΝΠ Ι^^
tgccgaaatcaacaccctgtcattttatggcagggtgtTTTTTT (N ::: guide sequence; first underline :::: tracr mate sequence; second underline = tracr sequence; bold = terminator)
[00282J Example chimeric RNA for S. thermophilus LMD-9 CRISPRl Cas9 (with PAM of NNAGAAW)
[00283] NNNNNNNNNh^ gttattgtactctcaaga tttaGAAAtaaatcttgcagaagctacaa agataaggcttcatgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT (N = guide sequence; first underline ::: tracr mate sequence; second underline :::: tracr sequence; bold = terminator)
[002841 Example chimeric RNA for S. thermophilus LMD-9 CRISPRl Cas9 (with PA M of NNAGAAW)
[CI0285] NNNNNNNNNNNNNNNNNNNNgttattgtactctcaGAAAtgcagaagctacaaagataaggcttca tgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT (N = guide sequence; first underline
= tracr mate sequence; second underline = tracr sequence; bold = terminator)
[002861 Example chimeric RNA for S. thermophilus LMD-9 CRISPR l Cas9 (with PAM of
NNAGAAW)
[ 00287] NNN^N^N^NNNNNNNNNNNNgttattgtactctcaGAAAtgcagaagctacaaagaraaggcttca tgcegaaatcaacaccctgtcattttatggeagggtgtTTTTTT (N = guide sequence; first underline = tracr mate sequence; second underline :::: tracr sequence; bold :::: terminator)
[00288] Example chimeric RNA for S. ihermophilus LMD-9 CRJSPRl Cas9 (with PAM of NNAGAAW)
[002891 N N N N N NNNNNNNNNNgttattgtactctcaagatttaGAAAtaaatcttgcagaagctacaa tgataaggcttcatgj^ (N = guide sequence; first underline :::: tracr mate sequence; second underline ::: tracr sequence; bold ::: terminator)
[00290] Example chimeric RNA for S. thennophilus LMD-9 CRISPR1 Cas9 (with PAM of NNAGAAW)
[00291] Ν>ΓΝ>ΓΝ>ΓΝ>Γ^
tgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT (N = guide sequence; first underline
= tracr mate sequence; second underline = tracr sequence; bold = terminator)
[00292] Example chimeric RNA for S. thermophilus LMD-9 CRISPR1 Cas9 (with PAM of
NNAGAAW)
[00293] ]^Ν>ΓΝ>^^
tgccgaaatcaacaccctgtcattttatggcagggtgtTTTTTT (N ::: guide sequence; first underline = tracr mate sequence; second underline = tracr sequence; bold = terminator)
[00294] Example chimeric RNA for S. thermophilus LMD-9 CRISP 3 Cas9 (with PAM of NGGNG)
[00295] NNNNNNNNNNNlSn^
cgtactcaacttgaaaaggtggcaecgattcggtgtTTTTTT (N = guide sequence; first underline = tracr mate sequence; second underline :::: tracr sequence; bold :::: terminator)
[00296] Codon-optimized version of Cas9 from S. thermophilus LMD-9 CRISPR3 locus (with an NLS at both 5' and 3' ends)
[CI0297] AI CiAAAAC X X iCX 'i Λί ιΛΛΛΛΛί ^ ( Gi X'AC 'AAAAAAGAAA
AAGACCAAGCCCTACAGCATCGGCCTGGACATCGGCACCAATAGCGTGGGCTGGGC
CGTGACCACCGACAACTACAAGGTGCCCAGCAAGAAAATGAAGGTGCTGGGCAACA
CCTCCAAGAAGTACATCAAGAAAAACCTGCTGGGCGTGCTGCTGTTCGACAGCGGC
ATTACAGCCGAGGGCAGACGGCTGAAGAGAACCGCCAGACGGCGGTACACCCGGC
GGAGAAACAGAATCCTGTATCTGCAAGAGATCTTCAGCACCGAGATGGCTACCCTG
GACGACGCCTTCTTCCAGCGGCTGGACGACAGCTTCCTGGTGCCCGACGACAAGCG
GGACAGCAAGTACCXX'ATCTI CGGCAACCTGGTGGAAGAGAAGGCCTACCACGACG
AGTTCCCCACCATCTACCACCTGAGAAAGTACCTGGCCGACAGCACCAAGAAGGCC
GACCTGAGACTGGTGTATCTGGCCCTGGCCCACATGATCAAGTACCGGGGCCACTTC
CTGATCGAGGGCGAGTTCAACAGCAAGAACAACGACATCCAGAAGAACTTCCAGGA
CTTCCTGGACACCTACAACGCCATCTTCGAGAGCGACCTGTCCCTGGAAAACAGCAA
GCAGCTGGAAGAGATCGTGAAGGACAAGATCAGCAAGCTGGAAAAGAAGGACCGC
ΛΊ ( Χ 'Ί'( ίΛΑ( )( 'Ί ( s'!"l'( ( ( '('( iC iCi ·Λί ·ΛΑ(ίΑΛ( Λ(}ί ( ίΛΑΊΧ ΊΎ( AGi GAGTTTC ΊΧ ΪΑΛ
GCTGATCGTGGGCAACCAGGCCGACTTCAGAAAGTGCTTCAACCTGGACGAGAAAG
TATATCGGCGACGACTACAGCGACGTGTTCCTGAAGGCCAAGAAGCTGTACGACGC
TATCCTGCTGAGCGGCTTCCTGACCGTGACCGACAACGAGACAGAGGCCCCACTGA
GCAGCGCCATGATTAAGCGGTACAACGAGCACAAAGAGGATCTGGCTCTGCTGAAA
GAGTACATCCGGAACATCAGCCTGAAAACCTACAATGAGGTGTTCAAGGACGACAC
CAAGAACGGCTACGCCGGCTACATCGACGGCAAGACCAACCAGGAAGATTTCTATG
TGTACCTGAAGAAGCTGCTGGCCGAGTTCGAGGGGGCCGACTACTTTCTGGAAAAA
CTACCAGATCCATCTGCAGGAAATGCGGGCCATCCTGGACAAGCAGGCCAAGTTCT
AC XVVri C X sGi C \\AGA A( Λ ΛΛ
CCTTACTACGTGGGCCCCCTGGCCAGAGGCAACAGCGATTTTGCCTGGTCCATCCGG AAGCGCAATGAGAAGATCACCCCCTGGAACTTCGAGGACGTGATCGACAAAGAGTC
CAGCGCCGAGGCCTTCATCAACCGGATGACCAGCTTCGACCTGTACCTGCCCGAGG AAAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGACATTCAATGTGTATAACGAG
AAGCAGAAAAAGGACATCGTGCGGCTGTACTTCAAGGACAAGCGGAAAGTGACCG ΛΊ AAGG AC ΛΊ CATC AG'! AC '( 'TG( ACGC X V\T( TAC XX Ί 7\{ C s ATi JG( ΛΊ CGAGC "IX 1 AAGGGCATCGAGAAGCAGTTCAACTCCAGCCTGAGCACATACCACGACCTGCTGAA CATTATCAACGACAAAGAATTTCTGGACGACTCCAGCAACGAGGCCATCATCGAAG AGATCATCCACACCCTGACCATCTTTGAGGACCGCGAGATGATCAAGCAGCGGCTG AGCAAGTTCGAGAACATCTTCGACAAGAGCGTGCTGAAAAAGCTGAGCAGACGGCA CTACACCGGCTGGGGCAAGCTGAGCGCCAAGCTGATCAACGGCATCCGGGACGAGA AGTCCGGCAACACAATCCTGGACTACCTGATCGACGACGGCATCAGCAACCGGAAC
( ( Ai iA AT( G( iG( iA( GAGG A CA AGGGCA A CA'S'C AA AG AAG I < GT A AGTC ( CTGi
CCGGCAGCCCCGCCATCAAGAAGGGAATCCTGCAGAGCATCAAGATCGTGGACGAG
CTCGTGAAAGTGATGGGCGGCAGAAAGCCCGAGAGCATCGTGGTGGAAATGGCTAG
A G A G A AC C AGT AC A CC A ATC AGGGC A AG AGC A AC AGC C AGC AG AG ACTG AA G A G A
CTGGAAAAGTCCCTGAAAGAGCTGGGCAGCAAGATTCTGAAAGAGAATATCCCTGC
C WAGi TGTC 'ΛΛ( ίΛ'Γ( Χ ίΛ('ΑΛ( ΛΛί ( )( '( { '!'{ J( ' AC ) ΑΛ( 'ί ·Λ( ( ( )( ί( 'ΊΧ )Ί Λ( ( 'ΊΧ )Ί Λ( Ί'
ACCTGCAGAATGGCAAGGACATGTATACAGGCGACGACCTGGATATCGACCGCCTG
AGCAACTACGACATCGACCATATTATCCCCCAGGCCT^
GACAACAAAGTGCTGGTGTCCTCCGCCAGCAACCGCGGCAAGTCCGATGATGTGCC
CAGCCTGGAAGTCGTGAAAAAGAGAAAGACCTTCTGGTATCAGCTGCTGAAAAGCA
AGCTGATTAGCCAGAGGAAGTTCGACAACCTGACCAAGGCCGAGAGAGGCGGCCTG
AGCCCTGAAGATAAGGCCGGCTTCATCCAGAGACAGCTGGTGGAAACCCGGCAGAT
CACCAAGCACGTGGCCAGACTGCTGGATGAGAAGTTTAACAACAAGAAGGACGAGA
ACAACCGGGCCGTGCGGACCGTGAAGATCATCACCCTGAAGTCCACCCTGGTGTCC
CAGTTCCGGAAGGACTT(XiAGCri jTATAAAGTGCX5CGAGATCAATGACTTTCACCAC
GCCCACGACGCCTACCTGAATGCCGTGGTGGCTTCCGCCCTGCTGAAGAAGTACCCT
AAGCTGGAACCXXjAGTTCGTGTACGGCXjACrrACCCX^AAGTACAACTCCTTCAGAGA
GCGGAAGTCCGCCACCGAGAAGGTGTACTTCTACTCCAACATCATGAATATCTTTAA
GAAGTCCATCTCCCTGGCCGATGGCAGAGTGATCGAGCGGCCCCTGATCGAAGTGA
ACGAAGAGACAGGCGAGAGCGTGTGGAACAAAGAAAGCGACCTGGCCACCGTGCG
GCGGGTGCTGAGTTATCCTCAAGTGAATGTCGTGAAGAAGGTGGAAGAACAGAACC
ACGGCCrGGATCGGGGCAAGCCCAAGGGCCTar'TCAACGCCAACCrGTCCAGCAAG
CCTAAGCCCAACTCCAACGAGAATCTCGTGGGGGCCAAAGAGTACCTGGACCCTAA
( JAAC HAC iC ί Χ}ΛΊ ( C i( X '( : Λ Γ( ΊΧ Χ-ΑΛ ΓΛί ΧΊΊΧ \ ί ( ΧΓ! ( ΊΧ GI GA AC iC X 'A
CAATCGAGAAGGGCGCTAAGAAAAAGATCACAAACGTGCTGGAATTTCAGGGGATC
TCTATCCTGGACCGGATCAACTACCGGAAGGATAAGCTGAACTTTCTGCTGGAAAAA
GGCTACAAGGACATTGAGCTGATTATCGAGCTGCCTAAGTACTCCCTGTTCGAACTG
AGCGACGGCTCCAGACGGATGCTGGCCTCCATCCTGTCCACCAACAACAAGCGGGG
CGAGATCCACAAGGGAAACCAGATCTTCCTGAGCCAGAAATTTGTGAAACTGCTGT
ACCACGCCAAGCGGATCTCCAACACCATCAATGAGAACCACCGGAAATACGTGGAA
AA( ACAAGAAAGAGTTTGAGGAA(jrGTTCTA(rrACATCCTGGAGTTCAACGAGAA
CTATGTGGGAGCCAAGAAGAACGGCAAACTGCTGAACTCCGCCTTCCAGAGCTGGC
AGAACCACAGCATCGACGAGCTGTGCAGCTCCTTCATCGGCCCTACCGGCAGCGAG
CGGAAGGGACTGTTTGAGCTGACCTCCAGAGGCTCTGCCGCCGACTTTGAGTTCCTG
GGAGTGAAGATCCCCCGGTACAGAGACTACACCCCCTCTAGTCTGCTGAAGGACGC
CACCCTGATCCACCAGAGCGTGACCGGCCTGTACGAAACCCGGATCGACCTGGCTA
Λί Ί 'ί ίΛί ίαί ίΛΛΛί ίί Π'ί ( ΊΧ ;( Ί ( Ί·Λ( Ί ΑΛί ιΛΑΛί Ί ΠΧ A AC 'l'AAC iA A A AAGAAATAA
Example 5: RNA-guided editing of bacterial genomes using CRISPR-Cas systems
[00298] Applicants used the CRIS PR-associated endonuclease Cas9 to introduce precise mutations in the genomes of Streptococcus pneumoniae and Escherichia coli. The approach relied on Cas9-directed cleavage at the targeted site to kill unmutated cells and circumvented the need for selectable markers or counter-selection systems. Cas9 specificity was reprogrammed by changing the sequence of short CRISPR RNA (crRNA) to make si gle- and muiti-iiucieotide changes carried on editing templates. Simultaneous use of two erRNAs enabled multiplex mutagenesis. In S. pneumoniae, nearly 100% of ceils that survived Cas9 cleavage contai ed the desired mutation, and 65% when used in combination with recombineering in E. coli. Applicaiits exhaustively analyzed Cas9 target requirements to define the range of targctah!e sequences and showed strategies for editing sites that do not meet these requirements, suggesting the versatility of this technique for bacterial genome engineering.
[00299] The understanding of gene function depends on the possibility of altering DNA sequences within the cel l in a controlled fashion. Site-specific mutagenesis in eukaryotes is achieved by the use of sequence-specific nucleases that promote homologous recombination of a template DNA containing the mutation of interest. Zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALE s) a d homing megaiiucieases can be programmed to cleave genomes in specific locations, but these approaches require engineering of new enzymes for each target sequence. In prokaryotic organisms, mutagenesis methods either introduce a selection marker in the edited locus or require a two-step process that includes a counter- selection system. More recently, phage recombination proteins have been used for recombineering, a tech ique that promotes homologuous recombination of linear DNA or oligonucleotides. However, because there is no selection of mutations, recombineering efficiency can be relatively low (0.1 -10% for point mutations down to 10"5-10"6 for larger modifications), in many cases requiring the screening of a large number of colonies. Therefore new technologies
that are affordable, easy to use and efficient are still in need for the genetic engineering of both eukaryottc and prokaryotic organisms.
[003001 Recent work on the CRISPR (clustered, regularly interspaced, short jjalindromie repeats) adaptive immune system of prokaryot.es has led to the identification of nucleases whose sequence specificity is programmed by small RNAs. CRISPR loci are composed of a series of repeats separated by 'spacer' sequences that match the genomes of bacteriophages and other mobile genetic elements. The repeat-spacer array is transcribed as a long precursor and processed within repeat sequences to generate small crRNA that specify the target sequences (also known as protospacers) cleaved by CRISPR systems. Essential for cleavage is the presence of a sequence motif immediately downstream of the target region, known as the protospacer-adjacent motif (PAM). CRISPR-associated (cas) genes usually flank the repeat-spacer array and encode the enzymatic machinery responsible for crRNA biogenesis and targeting. Cas9 is a dsDNA endonuclease that uses a crRNA guide to specify the site of cleavage. Loading of the crRNA guide onto Cas9 occurs during the processing of the crRNA precursor and requires a small R A amisense to the precursor, the tracrRNA, and RNAse III. In contrast to genome editing with ZFNs or TALENs, changing Cas9 target specificity does not require protein engineering but only the design of the short crRNA guide.
[00301] Applicants recently showed in S. pneumoniae that the introduction of a CRISPR system targeting a chromosomal locus leads to the killing of the transformed cells. It was observed that occasional survivors contained mutations in the target region, suggesting that Cas9 dsDNA endonuclease activity against endogenous targets could be used for genome editing. Applicants showed that marker-less mutations can be introduced through the transformation of a template DNA fragment that will recombine in the genome and eliminate Cas9 target recognition. Directing the specificity of Cas9 with several different crR As allows for the introduction of multiple mutations at the same time. Applicants also characterized in detail the sequence requirements for Cas9 targeting and show that the approach can be combined with recombmeering for genome editing in E. coli.
[00302] RESULTS: Genome editing by Cas9 cleavage of a chromosomal target
[00303] S. pneumoniae strain crR6 contains a Cas9-based CRISPR system that cleaves a target sequence present in the bacteriophage φ8232.5. This target was integrated into the srtA chromosomal locus of a second strain R6b2j2'\ An altered target sequence containing a mutation
in the PAM region was integrated into the srtA locus of a third strain R63 /0J , rendering this strain 'immune' to CR1SPR cleavage (Figure 28a). Applicants transformed R68iJ '5 and R6~ /u"1 cells with genomic DNA from crR6 cells, expecting that successful transformation of R682"' ;> cells should lead to cleavage of the target locus and cell death. Contrary to this expectation, Applicants isolated R68232'5 transformants, albeit with approximately 10-fold less efficiency than R6J /( transformants (Figure 28b). Genetic analysis of eight Rg823-1-5 transformants (Figure 28) revealed that the great majority are the product of a double recombination event that eliminates the toxicity of Cas9 targeting by replacing the φ8232.5 target with the crR6 genome's wild-type srtA locus, which does not contain the protospacer required for Cas9 recognition. These results were proof that the concurrent introduction of a CRISPR system targeting a genomic locus (the targeting construct) together with a template for recombination into the targeted locus (the editing template) led to targeted genome editing (Figure 23a).
[00304] To create a simplified system for genome editing, Applicants modified the CRISPR locus in strain crR6 by deleting cas cas2 and csn2, genes which have been shown to be dispensable for CRISPR targeting, yielding strain crR6M (Figure 28a). This strain retained the same properties of crR6 (Figure 28b). To increase the efficiency of Cas9~based editing and demonstrate that a template DNA of choice can be used to control the mutation introduced, Applicants co-transformed R68 3 -:> cells with PGR. products of the wild-type srtA gene or the mutant R6370'1 target, either of which should be resistant to cleavage by Cas9. This resulted in a 5- to 10-fold increase of the frequency of transformation compared with genomic crR6 DNA alone (Figure 23b). The efficiency of editing was also substantially increased, with 8/8 transformants tested containing a wild-type srtA copy and 7/8 containing the PAM mutation present in the R637 ' 1 target (Figure 23b and Figure 29a). Taken together, these results showed the potential of genome editing assisted by Cas9.
[00305] Analysis of Cas9 target requirements: To introduce specific changes in the genome, one must use an editing template carrying mutations that abolish Cas9-mediated cleavage, thereby preventing cell death. This is easy to achieve when the deletion of the target or its replacement by another sequence (gene insertion) is sought. When the goal is to produce gene fusions or to generate single -nucleotide mutations, the abolishment of Cas9 nuclease activity will only be possible by introducing mutations in the editing template that alter either the PAM or the protospacer sequences. To determine the constraints of CRISPR-mediated editing, Applicants
performed an exhaustive analysis of PAM and protospacer mutations that abrogate CRISPR targeting.
[003061 Previous studies proposed that S. pyogenes Cas9 requires an NGG PAM immediately downstream of the protospacer. However, because only a very limited number of PAM- mactivating mutations have been described so far, Applicants conducted a systematic analysis to find ail 5 -nucleotide sequences following the protospacer that eliminate CRISPR cleavage. Applicants used randomized oligonucleotides to generate all possible 1 ,024 PAM sequences in a heterogeneous PGR product that was transformed into crR6 or R6 cells. Constructs carrying functional PAMs were expected to be recognized and destroyed by Cas9 in erR6 but not R6 cells (Figure 24a). More than 2x 10"' colonies were pooled together to extract DNA for use as template for the co-amplification of al l targets. PGR products were deep sequenced and found to contain all 1,024 sequences, with coverage ranging from 5 to 42,472 reads (See section "Analysis of deep sequencing data"). The functionality of each PAM was estimated by the relative proportion of its reads in the crR6 sample over the R6 sample. Analysis of the first three bases of the PAM, averaging over the two last bases, clearly showed that the NGG pattern was under-represented in crR6 transformants (Figure 24b). Furthermore, the next two bases had no detectable effect on the NGG PAM (See section "Analysis of deep sequencing data"), demonstrating that the NGG N sequence was sufficient to license Cas9 activity. Partial targeting was observed for NAG PAM sequences (Figure 24b). Also the NNGGN pattern partially inactivated CRISPR targeting (Table G), indicating that the NGG motif can still be recognized by Cas9 with reduced efficiency when shifted by 1 bp. These data shed light onto the molecular mechanism of Cas9 target recognition, and they revealed that NGG (or CCN on the complementary strand) sequences are sufficient for Cas9 targeting and that NGG to NAG or NNGGN mutations in the editing template should be avoided. Owing to the high frequency of these tri-nucleotide sequences (once every 8 bp), this means that almost any position of the genome ca be edited. Indeed, Applicants tested ten randomly chosen targets carrying various PAMs and all were found to be functional (Figure 30).
[00307] Another way to disrupt Cas9~mediated cleavage is to introduce mutations in the protospacer region of the editing template. It is known that point mutations within the 'seed sequence' (the 8 to 10 protospacer nucleotides immediately adjacent to the PAM) can abolish cleavage by CRISPR nucleases. However, the exact length of this region is not known, and it is unclear whether mutations to any nucleotide in the seed can disrupt Cas9 target recognition.
Applicants followed the same deep sequencing approach described above to randomize the entire protospacer sequence involved in base pair contacts with the crRNA and to determine all sequences that disrupt targeting. Each position of the 20 matching nucleotides ( 1 ) in the spcl target present in R6C cells (Figure 23 a) was randomized and transformed into crR6 and R6 cel ls (Figure 24a). Consistent with the presence of a seed sequence, only mutations in the 12 nucleotides immediately upstream of the PAM abrogated cleavage by Cas9 (Figure 24c). However, different mutations displayed markedly different effects. The distal (from the PAM) positions of the seed (12 to 7) tolerated most mutations and only one particular base substitution abrogated targeting. In contrast, mutations to any nucleotide in the proximal positions (6 to 1, except 3) eliminated Cas9 activity, although at different levels for each particular substitution. At position 3, only two substitutions affected CRJSPR. activity and with different strength. Applicants concluded that, although seed sequence mutations can prevent CRISPR targeting, there are restrictions regarding the nucleotide changes that can be made in each position of the seed. Moreover, these restrictions can most likely vary for different spacer sequences. Therefore Applicants believe that mutations in the PAM sequence, if possible, should be the preferred editing strategy. Alternatively, multiple mutations in the seed sequence may be introduced to prevent Cas9 nuclease activity.
[00308] Cas9~mediated geraome editing lis 5. pneumoni :To develop a rapid and efficient method for targeted genome editing, Applicants engineered strain crR6Rk, a strain in which spacers can be easily introduced by PGR (Figure 33). Applicants decided to edit the β~ galactosidase (bgaA) gene of S. pneumoniae, whose activity can be easily measured. Applicants introduced alanine substitutions of amino acids in the active site of this enzyme: R481A (R→A) and 563A,E564A (NE-→AA) mutations. To illustrate different editing strategies, Applicants designed mutations of both the PAM sequence and the protospacer seed. In both cases the same targeting construct with a crRNA complementary to a region of the β-galactosidase gene that is adjacent to a TGG PAM sequence (CCA in the complementary strand, Figure 26) was used. The R→A editing template created a three-nucleotide mismatch on the protospacer seed sequence (CGT to GCA, also introducing a BtgZl restriction site). In the NE--->AA editing template Applicants simultaneously introduced a synonymous mutation that created an inactive PAM (TGG to TTG) along with mutations that are 21 8 nt downstream of the protospacer region (AAT GAA to GCT GCA, also generating a Tsel restriction site). This last editing strategy
demonstrated the possibility of using a remote PAM to make mutations in places where a proper target may be hard to choose. For example, although the S. pneumoniae R6 genome, which has a 39.7% GC content, contains on average one PAM motif every 12 bp, some PAM motifs are separated by up to 194 bp (Figure 33). In addition Applicants designed a AbgaA in-frame deletion of 6,664 bp. in all three cases, co-transformation of the targeting and editing templates produced 10-times more kanamycin-resistant cells than co-transformation with a control editing template containing wild-type bgaA. sequences (Figure 25b). Applicants genotyped 24 transformants (8 for each editing experiment) and found that all but one incorporated the desired change (Figure 25c). DNA sequencing also confirmed not only the presence of the introduced mutations but also the absence of secondary mutations in the target region (Figure 29b, c). Finally, Applicants measured β-galactosidase activity to confirm that all edited cells displayed the expected phenotype (Figure 25 d).
[00309] Cas9-mediated editing can also be used to generate multiple mutations for the study of biological pathways. Applicants decided to illustrate this for the sortase-dependent pathway that anchors surface proteins to the envelope of Gram-positive bacteria. Applicants introduced a .sona.se deletion by co-transformation of a chloramphenicol-resistant targeting construct and a AsrtA editing template (Figure 33a,b), followed by a AbgaA deletion using a kanamycin-resistant targeting construct that replaced the previous one. In S, pneumoniae, β-galactosidase is covalentiy linked to the cell wall by sortase. Therefore, deletion of srtA results in the release of the surface protein into the supernatant, whereas the double deletion has no detectable β- galactosidase activity (Figure 34c). Such a sequential selection can be iterated as many times as required to generate multiple mutations.
[003 J O] These two mutations may also be introduced at the same time. Applicants designed a targeting construct containing two spacers, one matching srtA and the other matching bgaA, and co-transformed it with both editing templates at the same time (Figure 25e). Genetic analysis of transformants showed that editing occurred in 6/8 cases (Figure 25 f). Notably, the remaining two clones each contained either a AsrtA or a AbgaA deletion, suggesting the possibility of performing combinatorial mutagenesis using Cas9. Finally, to eliminate the CRISPR sequences, Applicants introduced a plasmid containing the bgaA target and a spectinomycin resistance gene along with genomic DNA from the wild-type strain R.6. Spectinomycin-resistant transformants that retain the plasmid eliminated the CRISPR sequences (Figure 34a,d).
[00311] Mechanism and efficiency of editing: To understand the mechanisms underlying genome editing with Cas9, Applicants designed an experiment in which the editing efficiency was measured independently of Cas9 cleavage. Applicants integrated the ermAM erythromycin resistance gene in the srtA locus, and introduced a premature stop codon using Cas9-mediated editing (Figure 33). The resulting strain (JEN53) contains an ermAM(stop) allele and is sensitive to erythromycin. This strain may be used to assess the efficiency at which the ermAM gene is repaired by measuring the fraction of cells that restore antibiotic resistance with or without the use of Cas9 cleavage. JENS 3 was transformed with an editing template that restores the wild- type allele, together with either a kanamycin-resistant CRISPR construct targeting the ermAM(stop) allele (CRISPR: : ermAM (stop)) or a control construct without a spacer (CRISPR: :0) (Figure 26a,b). In the absence of kanamycin selection, the fraction of edited colonies was on the order of 10""' (erythromycin-resistant cfu/totai cfu) (Figure 26c), representing the baseline frequency of recombination without Cas9-mediated selection against u edited ceils. However, if kanamycin selection was applied and the control CRISPR construct was co- transformed, the fractio of edited colonies increased to about 10"1 (kanamycin- and erythromycin-resistant cru/kanamycin-resistant cfu) (Figure 26c). T his result shows that selection for the recombination of the CRISPR locus co-selected for recombination in the ermAM locus independen tly of Cas9 cleavage of the genome, suggesting that a subpopulation of cells is more prone to transformation and/or recombination. Transformation of the CRISPR: : ermAM (stop) construct followed by kanamycin selection resulted in an increase of the fraction of erythromycin-resistant, edited cells to 99 % (Figure 26c). To determine if this increase is caused by the killing of non-edited cells, Applicants compared the kanamycin- resistant colony forming units (cfu) obtained after co-transformation of JEN53 cells with the CRISPR: :ermAM(stop) or CRISPR: :0 constructs.
[00312] Applicants counted 5.3 times less kanamycin-resistant colonies after transformation of the crmAM(stop) construct (2.5x l04/4.7¾103, Figure 35a), a result that suggests that indeed targeting of a chromosomal locus by Cas9 leads to the killing of non-edited cells. Finally, because the introduction of dsDNA breaks in the bacterial chromosome is known to trigger repair mechanisms that increase the rate of recombi ation of the damaged DNA, Applicants investigated whether cleavage by Cas9 induces recombination of the editing template. Applicants counted 2.2 times more colonies after co -transformation with the CRISPR: :erm(stop) construct
than with the CRISPR: :0 construct (Figure 26d), indicating that there was a modest induction of recombination. Taken together, these results showed that co-selection of transformable cells, induction of recombination by Cas9-mcdiated cleavage and selection against non-edited ceils, each contributed to the high efficiency of genome editing in S, pneumoniae,
[00313] As cleavage of the genome by Cas9 should kill non-edited cells, one would not expect to recover any ceils that received the kanamycin resistance-containing Cas9 cassette but not the editing template. However, in the absence of the editing template Applicants recovered many kanamycin-resistant colonies after transformation of the CRISPR: :ermAM(stop) construct (Figure 35a). These cells that 'escape' CRISPR-ind uced death produced a background that determined a limit of the method. This background frequency may be calculated as the ratio of CRISPR: :ermAM(stop)/CRISPR : :0 cfu, 2.6* 10"3 (7.J xl0V2.7xl04) in this experiment, meaning that if the recombination frequency of the editing template is less than this value, CRISPR selection may not efficiently recover the desired mutants above the background. To understand the origin of these cel ls, Applicants genotyped 8 background colonies and found that 7 contained deletions of the targeting spacer (Figure 35b) and one harbored a presumably inactivating mutation in Cas9 (Figure 35c).
0Θ314] Gesiome editing with Cas9 in E. colt The activation of Cas9 targeting through the chromosomal integration of a CR ISPR-Cas system is only possible in organisms that are highly recombino genie. To develop a more general method that is applicable to other microbes, Applicants decided to perform genome editing in E, coli using a plasmid-based CRISPR-Cas system. Two plasmids were constructed: a pCas9 plasmid carrying the tracrRNA, Cas9 and a chloramphenicol resistance cassette (Figure 36), and a pCRISPR kanamycin-resistant plasmid carrying the array of CRISPR spacers. To measure the efficiency of editing independently of CRISPR selection. Applicants sought to introduce an A to C transversion in the rpsL gene that confers streptomycin resistance. Applicants constructed a pCRlSPR::rpsL plasmid harboring a spacer that would guide Cas9 cleavage of the wild-type, but not the mutant rpsL allele (Figure 27b). The pCas9 plasmid was first introduced into E. coli MG 1655 and the resulting strain was co-transformed with the pCRISPR::rpsL plasmid and W542, an editing oligonucleotide containing the A to C mutation, streptomycin-resistant colonies after transformation of the pCR!SPR::rpsL plasmid were only recovered, suggesting that Cas9 cleavage induces recombination of the oligonucleotide (Figure 37). However, the number of streptomycin-resistant
colonies was two orders of magnitude lower than the number of kanamycin -resistant colonies, which are presumably ceils thai escape cleavage by Cas9. Therefore, in these conditions, cleavage by Cas9 facilitated the introduction of the mutation, but with an efficiency that was not enough to select the mutant cells above the background of 'escapers' ,
{(KB 15] To improve the efficiency of genome editing in E. co!i, Applicants applied their CRISPR system with recombineering, using Cas9~induced cell death to select for the desired mutations. The pCas9 plasmid was introduced into the recombineering strain H E63 (31 ), which contains the Gam, Exo and Beta functions of the Cli-red phage. The resulting strain was co- tratisformed with the pCRISPR::rpsL p!asmid (or a pCRISPR::0 control) and the W542 oligonucleotide (Figure 27a). The recombineering efficiency was 5.3 X 1 Q~\ calculated as the fraction of total ceils that become streptomycin-resistant when the control plasmid was used (Figure 27c). in contrast, transformation with the pCRlSPR::rpsL plasmid increased the percentage of mutant ceils to 65 ± 14 % (Figures 27c and 29f). Applicants observed that the number of cfu was reduced by about three orders of magnitude after transformation of the pCRISPR::rpsL plasmid than the control plasmid (4,8χ 10 5.3χ 10\ Figure 38a), suggesting that selection results from C ISPR-induced death of non-edited cells. To measure the rate at which Cas9 cleavage was inactivated, an important parameter of Applicants' method, Applicants transformed cells with either pCRISPR::rpsL or the control plasmid without she W542 editing oligonucleotide (Figure 38a). This background of CRISPR 'escapers", measured as the ratio of pCR:iSPR::i-psL/pCRISPR::0 cfu, was 2 5 0 5 ( 1 .2 ! 0: 4.H Ι θ . Genotyping eight of these escapers revealed that in all cases there was a deletion of the targeting spacer (Figure 38b). This background was higher than the recombineering efficiency of the rpsL mutation, 5.3X 10 . which suggested that to obtain 65% of edited cells, Cas9 cleavage must induce oligonucleotide recombination. To confirm this, Applicants compared the number of kanamycin- and streptomycin-resistant cfu after transformatio of pCR!S PR : :rpsL or pCRISPR::0 (Figure 27d). As in the case for 5. pneumoniae. Applicants observed a modest induction of recombination, about 6,7 fold ( 2.0 10 '' 3 0 ··· H) ' } Taken together, these results indicated that the CRISPR system provided a method for selecting mutations introduced by recombineering.
[0Θ316] Applicants showed that CRISPR-Cas systems may be used for targeted genome editing in bacteria by the co-introduction of a targeting construct that ki lled wild-type cells and an editing template that both eliminated CRISPR cleavage and introduced the desired mutations.
Different types of mutations (insertions, deletions or sear-less single-nucleoiide substitutions) may be generated. Multiple mutations may be introduced at the same time. The specificity and versatility of editing using the CRISPR system relied on several unique properties of the Cas9 endonuclease: (i) its target specificity may be programmed with a small RNA, without the need for enzyme engineering, (ii) target specificity was very high, determined by a 20 bp RNA-DNA interaction with low probability of no -target recognition, (iii) almost any sequence may be targeted, the only requirement being the presence of an adjacent NGG sequence, (iv) almost any mutation in the NGG sequence, as well as mutations in the seed sequence of the protospacer, eliminates targeting.
[00317] Applicants showed that genome engineering using the CRISPR system worked not only in highly recombinogenic bacteria such as S. pneumoniae, but also in E, coli. Results in E. coli suggested that the method may be applicable to other microorganisms for which plasmids may be introduced. In E. coli, the approach complements recombineering of mutagenic oligonucleotides. To use this methodology in microbes where recombineering is not a possible, the host homologous recombination machinery may be used by providing the editing template on a plasmid. In addition, because accumulated evidence indicates that CRJS PR-mediated cleavage of the chromosome leads to cell death in many bacteria and arehaca , it is possible to envision the use of endogenous CRISPR-Cas systems for editing purposes.
[00318] In both S. pneumoniae and E. coli, Applicants observed that although editing was facilitated by a co-selection of transformable cells and a small induction of recombination at the target site by Cas9 cleavage, the mechanism that contributed the most to editing was the selection against no -edited ceils. Therefore the major limitatio of the method was the presence of a background of cells that escape CRISPR-induced cell death and lack the desired mutation. Applicants showed that these 'escapers' arose primarily through the deletion of the targeting spacer, presumably after the recombination of the repeat sequences that flank the targeting spacer. Future improvements may focus on the engineering of flanking sequences that can still support the biogenesis of functional crRNAs but that are sufficiently different from one another to eliminate recombination. Alternatively, the direct transformation of chimeric crRNAs may be explored. In the particular case of E. coli, the constructio of the CRISPR-Cas system was not possible if this organism was also used as a cloning host. Applicants solved this issue by placing
Cas9 and the tracrRNA on a different plasmid than the CR1SPR array. The engineering of an inducible system may also circumvent this limitation.
[003191 Although new DNA synthesis technologies provide the ability to cost-effectively create any sequence with a high throughput, it remains a challenge to integrate synthetic DNA in living cells to create functional genomes. Recently, the co-selection M AGE strategy was shown to improve the mutation efficiency of recombineering by selecting a subpopulation of cells that has an increased probability to achieve recombination at or around a given locus. In this method, the introduction of selectable mutations is used to increase the chances of ge erating earby non- selectable mutations. As opposed to the indirect selection provided by this strategy, the use of the CRISPR system makes it possible to directly select for the desired mutation and to recover it with a high efficiency. These technologies add to the toolbox of genetic engineers, and together with DNA synthesis, they may substantially advance both the ability to decipher gene function and to manipulate organisms for biotechnological purposes. Two other studies also relate to CRISPR-assisted engineering of mammalian genomes, it is expected that these crRNA-directed genome editing technologies may be broadly useful in the basic and medical sciences.
[00320J Strains and culture conditions. S. pneumoniae strain R6 was provided by Dr. Alexander Tomasz. Strain crR6 was generated in a previous study. Liquid cultures of S. pneumoniae were grown in THYE medium (30g/l Todd-Hewitt agar, 5 g/1 yeast extract). Cells were plated on tryptic soy agar (TSA) supplemented with 5 % defibrinated sheep blood. When appropriate, antibiotics were added as followings: kanamycin (400 ug/ml), chloramphenicol (5 erythromycin (1 μg/mϊ) streptomycin (100 .g/ml) or spectinomycin (100 uu rn! ). Measurements of β-galactosidase activity were made using the Miller assay as previously described.
[00321] E, coli strai s MG1655 and HME63 (derived from MG1655, A(argF-lac) U169 λ cI857 Acro-bioA galK tyr 145 UAG mutS<>amp) (31) were provided by Jeff Roberts and Donald Court, respectively. Liquid cultures of E. coli were grown in LB medium (Difco). When appropriate, antibiotics were added as followings: chloramphenicol (25 μ-g/ml), kanamycin (25 §/ηιί) and streptomycin (50 μ^'πιΓ).
[00322] S. pneumoniae transformation. Competent cells were prepared as described previously (23). For all genome editing transformations, cells were gently thawed on ice and resuspended in 10 volumes of M2 medium supplemented with 100 ng/ml of competence-
stimulating peptide CSP1(40), and followed by addition of editing constmcts (editing constructs were added to cells at a final concentration between 0.7 ng/μί to 2.5 p,g/ul). Cells were incubated 20 min at 37 °C before the addition of 2 μΐ of targeting constmcts and then incubated 40 min at 37 °C. Serial dilutions of cells were plated on the appropriate medium to determine the colony forming units (efu) count.
[00323] E, coli Lambda-red reeonifoiiieering. Strain HME63 was used for ail recombineermg experiments. Recombineering cells were prepared and handled according to a previously published protocol (6). Briefly, a 2 ml overnight culture (LB medium) inoculated from a single colony obtained from a plate was grown at 30 °C. The overnight culture was diluted 100-fold and grown at 30 °C with shaking (200rpm) until the ODeoo is from 0.4-0.5 (approximately 3 hrs). For Lambda-red induction, the culture was transferred to a 42 °C water bath to shake at 200rpm for 15 min. Immediately after induction, the culture was swirled in an ice- water slurry and chilled on ice for 5-10 min. Ceils were then washed and aliquoted according to the protocol. For electro-transformation, 50 μ! of cells were mixed with ImM of salt-free oligos (IDT) or 100-150 ng of piasmid DNA (prepared by QIAprep Spin Miniprep Kit, Qiagen). Cel ls were electroporated using 1mm Gene Puiser cuvette (Bio-rad) at 1.8kV and were immediately resuspended in 1 ml of room temperature LB medium. Cells were recovered at 30 °C for 1-2 hrs before being plated on LB agar with appropriate antibiotic resistance and incubated at 32 °C overnight.
[00324] Preparation of S. pneumoniae genomic DNA. For transformation purposes, S. pneumoniae genomic DNA was extracted using the Wizard Genomic DNA Purification Kit, following instructions provided by the manufacturer (Promega). For genotyping purposes, 700ul of overnight S. pneumoniae cultures were pelleted, resuspended in 60ul of lysozyme solution (2mg/ml) and incubated 30min at 37°C. The genomic DNA was extracted using QIAprep Spin Miniprep Kit (Qiagen).
[003251 Strain construction. All primers used in this study are provided in Table G. To generate S. pneumoniae crR6M, an intermediate strain, LAM226, was made. In this strain the aphA-3 gene (providing kanamycin resistance) adjacent to the CRISPR array of S. pneumoniae crR6 strain was replaced by a cat gene (providing chloramphenicol resistance). Briefly, crR6 genomic DNA was amplified using primers L448/L444 and L447/L481, respectively. The cat gene was amplified from piasmid pC194 using primers L445/L446. Each PGR product was gel-
purified and all three were fused by SOEing PGR with primers L448/L481. The resulting PGR product was transformed into competent S, pneumoniae crR6 cells and chloramphenicol -resistant transformants were selected. To generate S. pneumoniae crR6M, S. pneumoniae crR6 genomic DNA was amplified by PGR using primers L409/L488 and L448/L481, respectively. Each PGR product was gel -purified and they were fused by SOEing PGR with primers L409/L481 . The resulting PGR product was transformed into competent S. pneumoniae LAM226 cells and kanamycm-resistant transformants were selected,
[00326] To generate S. pneumoniae crR6Rc, S. pneumoniae crR6M genomic DNA was amplified by PGR using primers L430/W286, and S. pneumoniae LA 226 genomic DNA was amplified by PGR using primers W288/L481. Each PGR product was gel-purified and they were fused by SOEing PGR. with primers L43Q/L481. The resulting PGR product was transformed into competent S. pneumoniae crR6M cells and chloramphenicol-resistant transformants were selected.
[00327] To generate S. pneumoniae crR6Rk, S. pneumoniae crR6M genomic DNA was amplified by PGR using primers L430/W286 and W287/L481, respectively. Each PGR product was gel-purified and they were fused by SOEing PGR with primers L430/L481. The resulting PGR product was transformed into competent S. pneumoniae crR6Re ceils and kanamyein- resistant transformants were selected.
[00328] To generate JEN37, S. pneumoniae crR6Rk genomic DNA was amplified by PGR using primers L430/W356 and W357/L481 , respectively. Each PGR product was gel-purified and they were fused by SOEing PGR with primers L430/L481. The resulting PGR. product was transformed into competent S. pneumoniae crR6Rc cells and kanamyc in-resistant transformants were selected.
[00329] To generate JEN38, R6 genomic DNA was amplified using primers L422/L461 and L459/L426, respectively. The ermAM gene (specifying erythromycin resistance) was amplified from plasmid pFW 15 43 using primers L457/L458. Each PGR product was gel-purified and ail three were fused by SOEing PGR with primers L422/L426, The resulting PGR. product was transformed into competent S. pneumoniae crR6Rc cells and erythromycin-resistant transformants were selected.
[00330] S. pneumoniae JEN 53 was generated in two steps. First JE 43 was constructed as illustrated in Figure 33. JEN53 was generated by transforming genomic DNA of JEN25 into competent JEN43 cells and selecting on both chloramphenicol and erythromycin.
[00331] To generate S. pneumoniae JEN62, S, pneumoniae crR.6Rk genomic DNA was amplified by PGR using primers W256/W365 and W366/L403, respectively. Each PGR product was purified and ligated by Gibson assembly. The assembly product was transformed into competent S. pneumoniae crR6Rc cells and kanamycin-resistant transformants were selected.
[00332] Plasmid construction. pDB97 was constructed through phosphorylation and annealing of oligonucleotides B296/B297, followed by ligation in pLZ12spec digested by EcoRI/BamHI. Applicants fully sequenced pLZ12spec and deposited its sequence in genebank (accession: C1 12384).
[ 00333] pDB98 was obtained after cloning the CRJSPR leader sequence was cloned together with a repeat-spacer-repeat unit into pLZ12spec. This was achieved through amplification of crR6Rc DNA with primers B298/B320 and B299/B321 , followed by SOEing PGR of both products and cloning in pLZ12spec with restriction sites BamHI/EcoRI. In this way the spacer sequence in pDB98 was engineered to contain two Bsal restriction sites in opposite directions that allow for the scar-less cloning of new spacers.
[00334] pDB99 to pDBlQS were constructed by annealing of oligonucleotides B300/B301 (pDB99), B302/B303 (pDBlOO), B304/B305 (pDB lOl), B306/B307 (pDB102), B308/B309 (pDB103), B310/B311 (pDB104), B312/B313 (pDB105), B314/B315 (pDB106), B315/B317 (pDB107), B318/B319 (pDB108), followed by ligation in pDB98 cut by Bsal.
[00335] The pCas9 plasmid was constructed as follow. Essential CRISPR elements were amplified from Streptococcos pyogenes SF370 genomic DNA with flanking homology arms for Gibson Assembly. The tracrRNA and Cas9 were amplified with oiigos HC008 and HC010. The leader and CRISPR sequences were amplified HCOl 1/HC014 and HC015/HC009, so that two Bsal type IIS sites were introduced in between two direct repeats to facilitate easy insertion of spacers.
[00336] pCRISPR was constructed by subcloning the pCas9 CRISPR array in pZE21-MCSl through amplification with oiigos B298+B299 and restriction with EcoRI and BamHI. The rpsL targeting spacer was cloned by annealing of oiigos B352+B353 and cloning in the Bsal cut pCRISPR giving pCRISPR::rpsL.
[00337] Gesieratiosi of targetlsig and editing constructs. Targeting constructs used for genome editing were made by Gibson assembly of Left PCRs and Right PCRs (Table G). Editing constructs were made by SOEing PGR fusing PGR products A (PGR A), PGR products B (PGR B) and PGR products C (PGR C) when applicable (Table G). The CRISPR::0 and CRISP R: :ermAM(stop) targeting constructs were generated by PGR amplification of JEN62 and crR6 genomic DNA respectively, with oiigos L409 and L481.
[00338] Generation of targets with randomized PAM or protospacer sequences. The 5 nucleotides following the spacer 1 target were randomized through amplification of R68'l32' > genomic DNA with primers W377/ L426. This PGR product was then assembled with the cat gene and the srtA upstream region that were amplified from the same template with primers L422/W376. 80 ng of the assembled DN A was used to transform strains R6 and crR.6. Samples for the randomized targets were prepared using the following primers: B280-B290/L426 to randomize bases I -10 of the target and B269-B278/L426 to randomize bases 10-20, Primers L422/B268 and L422/B279 were used to amplify the cat gene and srtA upstream region to be assembled with the first and last 10 PGR products respectively. The assembled constructs were pooled together and 30 ng was transformed in R6 and crR6. After transformation, cells were plated on chloramphenicol selection. For each sample more than 2x 10" cells were pooled together in I ml of THYE and genomic DNA was extracted with the Promega Wizard kit. Primers B250/B251 were used to amplify the target region. PGR products were tagged and run on one Illumina MiSeq paired-end lane using 300 cycles.
[00339] Analysis of deep sequencin data,
[00340] Randomized PAM: For the randomized PAM experiment 3,429,406 reads were obtained for crR6 and 3,253,998 for R6. It is expected that only half of them will correspond to the PAM-target while the other half will sequence the other end of the PGR product. 1,623,008 of the crR6 reads and 1,537,131 of the R6 reads carried an error-free target sequence. The occurrence of each possible PAM among these reads is shown in supplementary file. To estimate the functionality of a PAM, its relative proportion in the crR6 sample over the R6 sample was computed and is denoted rjjk!m where I,j,k,l,m are one of the 4 possible bases. The following statistical model was constructed:
[00341] log(ryklffi) = μ + b2, + b3j + b4k + b2b3y+ b3b4,k · ;,,kl!l.
[00342] where ε is the residual error, b2 is the effect of the 2nd base of the PAM, b3 of the third, b4 of the fourth, b2b3 is the interaction between the second and third bases, b3b4 between the third and fourth bases. An analysis of variance was performed:
[00343] Anova table
[00344] When added to this model, hi or b5 do not appear to be significant and other interactions than the ones included can also be discarded. The model choice was made through successive comparisons of more or less complete models using the anova method in R. Tukey's honest significa ce test was used to determine if pairwise differences between effects are significant.
[00345] NGGNN patterns are significantly different from ail other patterns and cany the strongest effect (see table below).
[00346] In order to show that positions 1 , 4 or 5 do not affect the NGGNN pattern Applicants looked at theses sequences only. Their effect appears to be normally distributed (see QQ plot in Figure 71), and model comparisons using the anova method in R shows that the null model is the best one, i.e. there is no significant role of b1 , b4 and b5.
[00348] Partial interference of NAGNN and NNGGN patterns
[00349] NAGNN patterns are significantly different from all other patterns but cany a much smaller effect than NGGNN (see Tukey's ho est significance test below).
[00350] Finally, NTGGN and NCGGN patterns are similar and show significantly more CRISPR interference than NTGHN and NCGHN patterns (where H is A,T or C), as shown by a bonferroni adjusted pairwise student-test.
[00351] P rwise„c^
pooled SD
[003521 Taken together, these results allow concluding that NNGGN patterns in general produce either a complete interference in the case of NGGGN, or a partial interference in the case of NAGGN, NTGGN or NCGGN.
G G -Ar A _ -:■ 7 £475 .94075 - 53375 1S -07
5 G -C ; A 7 §911 .97511 62311 1E -07
G G -T :A -2.7809 - 2.9569 .6049 1E -07
3 G -A: 81643 .9S244 64043 1E -07
S G -C : C 77903 _ .95504 60303 1E -07
G G -Gr : _ -:■ 643- 67 .62468 - 47267 1S -07
G G -Tr _ 79713 -2 .97319 - 62113 1S -07
G G -A ; G 67068 _ , 84668 49 63 1E -07
G G -C ; G 73525 _ ,91125 55925 1E -07
S G -T:G -I .7976 _ . 2159 ·- 9736 1E -07
3 G -A; 76 2^ .59127 94326 <1E -07
G G -Cr 84114 .66513 -3, 01714 1S -07
G G -G:: .■ * 76 09 .588 OS 94003 1E -07
G G -I: ; 7€7 SI _ ,5:9161 94361 <1E -07
G G -G ϊ A 13964 _ ,31565 -1 , 96364 1E -07
3 -A; A -0 , 62511 -G .80111 -c .,4491 <1E -07
:; Ά- -C ; A. -0. 6594? -0 .83547 48346 1S -07
G :; Ά- -T : A. -0. 64126 -0 ,465 -0. S ? 26 1S -07
G : A -A;C -ΰ , 67679 -0 ,50670 -6. 35279 1E -07
-r : A~ -G ; C 63939 -0 ,46339 -6. 31539 .'IE -07
G; A- -G : C -G■ 50303 -0 .33363 -0. 6S5D3 <1E -07
G; A- -I : £ -G , 65754 -0 .46154 -0. 63354 <1E -07
:; A- -A; G -0. S31Q4 -0 .35503 -6. 70704 1S -07
G:; ¾- -C't -0. 59561 - 3..4196 -ϋ. 77161 1S -07
G:; ¾- -T ; G -0. 65795 -0 . 3195 -0. S3396 1S -07
-r : -A; T -0 , 62763 -0 ,45163 -6. 30363 1E -07
G : A~ -C ; T -0 , 701 3 -0 ,52549 -0 .8775 .: IE -07
G- .; A- - : T -G , 62445 -0 .44344 -0. 60045 <1E -07
G; A- - ; T -G . 62617 -0 .45216 -0 , 60417 <1E -07
Sb3:b4
G;G-G.;A -0,33532 -0.51133 -0.15332 lE-07
G:G-G;C -0,18113 -0.35719 -0.00513 0.036087
G:G-G:: -0,31626 -0.14026 -0,49226 lE-07
[00354] Randomized target
0Θ355] For the randomized target experiment 540,726 reads were obtained for crR.6 and 753,570 for R6. As before, only half of the reads are expected to sequence the interesting end of the PGR product. After filtering for reads that cany a target that is error-free or with a single
point mutation, 217,656 and 353, 141 reads remained for crR6 and R6 respectively. The relative proportion of each mutant in the crR.6 sample over the R6 sample was computed (Figure 24c). Ail mutations outside of the seed sequence (13-20 bases away from the PAM) show full interference. Those sequences were used as a reference to determine if other mutations inside the seed sequence can be said to significantly disrupt interference. A normal distribution was fitted to theses sequences using the fitdistr function of the MASS R package. The 0.99 quantile of the fitted distribution is shown as a dotted line in Figure 24c. Figure 72 shows a histogram of the data density with fitted normal distribution (black line) and .99 quantile (dotted line).
[00356] Table F. Relative abundance of PAM sequences in the crR6/R6 samples averaged over bases 1 and 5.
10357] Table G. Primers used in this study.
B21? TCCr¾5C£55ST TC SAT¾IT¾CT?iTCa G TXT¾GAS T¾IGi:TGTTTT3&
B2IS GXGACAGXAAXAT-7¾GA^TCC?GC?AGGAGTX
SSGXITCA^GICTXTGXAGCAASAG
B S GCCAATGAACGGGAACCCXXGGXC
B25S
3251 SiiSiSiTTairTS CTCArAXTT CT
B: :
3257
B25S CIXACGGT£C¾rAA¾GT A¾TITf C
B2SS TSGCT GAiTTCAGCCSXT-GC
B27S TirGA GAGGCA TG5C SSAAXCGAGCCAAS¾AAGC5;:AAG
BJ 1 CXITGAC A ^TG TGAA¾:ICGA5CCSAAS¾SSC CA¾G
B272 CTIT £CG¾GG ¾ATG CI J^T:: AGCCa¾Ji¾SAS Ck¾G sin I r C G C A G5CI5aAATC5A CC¾¾S¾¾;i-C5': ¾G
B274 CTTrG CGAGGCAG¾TQGC GAAATCGAGC AJ^ASiiCG A¾
CXirGAGGAGGCAAXGGCTGSAAXCGAGCCAAAAAAGHGCASG
CTTXGACGAGGCS¾?GGCTSAA¾^
32Ί7 CTTTGiC iS CJ^TG C GAJ^
Bin
B27S SCGCTTXXTTGSCXCGAXTTCAG
B2SS C ¾T" G:CIG? ¾¾TC5¾GCi¾ii?¾iiS.GCSC->.SGAi¾SSi¾.¾T!!
s:n
CAAr SCTSAAaTCGAGC AJ^ASGCG A¾ iiAGAAS.TC
B2S1 CS ATG GC I GAS ¾ "AGCC AS AA» SGCGC a a &K ¾ ¾TG
3284
B2S5
B iS
B2S? C&Ar SCTSAAaTCSAGC AJ^ASGCGCAa AAGAASTCfJiC
B2SS C* ATGGv T GASJ-TCGAGCC AS ¾A~ ¾GCGG a ¾Ga ¾GA~ %i?C&&CC
329* C a GCTGS¾AXCGA CCA ?¾ A CG;:AA!G&AGAAATCK¾CC¾ -C:
B « W a Si'C TCC AXC CGXACAACCCa CAACCGTG¾
ast-; cCAGS5T T TS G IG aC GATG Ag
B29S S GGAXCC T¾XTTCXTgA~aACXAAA¾ A X¾XGG
ATGAAX^CAACTiAACAAGTCX >GTGCTG
Βϊΰδ AA¾CAI'XTI'XTGXCCAXTXAGG¾AA¾AGi;ATGCTG
AAARCAGCAXCGXXTXXCGXAAaXGGAGSAAAAAX
3302 Jk½ Cir»iWtTC&^C&C3^TA5CaS^3U6J^X 5
B303
B304 JUkS^TrrT &TC& & SSC &iiT rG TlTSXTTS
BiOS AASACSJUir^A CaSS^T GXCGT TGaXGAASA
Β30ϊ> s.¾a xcs c aGA.aGXTsxc5 &AaaG¾sji,TCG65
BSS?
BiOS AAaCAAICrCT CaiiGGIT CCTTA&A^TCTCTG
Aa^ca aGA r xTas- GSAacc T GaGSGax
B3SS> a Aft CCS SXC S " SCTS S TTS>S
BJil AA&¾cac ck¾s :a:i&5 T i: TCCTsa QSXQG
Bii2 AajiC rCTC AraCTTS^TG¾AS.XXrc TTGXaxG
BiI3 a¾Aacar .cAa¾ a¾TTXc axaaGT xA5aGar
B314 S.RACTAGCrGIGS/r G CCG &aaC aG T -;
BJi5 AAA¾CQ¾¾GSCT5 TTTIG 5 ¾CI&TGSCaG:CTS
BiiS AA¾C arc GS.SAGGXC SSGC SJy--¾ATX¾TCX?XXG
B3I7
B31S
Βί··?
Βί_δ
B321 ia¾^&cc^T c^GJU¾^T ai^55T xc^xTTi^as T& i TSTrTT«
BJ52
BM3 5.<t5c &¾Aasi ¾; CGaacTCCGCscxscGTa ¾ASXA
HCSiiS SP
:SP
SP XTa¾ Aa¾raiTCTTc rcT£AAaxATacTTca5rcA:c:cTC Ta5CT5ac
HCGi 1 SP Ari arXTSA rCAGCXA'GGAGSX CXGSJiGXS^aTXTX& XGaaG
HC0L4 P XXTTXGTC
GAGACC;¾GXCXCGG¾¾GCTC:A^
HCG35 s? AG&CXXG
L 3¾ ST55 IAARICS GA SACS T C&AS SSi-S
L42.2 X cor e «ca
L 2≤ aaGc &aAs xTG a acc
GXAGCIT&XIC¾STCCX&GXG5
L44 GTiT rxGAaci axG GX5f &aa T c aa cr c~ cTQa ?
L4 5
L4 <S G&XATXSTSGASGCTaXTTXTGXGGSXTTXXASGCaX¾aajiCTATaXG c.£iaxAGXTTX¾TGCCTaa¾a^
L45?
L 5S CACCSGTGATCA TSQ C TASG
L4£S
L S · rTCAA&ITrrC A TSitTI CC
hm CCaiAITT TAGXTATTAAG&AaTAAXACC&GCCATCAGXCACCTCC
S T TGSSACCATTCASAACSQ^^^
W Sf
^S r i Tr T caTC&rcsi
327
J4I
Wi54 GXTrXICafiAaXCTGCG XTGCG
&RJ:i&XXG¾i&S¾k GQTGG¾aA aC
55S ArT CG AASCG5 A CGGT X X TTAA 5X X GG5ACCa T iliAa5CA5C
irTAAaAGa^CCGAX&CCGTTX¾CS&A£XG TT £G¾GCTATGCTGTIXI5A MS
370 STTCCT ¾& CAaAACGGXaXC5 T7XC rXT¾£AT C
wm Ga&AC GAX¾CCGTTTXGGXTTSAGS&ACaGGT&A£GGGC¾:TTXAS.C
CGAXXXCaGC AXTSCCTCSTC
m IccGxacAacccacAS.ccc.GC±AGTGAGCG? > "XGGGSCCA > xcaa¾ACSGC
win CT ¾ "& a G5 XG G ?TT5 A -;GAG XT aG&GCTaXGCXG~rX'TGa
ws XXGTXSCCACTCXT XTCTTXC
CAGSSXXGTCGGTXGTTGCGSXGSaGTIAACXCC ATCXCC
GC AGi' AacTcCA CGCaacAacccacaacc ~Gcx¾GXG
¾;40;: SXG5XAX XATCGTGS GXG¾i
4S4 XXACCSA&S GGA&XXTSXCTGC
40S AA&GCTS.SAG TTCCSC&&TT5S
¾r4il GTSGGXXGX¾CGGA GAGXXAaCTCCCaXC CXTC
4¾ SBT5GGAG aS.CTCAATCC5 A a¾ CCA aACCC 5
433
4J4 STGGTCaarTGGTSCTG AAXAGSXGAaGCXAATGGTSATS
W«3 CrGATTTGX¾ira¾:TTXIGaGACSX~aXGCXTC¾.C XXC
464
46S STT TGSGACCATTCAaG^CSGCa A XC AAAGC G CA TaATaiCAG
¾r4 J GTXXT&GAGCIAXGCTGXTXXGaSXGGXCCCAa¾ACGC -C¾GX GCa GIXG
S42 Ar¾CTTXA SCaGCGCGGaGXTCGGTXXTgXAGGAGXGGX¾G~&XaX¾:CA GA5TACaX 0358] Table H. Design of targeting and editing constmcts used in this study.
ı 77
Example 6: Optimization of the guide RNA for Streptococcus pyogenes Cas9 (referred to as SpCas ).
[00359] Applicants mutated the traerRNA and direct repeat sequences, or mutated the chimeric guide RNA to enhance the RNAs in cells.
[00360] The optimization is based on the observation that there were stretches of thymines (Ts) in the traerRNA and guide RNA, which might lead to early transcription termination by the pol 3 promoter. Therefore Applicants generated the following optimized sequences. Optimized traerRNA and corresponding optimized direct repeat are presented in pairs.
[00361] Optimized traerRNA 1 (mutation underlined):
[00362] GGAACCATTCAtAACAGCATAGCAAGTTAtAATAAGGCTAGTCCGTTATCA
ACTTGAA AA AGTGG C ACCG AGTCG GTGCTTTTT
[00363 S Optimized direct repeat 1 (mutation underlined):
[00364] GTTaTAGAGCTATGCTGTTaTGAATGGTCCCAAAAC
[00365] Optimized traerRNA 2 (mutation "underlined):
[00366] GGAACCATTCAAtACAGCATAGCAAGTTAAtATAAGGCTAGTCCGTTATCA
ACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTT
[00367] Optimized direct repeat 2 (mutation underlined):
[00368] GTaTTAGAGCTATGCTGTaTTGAATGGTCCCAAAAC
[00369] Applicants also optimized the chimeric guideRNA for optimal activity in eukaryotic cells.
[00370] Original guide RNA:
[00371] NmmmmmTNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAA TAAGGCTAGl X i ATCAA(TrTGAAAAAGTGGCA( GAGTCGGTGCTTTTTTT
[00372] Optimized chimeric guide RNA sequence 1 :
[00373] NNNNNNNNNNNNNNNNNNNNGTATTAGAGCTAGAAATA.GCAAGTTAATA TAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT
[00374] Optimized chimeric guide RNA sequence 2:
[00375] NNNNNNNNNNNNNNNNNNNNGTTTTAGAGCTATGCTCTTrTGGAAACAA AACAGCATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCAC
CGAGTCGGTGCTTTTTTT
[00376] Optimized chimeric guide RNA sequence 3:
[00377] NNNNNNNNNNNNNNNNNNNNGTATTAGAGCTATGCTGTATTGGAAACAA TACAGCATAGCAAGTTAATATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACC
GAGTC 'GGTi X I ΓΠΊ I
[00378] Applicants showed that optimized chimeric guide RNA works better as indicated in Figure 3. The experiment was conducted by co-transfectirsg 293FT cells with Cas9 and a U6~ guide RNA DNA cassette to express one of the four RNA forms shown above. The target of the guide RNA is the same target site in the human EmxT locus: "GTCACCTCCAATGACTAGGG"
Example 7: Optimization of Streptococcus thermophiles LMD-9 CR1SPRI Cas9 (referred to as StlCas9).
[00379] Applicants designed guide chimeric RNAs as shown in Figure 4,
[003801 The Stl Cas9 guide RNAs can undergo the same type of optimization as for SpCas9 guide RNAs, by breaking the stretches of poly thymines (Ts)
Example 8: Cas9 diversity and mutations
[00381] The CRISPR-Cas system is an adaptive immune mechanism against invading exogenous DNA employed by diverse species across bacteria and archaea. The type II CRISPR- Cas9 system consists of a set of genes encoding proteins responsible for the "acquisition" of foreign DNA into the CRISPR locus, as well as a set of genes encoding the "execution" of the DNA cleavage mechanism; these include the DNA nuclease (Cas9), a non-coding transaetivating cr-RNA (tracrRNA), and an array of foreign DNA-derived spacers flanked by direct repeats (crRNAs). Upon maturation by Cas9, the tracRNA and crRNA duplex guide the Cas9 nuclease to a target DNA sequence specified by the spacer guide sequences, and mediates double-stranded breaks in the DNA near a short sequence motif in the target DNA that is required for cleavage and specific to each CRISPR-Cas system. The type 11 CRISPR-Cas systems are found throughout the bacterial kingdom and highly diverse in in Cas9 protein sequence and size, tracrRNA and crRNA direct repeat sequence, genome organization of these elements, and the motif requirement for target cleavage. One species may have multiple distinct CRISPR-Cas systems.
[00382] Applicants evaluated 207 putative Cas9s from bacterial species identified based on sequence homology to known Cas9s and structures orthologous to known subdomains, including
the HNH endonuc lease domain and the RuvC endonuclease domains [information from the Eugene Koonin and Kira MakarovaJ. Phylo genetic analysis based on the protein sequence conservation of this set revealed five families of Cas9s, including three groups of large Cas9s (-1400 amino acids) and two of smal l Cas9s (~1 100 amino acids) (Figures 39 and 40A-F).
[00383] in this example, Applicants show that the following mutations can convert SpCas9 into a nicking enzyme: DIOA, E762A, H840A, N854A, N863A, D986A,
[00384] Applicants provide sequences showing where the mutation points are located within the SpCas9 gene (Figure 41). Applicants also show that the nickases are still able to mediate homologous recombination (Assay indicated in Figure 2), Furlhemiore, Applicants show thai SpCas9 with these mutations (individually) do not induce double strand break ( Figure 47).
[00385] Furthermore, potential nicking mutation sites were chosen based on sequence homology between Cas9 orthologs (named original set below). The nickase mutant Cas9s were re-cloned to incorporate both N' and C'-NLS sequences as in Cong, L et al.. Multiplex genome engineering using CRISP R/Cas systems, Science. 2013 Feb 15;339(6121 ):819-23. (sequences for NLS-E762A-NLS and >NLS-D986A-NLS listed below).
[00386] Nuclease and double-nicking activities for these potential nickases were tested in HEK 293 FT cells as follows: co-transfection of 400ng of nickase and 100 ng of U6-driven sgRNA (lOOng for one guide, or 50ng each for a pair of sgRNAs) by Lipofectamine 2000 into -200,000 ceils. DNAs from transfected ceils were collected for SURVEYOR analysis. Nickases do not result in indel mutations when co-transfected with a single sgRNA, but do when co- transfected with a pair of appropriately off-set sgRNAs. Based on data from the original DI OA SpCas9 nickase, the pair of sgRNA chosen (Al/Cl) for RuvC domain mutants have 0-bp offset and 5 '-overhang for maximal cleavage.
Original set: Mutant domain Functional?
Cbh-h SpCas9(D 10A)-NLS RuvC I nickase activity
Cbh-hSpCas9(E762A)-NLS RuvCII
Cbh-hSpCas9(H840A)-NLS HNH no activity
Cbh-hSpCas9(N854A)-NLS HNH wt nuclease activity
Cbh-hSpCas9(N863A)-NLS HNH nickase activity
Cbh-hSpCas9(D986A)-NLS RuvC HI
[00387] >NLS-E762A-NLS
ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAG CCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCC GTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACAC
CX ACXX X ACAGC IX AAGA G ACCTGA'^
AAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACG
GAAGAAC { GGATCTGI TATC IXX'AAGAGAL ( T! CAG( AAI GA ATGGI ^AG T
ACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAG
CACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAA
GTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCG
ACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCC
TGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAG
CTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGT
GGA£GCCAAGGCCP RCC TCTGCCAGACRGAGCAAGAGCAGACGGCRGGAAAKRC
TGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCC
CRGAGCCRGGGCCTGACCCCCAACRTCAAGAGCAACRRCGACCTGGCCGAGGATGC
CAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCC
AGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCC
ATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAG
CGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAG
('Ί ('Ί ( (ΠΧ Λ(Κ Λ(ί('Ί ί Ί'ί jAi ;ΛΛ(}Ί Λ(\\ΛΛί jACiA'l'l Ί ΊΧ' ΓΊ 'GACCA A CA AGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAG
ΊΊ( A rC'AAGCXX-A'ii ( ·Γ(;(ΊΛΛΛΛ(;Λ·!ί;(}Λ(Χ ;('Α(ΧΧΊΛ(Ί(;ΛΛ(Ί (Ί(ΊΧ Xri AAGCT GAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCC
ACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAA.GA.TTTTTAC CCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCC
CTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAA
AGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCT
TCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGA
GAAG&TGCTGCCCAAGCACAGCCTGCmTACGA&TACTFCACCa TA-FAACGAGCT
GACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCG
AGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTG AAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAAT CTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAA AATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAG ΛΊ AT( C )TG( 1 ( ·Λ( ( ΊΧ ΪΛ( 'Λ( Ί ( ·ΤΠ ( ·Λί -G CAGAGAGATi J AT( GAC sGA AC X Χ Κ Ί I AAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAG ΛΤΛΓΛ< X 'GC iCK ' )Q( )CAGi ·( 'TG AG( X X sAAG( TGA l ('ΛΛΓί iGC ΛΊ ('('( ;G( ·Λ( ΛΛί JC AGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAAC TTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGC CCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCA GCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTG AAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGccATGGCCAGAGAGAA CCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAA GAGGGCLATCAAAGAGC iXjGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACA CCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATG
1 AC X ) ] ( iC !.\( X V\{ Ί ί JGACATC A AC X 'GC id GT( ( GAC ΎΛ( ( ·ΛΊ GTi JGACC TAT
CGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAA GCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAA GATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGT TCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGC
i rc \V! ( AAC iAC iAC Λί Χ ΊΧΧ ΠΧ ΪΟΛ ΛΛί ί ( ίC ί ·ΛΊ ( 'Λ( ·ΛΛ ΛC i(■ΛC X7Γ( 'Λ(·ΛC iΛ·!· ( ( Ti iA 1 C( C GGA f GA AC A< Ί A AGTACX iAC GAG T AC \\AGC I GA I < C GGGAAG TC sAA AC sTG ATC V\( C X ΊΧ Ϊ AAGTC X \AAGC Ί ί JGI C ·'Γ( X 'GATTTC C X · AAGi · Α'ΠΊΧ X'.AC Π' TTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAAC GCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGT GTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGG AAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCA AGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACA AACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCG Ο ΑΑΠΤθσΐΟΑΩ€ ΐΟ€(:€€ΑΑΩΎΟΑΑ"ΤΑΐ€ ΟΑΑΑΑΑΟΑ(:€ΟΑΩ(πθ ΑΩΑ£ΑΟ GCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCC
AGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGC CTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGA
GTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAAT
CCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCAT
C AC li :Xl AAGl A(lXX l'(nii CiACi(-1GCiAAAA( !G( i Ci(!AACiACiAA rGi '!{;(}
CCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTG
ΛΛ(ΊΊ(ΧΊ(ΠΑ(ΧΊ( '( AG( (^^(l Al iACiAAC l iAAC l X ί (JAC iA l A X
TGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCG
AGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAA
GTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAA
TATCA.TCCACCTGTTTACCCTGACCAA.TCTGGGAGCCCCTGCCGCCTTCAAGTACTTT
GACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCAC
CCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCT
( ) ( ί ( ) A < ) G C C A ( ' A A A A G < Ϊ ( X G G ί X Ϊ G C X ' A ( ( 1 A Λ A Λ A ( iCCGGCC A GOV A Λ A Λ A Λ ( s Λ A
AAAGtaa
[003881 >NLS-D986A-NLS
ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAG CCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCC
GTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACAC
('( ·Λί ( XXsC 'Λί A.(i( ΛΊ (ΆΛί ·ΛΑ(ίΑΛ( ( TGATi GGAGi C ΧΊΧΧ Ί GTTC (ΪΑ( WGCGGCG AAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACG
<)AAGAAC<X.^ATil ΧΊ ΛΊ X T CAA ^
ACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAG
CACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAA
GTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCG
ACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCC
TGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAG
CTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGT
(s( ) AC XX X Λ Αθί ·( Χ'ΛΤί C Ί Π <Ί X C 'Λί ·Λ( Ί ·Λ( ·( 'AAGAGi Λ( ·Λ( XX Τί ΧΧΧΛΛΛΊΧ
TGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCC
CTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGC CAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCC AGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCC ATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAG
CTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCA
A ( ) A Λ ( ' G { T A. ( X ί C X X X J < Ύ Λ ί A. TTG A < X X i C G ( t A C X ( A. GC X ' ( · C I A A G A G TTC T A. ( ' A ( ·
TTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCT
GAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCC
ACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTAC
CCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCC
CTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAA
AGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCT
'!'( X XX C X 'Λί iCTTC ΆΊ ( '( · A( ·<ΧΧ s ATG AC C AAC TTC G ATA AC s A AC( Ί ( ·( XX 'A ( C s A
GAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCT
( lAC 'i A AAGX i - AA Al AC -Gl i iAi ί C iAC iGC iAAI GAGAAAGC C X 'GC ( ΊΊ'( ( ΊΧ ;Α( 'ί C i
AGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTG
AAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAAT
CTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAA
AATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAG
ATA rrGTGrrGAr<X TGACArrGTTTC
AAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAG
ΛΊ AC A( '( C XX TC XX XX AC ;G( Ί C · AC ·( X X sG AAGC ΊΧ Ϊ ATC A AC XX 'ATC C XX ;G AC 'AAGC
AGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAAC
TTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGC
CCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCA
GCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTG
AAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGA
ACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGA
AGAGGGCATCAAAGAGCri jGGCAGCCAGATCXriTiAAAGAACACCCCGTGGAAAAC
ACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATAT
GTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATA TCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGA AGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGA AGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAG ΊΊ( ί;Λί ΛΛΊ ΊΧ;Λί ( AACX IACIACIAC CiG( Cl iAC i-AAClTXiAl AAiiGi ί CiG CTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGA TCXTFGGACTCCCXXiATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAA GTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAG TTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGcCGCCTACCTGAAC GCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGT GTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGG Λ AA.'i'C XX K ' AAGGCl Λί X X A G I AC "i'Ti ΊΊ < Ί AC 'Λί ΧΆΛΓΑΤί 'Λ I ( A Λί ΊΎ Π TC 'Λ AGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACA AACXX : iAAA( 'iJGiJGAGAl X7rin X ;Al-AACiGCi( 'iJGiJAl'111 ί Λ('( ίΠΧΧ ίί GAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAG
(ί(ΧΧ :ΊΊΧ \( :·ΛΛΛ(;Α(Γ!(Ί ΛΊ ( ίΊί :ΧΧ ΛΛί;Λί;(}ΛΛ( AC X -rAACX 'rCiA rCX X- A ACi ClXii iACXX !AAGAA(ri Αί Χ^ ΧΧ ΊΊΧΧίΛί'Λί ( ί ('Α( ί ilGC ' CTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGA GTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAAT CCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCAT
( ΑΛί :ΊΧΧ (Ί·ΛΛ(Π \ίΊί (XlXri rCXiAGClXiGAAAAC (X XX iAAGAGAAlX ^'IXX! CCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTG ΛΑ(ΊΊΧ (ΊΧΓ! Λ( ClXX 'ACiC 'AC-rA-rCiACiAACX'-rCiAACX X'l ί (ΧΧΧιΛί ΪΑ'ΓΛΛ TGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCG AGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAA GTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAA TATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTT GACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCAC CCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCT
( ί ( X ί Λ ( ί ( X ' ί · Λ ί A. A A. A ( X ί C ' ( X ί C ! ( X ί ( X X Λ ( X ί A A A A Λ G G ( X G C ' A (XX A A A A A A ( I A Λ AAAG
Example 9: Supplement to DNA targeting specificity of the RNA-guided Cas9 nuclease [0Θ389] Cell culture and transfection
[00390] Human embryonic kidney (HEK) cell line 293 FT (Life Technologies) was maintained in D lbecco's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), 2mM GlutaMAX (Life Technologies), IQQU/mL penicillin, and 100μ¾'Ίιιί. streptomycin at 37°C with 5% C02 incubation.
[00391] 293FT ceils were seeded either onto 6-well plates, 24-well plates, or 96-well plates (Coming) 24 hours prior to transfection. Cells were transfected using Lipofectamine 2000 (Life Technologies) at 80-90% confluence following the manufacturer's recommended protocol. For each well of a 6-well plate, a total of 1 ug of Cas9+sgRNA plasmid was used. For each well of a 24-well plate, a total of 500ng Cas9+sgRNA plasmid was used unless otherwise indicated. For each well of a 96-well plate, 65 ng of Cas9 plasmid was used at a 1 :1 molar ratio to the U6- sgRNA PGR product.
[00392] Human embryonic stem cell line HUES9 (Harvard Stem Cell Institute core) was maintained in feeder-free conditions on GelTrex (Life Technologies) in mTesR medium (Stemcell Technologies) supplemented with lOOug ml Normocin (InvivoGen). HUES9 cells were transfected with Amaxa P3 Primary Cell 4~D Nucleofector Kit (Lonza) following the manufacturer's protocol.
[00393] SURVEYOR, nuclease assay for genome modification
[00394] 293FT cells were transfected with plasmid DNA as described above. Cells were incubated at 37°C for 72 hours post-transfection prior to genomic DNA extraction. Genomic DNA was extracted using the QuickExtract DNA Extraction Solution (Epicentre) following the manufacturer's protocol. Briefly, pelleted cells were resuspended in QuickExtract solution and incubated at 65°C for 15 minutes and 98°C for 10 minutes.
[00395] The genomic region flanking the CRISPR target site for each gene was PGR amplified (primers listed in Tables J and K), and products were purified using QiaQuick Spin Column (Qiagen) following the manufacturer's protocol. 400ng total of the purified PGR products were mixed with 2μ1 10X Taq DNA Polymerase PCR buffer (Enzymatics) and ultrapure water to a final volume of 20μ1, and subjected to a re-annealing process to enable heteroduplex formation: 95°C for lOmin, 95°C to 85°C ramping at - 2°C/s, 85°C to 25°C at -
0.25°C/s, and 25°C hold for 1 minute. After re-annealing, products were treated with SURVEYOR nuclease and SURVEYOR, enhancer S (Transgenomics) following the manufacturer's recommended protocol, and analyzed on 4-20% Novex TBE poly-acryiamide gels (Life Technologies). Gels were stamed with SYBR. Gold DNA stain (Life Technologies) for 30 minutes and imaged with a Gel Doc gel imaging system (Bio-rad). Quantification was based on relative band intensities.
[00396] Northern blot analysis of tracrR A expression in human eel Is
[00397] Northern blots were performed as previously described! . Briefly, RNAs were heated to 95°C for 5 in before loading on 8% denaturing polyacryl amide gels (SequaGel, National Diagnostics). Afterwards, RNA was transferred to a pre -hybridized Hybond N+ membrane (GE Healthcare) and crosslinked with Stratagene UV Crossiinker (Stratagene). Probes were labeled with [gamma-32P] ATP (Perkin Elmer) with T4 polynucleotide kinase (New England Biolabs). After washing, membrane was exposed to phosphor screen for one hour and scanned with phosphorimager (Typhoon).
[00398] Bisulfite sequencing to assess DNA methylation status
[00399] HEK 293 FT cells were transfected with Cas9 as described above. Genomic DNA was isolated with the DNeasy Blood & Tissue Kit (Qiagen) and bisulfite converted with EZ DNA Methylation-Lightning Kit (Zymo Research). Bisulfite PCR was conducted using KAPA2G Robust HotStart DNA Polymerase (KAPA Biosystems) with primers designed using the Bisulfite Primer Seeker (Zymo Research, Tables J and K). Resulting PCR. amplicons were gel- purified, digested with EcoRI and Hindlll, and li gated into a pUC19 backbone prior to transformation. Individual clones were then Sanger sequenced to assess DNA methylation status.
[00400] in vitro transcription and cleavage assay
[00401] HEK 293FT cells were transfected with Cas9 as described above. Whole cell lysates were then prepared with a lysis buffer (20 mM HEPES, 100 mM KC1, 5 mM MgC12, 1 mM DTT, 5% glycerol, 0.1% Triton X-100) supplemented with Protease Inhibitor Cocktail (Roche). T7-driven sgRNA was in vitro transcribed using custom oligos (Example 10) and HiScribe T7 In Vitro Transcription Kit (NEB), following the manufacturer's recommended protocol. To prepare methylated target sites, pUC19 plasmid was methylated by M.SssI and then linearized by Nhel. The in vitro cleavage assay was performed as follows: for a 20 uL cleavage reaction, 10 uL of cell lysate with incubated with 2 uL cleavage buffer (100 mM HEPES, 500 mM KC1, 25 mM
MgC12, 5 mM DTT, 25% glycerol), the in vitro transcribed RNA, and 300 ng pUC 19 plasmid DNA.
[00402 S Deep sequencing to assess targeting specificity
[00403] HEK 293 FT ceils plated in 96-well plates were transacted with Cas9 piasmid DNA and single guide RNA (sgRNA ) PCR cassette 72 hours prior to genomic DNA extraction (Fig, 72). The genomic region flanking the CRISPR target site for each gene was amplified (Fig. 74, Fig. 80, (Example 1 0) by a fusion PCR method to attach the lihimina P5 adapters as well as tmique sample-specific barcodes to the target amplicons (schematic described in Fig. 73). PCR products were purified using EconoSpin 96-weil Filter Plates (Epoch Life Sciences) following the manufacturer's recommended protocol.
[0Θ404] Barcoded and purified DNA samples were quantified by Quant-iT PicoGreen. dsDNA. Assay Kit or Qiibit 2.0 Fluorometer (Life Technologies) and pooled in an eqnimolar ratio. Sequencing libraries were then deep sequenced with the Alumina MiSeq Personal Sequencer
(Life Technologies).
0Θ4Θ5] Sequencing data analysis and indei detection
[004061 MiSeq reads were filtered by requiring an average Phred quality (Q score) of at least 23, as well as perfect sequence matches to barcodes and am licon forward primers. Reads from on- and off-target loci were analyzed by first performing Smith- Waterman alignments against amplicon sequences that included 50 nucleotides upstream and downstream of the target site (a total of 120 bp). Alignments, meanwhile, were analyzed for indels from 5 nucleotides upstream to 5 nucleotides downstream of the target site (a total of 30 bp). Analyzed target regions were discarded if part of their alignment fell outside the MiSeq read itself, or if matched base-pairs comprised less than 85% of their total length.
0Θ4Θ7] Negative controls for each sample provided a gauge for the inclusion or exclusion of indels as putative cutting events. For each sample, an indei was counted only if its quality score exceeded ~ σ, where was the mea quality-score of the negative control corresponding to that sample and σ was the standard deviation of same. This yielded whole target-region indei rates for both negative controls and their corresponding samples. Using the negative control's per-target-region-per-read error rate, *¾', the sample's observed indei count , and its read-count a maximum-likelihood estimate for the fraction of reads having target -regions with true- indels, . was derived by applying a binomial error model, as follows.
[00408] Letting the (unknown) number of reads in a sample having target regions incorrectly counted as having at least 1 indel be we can write (without making any assumptions about the number of true indels}
FtoHElp) = i ~ p) ) qs(l -^Ci-*}-*
a
[004091 since i?(i - pj s the number of reads having target-regions with no true indels. Meanwhile, because the number of reads observed to have indels is n, n = β + in other words the number of reads having target-regions with errors but no true indels plus the number of reads whose target-regions correctly have indels. We can then re-write the above
i!p) = Prc C n = E + Rp\p) = | R ~ ¾ ¾~^ί1 - Q}S~*
[00410] Taking all values of the frequency of target-regions with true-indels P to be equally probable a priori, ¾"°Κ¾ρ.) Λ Pre y?|?-.)_ xhe maximum-likelihood estimate (MLE) for the frequency of target regions with true-indels was therefore set as the value of P that maximized ^ot> niP}. This was evaluated numerically.
[00411] In order to place error bounds on the true-indel read frequencies in the sequencing libraries themselves, Wilson score intervals (2) were calculated for each sample, given the MLE- estimate for true-indel target-regions, and the number of reads Explicitly, the lower bound !- and upper bound ¾; were calculated as " -2 . \
I = i Rp + - z^Rpil - p) +■ z2/4 l/(R + z2)
[00412] where z, the standard score for the confidence required in normal distribution of variance 1 , was set to 1.96, meaning a confidence of 95%. The maximum upper bounds and minimum lower bounds for each biological replicate are listed in Figs. 80-83.
[00413 qRT-PCR analysis of relative Cas9 and sgR A expression
[00414] 293FT cells plated in 24- well plates were transfected as described above. 72 hours post-transfection, total RNA was harvested with miRNeasy Micro Kit (Qiageu). Reverse-strand synthesis for sgR As was performed with qScript Flex cDNA kit (V WR) and custom first-
strand synthesis primers (Tables J and ). qPCR analysis was performed with Fast SYBR Green Master Mix (Life Technologies) and custom primers (Tables J and K), using GAPDH as an endogenous control. Relative quantification was calculated by the AACT method.
[00415] Table I | Target site sequences. Tested target sites for S. pyogenes type II CRISP R system with the requisite PAM. Cells were transfected with Cas9 and either crRNA-tracrRNA or chimeric sgRNA for each target.
SURVEYOR assay
primer name genomic target primer sequence (5" to 3')
Sp-EMXl-Fl EMX! AAAACCACCCTTCTCTCTGGC
Sp-EMXl -Rl EMX! GGAGATTGGAGACACGGAGAG
Sp-EMX1-F2 EMX1 CCATCCCCTTCTGTGAATGT
Sp-EMX1-R2 EMX1 GGAGATTGGAGACACGGAGA
Sp-PVALB-F PVALB CTGGAAAGCCAATGCCTGAC
Sp-PVALB-R PVALB GGCAGCAAACTCCTTGTCCT
qRT-PCR for Cas9 and sgRNA expression
Bisulfite PCR and sequencing
Table K | Sequences for primers to test sgRNA architecture. Primers hybridize to the reverse strand of the U6 promoter unless otherwise indicated. The U6 priming site is in italics, the guide sequence is indicated as a stretch of Ns, the direct repeat sequence is highlighted in bold, and the tracrRNA sequence underlined. The secondary structure of each sgRNA architecture is shown in Fig. 43.
primer name primer sequence (5' to 3')
U6-Forward GCCTCTAG4 GGTA CCTGA GGGCCTA TTTCCCA TGA TTCC
ACCTCTAGAAAAAAAGCACCGACTCGGTGCCACTTTTTCAAGT
I: sgRNAfDR +12, TGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCT tracrRNA +85) AAAACNNNNNNNNNNNNNNNNNNNN GGTGTTTCGTCCTTTCC
AC A AG
ACCTCTAGAAAAAAAGCACCGACTCGGTGCCACTTTTTCAAGT
II: sgRNA(DR +12,
TGATAACGGACTAGCCTTATATTAACTTGCTATTTCTAGCTCT
tracrRNA +85)
AATAC N N N NN GCrGr7T GJ' CZ7T C4 mut2
CAAG
ACCTCTAGAAAAAAAGCACCGACTCGGTGCCACTTTTTCAAGT
111: sgRNAfDR +22, TGATAACGGACTAGCCTTATTTTAACTTGCTATGCTGTTTTGTT tracrRNA +85) TCC A A A A C A GC A T AGC TC T A A A A C NNNNNNNNNNNN
NNNNGGTGTTTCGTCCTTTCCA CAA G
ACCTCTAGAAAAAAAGCACCGACTCGGTGCCACTTTTTCAAGT
IV: sgRNA(DR
TGATAACGGACTAGCCTTATATTAACTTGCTATGCTGTATTGT
+22, tracrRNA +85)
TTCC A AT A C A GC A TAG C TC T A A T ACNNNNNNNNNN N N N
mut
NNNNGGTGTTTCGTCCTTTCCA CAA G
[004181 Table L j Ί ¾rget sites with alternate PAMs for testing PAM specificity of Cas9. All target sites for P jcificity testing are found within the human EMX1 locus.
Target site sequence (5' to 3') PAM
AGGCCCCAGTGGCTGCTCT NAA
ACATCAACCGGTGGCGCAT NAT
AAGGTGTGGTTCCAGAACC NAC
CC A C AC ATC A ACCGGTG G NAG
AAACGGCAGAAGCTGGAGG NTA
GGCAGAAGCTGGAGGAGGA NTT
GGTGTGGTTCCAGAACCGG NTC
AACCGGAGGACAAAGTACA NTG
TTCCAGAACCGGAGGACAA NCA
GTGTGGTTCCAGAACCGGA NCT
TCCAGAACCGGAGGACAAA NCC
C AG AAGCTG G AGG AG G A AG NCG
CATCAACCGGTGGCGCATT NGA
GCAGAAGCTGGAGGAGGAA NGT
CCTCCCTCCCTGGCCCAGG NGC
TCATCTC rGcccc:nx:x;:c:Tc: NAA
GGGAGGACATCGATGTCAC NAT
CAAACGGCAGAAGCTGGAG NAC
G GG TGG GC A AC C AC A A AC C NAG
GGTGGGCAACCACAAACCC NTA
GGCTCCCATCACATCAACC NTT
GAAGGGCCTGAGTCCGAGC NTC
CAACCGGTGGCGCATTGCC NTG
AGGAGGAAGGGCCTGAGTC NCA
AGCTG G A GG AG G A AG GG C C NCT
GCATTGCCACGAAGCAGGC NCC
ATTGCCACGAAGCAGGCCA NCG
AGAACCGGAGGACAAAGTA NGA
TCAACCGGTGGCGCATTGC NGT
G AAGCTG G AGG AGG AAGGG NGC
Example 10: Supplementary Sequences
[00419] All sequences are in the 5' to 3' direction. For U6 transcription, the string of underlined Ts serve as the transcriptional terminator.
[00420] > U6-short tracrRNA {Streptococcus pyogenes SF370)
[00421 ] gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaa cacaaagatattagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgc ttaccgtaacttgaaagtatttcgatttcttggctttatatatcttgtggaaaggacgaaacaccGGAACCATTCAAAACAGC ATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGA
GTC GGTGCTTTTTTT
[CI0422] (tracrRNA sequence in bold)
[00423] >U6-DR-guide sequence-DR (Streptococcus pyogenes SF370)
[00424] gagggcc ttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaa cacaaagatattagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgc ttaccgtaacttgaaagtatttcgatttcttggcttta^
aaaacNNNNNNNNNNNNNNNNNN
TTTTTT
[00425] (direct repeat sequence is highlighted in gray and the guide sequence is in bold Ns) [00426] > sgRNA containing +48 tracrRNA (Streptococcus pyogenes SF370)
[00427] gagggcctatitcccatgaticcticatatttgcatatacgatacaaggctgiiagagagataaitggaattaattigactgtaaa eacaaagatattagtaeaaaatacgtgaegtagaaagtaat
ttaccgtaactigaaagtaittcgatttcttggctitatatatcttgtggaaaggacgaaacaccNNNNNNNNNNN N N N
N gtit agagctagaaaiagcaagtiaaaataaggctagiccg TXXTTr
[00428] (guide sequence is in bold s and the traerRNA fragment is in bold)
[00429] > sgRNA containing +54 traerRNA (Streptococcus pyogenes SF370)
[00430] gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaa cacaaagatattagiacaaaatacgtgacgtagaaagtaataaittcitgggtagtttgcagttttaaaattatgttitaaaa
ttaccgtaacttgaaagtatttcgaiitciiggctttataiatciigt
NN¾ t†tag¾gct¾gaaatagcaagttaaaataaggctagtccgttatcaTTTTTTTT
[00431] (guide sequence is in bold Ns and the traerRNA fragment is in bold)
[004321 > sgRNA containing +67 traerRNA (Streptococcus pyogenes SF370)
[00433] gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaa cacaaagatattagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgc ttaccgtaacttgaaagtatttcgatttcttggctttatatatcttg ggaaaggacgaaacaccNNNNNNNNNNNNNNNNNN
NNg†ti¼ ¾¾c ¾gaaatagcaagttaaaataaggrt^
[ 00434] (guide sequence is in bold Ns and the traerRNA fragment is in bold)
[00435] > sgRNA containing +85 traerRNA (Streptococcus pyogenes SF370)
[00436] gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaa cacaaagatattagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgca
ttaccgtaacttgaaagtatttcgatttcttggctttatatatcttgtggaaaggacgaaacaccNNNNNNNNNNNNNNNNNN NNgt tagag agaaatageaagttaaaataaggctagtccgttatcaacttgaaaaagtggcacegagtcggtgeTTTTTT
I
[00437] (guide sequence is in bold Ns and the traerRNA fragment is in bold)
[00438] > CBh-NLS-SpCas9-NLS
[00439] CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACC
CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTT TCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATC AAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG
('( 1 ( ;G( ΛΎΤΛΊ Gi C '( 'AC Π'Α( ATGAC ΊΎΛΊ G< XsACTTTC '<Ί Λί ΊΊ ( ;G( AGTACATi TA CGTATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTC
CCCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTG
TGCAGCGATGGGGGCGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGG
GGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCG
GCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAA
Λ Λ( 'ί j ΛΛ(.ίί C s< X s( XX J( '( s< sC XX iGAGTCC J( " 1 Gi AC XX 1 ( ·( '( " 1 ' !'( '( i( C '( '( ϊ IX iC '( (
GCTCCGCCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCAC
Λ( s'l'C ! .\C iC X sOi ·( X J GA. C X SC 'i ( ' Ί'ί Ί'ί ( '!'( C 'Gi -Gi \ i iYAATJAGi JdAi ; < 7\A. GA. GC )
TAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCAC
CTGCCTGAAATCACTTTTTTTCAGGTTGGaccggtgccaccATGGACTATAAGGACCACG
ACGGAGACTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATG
GCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGACAA
GAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA
TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACC
GACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGG
C G A AAC AGC C G AGGC C AC C€ GGC TG A AGAG AAC C GC C AG AAG AAG AT AC AC C A
GACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCC
AAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGA
GGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGG
CCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGAC
AGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGAT
CAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCG
ACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAG
GAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAG
AC TGAGC AAG AGC AGAC GGC TGG A AA ATC TG ATC GC C C AGC TGC C C GGC GAGA
AGAAGAATGGCCTGTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGACCCCC
AACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAA
GGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGT
ACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGC
G AC ATC C TG AG AGTG A AC AC C GAG ATC AC C A AGGC C C C C C TGAGC GC C TC TAT
GATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCG
TGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAG
AACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAA
GTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGA
AGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAG
CATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGG
AAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTG
ACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATT
C GC C TGG ATG AC C AGA A AG A GC GAG G A A A C CATC AC C C C C TG G A AC TTC G A GG
AAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAAC
TTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTA
CGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGG
G AATG AG AAAGC CCGCCTTCC TG AGC G G C G AGC AG AAAAAG G C CATC G TG G AC
CTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTA
CTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATC
GGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGAC
AAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCT
GACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCT
ATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATAC
ACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGC
AGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGA
AACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCA
GAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATC
TGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTG
GACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGA
AATGGC C AGA GAG A AC C AGA C C AC C C AG AAGGGAC AG AAG A AC AGC C GC GAG
AG AATGAAG C GG ATC GAAG AGGGC ATC AAAG AG C TGGGC AG C C AG ATC C TG AA
AGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACT
ACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGG
CTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGA
CTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCG
AC A AC GTGC C C TC C GAAG AG G TC GTG A AG A A G ATG A AG A AC T AC TGGC G GC AG
CTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGC
CGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAG
CTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCG
GATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGA
TCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACA
AAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCC
GTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGT
GTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGC
AGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACT
TTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTG
ATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATT
TTGCCACCGTGCGGAA.4GTGCTGAGCATGCCCCA.4GTGAilTATCGTGAAii.4iiG
ACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAA
CAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCG
GCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAA
AAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCAT
CATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGG
GCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTG
TTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCA
GAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGG
CCAGCCACTATGAGii,4GCTGAAGGGCTCCCCCGAGGATAATGAGCAGAA.4CAG
CTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAG
CGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGT
C C GC C T AC A A C A AG C AC C GGGAT AAG C C CATC A GAG AG C AG GC C GAG A AT ATC
ATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTT
G AC AC C AC CATC G AC C GGAAG AGGT AC AC C AGC AC C AAAG AGG TG C TGGAC GC
CACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGT
CTCAGCTGGGAGGCGACTTTCTTTTTCTTAGCTTGACCAGCTTTCTTAGTAGCA
GCAGGACGCTTTAA
[00440] (NLS-hSpCas9- LS is liigliliglited in bold)
[00441 J > Sequencing aniplicon tor EMXl guides 1.1, 1.14, 1.17
[00442] CCAATGGGGAGGACATCGATGTCACCTCCAATGACTAGGGTGGGCAACC ACAAACCCACGAGGGCAGAGTGCTGCTTGCTGCTGGCCAGGCCCCTGCGTGGGCCC AAGCTGGACTCTGGCCAC
[00443] > Sequencing amplicon for EMXl guides 1 ,2, 1.16
ACGAAGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAGGGTGGGCA
ACCACAAACCCACGAG
[00445] > Sequencing amplicon for EMXl guides 1 ,3, 1 , 13, 1 , 15
[00446] GGAGGACAAAGTACAAACGGCAGAAGCTGGAGGAGGAAGGGCCTGAGTC
CGAGCAGAAGAAGAAGGGCTCCCATCACATCAACCGGTGGCGCATTGCCACGAAGC AGGCCAATGGGGAGGACATCGAT
[00447] > Sequencing amplicon for EMX l guides 1 .6
[00448] AGAAGCTGGAGGAGGAAGGGCCTGAGTCCGAGCAGAAGAAGAAGGGCTC C X 'ΛΤ( ACATC A AC X XX ΠΧΧ ·( 'GC 'ΛΊ ΊΧΧ ( A( '( - AAGi AGC sC X Λ ΛΊ ( ;G( ; AGG Ai ATCG ATGTCACCTCCAATGACTAGGGTGG
[00449] > Sequencing amplicon for EM X l guides 1 .10
[00450] CCTCAGTCTTCCCATCAGGCTCTCAGCTCAGCCTGAGTGTTGAGGCCCCAG TGGCTGCTCTGGGGGCCTCCTGAGTTTCTCATCTGTGCCCCTCCCTCCCTGGCCCAGG TGAAGGTGTGGTTCCA
[00451] > Sequencing amplicon for EMX 1 guides 1.1 1 , 1 .12
[00452] Ί CATC ΊΧ Π€X C X Χ Ί ( X X Ί ( ί ( TC sGi X X 'AC sGTG AAGi JTG'I GC ΠΊΧ X 'A AAC X GGAGGACAAAGTACAAACGGCAGAAGCTGGAGGAGGAAGGGCCTGAGTCCGAGCA
GAAGAAGAAGGGCTCCCATCACA
[00453] > Sequencing amplicon for EMXl guides 1.18, 1.19
[00454] CTCCAATGACTAGGGTGGGCAACCACAAACCCACGAGGGCAGAGTGCTG CTTGCTGCTGGCCAGGCCCCTGCGTGGGCCCAAGCTGGACTCTGGCCACTCCCTGGC CAGGCTTTGGGGAGGCCTGGAGT
[00455] > Sequencing amplicon for EMXl guides 1.20
[00456] CTGCTTGCTGCTGGCCAGGCCCCTGCGTGGGCCCAAGCTGGACTCTGGCC AC ΊΧ Χ Χ Ί GC sCCA.Gi ΊΎΤί J€X JGA.CX J< X "! GC Ϊ AC Π CATC X C X' X 'AC 'Λί JCX JCTTC Ϊ AAGC ' CCGGGGCCGCCATTGACAGAG
[00457] >T7 promoter F primer for annealing with target strand
[00458] GAAATTAATACGACTCACTATAGGG
[00459] >oiigo containing pUC19 target site 1 for methyl ation (T7 reverse)
[00460] AAAAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCC
ΊΎΛΤΤΠ ΛΛΓΊ TGi 'ΤΛ'ΠΎί 'TAGC Ί'ί 'ΤΛΛΛΛί ΛΛ( 'GAC 'GA.Gi ( Π GA.CAC '('Λ( '( ΧΊ'ΛΤ
AGTGAGTCGTATTAATTTC
[00461] >oiigo containing pUC19 target site 2 for methySation (T7 reverse)
[00462] AAAAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCC
TTATTTTAACTTGCTATTTCTAGCTCTAAAACGCAACAATTAATAGACTGGACCTATA
GTGAGTCGTATTAATTTC
Example 11: Oligo-mediated Cas9-induced Homologous Recombination
[00463] The oiigo homologous recombination test is a comparison of efficiency across different Cas9 variants and different HR template (oligo vs. plasmid).
[00464] 293FT cells were used. SpCas9 = Wildtype Cas9 and SpCas9n = nickase Cas9 (DIOA). The chimeric RNA target is the same EMXI Protospacer Target 1 as in Examples 5, 9 and 10 and oligos synthesized by IDT using PAGE purification.
[00465] Figure 44 depicts a design of the oligo DNA used as Homologous Recombination (HR) template in this experiment. Long oligos contain lOOhp homology to the EMXI locus and a Hindlll restriction site. 293 FT cells were co-transfected with: first, a plasmid containing a chimeric RNA targeting human EMXI locus and wild-type cas9 protein, and second, the oligo DNA as HR template. Samples are from 293FT cells collected 96 hours post transfection with Lipofectamine 2000. Al l products were amplified with an EMXI HR Primer, gel purified, followed by digestion with Hind III to detect the efficiency of integration of HR template into the human genome.
[00466] Figures 45 and 46 depict a comparison of HR efficiency induced by different combination of Cas9 protein and HR template. The Cas9 construct used were either wild-type Cas9 or the nickase version of Cas9 (Cas9n). The HR template used were: antisense oligo DNA (Antisense-Oligo in above figure), or sense oligo DNA (Sense-Oligo in above figure), or plasmid FIR template (HR template in above figure). The sense/anti -sense definition is that the actively- transcribed strand with sequence corresponding to the transcribed mRNA is defined as the sense
strand of genome. HR Efficiency is shown as percentage of Hindi!! digestion hand as against all genomic PGR. amplified product (bottom numbers).
Example 12: Autistic Mouse
[00467] Recent large-scale sequencing initiatives have produced a large number of genes associated with disease. Discovering the genes is only the beginning in understanding what the gene does and how it leads to a diseased phenotype. Current technologies and approaches to study candidate genes are slow and laborious. The gold standards, gene targeting and genetic knockouts, require a significant investment in time and resources, both monetary and in terms of research personnel. Applicants set out to utilize the hSpCas9 nuclease to target many genes and do so with higher efficiency and lower turnaround compared to any other technology. Because of the high efficiency of hSpCas9 Applicants can do RNA injection into mouse zygotes and immediately get genome-modified animals without the need to do any preliminary gene targeting in mESCs.
[00468] Chromodomain heiicase DNA binding protein 8 (CHD8) is a pivotal gene in involved in early "vertebrate development and morphogenesis. Mice lacking CHD8 die during embryonic development. Mutations in the CHD8 gene have been associated with autism spectrum disorder in humans. This association was made in three different papers published simultaneously in Nature. The same three studies identified a plethora of genes associated with autism spectrum disorder. Applicants' aim was to create knockout mice for the four genes that were found in all papers, Chd8, atnal2, Kctdl 3, and Scn2a. In addition, Applicants chose two other genes associated with autism spectrum disorder, schizophrenia, and ADHD, GITL CACNAIC, and CACNB2. And finally, as a positive control Applicants decide to target MeCP2,
[00469] For each gene Applicants designed three gRNAs that would likely knockout the gene. A knockout would occur after the hSpCas9 nuclease makes a double strand break and the error prone DNA repair pathway, non-homologous end joining, corrects the break, creating a mutation. The most likely result is a frameshift mutation that would knockout the gene. The targeting strategy involved finding proto-spacers in the exons of the gene that had a PAM sequence, NGG, and was unique in the genome. Preference was given to proto-spacers in the first exon, which would be most deleterious to the gene.
[00470] Each gRNA was validated in the mouse cell line, Neuro-N2a, by liposomal transient eo-transfeetion with hSpCas9. 72 hours post-transfection genomic DNA was purified using QuickExtraet DNA from Epicentre. PGR was performed to amplify the locus of interest. Subsequently the SURVEYOR Mutation Detection Kit from Transgenomics was followed. The SURVEYOR results for each gRNA and respective controls are shown in Figure Al , A positive SURVEYOR result is one large band corresponding to the genomic PGR and two smaller bands that are the product of the SURVEYOR, nuclease making a double-strand break at the site of a mutation. The average cutting efficiency of each gRNA was also determined for each gRNA, The gRNA that, was chosen for injection was the highest efficiency gRNA that was the most unique within the genome.
[00471] RNA (hSpCas9+gRNA RNA) was injected into the pronucleus of a zygote and later transplanted into a foster mother. Mothers were allowed to go full term and pups were sampled by tail snip 10 days postnatal, DNA was extracted and used as a template for PGR, which was then processed by SURVEYOR. Additionally, PGR products were sent, for sequencing. Animals that were detected as being positive in either the SURVEYOR assay or PGR sequencing would have their genomic PGR products cloned into a pUC19 vector and sequenced to determine putative mutations from each allele.
[00472] So far, mice pups from the Chd8 targeting experiment, have been fully processed up to the point of allele sequencing. The Surveyor results for 38 live pups (lanes 1-38) 1 dead pup (lane 39) and 1 wild-type pup for comparison (lane 40) are shown, in Figure A2. Pups 1-19 were injected with gRNA Chd8.2 and pups 20-38 were injected with gRNA Chd8.3. Of the 38 live pups, 13 were positive for a mutation. The one dead pup also had a mutation. There was no mutation detected in the wild-type sample. Genomic PGR. sequencing was consistent, with the SURVEYOR assay findings.
Example 13: CRISPR/Cas-Mediated Transcriptional Modulation
[00473] Figure 67 depicts a design of the CRISPR-TF (Transcription Factor) with transcriptional activation activity. The chimeric RNA is expressed by U6 promoter, while a human-codon-optimized, double-mutant version of the Cas9 protein (hSpCas9m), operably linked to triple NLS and a VP64 functional domain is expressed by a EFla promoter. The double
mutations, D10A and H840A, renders the cas9 protein unable to introduce any cleavage but maintained its capacity to bind to target DNA when guided by the chimeric R.NA.
[00474] Figure 68 depicts transcriptional activation of the human SOX2 gene with CRISPR- TF system (Chimeric RNA and the Cas9-NLS-VP64 fusion protein). 293FT cells were transfected with plasmids bearing two components: (1) U6-driven different chimeric RNAs targeting 20-bp sequences within or around the human SOX2 genomic locus, and (2) EF la- driven hSpCas9m (double mutant)- LS-VP64 fusion protein. 96 hours post transfection, 293FT ceils were harvested and the level of activation is measured by the induction of mRNA expression using a qRT-PCR assay. All expression levels are normalized against the control group (grey bar), which represents results from cells transfected with the CRISPR-TF backbone plasmid without chimeric RNA. The qRT-PCR. probes used for detecting the SOX 2 mRNA is Taqman Human Gene Expression Assay (Life Technologies). Ail experiments represents data from 3 biological replicates, n=3, error bars show s.e.m.
Example 14: NLS: Cas9 NLS
[00475] 293FT cells were transfected with plasmid containing two components: (1.) EFla promoter driving the expression of Cas9 (wild-type human-codon-optimized Sp Cas9) with different NLS designs (2) U6 promoter driving the same chimeric RNA targeting human EMX! locus.
[00476] Cel ls were collect at 72b. time point post transfection, and then extracted with 50 μΐ of the QuickExtraet genomic DNA extraction solution following manufacturer's protocol. Target EMX1 genomic DNA were PGR amplified and then Gel-purify with 1% agarose gel. Genomic PGR product were re-anneal and subjected to the Surveyor assay following manufacturer's protocol. The genomic cleavage efficiency of different constructs were measured using SDS- PAGE on a 4-12% TBE-PA.GE gel (Life Technologies), analyzed and quantified with Image Lab (Bio-rad) software, all following manufacturer's protocol.
[00477] Figure 69 depicts a design of different Cas9 NLS constructs. All Cas9 were the human-codon-optimized version of the Sp Cas9. NLS sequences are linked to the cas9 gene at either N-terminus or C-terminus. All Cas9 variants with different NLS designs were cloned into a backbone vector containing so it is driven by EFla promoter. On the same vector there is a
chimeric RNA targeting human EMXl locus driven by U6 promoter, together forming a two- component system,
[0Θ478] Table M. Cas9 NLS Design Test Results. Quantification of genomic cleavage of different cas9~nls constructs by surveyor assay.
[00479] Figure 70 depicts the efficiency of genomic cleavage induced by Cas9 variants bearing different NLS designs. The percentage indicate the portion of human EMXl genomic DNA that were cleaved by each construct. All experiments are from 3 biological replicates, n = 3, error indicates S.E.M,
Example 15: Engineering of Microalgae using Cas9
[00480] Methods of delivering Cas9
[00481] Method I : Applicants deliver Cas9 and guide RNA using a vector that expresses Cas9 under the control of a constitutive promoter such as Hsp70A-Rbc S2 or Beta2-tubulin.
[00482] Method 2: Applicants deliver Cas9 and T7 polymerase using vectors that expresses Cas9 and T7 polymerase under the control of a constitutive promoter such as Hsp70A-Rbc S2 or
Beta2 -tubulin. Guide RNA will be delivered using a vector containing T7 promoter driving the guide RNA.
[00483] Method 3: Applicants deliver Cas9 mRNA and in vitro transcribed guide RNA to algae cells. RNA can be in vitro transcribed. Cas9 mRNA will consist of the coding region for Cas9 as well as 3'UTR from Co l to ensure stabilization of the Cas9 mRNA.
[00484] For Homologous recombination. Applicants provide an additio al homology directed repair template.
[00485] Sequence for a cassette driving the expression of Cas9 under the control of beta-2 tubulin promoter, followed by the 3' UTR. of Cop i .
[00486] TCTTTCTTGCGCTATGACACTTCCAGCAAAAGGTAGGGCGGGCTGCGAGA CGGCTTCCCGGCGCTGCATGCAACACCGATGATGCTTCGACCCCCCGAAGCTCCTTC GGGGCTGCATGGGCGCTCCGATGCCGCTCCAGGGCGAGCGCTGTTTAAATAGCCAG
GCCCCCGATTGCAAAGACATTATAGCGAGCTACCAAAGCCATATTCAAACACCTAG
ΛΊ (Α( Ί·Λ( '( Λ(Ί Γ( Ί \( Λ(Α( ΧΑ( ΊΧ ( ;Λ( ΊΊ ΟΊ ί · ΛΊ ( '( Α( ΊΪ ( X l AAi iGi iGi ;
CGCCTCTTCCTCTTCGTTTCAGTCACAACCCGCAAACATGTACCCATACGATGTTCCA
GATTACGCrrTCGCCGAAGAAAAAGCGCAAGGTCGAAGCGTCCGACAAGAAGTACAG
CATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGT
ACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATC
AAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCGAGGCCAC
CCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGC
Ί Λ'1'( '!'( ·( \\Λ( ίΛ( ίΛ'Γ( ' ΓΊ'( \ ί ·( \\Λ(Χ ίΛ( ίΛ
AGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCAT
C "!"!'( ( sC 'ΛΛ( 'ΛΊ'ί C ΠΧΧ J A( GAC sGTi JG( C TACX ACGAGA AC Π Λί C '('('Λ( "('ΛΊ'ί 'I'A.CC
ACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTAT
CTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTG
AACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAA
CCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCC
TGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCC
GGCGAGAAGAAGAATGGCCTGTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGAC
( ( ( C 'ΛΛ( " Π'( 'ΛΛ(.ίΛ(.ίί A. AC 'ΓΊ'ί C !.\( C "I'i li■( '(X iA iC iA'l'i JC X 'AA AC TG( AGi TGAi JCA
AGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTAC
GCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATC CTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAG
ATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGC
TGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGC
ΤΛΓΑ'Π ( C )G( ίΛί ·( '('AC XX AGGAAGAGTTC"! AC 'AAGTTCATC Λ AC X ( ί ΛΊ ('( "!
GGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTG
( Ί GC XX jAAGi AGC X ·Λ( ί 'Π ( ί ;Λί A. AC X ·( 'Λί ΧΆΤί X 'C XX AC X'AC ϊ ΑΤί X V\( X ΊΧ XX )
AGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAA
CCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCT
GGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATC
ACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCAT
CGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGC
ACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATAC
C r rGAC X 'i i Ai X i AA FGAGAAAGi C ( XX C ΊΊ ( C -rC i AC iC X iC X i i Ai iC-AC iAAAAAC X iC -A
TCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAG
GACTAC "ΠΧ Λ AC ) ΑΛ ΑΛΊ (X sAi ·Τ( X 'TTCGAC! (X ί ΠΧΧ - AAA'! ("! (X ί XX X ΠΧΧ J AAGAT
CGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAA
GGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCC
TGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCAC
CTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGG
CAGGCriXiAGCCGGAAG(TrGATCAA(XiGCATCCGGGACAAGCAGTCCGGCAAGACA
ATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATC
C V\{ C sAC G AC 'Λί XX"! GACX "ΠΊΆΛ AG AC JGACATC X VXGAAAi XXX AX JTC Π < X X XX X A
GGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGA
AGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGG
CACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGA
AGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGA
GCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACG
AGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAA
ΓΊ GGAC \\1 ( 'ΛΛί Χ C X 1X H CX 'G
CTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGG
GCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGG
CGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAA
GGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAG
CTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGAT
GAA(LACTAAGTACGACGAGAATGACAAG(7rGAT(XXiGGAAGTGAAAGTGATCACCC
TGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCG
AC Ϊ ATC Λ AC 'ΛΛΓΎΛί C 'Λ( X Λ( X ·( '('('AC XiACXsC '( ΎΛ( X TGAAC C '( Χ.Π X X JTG( ;G A A( X
GCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAA
GGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCT
ACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACC
CTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGG
GGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCA
TGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAA
GACH <Ί ΛΊ X X TGCXX AA ACX^
GGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGT
GGTGGCX^AAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTG
CTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCT
GGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGT
ACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAA
CTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTG
(!CXACi(X'A(l Vr(!A(!AAG('l(!AAC : ΊΧ X ΧΧΧίΛ( ;ΑΊΑΛΊΧ!Λί \\ί;ΛΛΛί Λ( Ί^
GTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGT
ΊΧ ΊΧ C Cί C}ΛC}Ί ίΛΊ (Χ Ί sCX X CsAC (X Ί'ΑΑΊ ("Ί !ΛC ΛίΠ X Ί ίΊΧ CX}iX 'I'AC'A
ACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTT
ACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGAC
CGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAG
CATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAGCC
CCAAGAAGAAGAGAAAGGTGGAGGCCAGCTAAGGATCCGGCAAGACTGGCCCCGC
TTGGCAACGCAACAGTGAGCCCCTCCCTAGTGTGTTTGGGGATGTGACTATGTATTC
(ίΊΧ' sTGT l GGCX'A ( sGC HX'AACX X C sAACA ΑΊΊΧ JATAC XXX ·( ΧΊ TGi ·( 'ΛΤ'ΠΧΧΊ GT
CAGAATGTAACGTCAGTTGATGGTACT
[00487] Sequence for a cassette driving the expression of T7 polymerase under the control of beta-2 tubulin promoter, followed by the 3 ' UTR of Copl :
[004881 TCTTTCTTGCGCTATGACACTTCCAGCAAAAGGTAGGGCGGGCTGCGAGA CGGCTTCCCGGCGCTGCATGCAACACCGATGATGCTTCGACCCCCCGAAGCTCCTTC
GGGGCTGC TGGGCGCrCCGArGCCGCTCCAGGGCGAGCGC rrrAA^TAGCCAG GCCCCCGATTGCAAAGACATTATAGCGAGCTACCAAAGCCATATTCAAACACCTAG ΛΊ'( Λ( "! Λ( Χ 'Λ( '!"!'( Ί Λ( 'Λ( Λ( ί( )( 'ί Λ(Ί ('( ίΛ( ί( "!"!'( !'Γ(ίΛ'Γ( X ACTCCGCTAAGGGGG CGCCTCTTCCTCTTCGTTTCAGTCACAACCCGCAAACatgcctaagaagaagaggaaggttaacacgatt aaeaicgctaagaaegacttcictgacatega
cagttggcccttgageatgagteitaegagatgggtgaagcacgcttccgcaagaigtttgagcgicaacttaaagctggtgaggttgcggat aacgctgccgccaagcctctcatcactaccctactccctaagatgattgcacgcatcaacgactggtttgaggaagtgaaagctaag gcaagcgcccgacagccttccagticctgcaagaaatcaagccggaagccgtagcgtacatcaccattaagaceacteiggcttgcctaae cagtgctgacaatacaaccgttcaggctgtagcaagcgcaatcggtcgggccattgaggacgaggctcgcttcggtcgtatccgtgacctt gaagctaagcacttcaagaaaaacgttgaggaacaactcaacaagcgcgtagggcacgtctacaagaaagcatttatgcaagttgtcgag gctgacatgctctctaagggtctactcggtggcgaggcgtggtcttcgtggcataaggaagactctattcatgtaggagtacgctgcatcgag atgctcattgagtcaaccggaatggttagcttacaccgccaaaatgctggcgtagtaggtcaagactctgagactatcgaactcgcacctga atacgctgaggctatcgcaacccgtgcaggtgcgctggctggcatctctccgatgttccaaccttgcgtagttcctcctaagccgtggactgg cattactggtggtggctattgggctaacggtcgtcgtcctctggcgctggtgcgiactcacagtaagaaagcact
ittacatgcctgaggtgtacaaagcgaitaacattgegcaaaacacegeatggaaaatcaacaagaaagtcctagcggtcgccaacgtaatc accaagtggaagcattgtccggtcgaggacatccctgcgat¾^
gaggctctcaccgcgtggaaacgtgctgccgctgctgtgtaccgcaaggacaaggctcgcaagtctcgccgtatcagccttgagttcatgc ttgagcaagccaataagtttgctaaccataaggccatctggttcccttacaacatggactggcgcggtcgtgtttacgctgtgtca
ccgcaaggtaacgatatgaccaaaggactgcttacgctggcgaaaggtaaaccaatcggtaaggaaggttactactggctgaaaatccac ggtgcaaactgtgcgggtgtcgacaaggttc gttcc tgagcgcatcaagttcattgaggaaaaccacgagaacatcatggcttgcgctaa gtciccactggagaaeacttggtgggctgagcaagattctccgtteigcttccttgegttctgctttgagtacgctggggt.
ctgagctataactgeicccttccgeiggcgtttgacgggicttgctctggcaiccagcacttctcegcgatgctccgagatgaggtaggiggic gcgcggttaacttgettcctagtgaaaccgttcaggacatctaegggaitgttgeiaagaaagtc
atgggaccgaiaaegaagtagttaccgtgaccgatgagaacactggtgaaatctctgagaaagteaagctgggcactaaggcactggctg gtcaatggctggcttacggtgttactcgcagtgtgactaagcgttcagtcatgacgctggcttacgggtccaaagagttcggcttccgtcaac aagtgctggaagataccattcagccagctattgattccggcaagggtctgatgttcactcagccgaatcaggctgctggatacatggctaag ctgatttgggaatctgtgagcgtgacggtggtagc gcggitgaagcaatgaactggcttaagtctgctgctaagctgc ggctgctgaggtc
aaagataagaagactggagagaticttcgcaagcgtigcgctgtgcattgggtaactcctgatggtticccigigtggcaggaatacaagaa gcctattcagacgcgcttgaacctgatgttcctcggtcagttccgcttacagcctaccattaacaccaacaaagatagcgagattgatgcaca caaacaggagtctggtatcgctcctaactttgtacacagccaagacggtagccaccttcgtaagactgtagtgigggcacacgagaagtac ggaatcgaatcttttgcactgattcacgactccitcggt^acgattccggctgacgctgcgaaccigttcaaagcag
acacatatgagtcttgigatgtactggctgattictacgaccagttcgctgaccagttgcacgagtctcaattggacaaaatgccagcactf.ee ggctaaaggtaacttgaacctccgtgacatcttagagtcggacttcgcgttcgcgtaaGGATCCGGCAAGACTGGCCCC
GC llX iGC A AC XX A AC \\GTGAC X '( C Χ ΊΧ 'CCTA TG'i GTFi G G ATGTGACTATGTAT
TCGTGTGTTGGCCAACGGGTCAACCCGAACAGATTGATACCCGCCTTGGCATTTCCT
GTCAGAATGTAACGTCAGTTGATGGTACT
[00489] Sequence of guide R \ A driven by the T7 promoter (T7 promoter, Ns represent targeting sequence):
[004901 gaaatTAATACGACTCACTATA N N NNNNNNNNNNNNNNNgttttagagctaG
AAAtagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgcttttttt
[00491] Gene delivery:
[00492] Chlamydomonas reinhardtii strain CC-124 and CC-125 from the Chlamydomonas Resource Center will be used for electro poration. Electroporation protocol fol lows standard recommended protocol from the GeneArt Chlamydomonas Engineering kit.
[00493] Also, Applicants generate a line of Chlamydomonas reinhardtii that expresses Cas9 co stitutively. This can be done by using pChlamyl (linearized using Pwl) and selecting for hygromycm resistant colonies. Sequence for pChlamyl containing Cas9 is below. In this way to achieve gene knockout one simply needs to deliver RNA for the guideRNA. For homologous recombi ation Applicants deliver guideRNA as well as a linearized homologous recombination template.
[00494] pChlamyl -Cas9:
[00495] TGCGGTATTTCACACCGCATCAGGTGGCACTTTTCGGGGAAATGTGCGCG GAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGATT
ATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAAT CTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGC ACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTG
1 AGATAA( TACGATAi C X K J AC X K X 'T ^ ^
CGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAG
GGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTG
TTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGC
CATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCC
GGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTT
Λ( ί( 'Ί'( '("Π'( ΧΧ ΠΧ l X !A1 ( ni i n i !AAGl'AA( ni i JGi ( G( AGl i rri A-rc -Ai Ί ί
ATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTT
CmTGACTGGTGAGTACTCAACCAA(^ATTCTGMiAAJAGT(nATGCGGCGACCGA
GTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAA
AAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGC
TGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTT
TACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAA
AGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATT
ATTGAAGCATTTATCAGGGTTATTGTCTCATGACCAAAATCCCTTAACGTGAGTTTTC
( Π Γ( X'AC ΊΧ Ϊ AC X ( =' IX 'Λί jAi ( C ΧΧ.Π AGAAAAGA'iX AAAGGA'iX T! ( TTGAGATC '("Π"Γ
TTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT
ΠΧΤΠ TG( ( Χ ίΛΊ CAAGAGCTAC X Λ ΛΓΊ ΊΎΠ TrCX sA AGGTAAC TC X TIX AGC AG
AGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGTT
GCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGAT
AAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCG
AA(XiACCTACACCX5AACTGAGATAC(TrACAGCGTGAGCTATGAGAAAGCGCCACGC
TTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGG
AGAGC X ACGAGGG AGC ΠΧ X \\GGGGGAA AC G( Ί Χ7ΓΑΤ( TH'ATAGTi ( ΊΧ ΠΧ Χ ί
GGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGA
GCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGC
CTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACC
GCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTC
AGTGAGCGAGGAAGCGGTCGCTGAGGCTTGACATGATTGGTGCGTATGTTTGTATGA
AGCTACAGGACTGATTTGGCGGGCTATGAGGGCGGGGGAAGCTCTGGAAGGGCCGC
GA 1 GC XX XX sC XX < ΧΧ Ί (X AGAAGGi G( X ΛΎΛ( GGi X X XX ΊΧ ΧΧ X X X V\C C X 'ΛΊ ( G
GTATAAAAGCCCGCGACCCCGAACGGTGACCTCCACTTTCAGCGACAAACGAGCAC
TTATACATACGCGACTATTCTGCCGCTATACATAACCACTCAGCTAGCTTAAGATCC
CATCAAGCTTGCATGCCGGGCGCGCCAGAAGGAGCGCAGCCAAACCAGGATGATGT TTGATGGGGTATTTGAGCACTTGCAACCCTTATCCGGAAGCCCCCTGGCCCACAAAG GCTAGGCGCCAATGCAAGCAGTTCGCATGCAGCCCCTGGAGCGGTGCCCTCCTGAT A AACi X sGi X V\{ JC JGC sCX"! ΑΤί ΠΊΧ TTTAC ΊΊΊΊ Ί TA( AAGAGAAGTi Λ(Ί CAAC fX ' TTAAAATGGCCAGGTGAGTCGACGAGCAAGCCCGGCGGATCAGGCAGCGTGCTTGC AGATH GAC1 Ί GiXAACGiXX X ATTGI G
GTCTCAAGCAGCATCTAACCCTGCGTCGCCGTTTCCATTTGCAGGAGATTCGAGGTA CCATGTACCCATACGATGTTCCAGATTACGCTTCGCCGAAGAAAAAGCGCAAGGTC GAAGCGTCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGG CTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGG GCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGAC AGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACA CCAGACGGAAGAA( GGATC iXjCTATCTGCAAGAGAT(TrTCAGCAACGAGATGGCC AAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGA
1 Λ Λ ( ί Λ Λ C ! (' A C ' C A G ί G G C Λ ( C X X ' Λ T( Ί "! < · C A Λ ί A. T< X ί TG G A < X s A G G Ί G G < X Ί A C ' ( ' ACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGAC AAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGC CACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTT CATCCAGCTGGTGCAGACCTACAACC AGCTGTTCGAGGAAAACCCCATCAACGCCA GC XX j(X.i'l'{ JG.ACGC X ΆΑΧΚ JCX'ATC '( TGTCTGi X V\ A{ T Ai 'AAGAGC 'A Ai C sGi TC ) GAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGCAACCT GAT!iXXXTGAGCXlXXKX rrGAiXXXX AACTTC^
GGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGC TGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCG ACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCC CTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCT GAAAGCTCTCGTGCGGCAGCAGCTGCC GAGAAGTACAAAGAGATTTTCTTCGACC AGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTC Ί Λ( AACri rC'Al AACiCX'i A FCXlGCiAAAAGA FGi!Ai CiG( A( ί CiAC iAAC-l lC in- AAGC Ί ΛΛ(·Αί5Αί5Αί ίΑ( ( !GCTGC i i AiX'A C GGACX Ί TCGACAAC GG( AGC
ATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGA
TTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCG
CATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGA
CCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAA
( 'ί :ΊΊΧΧΧΚ C ACiACi(i r('Al( (;Λ(;( :: Ί ;Α( \\Λ(ΊΊ ίΛ ΓΛΛ(:ΛΛί ( 'rcic-
CCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTAT
AA(XiAGCriXjACX^AAAGTGAAATACGTGA(XXiAGGGAATGAGAAAG(X-CGCCTTCCT
GAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAA
GTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTC
CGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACG
ATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGAC
ATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGA
GGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGA
A(!CXX :XXiACiAl A(AC XXJ(-1GiXXX'A(X!(XX;A(X'i CiGAACiC-ICiA rC'AAC'iiC A FC'
CGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGC
CAACAGAAACT1XA X:xAGCTGA1XX:ACX}ACGACAG(X:nXAC:x;nXX'AAAGAGGACA
TCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAAT
CTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGA
CGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGG
CCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAA
GCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCC
GTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGG
(Χ'ίΧΧ;ΛΊ'ΑΊΧΠ \ί ΠΧΧίΛί ( A(X;: A( X iX AC'AX ΛΛ(ΧΧΧ :ΊΧ7Γ('( CiACXACXiAI G
TGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGC
TGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGT
CGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCC
AGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGAT
AAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGT
GGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGA
TCX (XXXAGTGAA GTGATi ACX { T
GATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCC
TACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAG
CGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGA
GCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATG
AACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCT
C Ϊ ATC ( ) AC ) AC 'Λ Λί C sGi G AAAC XXiC X Ϊ AC Ϊ ATC G'l GTi iGG ΑΤΑΛί ;G( ·( XX XsA TTTTC )
CCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAG
(s'l'CiCACjAC'Ai Ci iC 'ΓΊ'ί A(iC ΛΑΛί ·Λί i'l'C Ί^Γ<ΧΊ GCXXAAGAGGAAC'AGC GATAA
GCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCC
CCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAG
AAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTT
CGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGG
ACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAG
AGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTC
C ΆΛ TA'I'C sTGAAi ΊΊ ( { 1 { j'f'ACi 1 { JG( C A( ·( 'CAC TATGAGAAi ΧΊ GAAC sGC sC l < X { C CGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACG AC ) ATC ΛΊ C AGC 'AGAT( AGi C sAC s ΠΧ "f'C X'AAGAGAGT A'iX { TGGC C X ACGC ΤΛΛΤ CTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCA GGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTT CAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGC TGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGAC
AAGCTCCTTCGGGGCTGCATGGGCGCTCCGATGCCGCTCCAGGGCGAGCGCTGTTTA
AATAGCCAGGCCCCCGATTGCAAAGACATTATAGCGAGCTACCAAAGCCATATTCA
AACACCTAGATCACTACCACTTCTACACAGGCCACTCGAGCTTGTGATCGCACTCCG
CTAAGGGGGCGCCTCTTCCTCTTCGTTTCAGTCACAACCCGCAAACATGACACAAGA
ATCCCTGTTACTTCTCGACCGTATTGATTCGGATGATTCCTACGCGAGCCTGCGGAA
CGACCAGGAATTCTGGGAGGTGAGTCGACGAGCAAGCCCGGCGGATCAGGCAGCGT
GC "f'TC iCAC ) ΑΊ'ΊΊ (sACTl (iC A AC XX C X XX ATTC Π GT( C sAC C Ϊ A A( ;G( ΊΊ ΠΧΧ ·( ΊΧ ΧΊ CT
GTCGCTGTCTCAAGCAGCATCTAACCCTGCGTCGCCGTTTCCATTTGCAGCCGCTGG
CCCGCCGAGCCCTGGAGGAGCTCGGGCTGCCGGTGCCGCCGGTGCTGCGGGTGCCC GGCGAGAGCACCAACCCCGTACTGGTCGGCGAGCCCGGCCCGGTGATCAAGCTGTT
CGGCGAGCACTGGTGCGGTCCGGAGAGCCTCGCGTCGGAGTCGGAGGCGTACGCGG
TCCTGGCGGACGCCCCGGTGCCGGTGCCCCGCCTCCTCGGCCGCGGCGAGCTGCGGC
CCGGCACCGGAGCCTGGCCGTGGCCCTACCTGGTGATGAGCCGGATGACCGGCACC
ACCTGGCGGTCCGCGATGGACGGCACGACCGACCGGAACGCGCTGCTCGCCCTGGC
CCGCGAACTCGGCCGGGTGCTCGGCCGGCTGCACAGGGTGCCGCTGACCGGGAACA
CCGTGCTCACCCCCCATTCCGAGGTCTTCCCGGAACTGCTGCGGGAACGCCGCGCGG
CGACCGTCGAGGACCACCGCGGGTGGGGCTACCTCTCGCCCCGGCTGCTGGACCGC
CTGGAGGACTGGCTGCCGGACGTGGACACGCTGCTGGCCGGCCGCGAACCCCGGTT
CGTCCACGGCGACCTGCACGGGACCAACATCTTCGTGGACCTGGCCGCGACCGAGG
TCACCGGGATCGTCGACTTCACCGACGTCTATGCGGGAGACTCCCGCTACAGCCTGG
TGCAACTGCATCTCAACGCCTTCCGGGGCGACCGCGAGATCCTGGCCGCGCTGCTCG
A(XIGGGCGCAGTGGAAGCGGA(X IAGGA(TRTCGCCX^GCGAACTGCTCGCCTTCACC
TTCCTGCACGACTTCGAGGTGTTCGAGGAGACCCCGCTGGATCTCTCCGGCTTCACC
(ΊΛ Γ(Χ'ίΧ}Λαί!ΛΛ(Ί χ : ί( (ΠΊ ( Ί Ί ; χ χ ( (;(Χ ( ::Λ(·Λ( ( x cxxxx=G( ί ;·
CTGATAAGGATCCGGCAAGACTGGCCCCGCTTGGCAACGCAACAGTGAGCCCCTCC CTAGTGTGTTTGGGGATGTGACTATGTATTCGTGTGTTGGCCAACGGGTCAACCCGA ACAGATTGATACCCGCCTTGGCATTTCCTGTCAGAATGTAACGTCAGTTGATGGTAC
T
[00496] For all modified Chiamydomonas reinhardtii cells, Applicants used PGR, SURVEYOR nuclease assay, and DNA sequencing to verify successful modification.
Example 16: Use of Cas9 as a transcriptional repressor in bacteria
[00497] The ability to artificially control transcription is essential both to the study of gene function and to the construction of synthetic gene networks with desired properties. Applicants describe here the use of the RNA-guided Cas9 protein as a programmable transcriptional repressor.
[00498] Applicants have previously demonstrated how the Cas9 protein of Streptococcus pyogenes SF370 can be used to direct genome editing in Streptococcus pneumoniae. In this study Applicants engineered the crR6Rk strain containing a minimal CRISPR system, consisting of
cas9, the tracrRNA and a repeat. The D10A-H840 mutations were introduced into cas9 in this strain, giving strain crR6Rk**. Four spacers targeting different positions of the hgaA β- galactosidase gene promoter were cloned in the CRISPR array carried by the previously described pDB98 plasmid. Applicants observed a X to Y fold reduction in β-galactosidase activity depending on the targeted position, demonstrating the potential of Cas9 as a programmable repressor (Figure 73),
[00499] To achieve Cas9** repression in Escherichia coli a green fluorescence protein (GFP) reporter plasimd (pDB127) was constructred to express the gfpmutl gene from a constitutive promoter. The promoter was designed to carry several NPP PAMs on both strands, to measure the effect of €889* * binding at various positions. Applicants introduced the D10A-H840 mutations into pCas9, a plasmid described carrying the tracrRNA, cas9 and a minimal CRISPR array designed for the easy cloning of new spacers. Twenty-two different spacers were designed to target different regions of the gfpmut2 promoter and open reading frame. An approximately 20-fold reduction of fluorescence of was observed upon targeting regions overlapping or adjacent to the -35 and -10 promoter elements and to the Shine-Dalgarno sequence. Targets on both strands showed similar repression levels. These results suggest that the binding of Cas9** to any position of the promoter region prevents transcription initiation, presumably through steric inhibition of RNAP binding.
[00500] To determine whether Cas9** could prevent transcription elongation, Applicants directed it to the reading frame of gpfmut.2. A reduction in fluorescence was observed both when the coding and non-coding strands where targeted, suggesting that Cas9 binding is actual ly strong enough to represent an obstacle to the running RNAP. However, while a 40% reduction in expression was observed when the coding strand was the target, a 20-fold reduction was observed for the non-coding strand (Fig 21b, compare T9, T10 and Ti l to B9, B10 and Bl 1). To directly determine the effects of Cas9** binding on transcription, Applicants extracted RN.A from strains carrying either the T5, T 10, B 10 or a control construct that does not target pDB127 and subjected it to Northern blot analysis using either a probe binding before (B477) or after (B510) the B10 and T10 target sites. Consistent with Applicants' fluorescence methods, no gfpmut2 ' transcription was detected when Cas9** was directed to the promoter region (T5 target) and a transcription was observed after the targeting of the T10 region. Interestingly, a smaller transcript was observed with the B477 probe. This band corresponds to the expected size of a
transcript that would be interrupted by Cas9**, and is a direct indication of a transcriptional termination caused by dgRNA::Cas9** binding to the coding strand. Surprisingly, Applicants detected no transcript when the non-coding strand was targeted (B 10). Since Cas9** binding to the BIO region is unlikely to interfere with transcription initiation, this result suggests that the mRNA was degraded. DgRNA::Cas9 was shown to bind ssRNA in vitro. Applicants speculate that binding may trigger degradation of the mRNA by host nucleases. Indeed, ribosome stalling can induce cleavage on the translated mRNA in E. coii.
[00501] Some applications require a precise tuning gene expression rather than its complete repression. Applicants sought to achieve intermediate repression levels through the introduction of mismatches that will weaken the crRN A/target interactions. Applicants created a series of spacers based on the Bl, T5 and BIO constructs with increasing numbers of mutations in the 5' end of the crRNA. Up to 8 mutations in Bl and T5 did not affect the repression level, and a progressive increased in fluorescence was observed for additional mutations.
[00502| The observed repression with only an 8nt match between the crRNA and its target raises the question of off-targeting effects of the use of Cas9** as a transcriptional regulator. Since a good PAM (NGG) is also required for Cas9 binding, the number of nucleotides to match to obtain some level of respiration is 10. A l Ont match occurs randomly once every ~3M p, and such sites are thus likely to be found even in small bacterial genomes. However, to effectively repress transcription, such site needs to be in the promoter region of gene, which makes off-targeting much less likely. Applicants also showed that gene expression can be affected if the non-coding strand of a gene is targeted. For this to happen, a random target would have to be in the right orientation, but such events relatively more likely to happen. As a matter of fact, during the course of this study Applicants were unable to constmct one of the designed spacer on pCas9**. Applicants later found this spacer showed a 12bp match next to a good PAM in the essential murC gene. Such off-targeting could easily be avoided by a systematic blast of the designed spacers.
[00503] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed
in practicing the mvention. It is mtended that the following claims define the scope of the mvention and that methods and stmctures within the scope of these claims and their equivalents be covered thereby.
[00504] References:
1. LIrnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. & Gregory, P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636-646 (2010).
2. Bogdanove, A.J. & Voytas, D.F. TAL effectors: customizable proteins for DNA targeting. Science 333, 1843-1846 (201 1 ).
3. Stoddard, B.L. Homing endonuclease structure and function. O. Rev. Biophys. 38, 49- 95 (2005).
4. Bae, T. & Schneewind. O. Allelic replacement in Staphylococcus aureus with inducible counter-selection. Plasmid 55, 58-63 (2006).
5. Sung, C. ., Li, H., Claverys, J.P. & Morrison, D.A. An rpsL cassette, janus, for gene replacement through negative selection in Streptococcus pneumoniae. Appl. Environ. Microbiol. 67, 5190-5196 (2001).
6. S aran, S.K., Thomason, L.C., Kuznetsov, S.G. & Court, D.L. Recombineering: a homologous recombination-based method of genetic engineering. Nat. Protoc. 4, 206-223 (2009).
7. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
8. Deveau, H., Gameau, J.E. & Moineau, S. CRISPR/Cas system and its role in phage- bacteria interactions. Annu. Rev. Microbiol. 64, 475-493 (2010).
9. Horvath, P. & Barrangou, R. CRISPR/Cas, the immune system of bacteria and archaea. Science 327, 167-170 (2010).
10. Terns, M.P. & Terns, R.M. CRISPR-based adaptive immune systems. Curr. Opin. Microbiol. 14, 321 -327 (2011).
11. van der Oost, J., Jore, M.M., Westra, E.R., Lundgren, M. & Brouns, S.J. CRJSPR- based adaptive and heritable immunity in prokaryotes. Trends. Biochem. Sci. 34, 401-407 (2009).
12. Brouns, S.J. et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321, 960-964 (2008).
13. Carte, J., Wang, R., Li, PL, Terns, R.M. & Terns, M.P. Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes. Genes Dev. 22, 3489-3496 (2008).
14. Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471 , 602-607 (2011).
15. Hatoum-Aslan, A., Maniv, I & Marraffini, L.A. Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is .measured by a ruler mechanism anchored at the precursor processing site. Proc. Natl. Acad. Sci. U.S.A. 108, 21218-21222
(2011) .
.16. Haurwitz, R.E., Jinek, M., Wiedenheft, B., Zhou, K. & Doudna, J. A. Sequence- and structure-specific RNA processing by a CRISPR eiidonuciease. Science 329, 1355-1358 (2010).
17. Deveau, . et al. Phage response to CRISPR-encoded resistance in Streptococcus therniophilus. J. BacterioL 19Θ, 1390-1400 (2008).
18. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotem complex mediates specific DNA cleavage for adaptive immunity in bacteria, Proc. Nati. Acad. Sci. U.S.A. (2012).
19. Makarova, .S., Aravind, L., Wolf, Y.I. & Koonin, E.V. Unification of Cas protein families and a simple sce ario for the origin a d evolution of CRISPR-Cas systems. Biol. Direct. 6, 38 (2011).
20. Barrangou, R. RNA-mediated programmable DNA cleavage. Nat. Biotechnol. 30, 836-838 (2012).
21. Brouns, S.J. Molecular biology. A Swiss army knife of immunity. Science 337, 808- 809 (2012).
22. Carroll, D. A CRISPR Approach to Gene Targeting. MoL Ther. 20, 1658-1660
(2012) .
23. Bikard, D., Hatoum- Asian, A., Mueida, D. & Marraffini, L.A. CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. Ceil Host Microbe .12, 177-186 (20.12).
24. Sapranauskas, R. et ai. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coll. Nucleic Acids Res. (203 1).
25. Semenova, E. et al. Interference by clustered regularly mterspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc. Natl. Acad. Sci. U.S.A. (2011).
26. Wiedenheft, B. et al. RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. Proc. Natl. Acad. Sci. U.S.A. (2011).
27. Zahner, D. & Hakenbeck, R. The Streptococcus pneumoniae beta-galactosidase is a surface protein. J. Bacteriol 182, 5919-5921 (2000).
28. Marraffini, L.A., Dedent, A.C. & Schneewind, O. Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria. Microbiol, Mol. Biol. Rev. 70, 192-221 (2006).
29. Motamedi, M.R., Szigety, S.K. & Rosenberg, S.M. Double-strand-break repair recombination in Escherichia coli: physical evidence for a DNA replication mechanism in vivo. Genes Dev. 13, 2889-2903 (1999).
30. Hosaka, T. et al. The novel mutation K87E in ribosomai protein SI 2 enhances protein synthesis activity during the late growth phase in Escherichia coli. Mol. Genet. Genomics 271, 317-324 (2004).
31. Costantino, N. & Court, D.L. Enhanced levels of lambda Red-mediated recombinants in mismatch repair mutants. Proc. Natl. Acad. Set U.S.A. 100, 15748-15753 (2003).
32. Edgar, R. & Qimron, U. The Escherichia coli CRJSPR system protects from lambda lysogenization, lysogens, and prophage induction, J. Bacteriol. 192, 6291-6294 (2010).
33. Marraffini, L.A. & Sontheimer, E.j. Self versus non-self discrimination during CRISPR RNA-directed immunity. Nature 463, 568-571 (2010).
34. Fischer, S. et al. An archaea! immune system can detect multiple Protospacer Adjacent Motifs (PAMs) to target invader DNA. J. Biol. Ghent. 287, 33351-33363 (2012).
35. Gudbergsdottir, S. et al. Dynamic properties of the Sulfolobus CRISPR/Cas and CRISPR/Cmr systems when chal lenged with vector-borne viral and piasmid genes and protospacers. Mol. Microbiol 79, 35-49 (2011).
36. Wang, H.H. et al. Genome-scale promoter engineering by coselection MAGE, Nat Methods 9, 591-593 (2012).
37. Cong, L. et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science In press (2013).
38. Mali, P. et al. RNA-Guided Human Genome Engineering via Cas9. Science In press (2013).
39. Hoskins, J. et al. Genome of the bacterium Streptococcus pneumoniae strain R6, J. Bacteriol. 183, 5709-5717 (2001).
40. Havarstein, L.S., Coomaraswamy, G. & Morrison, D.A. An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae. Proc. Natl. Acad. Set U.S.A. 92, 11140- 1 1144 (1995).
41. Horinouchi, S. & Weisblum, B. Nucleotide sequence and functional map of pC194, a plasmid that specifies inducible chloramphenicol resistance. J. Bacterial. 150, 815-825 (1982).
42. Horton, R.M. In Vitro Recombination and Mutagenesis of DNA : SOEing Together Tailor-Made Genes. Methods Mol. Biol. 15, 251-261 (1993).
43. PodbieLski, A., Spellerberg, B., Woischnik, M,, Polil, B. & Lutticken, R. Novel series of plasmid vectors for gene inactivation and expression analysis in group A streptococci (GAS). Gene 177, 137-147 ( 1996).
44. Husmami, L. ., Scott, J.R., Lindahl, G. & Stenberg, L, Expression of the Arp protein, a member of the M protein family, is not sufficient to inhibit phagocytosis of Streptococcus pyogenes. Infection and immunity 63, 345-348 (1995).
45. Gibson, D.G. et al. Enzymatic assembly of DNA molecules up to several hundred kiiobases. Nat Methods 6, 343-345 (2009).
Claims
1. A nonmaturall occurring or engineered composition comprising a vector system comprising one or more vectors comprising
1. a first regulatory element operably linked to a CRISPR-Cas system chimeric R'NA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises
(a) a guide sequence capable of hybridizing to a target sequence in a eukaryoiic cell,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences (NLSs) in the proximity of a terminus of the CRISPR enzyme,
wherein (a), (b) and (c) are arranged in a 5' to 3s orientation,
wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence,
wherei the CRJSPR complex comprises the CRISPR enzyme complcxed with ( 1 ) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the CRISPR enzyme comprises one or more mutations in a catalytic domain thereby rendering the CRISPR enzyme to a nickase that cleaves a single DMA strand, and
wherein the chimeric RNA polynucleotide sequence comprises two or more hairpins,
2. The composition of claim 1, wherein multiple chiR A polynucleotide sequences are used, to provide a multiplexed system,
3, A mnliiplexed CRISPR enzyme sysiem, wherein the system comprises a vector system comprising one or more vectors comprising
L a first regulatory element operably Imked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises
(a) a guide sequence capable of hybridizing to a target sequence in a eukaryotrc cel l,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
II. a second regulatory element operably linked to an enzyme-coding sequence encoding a. CRISPR enzyme comprising at least one or more nuclear localization sequences (NLSs) in the proximity of a terminus of the CRISPR enzyme,
wherein ia), (b) and (c) are arranged hi a. 5 ' to 3 ' orientation,
wherein components 1 and 11 are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence,
wherein the CRISPR complex comprises the CRISPR enzyme com lexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the CRISPR enzyme comprises one or more mutations in a catalytic domain thereby rendering the CRISPR enzyme to a nickase that cleaves a single D A. strand, and
wherein the cbiRNA polynucleotide sequence comprises two or more hairpins, and wherein in the multiplexed system multiple chiRNA polynucleotide sequences are used.
4. The composition or system of claim 1 , 2 or 3, wherein the first regulatory element is a polymerase III promoter.
5. The composition or system of any preceding claim, wherein the second regulatory element is a polymerase II promoter.
6. The composition or system of any preceding claim, wherein the CRISPR enzyme comprises one or more NLSs of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic ceil.
7. The composition or system of any preceding claim, wherein the tracr sequence exhibits at least 50% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.
8. The composition or system of any preceding claim, wherein the CRISPR enzyme is a type Π CRJSPR system enzyme.
9. The composition or system of any preceding claim, wherein the CRISPR enzyme is a Cas9 enzyme.
10. The composition or system of any preceding claim, wherein the CRJ SPR enzyme is codo -optimized for expression in a eukaryotic ceil.
1 1. The composition or system of any preceding claim, wherein the guide sequence is at least 15 nucleotides in length.
12. The composition or system of any preceding claim, wherein the chimeric R A polynucleotide sequence comprises two, three, four or five hairpins.
1 3. The composition or system, of any preceding claim, wherein the catalytic domain is selected from the group comprising RuvCI, RuvCII, RuvCIII or HNH domain.
14. The composition or system of any preceding claim, wherein the CRISPR. enzyme comprises a mutation in a residue selected from the group consisting of D10, E762, H840, N854, N863, or D986 of SpCas9, or corresponding residues in other CRISPR enzymes.
15. The composition or system of any preceding claim, wherein the CRISPR enzyme comprises a mutation selected from the group comprising D10A, E762A, H840A, N854A, N863A or D986A in SpCas9, or corresponding residues in other CRISPR enzymes.
16. A non- aturally occurring or engineered composition comprising a. vector system comprising one or more vectors comprising
I. a. first regulatory element operabiy linked to
(a) a guide sequence capable of hybridizing to a. target sequence in a eukaryotie cell, and
(b) a tracr mate sequence,
II. a second regulatory element operabiy linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences CNLSs) in the proximity of a terminus of the CRISPR enzyme, and
I I I. a third regulatory element operabiy Imked to a tracr sequence,
wherein components I, II and III are located on the same or different vectors of the system.,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence,
wherein the CRISPR complex comprises the CRISPR enzyme com lexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, and
wherein the CRISPR enzyme comprises one or more mutations in a. catalytic domain thereby rendering the CRISPR enzyme to a nickase that cleaves a single D A. strand.
1 7. The composition of claim 16, wherein multiple guide sequences and a single tracr sequence are used, to provide a multiplexed system
18. A multiplexed CRISPR enzyme system, wherein the system comprises a vector system comprising one or more vectors comprising
L a first regulatory element operably linked to
(a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell , and
(b) a tracr male sequence,
II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences (NLSs) in the proximity of a terminus of the CR IS PR. enzyme, and
ML a third regulatory element operably linked to a tracr sequence,
wherein components I, II and HI are located on the same or different vectors of the system,
wherein when transcribed, the iracr mate sequence hybridizes to the iracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence,
wherein the CRISPR complex comprises the CR ISPR enzyme complexed with (! ) the guide sequence that is hybridized to the target sequence, and (2) the tracr male sequence thai is hybridized to the tracr sequence,
wherei the CRISPR enzyme comprises one or more mutations in a catalytic domain thereby rendering the CRISPR enzyme to a nicka.se that cleaves a single DMA strand, and
wherein in the multiplexed system multiple guide sequences and a single tracr sequence
:s used.
19. The composition or system of any of claims 16 to 18, wherein the first regulatory element, is a polymerase II I promoter.
20. The composition or system of any of claims 16 to 19, wherein the second regulatory element is a polymerase II promoter.
21. The composition or system of any of claims 16 to 20, wherein the third regulatory element is a polymerase III promoter.
22. The composition or system of any of claims 16 to 21, wherein the CRISPR enzyme comprises one or more NLSs of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell.
23. The composition or system of any of claims 16 to 22, wherein the tracr sequence exhibits at least 50% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.
24. The composition or system of any of claims 1.6 to 23, wherein the CRISPR enzyme is a type II CRISPR system enzyme.
25. The composition or system of any of claims 16 to 24, wherein the CRISPR enzyme is a Cas9 enzyme,
26. The composition or system of any of claims 36 to 25, wherein the CRISPR. enzyme is codon-opti ized for expression in a eukaryotic cell.
27. The composition or system of any of claims 16 to 26, wherein the guide sequence is at least 15 nucleotides in length.
28. The composition or system of any of claims 16 to 27, wherein the catalytic domain is selected from the group comprising RuvCI, RuvQ L RuvQII or HNH domain.
29. The composition or system of any of claims 16 to 28, wherein the CRISPR enzyme comprises a mutation in a residue selected from the group consisting of D10, E762, H840, N854, N863, or D986 of SpCas9, or corresponding residues in other CRISPR enzymes.
30. The composition or system of any of claims 16 to 29, wherein the CRISPR enzyme comprises a mutation selected from the group comprising D10A, E762A, H840A, N854A, N863A or D986A of SpCas9, or corresponding residues in other CRISPR enzymes.
31. A eukaryotic host cel l comprising the composition of any of the preceding claims.
32. An organism comprising the eukaryotic host cell of claim 31.
33. A non-human organism comprising the eukaryotic host cell of claim 31.
34. A kit comprising the composition or system of any of claims 1 to 30 and instructions for using said kit.
35. A method of altering the expression of a genomic locus of interest in a eukaryotic cell comprising
contacting the genomic locus with the composition or system of any of claims 1 to 30, and
determining if the expression of the genomic locus has been altered.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261736527P | 2012-12-12 | 2012-12-12 | |
US61/736,527 | 2012-12-12 | ||
US201361748427P | 2013-01-02 | 2013-01-02 | |
US61/748,427 | 2013-01-02 | ||
US201361791409P | 2013-03-15 | 2013-03-15 | |
US201361802174P | 2013-03-15 | 2013-03-15 | |
US61/802,174 | 2013-03-15 | ||
US61/791,409 | 2013-03-15 | ||
US201361835931P | 2013-06-17 | 2013-06-17 | |
US61/835,931 | 2013-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014093694A1 true WO2014093694A1 (en) | 2014-06-19 |
WO2014093694A9 WO2014093694A9 (en) | 2014-10-16 |
Family
ID=49883299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/074790 WO2014093694A1 (en) | 2012-12-12 | 2013-12-12 | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
Country Status (2)
Country | Link |
---|---|
US (6) | US20140310830A1 (en) |
WO (1) | WO2014093694A1 (en) |
Cited By (297)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2771468B1 (en) | 2012-12-12 | 2015-02-11 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
WO2015089351A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
WO2015089465A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
EP2764103B1 (en) | 2012-12-12 | 2015-08-19 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
EP2896697B1 (en) | 2012-12-12 | 2015-09-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9228208B2 (en) | 2013-12-11 | 2016-01-05 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
WO2016007604A1 (en) * | 2014-07-09 | 2016-01-14 | Gen9, Inc. | Compositions and methods for site-directed dna nicking and cleaving |
US9260752B1 (en) | 2013-03-14 | 2016-02-16 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
WO2016028682A1 (en) * | 2014-08-17 | 2016-02-25 | The Broad Institute Inc. | Genome editing using cas9 nickases |
WO2016036754A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049251A1 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
EP3004349A1 (en) * | 2013-05-29 | 2016-04-13 | Cellectis S.A. | A method for producing precise dna cleavage using cas9 nickase activity |
US9322006B2 (en) | 2011-07-22 | 2016-04-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
WO2016069591A2 (en) | 2014-10-27 | 2016-05-06 | The Broad Institute Inc. | Compositions, methods and use of synthetic lethal screening |
WO2016070037A2 (en) | 2014-10-31 | 2016-05-06 | Massachusetts Institute Of Technology | Massively parallel combinatorial genetics for crispr |
WO2016083811A1 (en) | 2014-11-27 | 2016-06-02 | Imperial Innovations Limited | Genome editing methods |
WO2016086227A2 (en) | 2014-11-26 | 2016-06-02 | The Regents Of The University Of California | Therapeutic compositions comprising transcription factors and methods of making and using the same |
WO2016086197A1 (en) | 2014-11-25 | 2016-06-02 | The Brigham And Women's Hospital, Inc. | Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
WO2016100974A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing |
WO2016106244A1 (en) | 2014-12-24 | 2016-06-30 | The Broad Institute Inc. | Crispr having or associated with destabilization domains |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
WO2016108926A1 (en) | 2014-12-30 | 2016-07-07 | The Broad Institute Inc. | Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis |
US9403141B2 (en) | 2013-08-05 | 2016-08-02 | Twist Bioscience Corporation | De novo synthesized gene libraries |
WO2016138488A2 (en) | 2015-02-26 | 2016-09-01 | The Broad Institute Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
WO2016138574A1 (en) | 2015-03-02 | 2016-09-09 | Sinai Health System | Homologous recombination factors |
EP2840140B1 (en) | 2012-12-12 | 2016-11-16 | The Broad Institute, Inc. | Crispr-Cas component systems, methods and compositions for sequence manipulation |
WO2016182893A1 (en) | 2015-05-08 | 2016-11-17 | Teh Broad Institute Inc. | Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof |
WO2016205745A2 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
WO2016205728A1 (en) | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Crispr mediated recording of cellular events |
WO2016205764A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
WO2017027910A1 (en) | 2015-08-14 | 2017-02-23 | The University Of Sydney | Connexin 45 inhibition for therapy |
WO2017044776A1 (en) * | 2015-09-10 | 2017-03-16 | Texas Tech University System | Single-guide rna (sgrna) with improved knockout efficiency |
WO2017066760A1 (en) | 2015-10-16 | 2017-04-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
WO2017070605A1 (en) | 2015-10-22 | 2017-04-27 | The Broad Institute Inc. | Type vi-b crispr enzymes and systems |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
WO2017074788A1 (en) | 2015-10-27 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075294A1 (en) | 2015-10-28 | 2017-05-04 | The Board Institute Inc. | Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
US9677067B2 (en) | 2015-02-04 | 2017-06-13 | Twist Bioscience Corporation | Compositions and methods for synthetic gene assembly |
WO2017114497A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
WO2017147196A1 (en) | 2016-02-22 | 2017-08-31 | Massachusetts Institute Of Technology | Methods for identifying and modulating immune phenotypes |
EP3219799A1 (en) | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
WO2017161325A1 (en) | 2016-03-17 | 2017-09-21 | Massachusetts Institute Of Technology | Methods for identifying and modulating co-occurant cellular phenotypes |
KR101785847B1 (en) * | 2015-05-12 | 2017-10-17 | 연세대학교 산학협력단 | Targeted genome editing based on CRISPR/Cas9 system using short linearized double-stranded DNA |
WO2017189683A1 (en) | 2016-04-26 | 2017-11-02 | Massachusetts Institute Of Technology | Extensible recombinase cascades |
US9834786B2 (en) | 2012-04-25 | 2017-12-05 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
US9834791B2 (en) | 2013-11-07 | 2017-12-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
WO2017219027A1 (en) | 2016-06-17 | 2017-12-21 | The Broad Institute Inc. | Type vi crispr orthologs and systems |
WO2018013840A1 (en) | 2016-07-13 | 2018-01-18 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
US9885026B2 (en) | 2011-12-30 | 2018-02-06 | Caribou Biosciences, Inc. | Modified cascade ribonucleoproteins and uses thereof |
US9895673B2 (en) | 2015-12-01 | 2018-02-20 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
WO2018035250A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018054911A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Cropscience Nv | Targeted genome optimization in plants |
US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2018073237A1 (en) | 2016-10-17 | 2018-04-26 | The University Court Of The University Of Edinburgh | Swine comprising modified cd163 and associated methods |
WO2018080573A1 (en) | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Crispr/cas global regulator screening platform |
WO2018083606A1 (en) | 2016-11-01 | 2018-05-11 | Novartis Ag | Methods and compositions for enhancing gene editing |
US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
US10000772B2 (en) | 2012-05-25 | 2018-06-19 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10053688B2 (en) | 2016-08-22 | 2018-08-21 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
WO2018170515A1 (en) | 2017-03-17 | 2018-09-20 | The Broad Institute, Inc. | Methods for identifying and modulating co-occurant cellular phenotypes |
WO2018170333A1 (en) | 2017-03-15 | 2018-09-20 | The Broad Institute, Inc. | Novel cas13b orthologues crispr enzymes and systems |
US10081807B2 (en) | 2012-04-24 | 2018-09-25 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
WO2018191750A2 (en) | 2017-04-14 | 2018-10-18 | The Broad Institute Inc. | Novel delivery of large payloads |
WO2018191520A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Respiratory and sweat gland ionocytes |
WO2018191388A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Novel type vi crispr orthologs and systems |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
WO2018195486A1 (en) | 2017-04-21 | 2018-10-25 | The Broad Institute, Inc. | Targeted delivery to beta cells |
WO2018195019A1 (en) | 2017-04-18 | 2018-10-25 | The Broad Institute Inc. | Compositions for detecting secretion and methods of use |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
WO2019003193A1 (en) | 2017-06-30 | 2019-01-03 | Novartis Ag | Methods for the treatment of disease with gene editing systems |
WO2019005884A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
US10202608B2 (en) | 2006-08-31 | 2019-02-12 | Gen9, Inc. | Iterative nucleic acid assembly using activation of vector-encoded traits |
WO2018083128A3 (en) * | 2016-11-02 | 2019-02-14 | Wageningen Universiteit | Microbial genome editing |
WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
WO2019071054A1 (en) | 2017-10-04 | 2019-04-11 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
WO2019074841A1 (en) * | 2017-10-09 | 2019-04-18 | Pioneer Hi-Bred International, Inc. | Type i-e crispr-cas systems for eukaryotic genome editing |
WO2019087113A1 (en) | 2017-11-01 | 2019-05-09 | Novartis Ag | Synthetic rnas and methods of use |
US10308931B2 (en) | 2012-03-21 | 2019-06-04 | Gen9, Inc. | Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis |
US10337001B2 (en) | 2014-12-03 | 2019-07-02 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
WO2019138083A1 (en) | 2018-01-12 | 2019-07-18 | Basf Se | Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a |
EP3514246A1 (en) | 2014-02-27 | 2019-07-24 | The Broad Institute Inc. | T cell balance gene expression and methods of use thereof |
WO2019143675A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2019143678A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
US10385359B2 (en) | 2013-04-16 | 2019-08-20 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
US10428319B2 (en) | 2017-06-09 | 2019-10-01 | Editas Medicine, Inc. | Engineered Cas9 nucleases |
CN110312803A (en) * | 2016-12-21 | 2019-10-08 | 许景焜 | Edit the composition and method of nucleic acid sequence |
US10450576B2 (en) | 2015-03-27 | 2019-10-22 | E I Du Pont De Nemours And Company | Soybean U6 small nuclear RNA gene promoters and their use in constitutive expression of small RNA genes in plants |
WO2019204585A1 (en) | 2018-04-19 | 2019-10-24 | Massachusetts Institute Of Technology | Single-stranded break detection in double-stranded dna |
US10457935B2 (en) | 2010-11-12 | 2019-10-29 | Gen9, Inc. | Protein arrays and methods of using and making the same |
US10457960B2 (en) | 2014-11-21 | 2019-10-29 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide RNAs |
EP3560330A1 (en) | 2018-04-24 | 2019-10-30 | KWS SAAT SE & Co. KGaA | Plants with improved digestibility and marker haplotypes |
WO2019210268A2 (en) | 2018-04-27 | 2019-10-31 | The Broad Institute, Inc. | Sequencing-based proteomics |
WO2019213660A2 (en) | 2018-05-04 | 2019-11-07 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
US10494621B2 (en) | 2015-06-18 | 2019-12-03 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
US10519457B2 (en) | 2013-08-22 | 2019-12-31 | E I Du Pont De Nemours And Company | Soybean U6 polymerase III promoter and methods of use |
WO2020006049A1 (en) | 2018-06-26 | 2020-01-02 | The Broad Institute, Inc. | Crispr/cas and transposase based amplification compositions, systems and methods |
WO2020002592A1 (en) | 2018-06-29 | 2020-01-02 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Traf2 inhibitors for use in the treatment of a cancer |
WO2020006036A1 (en) | 2018-06-26 | 2020-01-02 | Massachusetts Institute Of Technology | Crispr effector system based amplification methods, systems, and diagnostics |
WO2020028555A2 (en) | 2018-07-31 | 2020-02-06 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2020033601A1 (en) | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Novel cas12b enzymes and systems |
WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
WO2020041380A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
US10577630B2 (en) | 2013-06-17 | 2020-03-03 | The Broad Institute, Inc. | Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy |
WO2020047164A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma, Inc | Genetically engineered hematopoietic stem cells and uses thereof |
WO2020051507A1 (en) | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
WO2020077236A1 (en) | 2018-10-12 | 2020-04-16 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
US10640789B2 (en) | 2013-06-04 | 2020-05-05 | President And Fellows Of Harvard College | RNA-guided transcriptional regulation |
EP3653229A1 (en) | 2013-12-12 | 2020-05-20 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing |
US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
US10676754B2 (en) | 2014-07-11 | 2020-06-09 | E I Du Pont De Nemours And Company | Compositions and methods for producing plants resistant to glyphosate herbicide |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
WO2020131862A1 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
US10696965B2 (en) | 2017-06-12 | 2020-06-30 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
US10711285B2 (en) | 2013-06-17 | 2020-07-14 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
US10731181B2 (en) | 2012-12-06 | 2020-08-04 | Sigma, Aldrich Co. LLC | CRISPR-based genome modification and regulation |
WO2020163655A1 (en) | 2019-02-06 | 2020-08-13 | Fred Hutchinson Cancer Research Center | Minicircle producing bacteria engineered to differentially methylate nucleic acid molecules therein |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
US10781444B2 (en) | 2013-06-17 | 2020-09-22 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
WO2020206036A1 (en) | 2019-04-01 | 2020-10-08 | The Broad Institute, Inc. | Novel nucleic acid modifier |
WO2020229533A1 (en) | 2019-05-13 | 2020-11-19 | KWS SAAT SE & Co. KGaA | Drought tolerance in corn |
US10844373B2 (en) | 2015-09-18 | 2020-11-24 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
WO2020237217A1 (en) | 2019-05-23 | 2020-11-26 | Vor Biopharma, Inc | Compositions and methods for cd33 modification |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
US10851380B2 (en) | 2012-10-23 | 2020-12-01 | Toolgen Incorporated | Methods for cleaving a target DNA using a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein |
WO2020239680A2 (en) | 2019-05-25 | 2020-12-03 | KWS SAAT SE & Co. KGaA | Haploid induction enhancer |
WO2020243661A1 (en) | 2019-05-31 | 2020-12-03 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
WO2021003432A1 (en) | 2019-07-02 | 2021-01-07 | Fred Hutchinson Cancer Research Center | Recombinant ad35 vectors and related gene therapy improvements |
US10894242B2 (en) | 2017-10-20 | 2021-01-19 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
US10894959B2 (en) | 2017-03-15 | 2021-01-19 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
US10907274B2 (en) | 2016-12-16 | 2021-02-02 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
EP3772542A1 (en) | 2019-08-07 | 2021-02-10 | KWS SAAT SE & Co. KGaA | Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2 |
US10930367B2 (en) | 2012-12-12 | 2021-02-23 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and conveying results thereof |
US10936953B2 (en) | 2018-01-04 | 2021-03-02 | Twist Bioscience Corporation | DNA-based digital information storage with sidewall electrodes |
US10934536B2 (en) | 2018-12-14 | 2021-03-02 | Pioneer Hi-Bred International, Inc. | CRISPR-CAS systems for genome editing |
WO2021041977A1 (en) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions and methods for cd123 modification |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
WO2021041971A1 (en) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions and methods for cll1 modification |
US10946108B2 (en) | 2013-06-17 | 2021-03-16 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
WO2021055874A1 (en) | 2019-09-20 | 2021-03-25 | The Broad Institute, Inc. | Novel type vi crispr enzymes and systems |
WO2021074367A1 (en) | 2019-10-17 | 2021-04-22 | KWS SAAT SE & Co. KGaA | Enhanced disease resistance of crops by downregulation of repressor genes |
US11001829B2 (en) | 2014-09-25 | 2021-05-11 | The Broad Institute, Inc. | Functional screening with optimized functional CRISPR-Cas systems |
US11008588B2 (en) | 2013-06-17 | 2021-05-18 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
US11028388B2 (en) | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
US11041173B2 (en) | 2012-12-12 | 2021-06-22 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
CN113005147A (en) * | 2021-03-11 | 2021-06-22 | 中山大学附属第一医院 | Construction method and application of mouse animal model with USP8 mutation |
US11072789B2 (en) | 2012-06-25 | 2021-07-27 | Gen9, Inc. | Methods for nucleic acid assembly and high throughput sequencing |
US11084014B2 (en) | 2010-11-12 | 2021-08-10 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
US11092607B2 (en) | 2015-10-28 | 2021-08-17 | The Board Institute, Inc. | Multiplex analysis of single cell constituents |
EP3872190A1 (en) | 2020-02-26 | 2021-09-01 | Antibodies-Online GmbH | A method of using cut&run or cut&tag to validate crispr-cas targeting |
US11111521B2 (en) | 2011-12-22 | 2021-09-07 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11124796B2 (en) | 2014-09-24 | 2021-09-21 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
WO2021202938A1 (en) | 2020-04-03 | 2021-10-07 | Creyon Bio, Inc. | Oligonucleotide-based machine learning |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US11180793B2 (en) | 2015-04-24 | 2021-11-23 | Editas Medicine, Inc. | Evaluation of Cas9 molecule/guide RNA molecule complexes |
US11180751B2 (en) | 2015-06-18 | 2021-11-23 | The Broad Institute, Inc. | CRISPR enzymes and systems |
WO2021239986A1 (en) | 2020-05-29 | 2021-12-02 | KWS SAAT SE & Co. KGaA | Plant haploid induction |
US11214800B2 (en) | 2015-08-18 | 2022-01-04 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
GB202118058D0 (en) | 2021-12-14 | 2022-01-26 | Univ Warwick | Methods to increase yields in crops |
US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
US11242525B2 (en) | 2014-03-26 | 2022-02-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating sickle cell disease |
WO2022047165A1 (en) | 2020-08-28 | 2022-03-03 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
WO2022047168A1 (en) | 2020-08-28 | 2022-03-03 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
WO2022056459A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd5 modification |
WO2022056489A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd38 modification |
WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
WO2022072643A1 (en) | 2020-09-30 | 2022-04-07 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
US11299767B2 (en) | 2013-03-12 | 2022-04-12 | President And Fellows Of Harvard College | Method for generating a three-dimensional nucleic acid containing matrix |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11306309B2 (en) | 2015-04-06 | 2022-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide RNAs for CRISPR/CAS-mediated gene regulation |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
WO2022093983A1 (en) | 2020-10-27 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for treating hematopoietic malignancy |
WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
US11332738B2 (en) | 2019-06-21 | 2022-05-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
US11332736B2 (en) | 2017-12-07 | 2022-05-17 | The Broad Institute, Inc. | Methods and compositions for multiplexing single cell and single nuclei sequencing |
EP3998344A1 (en) * | 2014-10-09 | 2022-05-18 | Life Technologies Corporation | Crispr oligonucleotides and gene editing |
WO2022104090A1 (en) | 2020-11-13 | 2022-05-19 | Vor Biopharma Inc. | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
EP4001429A1 (en) | 2020-11-16 | 2022-05-25 | Antibodies-Online GmbH | Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq) |
US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
US11377676B2 (en) | 2017-06-12 | 2022-07-05 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
WO2022147347A1 (en) | 2020-12-31 | 2022-07-07 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
US11390884B2 (en) | 2015-05-11 | 2022-07-19 | Editas Medicine, Inc. | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells |
US11407837B2 (en) | 2017-09-11 | 2022-08-09 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
US11414657B2 (en) | 2015-06-29 | 2022-08-16 | Ionis Pharmaceuticals, Inc. | Modified CRISPR RNA and modified single CRISPR RNA and uses thereof |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11447527B2 (en) | 2018-09-18 | 2022-09-20 | Vnv Newco Inc. | Endogenous Gag-based capsids and uses thereof |
US11466271B2 (en) | 2017-02-06 | 2022-10-11 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
WO2022217086A1 (en) | 2021-04-09 | 2022-10-13 | Vor Biopharma Inc. | Photocleavable guide rnas and methods of use thereof |
US11492665B2 (en) | 2018-05-18 | 2022-11-08 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
US11492727B2 (en) | 2019-02-26 | 2022-11-08 | Twist Bioscience Corporation | Variant nucleic acid libraries for GLP1 receptor |
US11492728B2 (en) | 2019-02-26 | 2022-11-08 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
US11512347B2 (en) | 2015-09-22 | 2022-11-29 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
WO2022256440A2 (en) | 2021-06-01 | 2022-12-08 | Arbor Biotechnologies, Inc. | Gene editing systems comprising a crispr nuclease and uses thereof |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11542554B2 (en) | 2015-11-03 | 2023-01-03 | President And Fellows Of Harvard College | Method and apparatus for volumetric imaging |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11550939B2 (en) | 2017-02-22 | 2023-01-10 | Twist Bioscience Corporation | Nucleic acid based data storage using enzymatic bioencryption |
US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
US11560568B2 (en) | 2014-09-12 | 2023-01-24 | E. I. Du Pont De Nemours And Company | Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11566263B2 (en) | 2016-08-02 | 2023-01-31 | Editas Medicine, Inc. | Compositions and methods for treating CEP290 associated disease |
WO2023006933A1 (en) | 2021-07-30 | 2023-02-02 | KWS SAAT SE & Co. KGaA | Plants with improved digestibility and marker haplotypes |
WO2023015182A1 (en) | 2021-08-02 | 2023-02-09 | Vor Biopharma Inc. | Compositions and methods for gene modification |
US11578118B2 (en) | 2017-10-20 | 2023-02-14 | Fred Hutchinson Cancer Center | Systems and methods to produce B cells genetically modified to express selected antibodies |
US11578312B2 (en) | 2015-06-18 | 2023-02-14 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation |
US11591601B2 (en) | 2017-05-05 | 2023-02-28 | The Broad Institute, Inc. | Methods for identification and modification of lncRNA associated with target genotypes and phenotypes |
US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
US11603544B2 (en) | 2017-06-05 | 2023-03-14 | Fred Hutchinson Cancer Center | Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies |
WO2023049926A2 (en) | 2021-09-27 | 2023-03-30 | Vor Biopharma Inc. | Fusion polypeptides for genetic editing and methods of use thereof |
WO2023086422A1 (en) | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
WO2023093862A1 (en) | 2021-11-26 | 2023-06-01 | Epigenic Therapeutics Inc. | Method of modulating pcsk9 and uses thereof |
US11667911B2 (en) | 2015-09-24 | 2023-06-06 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/CAS-mediated genome editing |
WO2023105000A1 (en) | 2021-12-09 | 2023-06-15 | Zygosity Limited | Vector |
US11680268B2 (en) | 2014-11-07 | 2023-06-20 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
US11680296B2 (en) | 2017-10-16 | 2023-06-20 | Massachusetts Institute Of Technology | Mycobacterium tuberculosis host-pathogen interaction |
US11702662B2 (en) | 2011-08-26 | 2023-07-18 | Gen9, Inc. | Compositions and methods for high fidelity assembly of nucleic acids |
US11713485B2 (en) | 2016-04-25 | 2023-08-01 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
EP4219699A1 (en) | 2013-12-12 | 2023-08-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2023164636A1 (en) | 2022-02-25 | 2023-08-31 | Vor Biopharma Inc. | Compositions and methods for homology-directed repair gene modification |
WO2023196816A1 (en) | 2022-04-04 | 2023-10-12 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
EP4268831A2 (en) | 2018-09-12 | 2023-11-01 | Fred Hutchinson Cancer Center | Reducing cd33 expression to selectively protect therapeutic cells |
US11851690B2 (en) | 2017-03-14 | 2023-12-26 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
WO2024003579A1 (en) | 2022-06-30 | 2024-01-04 | University Of Newcastle Upon Tyne | Preventing disease recurrence in mitochondrial replacement therapy |
US11866697B2 (en) | 2017-05-18 | 2024-01-09 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
US11884915B2 (en) | 2021-09-10 | 2024-01-30 | Agilent Technologies, Inc. | Guide RNAs with chemical modification for prime editing |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
US11911415B2 (en) | 2015-06-09 | 2024-02-27 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for improving transplantation |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
WO2024042199A1 (en) | 2022-08-26 | 2024-02-29 | KWS SAAT SE & Co. KGaA | Use of paired genes in hybrid breeding |
US11920128B2 (en) | 2013-09-18 | 2024-03-05 | Kymab Limited | Methods, cells and organisms |
WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
WO2024073440A1 (en) | 2022-09-27 | 2024-04-04 | Genentech, Inc. | Inhibition of genotoxic stress to improve t cell engineering |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
US11963982B2 (en) | 2017-05-10 | 2024-04-23 | Editas Medicine, Inc. | CRISPR/RNA-guided nuclease systems and methods |
US11975029B2 (en) | 2017-02-28 | 2024-05-07 | Vor Biopharma Inc. | Compositions and methods for inhibition of lineage specific proteins |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
US11981917B2 (en) | 2013-06-04 | 2024-05-14 | President And Fellows Of Harvard College | RNA-guided transcriptional regulation |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
US12031132B2 (en) | 2018-03-14 | 2024-07-09 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US12043870B2 (en) | 2017-10-02 | 2024-07-23 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
US12058986B2 (en) | 2017-04-20 | 2024-08-13 | Egenesis, Inc. | Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements |
WO2024168253A1 (en) | 2023-02-10 | 2024-08-15 | Possible Medicines Llc | Delivery of an rna guided recombination system |
WO2024168265A1 (en) | 2023-02-10 | 2024-08-15 | Possible Medicines Llc | Aav delivery of rna guided recombination system |
WO2024168312A1 (en) | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
WO2024173645A1 (en) | 2023-02-15 | 2024-08-22 | Arbor Biotechnologies, Inc. | Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript |
US12084676B2 (en) | 2018-02-23 | 2024-09-10 | Pioneer Hi-Bred International, Inc. | Cas9 orthologs |
US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
US12098425B2 (en) | 2018-10-10 | 2024-09-24 | Readcoor, Llc | Three-dimensional spatial molecular indexing |
US12105089B2 (en) | 2017-07-17 | 2024-10-01 | The Broad Institute, Inc. | Cell atlas of the healthy and ulcerative colitis human colon |
US12110545B2 (en) | 2017-01-06 | 2024-10-08 | Editas Medicine, Inc. | Methods of assessing nuclease cleavage |
WO2024220741A1 (en) | 2023-04-19 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for the production of libraries |
Families Citing this family (305)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011002988A1 (en) | 2009-07-01 | 2011-01-06 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for severe combined immunodeficiency (scid) |
WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
JP6225182B2 (en) | 2012-07-11 | 2017-11-01 | サンガモ セラピューティクス, インコーポレイテッド | Methods and compositions for the treatment of lysosomal storage diseases |
CA2879997A1 (en) * | 2012-07-25 | 2014-01-30 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
SG11201504621RA (en) * | 2012-12-17 | 2015-07-30 | Harvard College | Rna-guided human genome engineering |
EP4428141A2 (en) | 2013-03-15 | 2024-09-11 | The General Hospital Corporation | Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
JP2016522679A (en) | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Therapeutic use of genome editing with the CRISPR / Cas system |
US10011850B2 (en) | 2013-06-21 | 2018-07-03 | The General Hospital Corporation | Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing |
JP2016528890A (en) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Therapeutic use of genome editing using the CRISPR / Cas system |
US10774338B2 (en) * | 2014-01-16 | 2020-09-15 | The Regents Of The University Of California | Generation of heritable chimeric plant traits |
BR112016019068A2 (en) | 2014-02-18 | 2017-10-10 | Univ Duke | construct, recombinant vector, pharmaceutical composition, method of inhibiting viral replication or expression of a target sequence in a cell infected with a virus, recombinant sau cas9 polypeptide, recombinant sau cas9 construct, recombinant construct for expression of an individual guide and kit |
CA3194412A1 (en) | 2014-02-27 | 2015-09-03 | Monsanto Technology Llc | Compositions and methods for site directed genomic modification |
US10349639B2 (en) | 2014-03-26 | 2019-07-16 | University Of Maryland, College Park | Targeted genome editing in zygotes of domestic large animals |
EP3140403A4 (en) | 2014-05-09 | 2017-12-20 | Université Laval | Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system |
EP3142707A4 (en) | 2014-05-13 | 2018-02-21 | Sangamo Therapeutics, Inc. | Methods and compositions for prevention or treatment of a disease |
AU2015274367B2 (en) | 2014-06-13 | 2020-11-26 | Beth Israel Deaconess Medical Center, Inc. | Products and methods to isolate mitochondria |
EP3919621A1 (en) | 2014-06-23 | 2021-12-08 | The General Hospital Corporation | Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq) |
US9970030B2 (en) | 2014-08-27 | 2018-05-15 | Caribou Biosciences, Inc. | Methods for increasing CAS9-mediated engineering efficiency |
EP3186375A4 (en) | 2014-08-28 | 2019-03-13 | North Carolina State University | Novel cas9 proteins and guiding features for dna targeting and genome editing |
AU2015317793B2 (en) | 2014-09-16 | 2021-11-11 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
US10040048B1 (en) | 2014-09-25 | 2018-08-07 | Synthego Corporation | Automated modular system and method for production of biopolymers |
WO2016065341A1 (en) | 2014-10-24 | 2016-04-28 | Avectas Limited | Delivery across cell plasma membranes |
AU2015360502A1 (en) | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
US11208638B2 (en) | 2015-01-12 | 2021-12-28 | The Regents Of The University Of California | Heterodimeric Cas9 and methods of use thereof |
EP3250689B1 (en) | 2015-01-28 | 2020-11-04 | The Regents of The University of California | Methods and compositions for labeling a single-stranded target nucleic acid |
US9650617B2 (en) | 2015-01-28 | 2017-05-16 | Pioneer Hi-Bred International. Inc. | CRISPR hybrid DNA/RNA polynucleotides and methods of use |
EP3858990A1 (en) | 2015-03-03 | 2021-08-04 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
US10066256B2 (en) | 2015-03-17 | 2018-09-04 | Bio-Rad Laboratories, Inc. | Detection of genome editing |
CN108124453B (en) | 2015-03-31 | 2022-04-05 | 爱克莱根科技公司 | Cas9 retroviral integrase and Cas9 recombinase system for targeted incorporation of DNA sequences into the genome of a cell or organism |
GB201506509D0 (en) | 2015-04-16 | 2015-06-03 | Univ Wageningen | Nuclease-mediated genome editing |
KR20230174291A (en) | 2015-05-06 | 2023-12-27 | 스니프르 테크놀로지스 리미티드 | Altering microbial populations & modifying microbiota |
JP2018515139A (en) | 2015-05-08 | 2018-06-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Universal donor stem cells and related methods |
US10392607B2 (en) | 2015-06-03 | 2019-08-27 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
WO2016196887A1 (en) | 2015-06-03 | 2016-12-08 | Board Of Regents Of The University Of Nebraska | Dna editing using single-stranded dna |
EP3302525A2 (en) | 2015-06-05 | 2018-04-11 | Novartis AG | Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders |
EP3310931B1 (en) | 2015-06-17 | 2021-11-17 | The UAB Research Foundation | Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
AU2016278982A1 (en) | 2015-06-17 | 2018-01-18 | The Uab Research Foundation | CRISPR/Cas9 complex for genomic editing |
US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
US10648020B2 (en) | 2015-06-18 | 2020-05-12 | The Broad Institute, Inc. | CRISPR enzymes and systems |
US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
US9580727B1 (en) | 2015-08-07 | 2017-02-28 | Caribou Biosciences, Inc. | Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides |
WO2017035416A2 (en) | 2015-08-25 | 2017-03-02 | Duke University | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases |
US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
CN114875012A (en) | 2015-08-28 | 2022-08-09 | 通用医疗公司 | Engineered CRISPR-Cas9 nuclease |
IL241462A0 (en) | 2015-09-10 | 2015-11-30 | Yeda Res & Dev | Heterologous engineering of betalain pigments in plants |
WO2017044843A1 (en) | 2015-09-11 | 2017-03-16 | The General Hospital Corporation | Full interrogation of nuclease dsbs and sequencing (find-seq) |
US9850484B2 (en) | 2015-09-30 | 2017-12-26 | The General Hospital Corporation | Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq) |
US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
DK3350327T3 (en) | 2015-10-23 | 2019-01-21 | Caribou Biosciences Inc | CONSTRUCTED CRISPR CLASS-2-NUCLEIC ACID TARGETING-NUCLEIC ACID |
JP6929865B2 (en) | 2015-11-13 | 2021-09-01 | タラ ムーア | How to treat corneal dystrophy |
CN106893739A (en) | 2015-11-17 | 2017-06-27 | 香港中文大学 | For the new method and system of target gene operation |
EP3397260A4 (en) | 2015-11-30 | 2019-10-16 | Flagship Pioneering Innovations V, Inc. | Methods and compositions relating to chondrisomes from blood products |
KR102093570B1 (en) | 2015-12-04 | 2020-03-25 | 카리부 바이오사이언시스 인코포레이티드 | Engineered nucleic acid targeting nucleic acid |
WO2017095830A1 (en) * | 2015-12-04 | 2017-06-08 | Massachusetts Institute Of Technology | Methods of treating fragile x syndrome and related disorders |
US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
JP6821598B2 (en) | 2015-12-07 | 2021-01-27 | ザイマージェン インコーポレイテッド | Promoter derived from Corynebacterium glutamicum |
US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
JP7449646B2 (en) | 2015-12-30 | 2024-03-14 | アヴェクタス リミテッド | Vector-free delivery of gene editing proteins and compositions to cells and tissues |
MY196175A (en) | 2016-01-11 | 2023-03-20 | Univ Leland Stanford Junior | Chimeric Proteins And Methods Of Regulating Gene Expression |
BR112018013663A2 (en) | 2016-01-11 | 2019-01-22 | Univ Leland Stanford Junior | chimeric proteins and immunotherapy methods |
US10876129B2 (en) | 2016-02-12 | 2020-12-29 | Ceres, Inc. | Methods and materials for high throughput testing of mutagenized allele combinations |
WO2017143071A1 (en) | 2016-02-18 | 2017-08-24 | The Regents Of The University Of California | Methods and compositions for gene editing in stem cells |
US12037601B2 (en) | 2016-03-04 | 2024-07-16 | Indoor Biotechnologies Inc. | Method of inactivating a FEL D1 gene using crispr |
JP2019515654A (en) | 2016-03-16 | 2019-06-13 | ザ ジェイ. デヴィッド グラッドストーン インスティテューツ | Methods and compositions for treating obesity and / or diabetes, and methods and compositions for identifying candidate treatment agents |
CA3026112A1 (en) | 2016-04-19 | 2017-10-26 | The Broad Institute, Inc. | Cpf1 complexes with reduced indel activity |
WO2017207589A1 (en) * | 2016-06-01 | 2017-12-07 | Kws Saat Se | Hybrid nucleic acid sequences for genome engineering |
GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
WO2018229521A1 (en) | 2016-06-16 | 2018-12-20 | Oslo Universitetssykehus Hf | Improved gene editing |
WO2018005445A1 (en) | 2016-06-27 | 2018-01-04 | The Broad Institute, Inc. | Compositions and methods for detecting and treating diabetes |
JP2019519242A (en) | 2016-06-30 | 2019-07-11 | ザイマージェン インコーポレイテッド | Method for generating a bacterial hemoglobin library and its use |
EP3478845A4 (en) | 2016-06-30 | 2019-07-31 | Zymergen, Inc. | Methods for generating a glucose permease library and uses thereof |
US11078481B1 (en) | 2016-08-03 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
ES2909556T3 (en) | 2016-08-08 | 2022-05-09 | Aerase Inc | Compositions and methods for treating cancer with arginine-lowering agents and immuno-oncology |
WO2018039145A1 (en) | 2016-08-20 | 2018-03-01 | Avellino Lab Usa, Inc. | Single guide rna, crispr/cas9 systems, and methods of use thereof |
WO2020225754A1 (en) | 2019-05-06 | 2020-11-12 | Mcmullen Tara | Crispr gene editing for autosomal dominant diseases |
US11078483B1 (en) | 2016-09-02 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for measuring and improving CRISPR reagent function |
IL247752A0 (en) | 2016-09-11 | 2016-11-30 | Yeda Res & Dev | Compositions and methods for regulating gene expression for targeted mutagenesis |
GB2569733B (en) | 2016-09-30 | 2022-09-14 | Univ California | RNA-guided nucleic acid modifying enzymes and methods of use thereof |
US10669539B2 (en) | 2016-10-06 | 2020-06-02 | Pioneer Biolabs, Llc | Methods and compositions for generating CRISPR guide RNA libraries |
US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
EP3529359B1 (en) | 2016-10-18 | 2023-12-13 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes for use in therapy |
CN110022904B (en) | 2016-10-20 | 2024-04-19 | 桑格摩生物治疗股份有限公司 | Methods and compositions for treating brile disease |
EP3535416A4 (en) | 2016-11-04 | 2020-05-13 | Flagship Pioneering Innovations V. Inc. | Novel plant cells, plants, and seeds |
US9816093B1 (en) | 2016-12-06 | 2017-11-14 | Caribou Biosciences, Inc. | Engineered nucleic acid-targeting nucleic acids |
RU2019121992A (en) | 2016-12-14 | 2021-01-15 | Лигандал, Инк. | METHODS AND COMPOSITIONS FOR DELIVERING PAYLOAD IN THE FORM OF NUCLEIC ACIDS AND PROTEINS |
ES2924063T3 (en) | 2016-12-22 | 2022-10-04 | Avectas Ltd | Vector-free intracellular release via reversible permeabilization |
US11624071B2 (en) | 2017-01-28 | 2023-04-11 | Inari Agriculture Technology, Inc. | Method of creating a plurality of targeted insertions in a plant cell |
EP3580337A4 (en) | 2017-02-10 | 2020-12-02 | Zymergen, Inc. | A modular universal plasmid design strategy for the assembly and editing of multiple dna constructs for multiple hosts |
US10828330B2 (en) | 2017-02-22 | 2020-11-10 | IO Bioscience, Inc. | Nucleic acid constructs comprising gene editing multi-sites and uses thereof |
AU2018254619B2 (en) | 2017-04-21 | 2022-07-21 | The General Hospital Corporation | Variants of Cpf1 (CAS12a) with altered PAM specificity |
CA3064828A1 (en) | 2017-05-25 | 2018-11-29 | The General Hospital Corporation | Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing |
EP3409104A1 (en) | 2017-05-31 | 2018-12-05 | Vilmorin et Cie | Tomato plant resistant to tomato yellow leaf curl virus, powdery mildew, and nematodes |
WO2020249996A1 (en) | 2019-06-14 | 2020-12-17 | Vilmorin & Cie | Resistance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus |
EP3409106A1 (en) | 2017-06-01 | 2018-12-05 | Vilmorin et Cie | Tolerance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus (tbrfv) |
EP3635112A2 (en) | 2017-06-06 | 2020-04-15 | Zymergen, Inc. | A htp genomic engineering platform for improving fungal strains |
ES2875579T3 (en) | 2017-06-06 | 2021-11-10 | Zymergen Inc | HTP genomic engineering platform to improve Escherichia coli |
MA52134A (en) | 2017-06-09 | 2020-04-15 | Vilmorin & Cie | COMPOSITIONS AND PROCEDURES FOR GENOMIC EDITING |
BR112019026226A2 (en) | 2017-06-13 | 2020-06-30 | Flagship Pioneering Innovations V, Inc. | compositions comprising curons and uses thereof |
CN111511375A (en) | 2017-06-30 | 2020-08-07 | 因提玛生物科学公司 | Adeno-associated virus vector for gene therapy |
WO2019023291A2 (en) | 2017-07-25 | 2019-01-31 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for making and decoding paired-guide rna libraries and uses thereof |
US11897920B2 (en) | 2017-08-04 | 2024-02-13 | Peking University | Tale RVD specifically recognizing DNA base modified by methylation and application thereof |
CN111278983A (en) | 2017-08-08 | 2020-06-12 | 北京大学 | Gene knockout method |
CN111278450B (en) | 2017-08-23 | 2024-04-09 | 通用医疗公司 | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
CN111655861A (en) | 2017-08-24 | 2020-09-11 | 内布拉斯加大学董事委员会 | Methods and compositions for in situ germline genome engineering |
CA3076249A1 (en) | 2017-09-21 | 2019-03-28 | Dana-Farber Cancer Institute, Inc. | Isolation, preservation, compositions and uses of extracts from justicia plants |
JP2020537541A (en) | 2017-09-29 | 2020-12-24 | インテリア セラピューティクス,インコーポレーテッド | Method of delivering MRNA in vitro using lipid nanoparticles |
CN118530993A (en) | 2017-09-29 | 2024-08-23 | 因特利亚治疗公司 | Compositions and methods for TTR gene editing and treatment of ATTR amyloidosis |
FI3688162T3 (en) | 2017-09-29 | 2024-05-15 | Intellia Therapeutics Inc | Formulations |
IL311278A (en) | 2017-09-29 | 2024-05-01 | Intellia Therapeutics Inc | Polynucleotides, compositions, and methods for genome editing |
EP3694993A4 (en) | 2017-10-11 | 2021-10-13 | The General Hospital Corporation | Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies |
US12018080B2 (en) | 2017-11-13 | 2024-06-25 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway |
JP7557367B2 (en) | 2017-11-17 | 2024-09-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | TIL expansion from fine needle aspirates and small biopsies |
JP2021503885A (en) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood |
CN111787941A (en) | 2017-12-05 | 2020-10-16 | 艾瑞思有限公司 | Methods and compositions for treating arginase 1deficiency |
AU2018378833A1 (en) | 2017-12-08 | 2020-07-09 | Synthetic Genomics, Inc. | Improving algal lipid productivity via genetic modification of a TPR domain containing protein |
AU2019209292B2 (en) | 2018-01-17 | 2023-10-05 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
WO2019147743A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
US11926835B1 (en) | 2018-01-29 | 2024-03-12 | Inari Agriculture Technology, Inc. | Methods for efficient tomato genome editing |
EP3749764A1 (en) | 2018-02-08 | 2020-12-16 | Zymergen, Inc. | Genome editing using crispr in corynebacterium |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
WO2019195738A1 (en) | 2018-04-06 | 2019-10-10 | Children's Medical Center Corporation | Compositions and methods for somatic cell reprogramming and modulating imprinting |
AU2019256287A1 (en) | 2018-04-17 | 2020-11-12 | The General Hospital Corporation | Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents |
KR20210003819A (en) | 2018-04-19 | 2021-01-12 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Compositions and methods for gene editing |
CN112368003A (en) | 2018-04-27 | 2021-02-12 | 艾欧凡斯生物治疗公司 | Gene editing of tumor infiltrating lymphocytes and use thereof in immunotherapy |
SG11202010631UA (en) | 2018-04-27 | 2020-11-27 | Genedit Inc | Cationic polymer and use for biomolecule delivery |
CN112513243A (en) | 2018-06-01 | 2021-03-16 | 阿维塔斯有限公司 | Cell engineering platform |
US11866719B1 (en) | 2018-06-04 | 2024-01-09 | Inari Agriculture Technology, Inc. | Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
WO2020003311A1 (en) | 2018-06-25 | 2020-01-02 | Yeda Research And Development Co. Ltd. | Systems and methods for increasing efficiency of genome editing |
CA3105658A1 (en) | 2018-07-13 | 2020-01-16 | The Regents Of The University Of California | Retrotransposon-based delivery vehicle and methods of use thereof |
CA3113190A1 (en) | 2018-07-31 | 2020-02-06 | Intellia Therapeutics, Inc. | Compositions and methods for hydroxyacid oxidase 1 (hao1) gene editing for treating primary hyperoxaluria type 1 (ph1) |
EP3607819A1 (en) | 2018-08-10 | 2020-02-12 | Vilmorin et Cie | Resistance to xanthomonas campestris pv. campestris (xcc) in cauliflower |
WO2020086144A2 (en) | 2018-08-15 | 2020-04-30 | Zymergen Inc. | APPLICATIONS OF CRISPRi IN HIGH THROUGHPUT METABOLIC ENGINEERING |
CN112867792A (en) | 2018-08-23 | 2021-05-28 | 桑格摩生物治疗股份有限公司 | Engineered target-specific base editor |
WO2020047300A1 (en) * | 2018-08-29 | 2020-03-05 | Io Biosciences, Inc. | Nucleic acid constructs comprising gene editing multi-sites and uses thereof |
US11479762B1 (en) | 2018-08-31 | 2022-10-25 | Inari Agriculture Technology, Inc. | Compositions, systems, and methods for genome editing |
JP2022502055A (en) | 2018-09-28 | 2022-01-11 | インテリア セラピューティクス,インコーポレイテッド | Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene Editing |
US11207425B2 (en) * | 2018-09-28 | 2021-12-28 | City University Of Hong Kong | Guide RNA molecule and method for treating cancer |
US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
KR20210091160A (en) | 2018-10-16 | 2021-07-21 | 인텔리아 테라퓨틱스, 인크. | Compositions and methods for immunotherapy |
WO2020082046A2 (en) | 2018-10-18 | 2020-04-23 | Intellia Therapeutics, Inc. | Compositions and methods for expressing factor ix |
MX2021004276A (en) | 2018-10-18 | 2021-09-08 | Intellia Therapeutics Inc | Compositions and methods for treating alpha-1 antitrypsin deficiencey. |
EP3867381A2 (en) | 2018-10-18 | 2021-08-25 | Intellia Therapeutics, Inc. | Compositions and methods for transgene expression from an albumin locus |
SG11202103732RA (en) | 2018-10-18 | 2021-05-28 | Intellia Therapeutics Inc | Nucleic acid constructs and methods of use |
US12116458B2 (en) | 2018-10-24 | 2024-10-15 | Genedit Inc. | Cationic polymer with alkyl side chains and use for biomolecule delivery |
US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
US11407995B1 (en) | 2018-10-26 | 2022-08-09 | Inari Agriculture Technology, Inc. | RNA-guided nucleases and DNA binding proteins |
EP3874037A4 (en) | 2018-10-31 | 2021-12-15 | Zymergen, Inc. | Multiplexed deterministic assembly of dna libraries |
US11434477B1 (en) | 2018-11-02 | 2022-09-06 | Inari Agriculture Technology, Inc. | RNA-guided nucleases and DNA binding proteins |
WO2020096986A2 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
EP3876957A1 (en) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
MX2021004775A (en) | 2018-11-05 | 2021-06-08 | Iovance Biotherapeutics Inc | Expansion of tils utilizing akt pathway inhibitors. |
CA3118624A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
US20220193131A1 (en) | 2018-12-19 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof |
US11946040B2 (en) | 2019-02-04 | 2024-04-02 | The General Hospital Corporation | Adenine DNA base editor variants with reduced off-target RNA editing |
CN112805026A (en) | 2019-02-06 | 2021-05-14 | 桑格摩生物治疗股份有限公司 | Methods for treating mucopolysaccharidosis type I |
WO2020163856A1 (en) | 2019-02-10 | 2020-08-13 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Modified mitochondrion and methods of use thereof |
EP3931310A1 (en) | 2019-03-01 | 2022-01-05 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
CN113811607A (en) | 2019-03-07 | 2021-12-17 | 加利福尼亚大学董事会 | CRISPR-Cas effector polypeptides and methods of use thereof |
JP2022524043A (en) * | 2019-03-08 | 2022-04-27 | ザイマージェン インコーポレイテッド | Repeated genome editing of microorganisms |
JP2022524081A (en) | 2019-03-08 | 2022-04-27 | オブシディアン セラピューティクス, インコーポレイテッド | Human Carbonic Amhydrase 2 Compositions and Methods for Adjustable Control |
US11053515B2 (en) | 2019-03-08 | 2021-07-06 | Zymergen Inc. | Pooled genome editing in microbes |
JP2022527302A (en) | 2019-03-28 | 2022-06-01 | インテリア セラピューティクス,インコーポレイテッド | Polynucleotides, compositions, and methods for polypeptide expression |
AU2020248337A1 (en) | 2019-03-28 | 2021-11-04 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof |
CN115141807A (en) | 2019-04-02 | 2022-10-04 | 桑格摩生物治疗股份有限公司 | Methods of treating beta-thalassemia |
CN114007597A (en) | 2019-04-23 | 2022-02-01 | 基因编辑有限公司 | Cationic polymers with alkyl side chains |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
CA3142035A1 (en) | 2019-05-28 | 2020-12-03 | Genedit Inc. | Polymer comprising multiple functionalized sidechains for biomolecule delivery |
WO2020254850A1 (en) | 2019-06-21 | 2020-12-24 | Vilmorin & Cie | Improvement of quality and permanence of green color of peppers at maturity and over-maturity |
BR112021026220A2 (en) | 2019-06-25 | 2022-02-15 | Inari Agriculture Tech Inc | Enhanced genome editing by homology-dependent repair |
WO2021019272A1 (en) | 2019-07-31 | 2021-02-04 | Vilmorin & Cie | Tolerance to tolcndv in cucumber |
WO2021028359A1 (en) | 2019-08-09 | 2021-02-18 | Sangamo Therapeutics France | Controlled expression of chimeric antigen receptors in t cells |
TW202118873A (en) | 2019-08-27 | 2021-05-16 | 美商維泰克斯製藥公司 | Compositions and methods for treatment of disorders associated with repetitive dna |
US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
JP2022548320A (en) | 2019-09-23 | 2022-11-17 | オメガ セラピューティクス, インコーポレイテッド | Compositions and methods for modulating apolipoprotein B (APOB) gene expression |
CN114729376A (en) | 2019-09-23 | 2022-07-08 | 欧米茄治疗公司 | Compositions and methods for modulating hepatocyte nuclear factor 4 alpha (HNF4 alpha) gene expression |
JP2022553389A (en) | 2019-10-25 | 2022-12-22 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Gene editing of tumor-infiltrating lymphocytes and its use in immunotherapy |
WO2021094805A1 (en) | 2019-11-14 | 2021-05-20 | Vilmorin & Cie | Resistance to acidovorax valerianellae in corn salad |
WO2021118626A1 (en) | 2019-12-10 | 2021-06-17 | Inscripta, Inc. | Novel mad nucleases |
US20230220341A1 (en) | 2019-12-11 | 2023-07-13 | lovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
US11060141B1 (en) | 2019-12-23 | 2021-07-13 | Stilla Technologies | Multiplex drop-off digital polymerase chain reaction methods |
EP4090743A1 (en) | 2020-01-13 | 2022-11-23 | Sana Biotechnology, Inc. | Modification of blood type antigens |
US20230073449A1 (en) | 2020-01-23 | 2023-03-09 | The Children's Medical Center Corporation | Stroma-free t cell differentiation from human pluripotent stem cells |
CA3173528A1 (en) | 2020-03-11 | 2021-09-16 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
WO2021191678A1 (en) | 2020-03-23 | 2021-09-30 | Avectas Limited | Engineering of dendritic cells for generation of vaccines against sars-cov-2 |
WO2021216622A1 (en) | 2020-04-21 | 2021-10-28 | Aspen Neuroscience, Inc. | Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom |
WO2021216623A1 (en) | 2020-04-21 | 2021-10-28 | Aspen Neuroscience, Inc. | Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom |
EP4138805A1 (en) | 2020-04-23 | 2023-03-01 | Genedit Inc. | Polymer with cationic and hydrophobic side chains |
WO2021222287A2 (en) | 2020-04-28 | 2021-11-04 | Intellia Therapeutics, Inc. | Methods of in vitro cell delivery |
CA3176826A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
US20230193212A1 (en) | 2020-05-06 | 2023-06-22 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
WO2021245435A1 (en) | 2020-06-03 | 2021-12-09 | Vilmorin & Cie | Melon plants resistant to scab disease, aphids and powdery mildew |
EP4161552A1 (en) | 2020-06-05 | 2023-04-12 | The Broad Institute, Inc. | Compositions and methods for treating neoplasia |
US20230276763A1 (en) | 2020-06-05 | 2023-09-07 | Vilmorin & Cie | Resistance in plants of solanum lycopersicum to the tobrfv |
CN111748539B (en) * | 2020-06-11 | 2021-10-22 | 中国农业科学院农产品加工研究所 | CRISPR/LpCas9 gene editing system and application thereof |
JP2023536699A (en) * | 2020-07-22 | 2023-08-29 | アルゲン バイオテクノロジーズ,インク. | Method and system for determining drug efficacy |
WO2022026516A1 (en) * | 2020-07-29 | 2022-02-03 | The Board Of Regents Of The University Of Texas System | Transgene cassettes, aav vectors, and aav viral vectors for expression of human codon-optimized cstb |
CN116096378A (en) | 2020-08-10 | 2023-05-09 | 诺华股份有限公司 | Treatment of retinal degenerative diseases |
KR20230079203A (en) | 2020-10-02 | 2023-06-05 | 빌모린 & 씨아이이 | Melon with extended shelf life |
CA3195019A1 (en) | 2020-10-06 | 2022-04-14 | Maria Fardis | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
MX2023006612A (en) | 2020-12-03 | 2023-06-19 | Vilmorin & Cie | Tomato plants resistant to tobrfv, tmv, tomv and tommv and corresponding resistance genes. |
EP4259792A1 (en) | 2020-12-11 | 2023-10-18 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing involving deamination |
IL303505A (en) | 2020-12-11 | 2023-08-01 | Intellia Therapeutics Inc | Compositions and methods for reducing mhc class ii in a cell |
WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
EP4262827A1 (en) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
JP2024501287A (en) | 2020-12-23 | 2024-01-11 | フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド | In vitro assembly of RNA-confined Anellovirus capsids |
JP2024501246A (en) | 2020-12-23 | 2024-01-11 | インテリア セラピューティクス,インコーポレイテッド | Compositions and methods for genetically modifying CIITA in cells |
MX2023007466A (en) | 2020-12-23 | 2023-08-18 | Intellia Therapeutics Inc | Compositions and methods for reducing hla-a in a cell. |
CN116848235A (en) | 2020-12-30 | 2023-10-03 | 因特利亚治疗公司 | Engineered T cells |
CN112680479A (en) * | 2021-01-13 | 2021-04-20 | 汪利平 | Preparation method of zebra fish with CYP1B1 gene deletion |
WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
JP2024505084A (en) | 2021-02-01 | 2024-02-02 | アヴェクタス リミテッド | delivery platform |
WO2022170194A2 (en) | 2021-02-08 | 2022-08-11 | Intellia Therapeutics, Inc. | Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy |
WO2022170172A1 (en) | 2021-02-08 | 2022-08-11 | Intellia Therapeutics, Inc. | Natural killer cell receptor 2b4 compositions and methods for immunotherapy |
EP4288089A2 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy |
WO2022198141A1 (en) | 2021-03-19 | 2022-09-22 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
JP2024519601A (en) | 2021-03-31 | 2024-05-20 | エントラーダ セラピューティクス,インコーポレイティド | Cyclic cell-penetrating peptides |
WO2022208489A1 (en) | 2021-04-02 | 2022-10-06 | Vilmorin & Cie | Semi-determinate or determinate growth habit trait in cucurbita |
EP4322921A1 (en) | 2021-04-17 | 2024-02-21 | Intellia Therapeutics, Inc. | Lipid nanoparticle compositions |
BR112023021477A2 (en) | 2021-04-17 | 2024-01-30 | Intellia Therapeutics Inc | LIPID NANOPARTICLE COMPOSITIONS |
CA3216875A1 (en) | 2021-04-17 | 2022-10-20 | Intellia Therapeutics, Inc. | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
TW202308669A (en) | 2021-04-19 | 2023-03-01 | 美商艾歐凡斯生物治療公司 | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
CA3217862A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
EP4337263A1 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity |
EP4337261A2 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Compositions and methods for modulating mrna splicing |
KR20240012425A (en) | 2021-05-10 | 2024-01-29 | 엔트라다 테라퓨틱스, 인크. | Compositions and methods for intracellular therapeutics |
US20240269180A1 (en) | 2021-05-17 | 2024-08-15 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
CA3222341A1 (en) | 2021-06-11 | 2022-12-15 | Kunwoo Lee | Biodegradable polymer comprising side chains with polyamine and polyalkylene oxide groups |
KR20240038967A (en) | 2021-06-23 | 2024-03-26 | 엔트라다 테라퓨틱스, 인크. | Antisense compounds and methods for targeting CUG repeats |
EP4367242A2 (en) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
CA3226111A1 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
EP4377446A1 (en) | 2021-07-28 | 2024-06-05 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
EP4380353A1 (en) | 2021-08-06 | 2024-06-12 | Vilmorin & Cie | Resistance to leveillula taurica in pepper |
JP2024534114A (en) | 2021-08-24 | 2024-09-18 | インテリア セラピューティクス,インコーポレイテッド | Programmed cell death protein 1 (PD1) compositions and methods for cell therapy |
WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
MX2024005318A (en) | 2021-11-01 | 2024-09-23 | Tome Biosciences Inc | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo. |
CN118369110A (en) | 2021-11-03 | 2024-07-19 | 英特利亚治疗股份有限公司 | CD38 compositions and methods for immunotherapy |
EP4426832A1 (en) | 2021-11-03 | 2024-09-11 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Precise genome editing using retrons |
CA3237410A1 (en) | 2021-11-10 | 2023-05-19 | Friedrich Graf Finck VON FINCKENSTEIN | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
US20230279442A1 (en) | 2021-12-15 | 2023-09-07 | Versitech Limited | Engineered cas9-nucleases and method of use thereof |
WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
EP4448549A2 (en) | 2021-12-17 | 2024-10-23 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
WO2023122805A1 (en) | 2021-12-20 | 2023-06-29 | Vestaron Corporation | Sorbitol driven selection pressure method |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
CA3240593A1 (en) | 2021-12-23 | 2023-06-29 | Joel D. Richter | Therapeutic treatment for fragile x-associated disorder |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
EP4256950A1 (en) | 2022-04-06 | 2023-10-11 | Vilmorin et Cie | Tolerance to cgmmv in cucumber |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
WO2023220040A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified capsid for gene therapy |
WO2023220043A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified genome for gene therapy |
WO2023219933A1 (en) | 2022-05-09 | 2023-11-16 | Entrada Therapeutics, Inc. | Compositions and methods for delivery of nucleic acid therapeutics |
WO2023220035A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus compositions and methods for gene therapy |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2023230566A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating cytokines |
WO2023230573A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of immune responses |
WO2023230578A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating circulating factors |
WO2023230549A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of tumor suppressors and oncogenes |
WO2023230570A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating genetic drivers |
TW202408595A (en) | 2022-06-16 | 2024-03-01 | 美商英特利亞醫療公司 | Methods and compositions for genetically modifying a cell |
WO2023250511A2 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression |
WO2024006955A1 (en) | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
WO2024005864A1 (en) | 2022-06-30 | 2024-01-04 | Inari Agriculture Technology, Inc. | Compositions, systems, and methods for genome editing |
EP4299739A1 (en) | 2022-06-30 | 2024-01-03 | Inari Agriculture Technology, Inc. | Compositions, systems, and methods for genome editing |
WO2024005863A1 (en) | 2022-06-30 | 2024-01-04 | Inari Agriculture Technology, Inc. | Compositions, systems, and methods for genome editing |
EP4299733A1 (en) | 2022-06-30 | 2024-01-03 | Inari Agriculture Technology, Inc. | Compositions, systems, and methods for genome editing |
WO2024020346A2 (en) | 2022-07-18 | 2024-01-25 | Renagade Therapeutics Management Inc. | Gene editing components, systems, and methods of use |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
WO2024026406A2 (en) | 2022-07-29 | 2024-02-01 | Vestaron Corporation | Next Generation ACTX Peptides |
WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2024098027A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
WO2024102434A1 (en) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
WO2024137766A2 (en) | 2022-12-21 | 2024-06-27 | Intellia Therapeutics, Inc. | Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing |
WO2024138194A1 (en) | 2022-12-22 | 2024-06-27 | Tome Biosciences, Inc. | Platforms, compositions, and methods for in vivo programmable gene insertion |
WO2024141599A1 (en) | 2022-12-29 | 2024-07-04 | Vilmorin & Cie | Tomato plants resistant to resistance-breaking tswv strains and corresponding resistance genes |
WO2024186890A1 (en) | 2023-03-06 | 2024-09-12 | Intellia Therapeutics, Inc. | Compositions and methods for hepatitis b virus (hbv) genome editing |
WO2024186971A1 (en) | 2023-03-07 | 2024-09-12 | Intellia Therapeutics, Inc. | Cish compositions and methods for immunotherapy |
WO2024211287A1 (en) | 2023-04-03 | 2024-10-10 | Seagen Inc. | Production cell lines with targeted integration sites |
WO2024220574A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
WO2024220598A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
WO2024220560A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
WO2024218295A1 (en) | 2023-04-21 | 2024-10-24 | Vib Vzw | Allelic combinations in crops for yield increase |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
EP0264166A1 (en) | 1986-04-09 | 1988-04-20 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
WO1991016024A1 (en) | 1990-04-19 | 1991-10-31 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
WO1993024641A2 (en) | 1992-06-02 | 1993-12-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Adeno-associated virus with inverted terminal repeat sequences as promoter |
US20030087817A1 (en) | 1999-01-12 | 2003-05-08 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6603061B1 (en) | 1999-07-29 | 2003-08-05 | Monsanto Company | Agrobacterium-mediated plant transformation method |
US20090100536A1 (en) | 2001-12-04 | 2009-04-16 | Monsanto Company | Transgenic plants with enhanced agronomic traits |
US7868149B2 (en) | 1999-07-20 | 2011-01-11 | Monsanto Technology Llc | Plant genome sequence and uses thereof |
US20110059502A1 (en) | 2009-09-07 | 2011-03-10 | Chalasani Sreekanth H | Multiple domain proteins |
US9409700B1 (en) | 2013-11-22 | 2016-08-09 | Trent Haling | Nozzle protector assembly |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104531672B (en) | 2007-03-02 | 2020-01-10 | 杜邦营养生物科学有限公司 | Cultures with improved phage resistance |
US8546553B2 (en) | 2008-07-25 | 2013-10-01 | University Of Georgia Research Foundation, Inc. | Prokaryotic RNAi-like system and methods of use |
US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
WO2010054108A2 (en) | 2008-11-06 | 2010-05-14 | University Of Georgia Research Foundation, Inc. | Cas6 polypeptides and methods of use |
US10087431B2 (en) | 2010-03-10 | 2018-10-02 | The Regents Of The University Of California | Methods of generating nucleic acid fragments |
MX2012013037A (en) | 2010-05-10 | 2013-07-29 | Univ California | Endoribonuclease compositions and methods of use thereof. |
WO2012164565A1 (en) | 2011-06-01 | 2012-12-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for downregulating prokaryotic genes |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
WO2013141680A1 (en) * | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
US9637739B2 (en) * | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
ES2636902T3 (en) | 2012-05-25 | 2017-10-10 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modulation |
SG10201809566SA (en) | 2012-10-23 | 2018-11-29 | Toolgen Inc | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
CA2891347C (en) | 2012-12-06 | 2018-02-27 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
SG11201504621RA (en) | 2012-12-17 | 2015-07-30 | Harvard College | Rna-guided human genome engineering |
-
2013
- 2013-12-12 WO PCT/US2013/074790 patent/WO2014093694A1/en active Application Filing
- 2013-12-12 US US14/105,031 patent/US20140310830A1/en not_active Abandoned
-
2014
- 2014-02-18 US US14/183,471 patent/US8889356B2/en active Active
- 2014-04-22 US US14/258,458 patent/US8932814B2/en active Active
-
2016
- 2016-08-05 US US15/229,702 patent/US20170191078A1/en not_active Abandoned
-
2018
- 2018-04-30 US US15/967,464 patent/US20180355375A1/en active Pending
-
2020
- 2020-07-24 US US16/938,110 patent/US20200354742A1/en active Pending
Patent Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
EP0264166A1 (en) | 1986-04-09 | 1988-04-20 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
WO1991016024A1 (en) | 1990-04-19 | 1991-10-31 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
WO1993024641A2 (en) | 1992-06-02 | 1993-12-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Adeno-associated virus with inverted terminal repeat sequences as promoter |
US20030087817A1 (en) | 1999-01-12 | 2003-05-08 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7868149B2 (en) | 1999-07-20 | 2011-01-11 | Monsanto Technology Llc | Plant genome sequence and uses thereof |
US6603061B1 (en) | 1999-07-29 | 2003-08-05 | Monsanto Company | Agrobacterium-mediated plant transformation method |
US20090100536A1 (en) | 2001-12-04 | 2009-04-16 | Monsanto Company | Transgenic plants with enhanced agronomic traits |
US20110059502A1 (en) | 2009-09-07 | 2011-03-10 | Chalasani Sreekanth H | Multiple domain proteins |
US9409700B1 (en) | 2013-11-22 | 2016-08-09 | Trent Haling | Nozzle protector assembly |
Non-Patent Citations (135)
Title |
---|
"METHODS IN ENZYMOLOGY", ACADEMIC PRESS, INC |
A. R. GRUBER ET AL., CELL, vol. 106, no. 1, 2008, pages 23 - 24 |
A.R. GRUBER ET AL., CELL, vol. 106, no. 1, 2008, pages 23 - 24 |
AHMAD ET AL., CANCER RES, vol. 52, 1992, pages 4817 - 4820 |
AMRANN ET AL.: "Gene", 1988, pages: 301 - 315 |
ANDERSON, SCIENCE, vol. 256, 1992, pages 808 - 813 |
BAE, T.; SCHNEEWIND, O: "Allelic replacement in Staphylococcus aurcus with inducible counter-selection", PLASMID, vol. 55, 2006, pages 58 - 63 |
BALDARI ET AL., EMBO J, vol. 6, 1987, pages 229 - 234 |
BANEIJI ET AL., CELL, vol. 33, 1983, pages 729 - 740 |
BARRANGOU, R: "RNA-mediated programmable DNA cleavage", NAT. BIOTECHNOL., vol. 30, 2012, pages 836 - 838 |
BEHR ET AL., BIOCONJUGATE CHEM., vol. 5, 1994, pages 382 - 189 |
BIKARD, D; HATOUM-ASLAN, A.; MUCIDA, D; MARRAFFINI, L A: "CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection", CELL HOST MICROBE, vol. 12, 2012, pages 177 - 186 |
BIOUNS, S J.: "Molecular biology A Swiss army knife of immunity", SCIENCE, vol. 337, 2012, pages 808 - 809 |
BLAESE ET AL., CANCER GENE THER., vol. 2, 1995, pages 291 - 297 |
BLAKE WIEDENHEFT ET AL: "RNA-guided genetic silencing systems in bacteria and archaea", NATURE, vol. 482, no. 7385, 15 February 2012 (2012-02-15), pages 331 - 338, XP055116249, ISSN: 0028-0836, DOI: 10.1038/nature10886 * |
BOGDANOVE, A.J.; VOYTAS, D.F.: "TAL effectors: customizable proteins for DNA targeting", SCIENCE, vol. 333, 2011, pages 1843 - 1846 |
BOSHART ET AL., CELL, vol. 41, 1985, pages 521 - 530 |
BROUNS, S.J. ET AL.: "Small CRISPR RNAs guide antiviral defense in prokaryotes", SCIENCE, vol. 321, 2008, pages 960 - 964 |
BUCHSCHER ET AL., J. VIROL., vol. 66, 1992, pages 2731 - 2739 |
BYRNE; RUDDLE, PROC NATL. 4CAD SCI USA, vol. 86, 1989, pages 5473 - 5477 |
CALAME; EATON, ADV. IMMUNOL, vol. 43, 1988, pages 235 - 275 |
CAMPES; TILGHMAN, GENES DEV., vol. 3, 1989, pages 537 - 546 |
CARROLL, D A: "CRISPR Appioach to Gene Targeting", MOL. THER, vol. 20, 2012, pages 1658 - 1660 |
CARTE, J.; WANG, R.; LI, H.; TERNS, R.M.; TERNS, M.P: "Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes", GENES DEV., vol. 22, 2008, pages 3489 - 3496 |
CONG, L ET AL., SCIENCE, vol. 339, no. 6121, 15 February 2013 (2013-02-15), pages 819 - 23 |
CONG, L. ET AL.: "Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, 2013 |
COSTANTINO N; COURT, D L: "Enhanced levels of lambda Red-mediated recombinants in mismatch repair mutants", PROC. NATL. ACAD. SCI. U.S.A., vol. 100, 2003, pages 15748 - 15753 |
CRYSTAL, SCIENCE, vol. 270, 1995, pages 404 - 410 |
DELTCHEVA, E ET AL.: "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III", NATURE, vol. 471, 2011, pages 602 - 607 |
DEVEAU, H ET AL.: "Phage response to CRISPR-encoded resistance in Streptococcus thermophilus", J. BACTERIOL., vol. 190, 2008, pages 1390 - 1400 |
DEVEAU, H.; GARNEAU, J.E.; MOINEAU, S.: "CRISPR/Cas system and its role in phage- bacteria interactions", ANNU. REV. MICROBIOL., vol. 64, 2010, pages 475 - 493 |
DILLON, TITECH, vol. 11, 1993, pages 167 - 175 |
EDGAR, R.; QIMRON, U: "The Escherichia colt CRISPR system protects from lambda lysogenization, lysogens, and prophage induction", J BACTERIOL., vol. 192, 2010, pages 6291 - 6294 |
EDLUND ET AL., SCIENCE, vol. 230, 1985, pages 912 - 916 |
ELIAS I TRABOULSI,: "Genetic Diseases of the Eye, Second Edition", 2012, OXFORD UNIVERSITY PRESS |
ELITZA DELTCHEVA ET AL: "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III", NATURE, vol. 471, no. 7340, 31 March 2011 (2011-03-31), pages 602 - 607, XP055068535, ISSN: 0028-0836, DOI: 10.1038/nature09886 * |
F. M. AUSUBEL, ET AL.: "CURRENT PROTOCOLS IN MOLECULAR BIOLOGY", 1987 |
FISCHER, S. ET AL.: "An archaeal immune system can detect multiple Protospacer Adjacent Motifs (PAMs) to target invader DNA", J. BIOL. CHEM., vol. 287, 2012, pages 33351 - 33363 |
G. GASIUNAS ET AL: "PNAS Plus: Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 39, 25 September 2012 (2012-09-25), pages E2579 - E2586, XP055068588, ISSN: 0027-8424, DOI: 10.1073/pnas.1208507109 * |
GAJ THOMAS ET AL: "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering", TRENDS IN BIOTECHNOLOGY, vol. 31, no. 7, 1 July 2013 (2013-07-01), pages 397 - 405, XP028571313, ISSN: 0167-7799, DOI: 10.1016/J.TIBTECH.2013.04.004 * |
GAO ET AL., GENE THERAPY, vol. 2, 1995, pages 710 - 722 |
GASIUNAS, G.; BARRANGOU, R.; HORVATH, P; SIKSNYS, V: "Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria", PROC NATL. ACAD SCI. U.S.A, 2012 |
GIBSON, D.G. ET AL.: "Enzymatic assembly of DNA molecules up to several hundred kilobases", NAT METHODS, vol. 6, 2009, pages 343 - 345 |
GOEDDEL: "GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY", vol. 185, 1990, ACADEMIC PRESS |
GROENEN ET AL., MOL. MICROBIOL., vol. 10, 1993, pages 1057 - 1065 |
GUDBERGSDOTTIR, S. ET AL.: "Dynamic properties of the Sulfolobus CRISPR/Cas and CRISPR Cmr systems when challenged with vector-borne viral and plasmid genes and protospacers", MOL. MICROBIOL, vol. 79, 2011, pages 35 - 49 |
HADDADA ET AL.: "Current Topics in Microbiology and Immunology", 1995 |
HARLOW; LANE: "ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE", 1987 |
HATOUM-ASLAN, A.; MANIV, I; MARRAFFINI, L A: "Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is measured by a ruler mechanism anchored at the precursor processing site", PROC. NATL. ACAD. SCI. U.S.A, vol. 108, pages 21218 - 21222 |
HAURWITZ, R.E; JINEK, M.; WIEDENHEFT, B; ZHOU, K; DOUDNA, J.A: "Sequence- and structure-specific RNA processing by a CRISPR endonuclease", SCIENCE, vol. 329, 2010, pages 1355 - 1358 |
HAVARSTEIN, L.S.; COOMARASWAMY, G; MORRISON, D.A: "An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae", PROC. NATL. ACAD. SCI. U.S.A., vol. 92, 1995, pages 11140 - 11144 |
HERMONAT; MUZYCZKA, PNAS, vol. 81, 1984, pages 6466 - 6470 |
HOE ET AL., EMERG INFECT DIS, vol. 5, 1999, pages 254 - 263 |
HORINOUCHI, S.; WEISBLUM, B: "Nucleotide sequence and functional map of pC194, a plasmid that specifies inducible chloramphenicol resistance", J. BACTERIOL., vol. 150, 1982, pages 815 - 825 |
HORTON, R.M: "In Vitro Recombination and Mutagenesis of DNA : SOEing Together Tailor-Made Genes", METHODS MOL. BIOL., vol. 15, 1993, pages 251 - 261 |
HORVATH. P.; BARRANGOU, R.: "CRISPR/Cas. the immune system of bacteria and archaea", SCIENCE, vol. 327, 2010, pages 167 - 170 |
HOSAKA, T. ET AL.: "The novel mutation K87E in nbosomal protein Sl 2 enhances protein synthesis activity during the late giowth phase in Escherichia coli", MOL. GENET. GENOMICS, vol. 271, 2004, pages 317 - 324 |
HOSKINS, J. ET AL.: "Genome of the bacterium Streptococcus pneumoniae strain R6", J B?CTERIOL, vol. 183, 2001, pages 5709 - 5717 |
HUSMANN, L.K.; SCOTT. J.R.; LINDAHL, G; STENBERG, L.: "Expression ofthe Arp protein, a member of the M protein family, is not sufficient to inhibit phagocytosis of Streptococcus pvogenes", INFECTION AND IMMUNITY, vol. 63, 1995, pages 345 - 348 |
ISHINO ET AL., J. BACTERIOL., vol. 169, 1987, pages 5429 - 5433 |
JANSEN ET AL., MOL. MICROBIOL, vol. 41, 2002, pages 1565 - 1575 |
JANSSEN ET AL., OMICS J. INTEG. BIOL, vol. 6, 2002, pages 23 - 33 |
JIANG WENYAN ET AL: "RNA-guided editing of bacterial genomes using CRISPR-Cas systems", NATURE BIOTECHNOLOGY,, vol. 31, no. 3, 29 January 2013 (2013-01-29), pages 233 - 239, XP002699849 * |
JINEK, M. ET AL.: "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", SCIENCE, vol. 337, 2012, pages 816 - 821 |
JOHANN ET AL., J VIROL., vol. 66, 1992, pages 1635 - 1640 |
KAUFMAN ET AL., EMBO J., vol. 6, 1987, pages 187 - 195 |
KESSEL; GRUSS, SCIENCE, vol. 249, 1990, pages 374 - 379 |
KOTIN, HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801 |
KREMER; PERRICAUDET, BRITISH MEDICAL BULLETIN, vol. 51, no. 1, 1995, pages 31 - 44 |
KRZYSZTOF CHYLINSKI ET AL: "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems", RNA BIOLOGY, vol. 10, no. 5, 1 May 2013 (2013-05-01), pages 726 - 737, XP055116068, ISSN: 1547-6286, DOI: 10.4161/rna.24321 * |
KUIJAN; HERSKOWITZ, CELL, vol. 30, 1982, pages 933 - 943 |
L. CONG ET AL: "Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, vol. 339, no. 6121, 15 February 2013 (2013-02-15), pages 819 - 823, XP055102030, ISSN: 0036-8075, DOI: 10.1126/science.1231143 * |
L. CONG ET AL: "Supplementary Material to : Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, vol. 339, no. 6121, 3 January 2013 (2013-01-03), pages 819 - 823, XP055067744, ISSN: 0036-8075, DOI: 10.1126/science.1231143 * |
LUCKLOW; SUMMERS, VIROLOGY, vol. 170, 1989, pages 31 - 39 |
LUKE A. GILBERT ET AL: "CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes", CELL, vol. 154, no. 2, 1 July 2013 (2013-07-01), pages 442 - 451, XP055115843, ISSN: 0092-8674, DOI: 10.1016/j.cell.2013.06.044 * |
M. JINEK ET AL: "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity (Supplementary Material)", SCIENCE, vol. 337, no. 6096, 28 June 2012 (2012-06-28), pages 816 - 821, XP055067747, ISSN: 0036-8075, DOI: 10.1126/science.1225829 * |
M. JINEK ET AL: "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity", SCIENCE, vol. 337, no. 6096, 17 August 2012 (2012-08-17), pages 816 - 821, XP055067740, ISSN: 0036-8075, DOI: 10.1126/science.1225829 * |
M.J. MACPHERSON, B.D. HAMES AND G.R. TAYLO: "PCR 2: A PRACTICAL APPROACH", 1995 |
MAKAROVA, K.S; ARAVIND, L.; WOLF, Y I; KOONIN, E. V: "Unification of Cas piotein families and a simple scenario for the origin and evolution of CRISPR-Cas systems", BIOL. DIRECT., vol. 6, 2011, pages 38 |
MALI, P. ET AL.: "RNA-Guided Human Genome Engineering via Cas9", SCIENCE, 2013 |
MARRAFFINI, I.A; SONTHEIMER, E.J: "Self versus non-self discrimination during CRISPR RNA-directed immunity", N?TURE, vol. 463, 2010, pages 568 - 571 |
MARRAFFINI, L A; DEDENT, A C; SCHNEEWIND, 0: "Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria", MICROBIOL. MOL. BIOL. REV, vol. 70, 2006, pages 192 - 221 |
MASEPOHL ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1307, 1996, pages 26 - 30 |
MCIVOR EL; POLAK U; NAPIERALA M, RNA BIOL, vol. 7, no. 5, September 2010 (2010-09-01), pages 551 - 8 |
MICHAEL P TERNS ET AL: "CRISPR-based adaptive immune systems", CURRENT OPINION IN MICROBIOLOGY, vol. 14, no. 3, 1 June 2011 (2011-06-01), pages 321 - 327, XP055097823, ISSN: 1369-5274, DOI: 10.1016/j.mib.2011.03.005 * |
MILLER ET AL., J VIROL., vol. 65, 1991, pages 2220 - 2224 |
MILLER, NATURE, vol. 357, 1992, pages 455 - 460 |
MITAM; CASKEY, IIBIECH, vol. 11, 1993, pages 162 - 166 |
MOJICA ET AL., MOL MICROBIOL, vol. 17, 1995, pages 85 - 93 |
MOJICA ET AL., MOL. MICROBIOL., vol. 36, 2000, pages 244 - 246 |
MOL CELL. BIOL., vol. 8, no. 1, 1988, pages 466 - 472 |
MORRELL ET AL.: "Crop genomics:advances and applications", NAT REV GENET., vol. 13, no. 2, 29 December 2011 (2011-12-29), pages 85 - 96 |
MOTAMEDI, M R; SZIGETY, S K.; ROSENBERG, S.M: "Double-strand-break repair recombination in Escherichia coli: physical evidence for a DNA replication mechanism in vivo", GENES DEV, vol. 13, 1999, pages 2889 - 2903 |
MUZYCZKA, J. CLIN. INVEST., vol. 94, 1994, pages 1351 |
NABEL; FELGNER, TIBTECH, vol. 11M, 1993, pages 211 - 217 |
NAKATA ET AL., T. BACTENOL, vol. 171, 1989, pages 3553 - 3556 |
NUCLEIC ACIDS RES., vol. 9, 1981, pages 133 - 148 |
PA CARR; GM CHURCH, NATURE BIOTECHNOLOGY, vol. 27, no. 12, 2009, pages 1151 - 62 |
PINKERT, GENES DEV., vol. 1, 1987, pages 268 - 277 |
PODBIELSKI, A.; SPELLERBERG, B.; WOISCHNIK, M.; POHL, B; LUTTICKEN, R: "Novel series of plasmid vectors for gene inactivation and expression analysis in group A streptococci (GAS", GENE, vol. 177, 1996, pages 137 - 147 |
PROC. NATL. ACAD. SCI. USA., vol. 78, no. 3, 1981, pages 1527 - 31 |
QUEEN; BALTIMORE, CELL, vol. 33, 1983, pages 741 - 748 |
REMY ET AL., BIOCONJUGATE CHEM, vol. 5, 1994, pages 647 - 654 |
ROBERT D. WELLS; TETSUO ASHIZAWA: "Genetic Instabilities and Neurological Diseases", 13 October 2011, ACADEMIC PRESS |
SAMBROOK ET AL.,: "MOLECULAR CLONING A LABORATORY MANUAI", 1989, COLD SPRING HARBOR LABORATORY PRESS, article "Chapters 16 and 17" |
SAMBROOK; FRITSCH; MANIATIS: "MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition", 1989 |
SAMULSKI ET AL., J. VIROL., vol. 63, 1989, pages 03822 - 3828 |
SAPRANAUSKAS, R ET AL.: "The Streptococcus thermophilus CRISPR/Cas system provides immunity m Escherichia coli", NUCLEIC ACIDS RES., 2011 |
SCHULTZ ET AL., GENE, vol. 54, 1987, pages 113 - 123 |
SEED, NATURE, 1987, pages 329 840 |
SEMENOVA, E ET AL.: "Interference by clustered regularly interspaced short palindromic iepeat (CRISPR) RNA is governed by a seed sequence", PROC NATL. ACAD. SCI. U.S.A, 2011 |
SHARAN, S.K.; THOMASON. L.C.; KUZNETSOV, S.G.; COURT, D.L.: "Recombineering: a homologous recombination-based method of genetic engineering", NAT. PROTOC., vol. 4, 2009, pages 206 - 223 |
SMITH ET AL., MOL. CELL BIOL, vol. 3, 1983, pages 2156 - 2165 |
SMITH; JOHNSON, GENE, vol. 67, 1988, pages 31 - 40 |
SOMMNERFELT ET AL., VIROL, vol. 176, 1990, pages 58 - 59 |
STODDARD, B.L: "Homing endonuclease structure and function", Q. REV. BIOPHYS., vol. 38, 2005, pages 49 - 95 |
STUDIER ET AL.: "GENE EXPRESSION TECHNOLOGY- METHODS IN ENZYMOLOGY", vol. 185, 1990, ACADEMIC PRESS, pages: 60 - 89 |
SUNG, C.K.; LI, H.; CLAVERYS, J.P; MORRISON, D.A: "An rpsL cassette, janus, for gene replacement through negative selection in Streptococcus pneumoniae", APPL. ENVIRON. MICROBIOL., vol. 67, 2001, pages 5190 - 5196 |
TERNS, M.P.; TERNS, R.M: "CRISPR-based adaptive immune systems", CURR. OPIN. MICROBIOL., vol. 14, 2011, pages 321 - 327 |
TIJSSEN: "Laboratory Techniques In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes Part I", 1993, ELSEVIER, article "Overview of principles of hybridization and the strategy of nucleic acid probe assay" |
TRATSCHIN ET AL., MOL. CELL. BIOL., vol. 4, 1984, pages 2072 - 2081 |
TRATSCHIN ET AL., MOL. CELL. BIOL., vol. 5, 1985, pages 3251 - 3260 |
URNOV, F.D.; REBAR, E.J.; HOLMES, M.C.; ZHANG, H.S.; GREGORY, P.D.: "Genome editing with engineered zinc finger nucleases", NAT. REV. GENET., vol. 11, 2010, pages 636 - 646 |
VAN BRUNT, BIOTECHNOLOGY, vol. 6, no. 10, 1988, pages 1149 - 1154 |
VAN DER OOST, J.; JORE. M.M.; WESTRA, E.R.; LUNDGREN, M.; BROUNS, S.J: "CRISPR-based adaptive and heritable immunity in prokaryotes", TRENDS. BIOCHEM. SCI., vol. 34, 2009, pages 40 - 407 |
VAN EMBDEN ET AL., J BACTERIOL., vol. 182, 2000, pages 2393 - 2401 |
VIGNE, RESTORATIVE NEUROLOGY AND NEUROSCIENCE, vol. 8, 1995, pages 35 - 36 |
WANG HAOYI ET AL: "One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering", CELL, vol. 153, no. 4, 9 May 2013 (2013-05-09), pages 910 - 918, XP028538358, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2013.04.025 * |
WANG, H. H ET AL.: "Genome-scale promoter engineering by coselection MAGE", NAT METHODS, vol. 9, 2012, pages 591 - 593 |
WEST ET AL., VIROLOGY, vol. 160, 1987, pages 38 - 47 |
WIEDENHEFT, B ET AL.: "RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions", PROC NATL ACAD. SCI U.S.A, 2011 |
WILSON ET AL., 1. VIROL, vol. 63, 1989, pages 2374 - 2378 |
WINOTO; BALTIMORE, EMBO J., vol. 8, 1989, pages 729 - 733 |
YU ET AL., GENE I HERAPY, vol. 1, 1994, pages 13 - 26 |
ZAHNER D; HAKENBECK, R: "The Streptococcus pneumonlae beta-galactosidase is a surface protein", J. BACTERIOL, vol. 182, 2000, pages 5919 - 5921 |
Cited By (532)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10202608B2 (en) | 2006-08-31 | 2019-02-12 | Gen9, Inc. | Iterative nucleic acid assembly using activation of vector-encoded traits |
US10457935B2 (en) | 2010-11-12 | 2019-10-29 | Gen9, Inc. | Protein arrays and methods of using and making the same |
US11845054B2 (en) | 2010-11-12 | 2023-12-19 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
US11084014B2 (en) | 2010-11-12 | 2021-08-10 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
US10982208B2 (en) | 2010-11-12 | 2021-04-20 | Gen9, Inc. | Protein arrays and methods of using and making the same |
US9322006B2 (en) | 2011-07-22 | 2016-04-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US12006520B2 (en) | 2011-07-22 | 2024-06-11 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US11702662B2 (en) | 2011-08-26 | 2023-07-18 | Gen9, Inc. | Compositions and methods for high fidelity assembly of nucleic acids |
US11976318B2 (en) | 2011-12-22 | 2024-05-07 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11111521B2 (en) | 2011-12-22 | 2021-09-07 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11566277B2 (en) | 2011-12-22 | 2023-01-31 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11639518B2 (en) | 2011-12-22 | 2023-05-02 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11293052B2 (en) | 2011-12-22 | 2022-04-05 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11293051B2 (en) | 2011-12-22 | 2022-04-05 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11549136B2 (en) | 2011-12-22 | 2023-01-10 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11566276B2 (en) | 2011-12-22 | 2023-01-31 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US10435678B2 (en) | 2011-12-30 | 2019-10-08 | Caribou Biosciences, Inc. | Modified cascade ribonucleoproteins and uses thereof |
US11939604B2 (en) | 2011-12-30 | 2024-03-26 | Caribou Biosciences, Inc. | Modified cascade ribonucleoproteins and uses thereof |
US9885026B2 (en) | 2011-12-30 | 2018-02-06 | Caribou Biosciences, Inc. | Modified cascade ribonucleoproteins and uses thereof |
US10954498B2 (en) | 2011-12-30 | 2021-03-23 | Caribou Biosciences, Inc. | Modified cascade ribonucleoproteins and uses thereof |
US10711257B2 (en) | 2011-12-30 | 2020-07-14 | Caribou Biosciences, Inc. | Modified cascade ribonucleoproteins and uses thereof |
US10308931B2 (en) | 2012-03-21 | 2019-06-04 | Gen9, Inc. | Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis |
US10081807B2 (en) | 2012-04-24 | 2018-09-25 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
US10927369B2 (en) | 2012-04-24 | 2021-02-23 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
US9834786B2 (en) | 2012-04-25 | 2017-12-05 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
US10301646B2 (en) | 2012-04-25 | 2019-05-28 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
US11401532B2 (en) | 2012-05-25 | 2022-08-02 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11242543B2 (en) | 2012-05-25 | 2022-02-08 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10669560B2 (en) | 2012-05-25 | 2020-06-02 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10676759B2 (en) | 2012-05-25 | 2020-06-09 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10513712B2 (en) | 2012-05-25 | 2019-12-24 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11970711B2 (en) | 2012-05-25 | 2024-04-30 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10519467B2 (en) | 2012-05-25 | 2019-12-31 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11814645B2 (en) | 2012-05-25 | 2023-11-14 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10612045B2 (en) | 2012-05-25 | 2020-04-07 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10443076B2 (en) | 2012-05-25 | 2019-10-15 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10577631B2 (en) | 2012-05-25 | 2020-03-03 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11674159B2 (en) | 2012-05-25 | 2023-06-13 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10113167B2 (en) | 2012-05-25 | 2018-10-30 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10227611B2 (en) | 2012-05-25 | 2019-03-12 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10982231B2 (en) | 2012-05-25 | 2021-04-20 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10626419B2 (en) | 2012-05-25 | 2020-04-21 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10428352B2 (en) | 2012-05-25 | 2019-10-01 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10982230B2 (en) | 2012-05-25 | 2021-04-20 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11634730B2 (en) | 2012-05-25 | 2023-04-25 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10421980B2 (en) | 2012-05-25 | 2019-09-24 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10988782B2 (en) | 2012-05-25 | 2021-04-27 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10570419B2 (en) | 2012-05-25 | 2020-02-25 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10415061B2 (en) | 2012-05-25 | 2019-09-17 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10988780B2 (en) | 2012-05-25 | 2021-04-27 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11001863B2 (en) | 2012-05-25 | 2021-05-11 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10752920B2 (en) | 2012-05-25 | 2020-08-25 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10407697B2 (en) | 2012-05-25 | 2019-09-10 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10400253B2 (en) | 2012-05-25 | 2019-09-03 | The Regents Of The University Of California | Methods and compositions or RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11008589B2 (en) | 2012-05-25 | 2021-05-18 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11549127B2 (en) | 2012-05-25 | 2023-01-10 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US12123015B2 (en) | 2012-05-25 | 2024-10-22 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10900054B2 (en) | 2012-05-25 | 2021-01-26 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11479794B2 (en) | 2012-05-25 | 2022-10-25 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11473108B2 (en) | 2012-05-25 | 2022-10-18 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10000772B2 (en) | 2012-05-25 | 2018-06-19 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10385360B2 (en) | 2012-05-25 | 2019-08-20 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11008590B2 (en) | 2012-05-25 | 2021-05-18 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10774344B1 (en) | 2012-05-25 | 2020-09-15 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11332761B2 (en) | 2012-05-25 | 2022-05-17 | The Regenis of Wie University of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11028412B2 (en) | 2012-05-25 | 2021-06-08 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10266850B2 (en) | 2012-05-25 | 2019-04-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10597680B2 (en) | 2012-05-25 | 2020-03-24 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10563227B2 (en) | 2012-05-25 | 2020-02-18 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10301651B2 (en) | 2012-05-25 | 2019-05-28 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10358658B2 (en) | 2012-05-25 | 2019-07-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11293034B2 (en) | 2012-05-25 | 2022-04-05 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10550407B2 (en) | 2012-05-25 | 2020-02-04 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10640791B2 (en) | 2012-05-25 | 2020-05-05 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11274318B2 (en) | 2012-05-25 | 2022-03-15 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10487341B2 (en) | 2012-05-25 | 2019-11-26 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10308961B2 (en) | 2012-05-25 | 2019-06-04 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10358659B2 (en) | 2012-05-25 | 2019-07-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11186849B2 (en) | 2012-05-25 | 2021-11-30 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10533190B2 (en) | 2012-05-25 | 2020-01-14 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10526619B2 (en) | 2012-05-25 | 2020-01-07 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10793878B1 (en) | 2012-05-25 | 2020-10-06 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10351878B2 (en) | 2012-05-25 | 2019-07-16 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10337029B2 (en) | 2012-05-25 | 2019-07-02 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11072789B2 (en) | 2012-06-25 | 2021-07-27 | Gen9, Inc. | Methods for nucleic acid assembly and high throughput sequencing |
US10851380B2 (en) | 2012-10-23 | 2020-12-01 | Toolgen Incorporated | Methods for cleaving a target DNA using a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein |
US10731181B2 (en) | 2012-12-06 | 2020-08-04 | Sigma, Aldrich Co. LLC | CRISPR-based genome modification and regulation |
US10745716B2 (en) | 2012-12-06 | 2020-08-18 | Sigma-Aldrich Co. Llc | CRISPR-based genome modification and regulation |
EP2840140B1 (en) | 2012-12-12 | 2016-11-16 | The Broad Institute, Inc. | Crispr-Cas component systems, methods and compositions for sequence manipulation |
EP2764103B1 (en) | 2012-12-12 | 2015-08-19 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
EP2896697B1 (en) | 2012-12-12 | 2015-09-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
US9822372B2 (en) | 2012-12-12 | 2017-11-21 | The Broad Institute Inc. | CRISPR-Cas component systems, methods and compositions for sequence manipulation |
EP2825654B1 (en) | 2012-12-12 | 2017-04-26 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
EP2771468B1 (en) | 2012-12-12 | 2015-02-11 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
US9840713B2 (en) | 2012-12-12 | 2017-12-12 | The Broad Institute Inc. | CRISPR-Cas component systems, methods and compositions for sequence manipulation |
US11041173B2 (en) | 2012-12-12 | 2021-06-22 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
US10930367B2 (en) | 2012-12-12 | 2021-02-23 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and conveying results thereof |
US11299767B2 (en) | 2013-03-12 | 2022-04-12 | President And Fellows Of Harvard College | Method for generating a three-dimensional nucleic acid containing matrix |
US10125361B2 (en) | 2013-03-14 | 2018-11-13 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
US9725714B2 (en) | 2013-03-14 | 2017-08-08 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
US9809814B1 (en) | 2013-03-14 | 2017-11-07 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
US9909122B2 (en) | 2013-03-14 | 2018-03-06 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
US11312953B2 (en) | 2013-03-14 | 2022-04-26 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
US9410198B2 (en) | 2013-03-14 | 2016-08-09 | Caribou Biosciences, Inc. | Compostions and methods of nucleic acid-targeting nucleic acids |
US9803194B2 (en) | 2013-03-14 | 2017-10-31 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
US9260752B1 (en) | 2013-03-14 | 2016-02-16 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
US9738908B2 (en) | 2013-03-15 | 2017-08-22 | System Biosciences, Llc | CRISPR/Cas systems for genomic modification and gene modulation |
US10202619B2 (en) | 2013-03-15 | 2019-02-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
US12037596B2 (en) | 2013-04-16 | 2024-07-16 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
US10975390B2 (en) | 2013-04-16 | 2021-04-13 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
US10385359B2 (en) | 2013-04-16 | 2019-08-20 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
EP3004349A1 (en) * | 2013-05-29 | 2016-04-13 | Cellectis S.A. | A method for producing precise dna cleavage using cas9 nickase activity |
EP3004349B1 (en) * | 2013-05-29 | 2018-03-28 | Cellectis S.A. | A method for producing precise dna cleavage using cas9 nickase activity |
US10640789B2 (en) | 2013-06-04 | 2020-05-05 | President And Fellows Of Harvard College | RNA-guided transcriptional regulation |
US11981917B2 (en) | 2013-06-04 | 2024-05-14 | President And Fellows Of Harvard College | RNA-guided transcriptional regulation |
US10767194B2 (en) | 2013-06-04 | 2020-09-08 | President And Fellows Of Harvard College | RNA-guided transcriptional regulation |
US12018275B2 (en) | 2013-06-17 | 2024-06-25 | The Broad Institute, Inc. | Delivery and use of the CRISPR-CAS systems, vectors and compositions for hepatic targeting and therapy |
US11597949B2 (en) | 2013-06-17 | 2023-03-07 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
US10577630B2 (en) | 2013-06-17 | 2020-03-03 | The Broad Institute, Inc. | Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy |
US10946108B2 (en) | 2013-06-17 | 2021-03-16 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
US11008588B2 (en) | 2013-06-17 | 2021-05-18 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
US10781444B2 (en) | 2013-06-17 | 2020-09-22 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
US10711285B2 (en) | 2013-06-17 | 2020-07-14 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
US10773232B2 (en) | 2013-08-05 | 2020-09-15 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US9403141B2 (en) | 2013-08-05 | 2016-08-02 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US10583415B2 (en) | 2013-08-05 | 2020-03-10 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US10618024B2 (en) | 2013-08-05 | 2020-04-14 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US10632445B2 (en) | 2013-08-05 | 2020-04-28 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US10639609B2 (en) | 2013-08-05 | 2020-05-05 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US9409139B2 (en) | 2013-08-05 | 2016-08-09 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US9555388B2 (en) | 2013-08-05 | 2017-01-31 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US11559778B2 (en) | 2013-08-05 | 2023-01-24 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US10384188B2 (en) | 2013-08-05 | 2019-08-20 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US11452980B2 (en) | 2013-08-05 | 2022-09-27 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US9833761B2 (en) | 2013-08-05 | 2017-12-05 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US10272410B2 (en) | 2013-08-05 | 2019-04-30 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US9839894B2 (en) | 2013-08-05 | 2017-12-12 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US11185837B2 (en) | 2013-08-05 | 2021-11-30 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US9889423B2 (en) | 2013-08-05 | 2018-02-13 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US10227581B2 (en) | 2013-08-22 | 2019-03-12 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US10519457B2 (en) | 2013-08-22 | 2019-12-31 | E I Du Pont De Nemours And Company | Soybean U6 polymerase III promoter and methods of use |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US11773400B2 (en) | 2013-08-22 | 2023-10-03 | E.I. Du Pont De Nemours And Company | Methods for producing genetic modifications in a plant genome without incorporating a selectable transgene marker, and compositions thereof |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US11920128B2 (en) | 2013-09-18 | 2024-03-05 | Kymab Limited | Methods, cells and organisms |
US11149267B2 (en) | 2013-10-28 | 2021-10-19 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
US10640788B2 (en) | 2013-11-07 | 2020-05-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAs |
US10190137B2 (en) | 2013-11-07 | 2019-01-29 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
US9834791B2 (en) | 2013-11-07 | 2017-12-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
US11390887B2 (en) | 2013-11-07 | 2022-07-19 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
US10208317B2 (en) | 2013-12-11 | 2019-02-19 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse embryonic stem cell genome |
US11820997B2 (en) | 2013-12-11 | 2023-11-21 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
US10711280B2 (en) | 2013-12-11 | 2020-07-14 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse ES cell genome |
US9228208B2 (en) | 2013-12-11 | 2016-01-05 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11407985B2 (en) | 2013-12-12 | 2022-08-09 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing |
EP3653703A1 (en) | 2013-12-12 | 2020-05-20 | The Broad Institute, Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
EP3653704A1 (en) | 2013-12-12 | 2020-05-20 | The Broad Institute, Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
EP4219699A1 (en) | 2013-12-12 | 2023-08-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
US10851357B2 (en) | 2013-12-12 | 2020-12-01 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
EP4183876A1 (en) | 2013-12-12 | 2023-05-24 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
US11597919B2 (en) | 2013-12-12 | 2023-03-07 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
US11155795B2 (en) | 2013-12-12 | 2021-10-26 | The Broad Institute, Inc. | CRISPR-Cas systems, crystal structure and uses thereof |
EP3540051A1 (en) | 2013-12-12 | 2019-09-18 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
EP3653229A1 (en) | 2013-12-12 | 2020-05-20 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing |
US10550372B2 (en) | 2013-12-12 | 2020-02-04 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
US11591581B2 (en) | 2013-12-12 | 2023-02-28 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
WO2015089354A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
WO2015089465A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
EP3470089A1 (en) | 2013-12-12 | 2019-04-17 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
WO2015089351A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
EP3514246A1 (en) | 2014-02-27 | 2019-07-24 | The Broad Institute Inc. | T cell balance gene expression and methods of use thereof |
US11209440B2 (en) | 2014-02-27 | 2021-12-28 | The Broad Institute, Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
US11028388B2 (en) | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
US10253312B2 (en) | 2014-03-10 | 2019-04-09 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10) |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US11268086B2 (en) | 2014-03-10 | 2022-03-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10) |
US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US11242525B2 (en) | 2014-03-26 | 2022-02-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating sickle cell disease |
WO2016007604A1 (en) * | 2014-07-09 | 2016-01-14 | Gen9, Inc. | Compositions and methods for site-directed dna nicking and cleaving |
US10676754B2 (en) | 2014-07-11 | 2020-06-09 | E I Du Pont De Nemours And Company | Compositions and methods for producing plants resistant to glyphosate herbicide |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
WO2016028682A1 (en) * | 2014-08-17 | 2016-02-25 | The Broad Institute Inc. | Genome editing using cas9 nickases |
EP3686279A1 (en) | 2014-08-17 | 2020-07-29 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
WO2016036754A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification |
US11560568B2 (en) | 2014-09-12 | 2023-01-24 | E. I. Du Pont De Nemours And Company | Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use |
US11459557B2 (en) | 2014-09-24 | 2022-10-04 | The Broad Institute, Inc. | Use and production of CHD8+/− transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
US11124796B2 (en) | 2014-09-24 | 2021-09-21 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
US11197467B2 (en) | 2014-09-24 | 2021-12-14 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-cas systems and compositions for modeling mutations in leukocytes |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049251A1 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
US11001829B2 (en) | 2014-09-25 | 2021-05-11 | The Broad Institute, Inc. | Functional screening with optimized functional CRISPR-Cas systems |
EP3998344A1 (en) * | 2014-10-09 | 2022-05-18 | Life Technologies Corporation | Crispr oligonucleotides and gene editing |
WO2016069591A2 (en) | 2014-10-27 | 2016-05-06 | The Broad Institute Inc. | Compositions, methods and use of synthetic lethal screening |
TWI716367B (en) * | 2014-10-31 | 2021-01-21 | 麻省理工學院 | Massively parallel combinatorial genetics for crispr |
WO2016070037A3 (en) * | 2014-10-31 | 2016-06-23 | Massachusetts Institute Of Technology | Massively parallel combinatorial genetics for crispr |
WO2016070037A2 (en) | 2014-10-31 | 2016-05-06 | Massachusetts Institute Of Technology | Massively parallel combinatorial genetics for crispr |
EP3708155A1 (en) | 2014-10-31 | 2020-09-16 | Massachusetts Institute Of Technology | Massively parallel combinatorial genetics for crispr |
US11680268B2 (en) | 2014-11-07 | 2023-06-20 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
US10457960B2 (en) | 2014-11-21 | 2019-10-29 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide RNAs |
US11697828B2 (en) | 2014-11-21 | 2023-07-11 | Regeneran Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide RNAs |
WO2016086197A1 (en) | 2014-11-25 | 2016-06-02 | The Brigham And Women's Hospital, Inc. | Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease |
EP3626832A2 (en) | 2014-11-25 | 2020-03-25 | The Brigham and Women's Hospital, Inc. | Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease |
WO2016086227A2 (en) | 2014-11-26 | 2016-06-02 | The Regents Of The University Of California | Therapeutic compositions comprising transcription factors and methods of making and using the same |
WO2016083811A1 (en) | 2014-11-27 | 2016-06-02 | Imperial Innovations Limited | Genome editing methods |
US10337001B2 (en) | 2014-12-03 | 2019-07-02 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
US10696986B2 (en) | 2014-12-12 | 2020-06-30 | The Board Institute, Inc. | Protected guide RNAS (PGRNAS) |
EP3889260A1 (en) | 2014-12-12 | 2021-10-06 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
US11624078B2 (en) | 2014-12-12 | 2023-04-11 | The Broad Institute, Inc. | Protected guide RNAS (pgRNAS) |
WO2016100974A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
EP3702456A1 (en) | 2014-12-24 | 2020-09-02 | The Broad Institute, Inc. | Crispr having or associated with destabilization domains |
WO2016106244A1 (en) | 2014-12-24 | 2016-06-30 | The Broad Institute Inc. | Crispr having or associated with destabilization domains |
WO2016108926A1 (en) | 2014-12-30 | 2016-07-07 | The Broad Institute Inc. | Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis |
US12116619B2 (en) | 2014-12-30 | 2024-10-15 | The Broad Institute, Inc. | CRISPR mediated in vivo modeling and genetic screening of tumor growth and metastasis |
US11697668B2 (en) | 2015-02-04 | 2023-07-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
US9677067B2 (en) | 2015-02-04 | 2017-06-13 | Twist Bioscience Corporation | Compositions and methods for synthetic gene assembly |
US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
US11427869B2 (en) | 2015-02-26 | 2022-08-30 | The Broad Institute, Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
WO2016138488A2 (en) | 2015-02-26 | 2016-09-01 | The Broad Institute Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
WO2016138574A1 (en) | 2015-03-02 | 2016-09-09 | Sinai Health System | Homologous recombination factors |
US10450576B2 (en) | 2015-03-27 | 2019-10-22 | E I Du Pont De Nemours And Company | Soybean U6 small nuclear RNA gene promoters and their use in constitutive expression of small RNA genes in plants |
US11851652B2 (en) | 2015-04-06 | 2023-12-26 | The Board Of Trustees Of The Leland Stanford Junior | Compositions comprising chemically modified guide RNAs for CRISPR/Cas-mediated editing of HBB |
US11306309B2 (en) | 2015-04-06 | 2022-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide RNAs for CRISPR/CAS-mediated gene regulation |
US11535846B2 (en) | 2015-04-06 | 2022-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide RNAS for CRISPR/Cas-mediated gene regulation |
US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
US11691118B2 (en) | 2015-04-21 | 2023-07-04 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
US10744477B2 (en) | 2015-04-21 | 2020-08-18 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
US11180793B2 (en) | 2015-04-24 | 2021-11-23 | Editas Medicine, Inc. | Evaluation of Cas9 molecule/guide RNA molecule complexes |
WO2016182893A1 (en) | 2015-05-08 | 2016-11-17 | Teh Broad Institute Inc. | Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof |
US11390884B2 (en) | 2015-05-11 | 2022-07-19 | Editas Medicine, Inc. | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells |
KR101785847B1 (en) * | 2015-05-12 | 2017-10-17 | 연세대학교 산학협력단 | Targeted genome editing based on CRISPR/Cas9 system using short linearized double-stranded DNA |
US11911415B2 (en) | 2015-06-09 | 2024-02-27 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for improving transplantation |
US11643669B2 (en) | 2015-06-17 | 2023-05-09 | Massachusetts Institute Of Technology | CRISPR mediated recording of cellular events |
WO2016205728A1 (en) | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Crispr mediated recording of cellular events |
US11060115B2 (en) | 2015-06-18 | 2021-07-13 | The Broad Institute, Inc. | CRISPR enzymes and systems |
WO2016205764A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
EP3666895A1 (en) | 2015-06-18 | 2020-06-17 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
US12123032B2 (en) | 2015-06-18 | 2024-10-22 | The Broad Institute, Inc. | CRISPR enzyme mutations reducing off-target effects |
EP4159856A1 (en) | 2015-06-18 | 2023-04-05 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
US11773412B2 (en) | 2015-06-18 | 2023-10-03 | The Broad Institute, Inc. | Crispr enzymes and systems |
US20180127745A1 (en) * | 2015-06-18 | 2018-05-10 | The Broad Institute Inc. | Cell sorting |
US10876100B2 (en) | 2015-06-18 | 2020-12-29 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
US10494621B2 (en) | 2015-06-18 | 2019-12-03 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
US11421250B2 (en) | 2015-06-18 | 2022-08-23 | The Broad Institute, Inc. | CRISPR enzymes and systems |
US11578312B2 (en) | 2015-06-18 | 2023-02-14 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation |
WO2016205745A2 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
US11180751B2 (en) | 2015-06-18 | 2021-11-23 | The Broad Institute, Inc. | CRISPR enzymes and systems |
US11236327B2 (en) | 2015-06-18 | 2022-02-01 | The Broad Institute, Inc. | Cell sorting |
US11414657B2 (en) | 2015-06-29 | 2022-08-16 | Ionis Pharmaceuticals, Inc. | Modified CRISPR RNA and modified single CRISPR RNA and uses thereof |
WO2017027910A1 (en) | 2015-08-14 | 2017-02-23 | The University Of Sydney | Connexin 45 inhibition for therapy |
EP4043074A1 (en) | 2015-08-14 | 2022-08-17 | The University of Sydney | Connexin 45 inhibition for therapy |
US11214800B2 (en) | 2015-08-18 | 2022-01-04 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
WO2017044776A1 (en) * | 2015-09-10 | 2017-03-16 | Texas Tech University System | Single-guide rna (sgrna) with improved knockout efficiency |
US11807956B2 (en) | 2015-09-18 | 2023-11-07 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
US10844373B2 (en) | 2015-09-18 | 2020-11-24 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
US11512347B2 (en) | 2015-09-22 | 2022-11-29 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
US11667911B2 (en) | 2015-09-24 | 2023-06-06 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/CAS-mediated genome editing |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
EP4265633A2 (en) | 2015-10-16 | 2023-10-25 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
WO2017066760A1 (en) | 2015-10-16 | 2017-04-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
WO2017070605A1 (en) | 2015-10-22 | 2017-04-27 | The Broad Institute Inc. | Type vi-b crispr enzymes and systems |
US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
WO2017074788A1 (en) | 2015-10-27 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
US11092607B2 (en) | 2015-10-28 | 2021-08-17 | The Board Institute, Inc. | Multiplex analysis of single cell constituents |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
US11186825B2 (en) | 2015-10-28 | 2021-11-30 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 |
US11180730B2 (en) | 2015-10-28 | 2021-11-23 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075294A1 (en) | 2015-10-28 | 2017-05-04 | The Board Institute Inc. | Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
US11542554B2 (en) | 2015-11-03 | 2023-01-03 | President And Fellows Of Harvard College | Method and apparatus for volumetric imaging |
US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
US11884717B2 (en) | 2015-11-19 | 2024-01-30 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
US9895673B2 (en) | 2015-12-01 | 2018-02-20 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
US10384189B2 (en) | 2015-12-01 | 2019-08-20 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
US10987648B2 (en) | 2015-12-01 | 2021-04-27 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
WO2017114497A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
EP4219689A2 (en) | 2015-12-30 | 2023-08-02 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
WO2017147196A1 (en) | 2016-02-22 | 2017-08-31 | Massachusetts Institute Of Technology | Methods for identifying and modulating immune phenotypes |
WO2017158153A1 (en) | 2016-03-17 | 2017-09-21 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Conditional crispr sgrna expression |
WO2017161325A1 (en) | 2016-03-17 | 2017-09-21 | Massachusetts Institute Of Technology | Methods for identifying and modulating co-occurant cellular phenotypes |
US11427861B2 (en) | 2016-03-17 | 2022-08-30 | Massachusetts Institute Of Technology | Methods for identifying and modulating co-occurant cellular phenotypes |
EP3219799A1 (en) | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
US12049651B2 (en) | 2016-04-13 | 2024-07-30 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
US11713485B2 (en) | 2016-04-25 | 2023-08-01 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
WO2017189683A1 (en) | 2016-04-26 | 2017-11-02 | Massachusetts Institute Of Technology | Extensible recombinase cascades |
US10752904B2 (en) | 2016-04-26 | 2020-08-25 | Massachusetts Institute Of Technology | Extensible recombinase cascades |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
WO2017219027A1 (en) | 2016-06-17 | 2017-12-21 | The Broad Institute Inc. | Type vi crispr orthologs and systems |
US11788083B2 (en) | 2016-06-17 | 2023-10-17 | The Broad Institute, Inc. | Type VI CRISPR orthologs and systems |
WO2018013840A1 (en) | 2016-07-13 | 2018-01-18 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
EP4219462A1 (en) | 2016-07-13 | 2023-08-02 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
US12031150B2 (en) | 2016-07-13 | 2024-07-09 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
US11566263B2 (en) | 2016-08-02 | 2023-01-31 | Editas Medicine, Inc. | Compositions and methods for treating CEP290 associated disease |
US11999947B2 (en) | 2016-08-03 | 2024-06-04 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
WO2018035250A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
US11630103B2 (en) | 2016-08-17 | 2023-04-18 | The Broad Institute, Inc. | Product and methods useful for modulating and evaluating immune responses |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
US10975372B2 (en) | 2016-08-22 | 2021-04-13 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
US10053688B2 (en) | 2016-08-22 | 2018-08-21 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
US12084663B2 (en) | 2016-08-24 | 2024-09-10 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
US10754994B2 (en) | 2016-09-21 | 2020-08-25 | Twist Bioscience Corporation | Nucleic acid based data storage |
US11263354B2 (en) | 2016-09-21 | 2022-03-01 | Twist Bioscience Corporation | Nucleic acid based data storage |
US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
US11562103B2 (en) | 2016-09-21 | 2023-01-24 | Twist Bioscience Corporation | Nucleic acid based data storage |
US12056264B2 (en) | 2016-09-21 | 2024-08-06 | Twist Bioscience Corporation | Nucleic acid based data storage |
WO2018054911A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Cropscience Nv | Targeted genome optimization in plants |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
WO2018073237A1 (en) | 2016-10-17 | 2018-04-26 | The University Court Of The University Of Edinburgh | Swine comprising modified cd163 and associated methods |
WO2018080573A1 (en) | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Crispr/cas global regulator screening platform |
WO2018083606A1 (en) | 2016-11-01 | 2018-05-11 | Novartis Ag | Methods and compositions for enhancing gene editing |
WO2018083128A3 (en) * | 2016-11-02 | 2019-02-14 | Wageningen Universiteit | Microbial genome editing |
US10907274B2 (en) | 2016-12-16 | 2021-02-02 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
CN110312803B (en) * | 2016-12-21 | 2024-04-30 | 许景焜 | Compositions and methods for editing nucleic acid sequences |
CN110312803A (en) * | 2016-12-21 | 2019-10-08 | 许景焜 | Edit the composition and method of nucleic acid sequence |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US12110545B2 (en) | 2017-01-06 | 2024-10-08 | Editas Medicine, Inc. | Methods of assessing nuclease cleavage |
US11466271B2 (en) | 2017-02-06 | 2022-10-11 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
US11550939B2 (en) | 2017-02-22 | 2023-01-10 | Twist Bioscience Corporation | Nucleic acid based data storage using enzymatic bioencryption |
US11975029B2 (en) | 2017-02-28 | 2024-05-07 | Vor Biopharma Inc. | Compositions and methods for inhibition of lineage specific proteins |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11851690B2 (en) | 2017-03-14 | 2023-12-26 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
US10894959B2 (en) | 2017-03-15 | 2021-01-19 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
EP4361261A2 (en) | 2017-03-15 | 2024-05-01 | The Broad Institute Inc. | Novel cas13b orthologues crispr enzymes and systems |
WO2018170333A1 (en) | 2017-03-15 | 2018-09-20 | The Broad Institute, Inc. | Novel cas13b orthologues crispr enzymes and systems |
US11739308B2 (en) | 2017-03-15 | 2023-08-29 | The Broad Institute, Inc. | Cas13b orthologues CRISPR enzymes and systems |
WO2018170515A1 (en) | 2017-03-17 | 2018-09-20 | The Broad Institute, Inc. | Methods for identifying and modulating co-occurant cellular phenotypes |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
WO2018191520A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Respiratory and sweat gland ionocytes |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
WO2018191388A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Novel type vi crispr orthologs and systems |
WO2018191750A2 (en) | 2017-04-14 | 2018-10-18 | The Broad Institute Inc. | Novel delivery of large payloads |
WO2018195019A1 (en) | 2017-04-18 | 2018-10-25 | The Broad Institute Inc. | Compositions for detecting secretion and methods of use |
US12058986B2 (en) | 2017-04-20 | 2024-08-13 | Egenesis, Inc. | Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements |
WO2018195486A1 (en) | 2017-04-21 | 2018-10-25 | The Broad Institute, Inc. | Targeted delivery to beta cells |
US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
US11591601B2 (en) | 2017-05-05 | 2023-02-28 | The Broad Institute, Inc. | Methods for identification and modification of lncRNA associated with target genotypes and phenotypes |
US11963982B2 (en) | 2017-05-10 | 2024-04-23 | Editas Medicine, Inc. | CRISPR/RNA-guided nuclease systems and methods |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11866697B2 (en) | 2017-05-18 | 2024-01-09 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
US11603544B2 (en) | 2017-06-05 | 2023-03-14 | Fred Hutchinson Cancer Center | Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies |
US10428319B2 (en) | 2017-06-09 | 2019-10-01 | Editas Medicine, Inc. | Engineered Cas9 nucleases |
US11098297B2 (en) | 2017-06-09 | 2021-08-24 | Editas Medicine, Inc. | Engineered Cas9 nucleases |
US10696965B2 (en) | 2017-06-12 | 2020-06-30 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
US11332740B2 (en) | 2017-06-12 | 2022-05-17 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
US11377676B2 (en) | 2017-06-12 | 2022-07-05 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
WO2019005884A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
WO2019003193A1 (en) | 2017-06-30 | 2019-01-03 | Novartis Ag | Methods for the treatment of disease with gene editing systems |
US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
US12105089B2 (en) | 2017-07-17 | 2024-10-01 | The Broad Institute, Inc. | Cell atlas of the healthy and ulcerative colitis human colon |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11407837B2 (en) | 2017-09-11 | 2022-08-09 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
US12043870B2 (en) | 2017-10-02 | 2024-07-23 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
WO2019071054A1 (en) | 2017-10-04 | 2019-04-11 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
WO2019074841A1 (en) * | 2017-10-09 | 2019-04-18 | Pioneer Hi-Bred International, Inc. | Type i-e crispr-cas systems for eukaryotic genome editing |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11680296B2 (en) | 2017-10-16 | 2023-06-20 | Massachusetts Institute Of Technology | Mycobacterium tuberculosis host-pathogen interaction |
US11578118B2 (en) | 2017-10-20 | 2023-02-14 | Fred Hutchinson Cancer Center | Systems and methods to produce B cells genetically modified to express selected antibodies |
US11745159B2 (en) | 2017-10-20 | 2023-09-05 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
US10894242B2 (en) | 2017-10-20 | 2021-01-19 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
WO2019087113A1 (en) | 2017-11-01 | 2019-05-09 | Novartis Ag | Synthetic rnas and methods of use |
US11332736B2 (en) | 2017-12-07 | 2022-05-17 | The Broad Institute, Inc. | Methods and compositions for multiplexing single cell and single nuclei sequencing |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
US12086722B2 (en) | 2018-01-04 | 2024-09-10 | Twist Bioscience Corporation | DNA-based digital information storage with sidewall electrodes |
US10936953B2 (en) | 2018-01-04 | 2021-03-02 | Twist Bioscience Corporation | DNA-based digital information storage with sidewall electrodes |
WO2019138083A1 (en) | 2018-01-12 | 2019-07-18 | Basf Se | Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a |
US12121524B2 (en) | 2018-01-17 | 2024-10-22 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
WO2019143675A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
US12005127B2 (en) | 2018-01-17 | 2024-06-11 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
WO2019143678A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
US12084676B2 (en) | 2018-02-23 | 2024-09-10 | Pioneer Hi-Bred International, Inc. | Cas9 orthologs |
US12031132B2 (en) | 2018-03-14 | 2024-07-09 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
WO2019204585A1 (en) | 2018-04-19 | 2019-10-24 | Massachusetts Institute Of Technology | Single-stranded break detection in double-stranded dna |
WO2019206927A1 (en) | 2018-04-24 | 2019-10-31 | KWS SAAT SE & Co. KGaA | Plants with improved digestibility and marker haplotypes |
EP3560330A1 (en) | 2018-04-24 | 2019-10-30 | KWS SAAT SE & Co. KGaA | Plants with improved digestibility and marker haplotypes |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019210268A2 (en) | 2018-04-27 | 2019-10-31 | The Broad Institute, Inc. | Sequencing-based proteomics |
WO2019213660A2 (en) | 2018-05-04 | 2019-11-07 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
US11732294B2 (en) | 2018-05-18 | 2023-08-22 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
US11492665B2 (en) | 2018-05-18 | 2022-11-08 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
WO2020006049A1 (en) | 2018-06-26 | 2020-01-02 | The Broad Institute, Inc. | Crispr/cas and transposase based amplification compositions, systems and methods |
WO2020006036A1 (en) | 2018-06-26 | 2020-01-02 | Massachusetts Institute Of Technology | Crispr effector system based amplification methods, systems, and diagnostics |
WO2020002592A1 (en) | 2018-06-29 | 2020-01-02 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Traf2 inhibitors for use in the treatment of a cancer |
WO2020028555A2 (en) | 2018-07-31 | 2020-02-06 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2020033601A1 (en) | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Novel cas12b enzymes and systems |
WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
WO2020041380A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
US11903973B2 (en) | 2018-08-28 | 2024-02-20 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
WO2020047164A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma, Inc | Genetically engineered hematopoietic stem cells and uses thereof |
WO2020051507A1 (en) | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
EP4268831A2 (en) | 2018-09-12 | 2023-11-01 | Fred Hutchinson Cancer Center | Reducing cd33 expression to selectively protect therapeutic cells |
US11447527B2 (en) | 2018-09-18 | 2022-09-20 | Vnv Newco Inc. | Endogenous Gag-based capsids and uses thereof |
US11505578B2 (en) | 2018-09-18 | 2022-11-22 | Vnv Newco Inc. | Endogenous Gag-based capsids and uses thereof |
US12098425B2 (en) | 2018-10-10 | 2024-09-24 | Readcoor, Llc | Three-dimensional spatial molecular indexing |
WO2020077236A1 (en) | 2018-10-12 | 2020-04-16 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
US11807878B2 (en) | 2018-12-14 | 2023-11-07 | Pioneer Hi-Bred International, Inc. | CRISPR-Cas systems for genome editing |
US10934536B2 (en) | 2018-12-14 | 2021-03-02 | Pioneer Hi-Bred International, Inc. | CRISPR-CAS systems for genome editing |
US11384344B2 (en) | 2018-12-17 | 2022-07-12 | The Broad Institute, Inc. | CRISPR-associated transposase systems and methods of use thereof |
WO2020131862A1 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2020163655A1 (en) | 2019-02-06 | 2020-08-13 | Fred Hutchinson Cancer Research Center | Minicircle producing bacteria engineered to differentially methylate nucleic acid molecules therein |
US11492728B2 (en) | 2019-02-26 | 2022-11-08 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
US11492727B2 (en) | 2019-02-26 | 2022-11-08 | Twist Bioscience Corporation | Variant nucleic acid libraries for GLP1 receptor |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
WO2020206036A1 (en) | 2019-04-01 | 2020-10-08 | The Broad Institute, Inc. | Novel nucleic acid modifier |
WO2020229533A1 (en) | 2019-05-13 | 2020-11-19 | KWS SAAT SE & Co. KGaA | Drought tolerance in corn |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
WO2020237217A1 (en) | 2019-05-23 | 2020-11-26 | Vor Biopharma, Inc | Compositions and methods for cd33 modification |
WO2020239680A2 (en) | 2019-05-25 | 2020-12-03 | KWS SAAT SE & Co. KGaA | Haploid induction enhancer |
WO2020243661A1 (en) | 2019-05-31 | 2020-12-03 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
US11332738B2 (en) | 2019-06-21 | 2022-05-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
WO2021003432A1 (en) | 2019-07-02 | 2021-01-07 | Fred Hutchinson Cancer Research Center | Recombinant ad35 vectors and related gene therapy improvements |
EP3772542A1 (en) | 2019-08-07 | 2021-02-10 | KWS SAAT SE & Co. KGaA | Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2 |
WO2021041977A1 (en) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions and methods for cd123 modification |
WO2021041971A1 (en) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions and methods for cll1 modification |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
WO2021055874A1 (en) | 2019-09-20 | 2021-03-25 | The Broad Institute, Inc. | Novel type vi crispr enzymes and systems |
US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
WO2021074367A1 (en) | 2019-10-17 | 2021-04-22 | KWS SAAT SE & Co. KGaA | Enhanced disease resistance of crops by downregulation of repressor genes |
EP3872190A1 (en) | 2020-02-26 | 2021-09-01 | Antibodies-Online GmbH | A method of using cut&run or cut&tag to validate crispr-cas targeting |
US12057197B2 (en) | 2020-04-03 | 2024-08-06 | Creyon Bio, Inc. | Oligonucleotide-based machine learning |
WO2021202938A1 (en) | 2020-04-03 | 2021-10-07 | Creyon Bio, Inc. | Oligonucleotide-based machine learning |
US12031126B2 (en) | 2020-05-08 | 2024-07-09 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
WO2021239986A1 (en) | 2020-05-29 | 2021-12-02 | KWS SAAT SE & Co. KGaA | Plant haploid induction |
WO2022047165A1 (en) | 2020-08-28 | 2022-03-03 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
WO2022047168A1 (en) | 2020-08-28 | 2022-03-03 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
WO2022056459A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd5 modification |
WO2022056489A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd38 modification |
WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
WO2022072643A1 (en) | 2020-09-30 | 2022-04-07 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
WO2022093983A1 (en) | 2020-10-27 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for treating hematopoietic malignancy |
WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
WO2022104090A1 (en) | 2020-11-13 | 2022-05-19 | Vor Biopharma Inc. | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors |
EP4001429A1 (en) | 2020-11-16 | 2022-05-25 | Antibodies-Online GmbH | Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq) |
WO2022147347A1 (en) | 2020-12-31 | 2022-07-07 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
CN113005147A (en) * | 2021-03-11 | 2021-06-22 | 中山大学附属第一医院 | Construction method and application of mouse animal model with USP8 mutation |
WO2022217086A1 (en) | 2021-04-09 | 2022-10-13 | Vor Biopharma Inc. | Photocleavable guide rnas and methods of use thereof |
WO2022256440A2 (en) | 2021-06-01 | 2022-12-08 | Arbor Biotechnologies, Inc. | Gene editing systems comprising a crispr nuclease and uses thereof |
WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
WO2023006933A1 (en) | 2021-07-30 | 2023-02-02 | KWS SAAT SE & Co. KGaA | Plants with improved digestibility and marker haplotypes |
WO2023015182A1 (en) | 2021-08-02 | 2023-02-09 | Vor Biopharma Inc. | Compositions and methods for gene modification |
US11884915B2 (en) | 2021-09-10 | 2024-01-30 | Agilent Technologies, Inc. | Guide RNAs with chemical modification for prime editing |
WO2023049926A2 (en) | 2021-09-27 | 2023-03-30 | Vor Biopharma Inc. | Fusion polypeptides for genetic editing and methods of use thereof |
WO2023086422A1 (en) | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
WO2023093862A1 (en) | 2021-11-26 | 2023-06-01 | Epigenic Therapeutics Inc. | Method of modulating pcsk9 and uses thereof |
WO2023105000A1 (en) | 2021-12-09 | 2023-06-15 | Zygosity Limited | Vector |
WO2023111541A1 (en) | 2021-12-14 | 2023-06-22 | The University Of Warwick | Methods to increase yields in crops |
GB202118058D0 (en) | 2021-12-14 | 2022-01-26 | Univ Warwick | Methods to increase yields in crops |
WO2023164636A1 (en) | 2022-02-25 | 2023-08-31 | Vor Biopharma Inc. | Compositions and methods for homology-directed repair gene modification |
WO2023196816A1 (en) | 2022-04-04 | 2023-10-12 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
WO2024003579A1 (en) | 2022-06-30 | 2024-01-04 | University Of Newcastle Upon Tyne | Preventing disease recurrence in mitochondrial replacement therapy |
WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
WO2024042199A1 (en) | 2022-08-26 | 2024-02-29 | KWS SAAT SE & Co. KGaA | Use of paired genes in hybrid breeding |
WO2024073440A1 (en) | 2022-09-27 | 2024-04-04 | Genentech, Inc. | Inhibition of genotoxic stress to improve t cell engineering |
WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
WO2024168312A1 (en) | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
WO2024168253A1 (en) | 2023-02-10 | 2024-08-15 | Possible Medicines Llc | Delivery of an rna guided recombination system |
WO2024168265A1 (en) | 2023-02-10 | 2024-08-15 | Possible Medicines Llc | Aav delivery of rna guided recombination system |
WO2024173645A1 (en) | 2023-02-15 | 2024-08-22 | Arbor Biotechnologies, Inc. | Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript |
WO2024220741A1 (en) | 2023-04-19 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for the production of libraries |
Also Published As
Publication number | Publication date |
---|---|
US20140310830A1 (en) | 2014-10-16 |
US20200354742A1 (en) | 2020-11-12 |
US20180355375A1 (en) | 2018-12-13 |
US20140234972A1 (en) | 2014-08-21 |
US20140248702A1 (en) | 2014-09-04 |
WO2014093694A9 (en) | 2014-10-16 |
US8889356B2 (en) | 2014-11-18 |
US8932814B2 (en) | 2015-01-13 |
US20170191078A1 (en) | 2017-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240117365A1 (en) | Crispr-cas component systems, methods and compositions for sequence manipulation | |
US20200354742A1 (en) | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes | |
EP2848690B1 (en) | Crispr-cas component systems, methods and compositions for sequence manipulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13814372 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13814372 Country of ref document: EP Kind code of ref document: A1 |